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Abstract 
 
αvβ3-integrin expression is vastly upregulated in tumour vasculature, and has 
long been considered a key molecule in promoting tumour angiogenesis. 
However, its initial promise as a target in anti-angiogenic therapy has wavered 
since the αvβ3-integrin antagonist cilengitide did not meet its end point in Phase 
III clinical trials for the treatment of glioblastoma. This failure corresponds with the 
enhanced tumour growth and angiogenesis observed in β3-integrin-knockout 
mice, which potentially occurs via a compensatory upregulation of VEGFR2 and 
enhancement in VEGFR2-neuropilin-1 interactions. Here, I show that tumour 
growth and angiogenesis are sensitive to neuropilin-1 perturbation even with only 
a 50% reduction in β3-integrin expression.  β3-integrin-heterozygous, but not 
wild-type, mice show an increased dependence on neuropilin-1 that is not related 
to changes in neuropilin-1-mediated VEGFR2 function. Rather, the suppression 
of β3-integrin leads to the activation of a neuropilin-1-dependent endothelial cell 
migration pathway via a mechanism in which NRP1 is mobilised away from 
mature focal adhesions following VEGF-stimulation. Concordantly, the 
simultaneous genetic targeting of both molecules significantly impairs paxillin 
activation and focal adhesion turnover in endothelial cells, and thus inhibits 
endothelial cell migration, and tumour growth and angiogenesis, even in 
established tumours. These findings therefore provide important pre-clinical 
evidence that pharmacologically targeting both molecules in unison might be an 
effective anti-angiogenic therapy for patients with advanced cancers. 
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1. Introduction 
 
1.1 Preface to the Introduction 
The process by which blood vessels form from existing vessels is known as 
angiogenesis. In cancer, tumours must recruit their own blood supply by 
angiogenesis in order to grow beyond a certain size and spread (metastasise) 
around the body. This thesis examines the dual role of two molecules, αvβ3-
integrin and neuropilin-1, associated with the cellular drivers of angiogenesis, 
endothelial cells, to coordinate the process. The results presented aim to promote 
a discussion on whether the molecules may be used as dual targets in anti-
angiogenic therapy to improve cancer prognosis. The following introduction will 
cover what is already known about the topic and the relevant molecules in detail, 
starting with a brief overview of the vascular system. 
 
 
1.2 The Vascular System 
In vertebrates, the vascular system, or circulatory system, is an organ system 
that supports the flow of both blood and lymph fluid throughout the body. To 
achieve this, there are two distinct components of the vascular system: the 
cardiovascular system, which circulates blood, and the lymphatic system, which 
transports lymph [1]. Blood contains plasma, red blood cells (erythrocytes), 
immune/white blood cells (leukocytes), and platelets, whilst lymph mainly 
consists of plasma originally derived from the blood, and leukocytes. 
 
In the cardiovascular system, cyclical contractions of the heart pump blood 
through specialised blood vessels, delivering oxygen, nutrients, hormones and 
leukocytes to tissues, and removing carbon dioxide and other metabolic waste 
products from them. The system is a ‘closed loop’, meaning blood never leaves 
the vessel circuit. Instead, blood is oxygenated at the lungs, and travels through 
arteries and arterioles to capillary beds, where gases and metabolites are 
allowed to exchange with those in the surrounding tissues, and blood cells can 
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leave by extravasation. Deoxygenated blood is then returned to the heart through 
venules and veins for further circuits around the body. 
The lymphatic system, in contrast, is ‘open’. It mainly functions as a drainage 
system, in which plasma that has leaked into the interstitial space surrounding 
tissues is unidirectionally returned to blood vessels as lymph in lymphatic 
vessels, via lymph nodes. As its name suggests, lymph contains lymphocytes, 
and so it is also heavily involved in the immune response. 
 
 
1.2.1 Blood vessel function and architecture 
Blood vessels, although specialised for their environment and physiological 
function, generally consist of three layers: the tunica intima, the tunica media and 
the tunica adventitia. The tunica intima, the innermost layer in direct contact with 
the flow of blood in the lumen, is a single sheet of endothelial cells (ECs) which 
forms a tube and an underlying basement membrane (BM). Vascular mural cells, 
such as smooth muscle cells (vSMCs) and pericytes, surround the tunica intima 
to help form the tunica media, and the outermost tunica adventitia is composed of 
fibrous connective tissue. 
 
Differently sized blood vessels have different compositions of the vessel wall to 
suit their physiological function. Larger vessels, like arteries and veins, contain 
elastic layers, and have multiple layers of vSMCs, collagen, elastin and 
proteoglycans within the tunica media, and an elastic and collagenous tunica 
adventitia [2]. In smaller vessels, like capillaries, however, the endothelial tube is 
only sparsely covered in pericytes, and there is no perceptible adventitial layer 
[3]. A key difference between arteries and veins is that arteries have stronger 
elastic vessel walls for withstanding high blood pressures, whereas veins contain 
valves for preventing the backflow of blood under low pressure [2] (Figure 1.1). 
 
 
 
 
 
 
Artery
Vein
Large Vessels
Small Vessels
Fibrous
connective
tissue
External
elastic
tissue
Smooth
muscle
Internal
elastic
tissue
Endothelium
FlowVenule Arteriole
Endothelial
cell
Smooth
muscle
cell
Pericyte
Capillaries
Pericyte
Smooth
muscle cell
Figure 1.1: Blood vessel architecture. The vascular walls of large vessels (arteries and veins) 
consists of a tunica intima, which comprises a layer of endothelial cells, a basement membrane, and 
an internal elastic layer; a tunica media, composed of multiple layers of vascular smooth muscle 
cells, collagen, elastin and proteoglycans; and an elastic and collagenous tunica adventitia. Arteries 
have strong elastic walls for withstanding high blood pressures, and veins contain valves for 
preventing the backflow of blood under low pressure. Smaller vessels have a tunica intima without 
an elastic layer, and a tunica media that consists of sparsely covered smooth muscle cells or 
pericytes in capillaries. Small vessels have no perciptible tunica adventitia. Figure adapted from [2].
15
16 
1.2.1.1 Endothelial cells 
The ECs lining blood vessel walls are remarkably heterogeneous themselves, 
both between tissues and vessels, and even within organs [4] (reviewed in [5,6]). 
Firstly, at a morphological level, the endothelium can be classified as continuous, 
fenestrated or discontinuous, according to the physiological requirement of the 
tissue [2,7] (Figure 1.2A). Continuous endothelium is a contiguous layer of cells 
connected closely to one another by inter-endothelial junctions, and surrounded 
by an uninterrupted BM. It is found in arteries, veins, and capillaries of the brain, 
skin, heart, and lung [8]. Fenestrated endothelium is similar, except for the 
presence of small 80-100 nm-wide openings, called fenestrae, which allow 
macromolecules to rapidly pass through [2]. This endothelium is therefore 
characteristic of capillaries in areas involved in filtration or secretion, such as 
exocrine and endocrine glands, gastric and intestinal mucosa, the choroid plexus, 
glomeruli, and renal tubules [7]. Discontinuous endothelium has larger fenestrae, 
which give rise to large gaps in the cells, and a discontinuous or absent BM. It is 
mainly found in sinusoidal vascular beds, such as those in the liver [7,8]. 
 
ECs may also differ in size, shape, orientation relative to the direction of blood 
flow, the complexity of inter-endothelial junctions, and the presence of 
plasmalemmal vesicles known as Weibel-Palade bodies [2,9]. For example, 
microvascular ECs are thinner, more flattened and elongated compared to larger 
vessels; they also tend to have less complex endothelial junctions and fewer 
Weibel-Pilade bodies [9]. In normal resting blood vessels, ECs are generally 
referred to as quiescent ‘phalanx’ cells due to their resemblance to a close 
formation of marching soldiers; in this state, ECs are tightly aligned in a 
monolayer in the direction of blood flow to maintain optimum perfusion [10]. 
 
The endothelial intercellular junctions are tight junctions, adherens junctions, and 
gap junctions, which differ in their junctional protein composition (reviewed in 
[11,12]). For example, tight junctions contain claudins and occludins, whilst 
adherens junctions contain cadherins (Figure 1.2B). Intercellular junctions 
mediate adhesion and communication between adjoining ECs to control vascular 
homeostasis in a way that depends on the permeability requirements of their 
environment [11]. As an example, whilst adherens junctions are ubiquitous 
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across all blood vessels, tight junctions are poorly organised in post-capillary 
venules, where solutes and cells rapidly exchange between blood and tissues, 
but are highly complex in brain microvasculature to lower the permeability 
between blood and the nervous system [11,12]. 
 
ECs can control vascular homeostasis in many different ways, and they therefore 
observe considerable functional heterogeneity. As well as being able to perform 
organ-specific functions like differential permeability highlighted above, ECs 
control leukocyte homing, diapedesis (leukocyte extravasation), vascular tone 
(vasoconstriction and vasodilation), coagulation, thrombosis and fibrinolysis, 
acute inflammation and blood vessel formation [2] (reviewed in [13]). 
 
1.2.1.2 Extracellular Matrix 
ECs are adhered to and embedded within an extracellular matrix (ECM), which is 
organised into two different compartments [14]. The first of these is the BM, 
which lies in-between the ECs and their supporting mural cells. The BM consists 
of a network of molecules including collagen type IV, laminins, nidogens, heparan 
sulfate proteoglycans (HPSGs), such as perlecan, and fibronectin [14,15]. In 
most normal adult tissues, quiescent ECs mainly adhere to this ECM [14,16]. 
However, during angiogenesis, when ECs are required to sprout out to form new 
vessels, enzymes like matrix metalloproteinases (MMPs) can degrade the BM, 
allowing ECs to invade through, and adhere to, components of a second ECM, 
the interstitial matrix, until the newly formed vessels mature and regain another 
BM [14,16]. The interstitial ECM normally mainly contains elastin and fibrillar 
collagens like collagen type I, but during angiogenesis, fibrin and the 
glycoproteins fibronectin and vitronectin extravasate into a ‘provisional’ interstitial 
matrix from blood plasma [16,17]. 
 
1.2.1.3 Pericytes 
Pericytes, like vSMCs, must associate with nascent blood vessels in order for 
them to stabilise and mature. These cells share, and co-synthesise, the BM with 
ECs, although they are on the opposite side of it [18]. Pericyte coverage of the 
endothelial tube is only partial, and varies between capillaries of different tissues 
for functional reasons [19]. Pericytes have primary cytoplasmic processes that 
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run along the length of the tube, and secondary processes that extend out 
perpendicularly to encircle, or ‘girdle’, the vessel [20]. Where holes arise in the 
BM separating ECs and pericytes, endothelial-pericyte, or peg-socket, contacts 
can be made, in which pericyte cytoplasmic fingers are inserted into endothelial 
invaginations [18]. These peg-socket contacts can contain tight-, gap-, and 
adherens junctions [19,21]. Additionally, there are further endothelial-pericyte 
contacts called adhesion plaques, which contain fibronectin deposits [21]. See 
Figure 1.2C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basement
membrane
Figure 1.2: Morphological features of blood vessels. A The endothelium of blood vessels can be 
morphologically classified as continuous, fenestrated, and discontinuous, depending on the 
physiological requirements of the tissue. Continuous endothelium is a layer of cells connected 
closely to one another by inter-endothelial junctions, and surrounded by an uninterrupted basement 
membrane (BM). Fenestrated endothelium additionally contains small 80-100 nm-wide openings, 
called fenestrae, which allow macromolecules to rapidly pass through. Discontinuous endothelium 
has larger fenestrae, which give rise to large gaps in the cells, and a discontinuous or absent BM.    
B Inter-endothelial adhesion junctions include tight junctions and adherens junctions, which differ in 
their protein composition. C Pericytes share a BM with, and encircle, endothelial cells in mature 
blood vessels. Endothelial-pericyte contacts can be made where holes arise in the BM separating 
ECs and pericytes (peg-sockets), or at adhesion plaques. Figures adapted from [2], [33], and [106].
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1.3 Blood vessel development/formation 
Blood vessels represent the first ‘organ’ to form and function during 
embryogenesis [22]. During a lifespan, blood vessels can form in three main 
different ways: vasculogenesis, sprouting angiogenesis, and intussusception. 
Vasculogenesis is the term used to describe how blood vessels form into a 
primitive network de novo from differentiating angioblasts in the developing 
embryo. After arterial or venous differentiation has been specified, blood vessels 
can expand and pattern from this vascular ‘plexus’ by sprouting angiogenesis, or 
intussusception, the splitting of vessels by interstitial tissue columns entering and 
partitioning the lumen [23,24].  A final, more controversial method of blood vessel 
formation is postnatal vasculogenesis, in which bone-marrow-derived cells 
(BMDCs) and/or endothelial progenitor cells (EPCs) are recruited and 
incorporated into the endothelial lining [24] (Figure 1.3). After branching, nascent 
vessels can expand their lumens, and recruit mural cells for stabilisation, which 
themselves can proliferate, migrate, and differentiate to help remodel stronger, 
more contractile and elastic mature vessels that can control perfusion [25,26]. 
This constitutes a separate process known as arteriogenesis. Finally, during the 
patterning process, blood vessels can also be ‘pruned’ and specialised to meet 
local tissue demands [26]. 
 
 
1.3.1 Vasculogenesis 
The process of vasculogenesis begins extraembryonically in the yolk sac. Here, 
hemangioblasts, which are mesoderm-derived progenitors of both ECs and 
hematopoietic cells, form aggregates called ‘blood islands’ [22]. Cells on the 
periphery of these aggregates differentiate into angioblasts, which migrate and 
further differentiate into ECs. These ECs are then able to assemble into the 
endothelial tubes that ultimately make up the vascular plexus [25]. 
 
 
 
 
 
Figure 1.3: Blood vessel formation. Following the de novo formation of blood vessels by 
vasculogenesis in the developing embryo, new blood vessels can form by: A postnatal 
vasculogenesis, the recruitment of endothelial progenitor cells (EPC) that differentiate into 
endothelial cells (EC); B sprouting angiogenesis; and C intussusceptive angiogenesis, the splitting 
of vessels by interstitial tissue columns entering and partitioning the lumen. Figure adapted from 
[24].
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1.3.2 Angiogenesis 
Angiogenesis is strictly defined as the formation of blood vessels from pre-
existing vasculature, meaning both sprouting angiogenesis and intussusceptive 
angiogenesis are encompassed by the term. It occurs during embryonic 
development in order to establish an advanced system of stable vessels after the 
primitive vascular plexus has formed by vasculogenesis, and subsequently also 
occurs postnatally to support growing tissues [17]. In adults, where most blood 
vessels are quiescent, physiological angiogenesis is less common. However, it 
remains an important process in the uterus and ovary during the menstrual cycle, 
in the placenta during pregnancy, in skeletal muscle after exercise, and in 
regenerating tissues following injury [27]. Unfortunately, angiogenesis can 
become dysregulated and contribute to a range of pathological conditions, 
including cancer. 
 
Angiogenesis is a complicated process with many stages and molecular ‘players’ 
expressed by different cell types. It will be discussed in greater mechanistic detail 
in the next sub-chapter, but as an overview: Angiogenesis initiates when hypoxic, 
inflammatory or tumour cells release a plethora of pro-angiogenic growth factors, 
such as vascular endothelial growth factors (VEGFs), angiopoietin 2 (ANG2), or 
fibroblast growth factors (FGFs). This tips the balance away from anti-angiogenic 
factors to turn on the angiogenic ‘switch’, triggering the removal of pericytes from 
nearby capillaries and degradation of the BM and ECM by proteases like MMPs. 
ECs loosen their intercellular junctions, proliferate, and, in response to integrin 
signalling, migrate onto newly forming and remodelling ECM, guided 
chemotactically towards the released soluble growth factors. Finally, ECs re-
establish their junctions and are covered by new BM and pericytes to form tube-
like structures that support blood flow to the original growth factor-releasing cells 
[24]. Vessels made from ECs that are not covered with pericytes are unstable, 
and undergo regression [28]. See Figure 1.4, which includes molecular players 
mentioned in the following chapter. 
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1.3.2.1 Mechanisms of Angiogenic sprouting 
To examine the process of sprouting angiogenesis in more detail, each important 
step, which is not necessarily sequential, has been divided into the following 
sections below: i) Hypoxia and growth factor release; ii) Pericyte removal and BM 
degradation; iii) EC junction loosening and ECM deposition; iv) Endothelial tip cell 
selection and guidance; v) EC migration and vessel anastomosis; vi) Vessel 
maturation. 
 
i) Hypoxia and growth factor release: 
When tissues grow enough to outstrip their oxygen supply, they are said to 
become ‘hypoxic’, and must recruit new blood vessels by angiogenesis to meet 
their oxygen demand again. Under hypoxia, oxygen sensors called prolyl 
hydroxylase domains (PHDs) can no longer use oxygen to hydoxylate hypoxia-
inducible factors (HIFs), such as HIF-1α, meaning HIFs escape proteasomal 
degradation and are stabilised [24,29]. HIFs can then bind hypoxia response 
elements in DNA to induce the expression of genes involved in angiogenesis, 
such as VEGF, VEGF receptors 1 and 2 (VEGFR1 and VEGFR2), neuropilin-1, 
ANG2, nitric oxide synthase, transforming growth factor-β (TGFβ), platelet-
derived growth factor-BB (PDGF-BB), endothelin-1, interleukin-8, insulin growth 
factor 2 (IGF2), TIE1, and cyclooxygenase-2 [25] (reviewed in [30]). Hypoxic 
tissues therefore release growth factors, setting up gradients towards nearby ECs 
that in response upregulate their own angiogenic growth factors and receptors. 
Growth factor binding to cell receptors initiates different angiogenesis signalling 
cascades and responses. 
	  
ii) Pericyte removal and BM degradation: 
Pericytes, which normally stably interact with ECs and suppress their proliferation 
via ANG1 (a ligand of the TIE2 endothelial receptor), detach from the vessel wall 
in response to ANG2, which can antagonise ANG1 through competition [24]. 
Meanwhile, the BM ECM is degraded by proteinases including MMPs, such as 
MT-MMP1, and ADAMs (A disintegrin and metalloproteinases), thus liberating the 
pericytes further [24,29,31]. 
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iii) EC junction loosening and ECM deposition: 
In tandem, angiogenic factors also cause EC junctions to loosen. For example, 
the transmembrane adherens junction protein VE-cadherin, a major regulator of 
vessel integrity and permeability, loses its adhesive function between ECs partly 
due to its VEGF-mediated endocytosis [24,31,32] reviewed in [33,34]). 
Endothelial quiescence is also disrupted by ANG2, which inhibits ANG1-mediated 
TIE2 clustering in trans at cell-cell junctions [24]. As ECs loosen their junctions, 
blood vessels dilate in response to nitric oxide, and VEGF increases their 
permeability, allowing ECM proteins like fibrin, fibronectin and vitronectin to 
extravasate and lay down a provisional interstitial ECM for migrating ECs 
[16,17,24,25]. 
 
iv) Endothelial tip cell selection and guidance: 
To direct angiogenic sprouting toward a growth factor stimulus in a coordinated 
manner, an endothelial ‘tip’ cell must be selected to lead and guide an emerging 
sprout [35]. These tip cells are motile; they extend out filopodia in response to 
guidance cues, allowing them to migrate down the growth factor gradient. Lying 
adjacent are endothelial ‘stalk’ cells, which form a vessel lumen and proliferate to 
elongate the sprout from behind [29]. Tip/stalk cell specification and guidance is 
mainly regulated by the VEGF, NOTCH, and WNT pathways, as reviewed 
extensively recently by [24,29,31,36-38], and briefly described below. 
 
ECs compete for the tip position following their upregulation of the NOTCH 
ligand, Delta-like-ligand 4 (DLL4), partly in response to VEGF activation of 
VEGFR2 [38-40]. DLL4 binds to NOTCH receptors on neighbouring ECs, causing 
them to decrease their VEGFR2, VEGFR3, and neuropilin-1 expression, and 
increase their levels of the VEGF decoy receptor, VEGFR1 [31,38,40]. This 
signalling specifies these neighbouring cells as the stalk cells, making them less 
responsive to sprouting signals from VEGF, yet more responsive to the VEGFR1 
ligand, placental growth factor (PlGF) [24]. Stalk cells additionally preferentially 
express another NOTCH ligand, JAGGED1, which heightens the tip/stalk divide 
by antagonising DLL4-NOTCH activation back on tip cells [41]. Following this 
initial tip/stalk cell specification, ECs continue to dynamically compete for the tip 
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position based on the degree of their VEGFR2:VEGFR1 level ratio, meaning tip 
cells are always best equipped to respond to VEGF and take the lead [38,40]. 
 
Tip cells are guided in response to cues from VEGF, ephrins, semaphorins, and 
Slits, which coordinate filopodial extension [24]. Meanwhile, stalk cells create 
perfused vessels by establishing the lumen, utilising VEGF, VE-cadherin, CD34, 
sialomucins, and hedgehog [24]. Stalk cell proliferation, responsible for vessel 
elongation, is partly mediated by NOTCH-induced WNT signalling through 
FRIZZLED receptors [24]. 
 
v) EC migration and vessel anastomosis: 
As ECs are specified, guided and proliferated, they use their adhesion molecules, 
such as integrins, to adhere to, and migrate through continuously remodelling 
interstitial ECM. Migration is achieved by ECs propelling themselves forwards 
whilst constantly assembling and disassembling their adhesions with the 
surrounding ECM, which is degraded by proteinases and re-scaffolded by 
extravasating glycoproteins into a more accommodating environment for 
invasion. As proteinases (MMPs, plasminogen activators, heparinases, 
chymases etc.), degrade the ECM, growth factors (FGF, VEGF, and insulin 
growth factor 1 (IGF1)) sequestered within it are mobilised to enhance the 
angiogenic response [17,24,25]. 
 
Sprouting vessels are redundant unless they reconnect with the circulation to 
maintain blood flow. Tip cells therefore undergo anastomosis with cells from other 
nearby sprouts to form perfused vessel loops [29]. Anastomosis is facilitated by 
the accumulation of macrophages, and reaches conclusion when VE-cadherin-
containing junctions form, and vessels stabilise and mature (see below) [29,42]. 
 
vi) Vessel maturation: 
Once nascent blood vessel sprouts anastomose, the network becomes subject to 
a remodelling process, in which vascular branches either mature or regress to 
meet the oxygen requirements of the surrounding tissue. In order to become 
quiescent and functional, vessels must mature by re-establishing endothelial 
intercellular junctions, forming a new BM, and recruiting stabilising mural cells, 
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mainly through TGF-β, PDGF-B, and ANG1 signalling, as described below. If 
vessels do not become perfused, they undergo regression [26]. 
 
TGF-β, as well as promoting the recruitment of pericytes by regulating their 
proliferation, migration, and differentiation from precursor cells, is involved in BM 
deposition through its induction of the expression of fibronectin and collagens I, 
IV, and V [26,29,38,43]. BM maturation is further aided by TGF-β due to its 
signalling inducing the expression of the protease inhibitor plasminogen activator 
inhibitor-1 (PAI-1), which, along with tissue inhibitors of metalloproteinases 
(TIMPs), prevents ECM degradation [24,26,29,44]. 
 
Aside from TGF-β, mural cell recruitment is controlled by endothelial PDGF-B, 
which is secreted and subsequently signalled through PDGF receptor-β (PDGFR-
β) in mural cells to stimulate their migration and proliferation towards the 
immature vessel [29,45,46]. The binding of ANG1, expressed on the surfaces of 
mural cells, to TIE2 receptors on ECs promotes a stable interaction between 
these cells, and tightens endothelial junctions, as mentioned above (reviewed by 
[47]). However, ANG1’s role in mural cell recruitment is now contentious [38]. 
EC/mural cell interactions are also enhanced by sphingosine-1-phosphate (S1P), 
which increases the expression of N-cadherin at this junctional interface, and 
downregulates endothelial ANG2 [38,48]. S1P further promotes maturation by 
inhibiting VEGF signalling and stabilising VE-cadherin-containing junctions in 
ECs [38,49]. 
 
Mural cell recruitment and vessel maturation have additionally been shown to be 
regulated by other pathways, including DLL4/NOTCH [36], ephrins/Eph receptors 
[50], WNT [51], and integrins [52]. 
 
 
 
 
 
 
 
S1P
Figure 1.4: Mechanism of angiogenic sprouting. The schematic highlights the stages of 
angiogenesis, as described in the main text, and includes the key molecular players (in red). A The 
release of local angiogenic factors results in pericyte removal, basement membrane degradation, 
the loosening of endothelial junctions, increased blood vessel permeability, and the selection of a tip 
cell. B Tip cells are guided in response to environmental cues, whilst the stalk cells behind form a 
vessel lumen, proliferate and elongate to extend the forming sprouting endothelial cells, which 
migrate through the remodelling extracellular matrix in an integrin-dependent manner. C Sprouting 
vessels anastomose with other sprouts, and mature by depositing new basement membrane, 
re-establishing endothelial junctions, and recruiting pericytes. Figure adapted from [24].
Selection of tip cellA
Stalk elongation and tip guidanceB
Vessel anastomosis and maturationC
Loosening junctions
(VE-cadherin)
Basement membrane
degradation (MMPs)
Tip cell formaion
(VEGFR2, DLL4,
JAGGED1, NOTCH,
NRP1, integrins, HIF-1α)
Angiogenic factors
(VEGF, VEGF-C,
FGFs, ANG2)
Pericyte detachment
(ANG2)
Permeability, vasodilation,
and extravasation
(VEGF, nitric oxide)
Lumen formation (VE-cadherin, CD34, sialomucins, VEGF)
Pericyte recruitment (PDGF-B, ANG1,
NOTCH, ephrin-B2, FGF)
Tip cell guidance and adhesion
(semaphorins, ephrins, Slits, integrins)
Liberation of angiogenic
factors from ECM
(VEGF, FGFs)
ECM
Flow
Stalk elongation
(VEGFR1, NOTCH,
WNT, NRARP, PlGF, FGFs, EGFL7)
Myeloid cell recruitment
(ANG2, SDF-1α, PlGF) Ajacent vessel
sprout
FlowQuiescent vessel
Flow
Transendothelial lipid transport (VEGF-B)
Vascular maintenance
(VEGF, ANG1, FGFs, NOTCH)
Barrier formation
(VE-cadherin, ANG1)
Barrier stabilisation
(VE-cadherin, TIE2, S1P)
Basement membrane
deposition (NOTCH, PAI-1, TIMPs)
Pericyte maturation
(PDGF-B, PDGFRβ,
ephrin-B2, ANG1,
NOTCH, TGFβ1, S1P)
27
28 
1.3.2.2 The VEGF family and its receptors 
Of all the pro-angiogenic growth factors released in angiogenesis, VEGFs are 
seen as the most important, demonstrated by the fact that they are upregulated 
by up to 30-fold within minutes of the stabilisation of HIFs [17]. VEGFs are 
dimeric glycoproteins that belong to the PDGF supergene family. In mammals, 
the family members include VEGF-A, -B, -C, -D, and placental growth factor, 
each of which shares a common structure that comprises a VEGF homology 
domain with eight characteristically spaced cysteine residues [53,54]. VEGFs can 
bind different variants of type III receptor tyrosine kinases, VEGF receptors 1, 2 
and 3 (VEGFR1/2/3), causing them to homo- or hetero-dimerise [55,56] (Figure 
1.5A). VEGFR signalling cascades are activated downstream of this ligand-
induced dimerisation by activation of the kinase domain, and can be further 
regulated by the recruitment of co-receptors, such as neuropilins and integrins 
[55]. 
 
VEGF-A, the major mediator of angiogenesis, signals mainly through VEGFR2, 
which is upregulated in ECs of angiogenic vessels [57]. VEGFR2 activation leads 
to EC migration, proliferation, differentiation and survival, as well as vessel 
sprouting and permeability, through a variety of different signalling pathways 
[54,58]. 
 
VEGF-C binds VEGFR2 weakly, but mainly activates VEGFR3 to also induce tip 
cell sprouting, although not as efficaciously as VEGF-A [38]. Despite this, 
VEGFR3 is primarily involved in vasculogenesis and lymphangiogenesis (the 
lymphatic vessel equivalent of angiogenesis) [24]. VEGF-D also binds both 
VEGFR2 and VEGFR3, although not the former in mice, and has some 
angiogenic and lymphangiogenic potential [53].  
 
The role of VEGFR1 in angiogenesis (otherwise known as Flt1 - FMS-like 
tyrosine kinase) is much less certain. Indeed, its affinity for VEGF-A is higher 
than that of VEGFR2, yet its kinase activity is much weaker [58]. This has led to 
the proposal that VEGFR1 acts as a ‘decoy’ for VEGF-A, preventing its more 
potent activation of angiogenesis via VEGFR2. As described above, this probably 
explains how stalk cells, which have high levels of VEGFR1, are less responsive 
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to sprouting signals from VEGF-A. As well as existing in a membrane-anchored 
form, VEGFR1 can be alternatively spliced to become soluble (sFlt1). In this 
form, VEGFR1 can similarly inhibit signaling by sequestering free endogenous 
VEGF-A [24,54,58]. Aside from VEGFR1’s disputed role in angiogenesis, it also 
acts as a receptor for VEGF-B, whose in vivo role is poorly defined, and PlGF, 
which is more associated with arteriogenesis [53]. 
 
It is worth noting here that VEGFs are produced by different cells, and function as 
cytokines not only for ECs, but for various cell types, including EPCs, lymphatic 
ECs, and mural cells [58]. Given their overwhelmingly dominant role in 
angiogenesis, I will focus on VEGF-A, and VEGFR2 in this thesis. 
 
1.3.2.2.1 VEGF-A 
The dominance of VEGF-A (hitherto, and hereafter referred to as VEGF) in 
vasculogenesis and angiogenesis is highlighted by the fact that mice lacking a 
single VEGF allele die at approximately embryonic day (E)9.5 with severe 
vascular defects [59,60]. VEGF coordinates the angiogenic response in many 
different contexts by binding its receptors VEGFR1 and VEGFR2, as well as its 
‘co-receptors’ neuropilin-1 (NRP1) and neuropilin-2 (NRP2), to induce EC 
sprouting, migration, proliferation, survival, and permeability through different 
mechanisms [53,61]. For example, VEGF can promote EC survival by inducing 
the expression of the anti-apoptotic proteins Bcl2 and A1 [62], and 
permeability/vasodilation by inducing the expression of endothelial nitric oxide 
synthase (eNOS) [63]. 
 
Due to alternative splicing and proteolytic processing, there are four main 
isoforms of VEGF, each denoted by their number of amino acids (VEGF121, 
VEGF165, VEGF189, and VEGF206) [22]. These isoforms differ in their ability to bind 
HPSGs in the ECM [53]. Because of this, different VEGF isoforms are either 
soluble (VEGF121 and VEGF165) or matrix-bound (VEGF189 and VEGF206), and 
have identifiable, yet overlapping functions [53]. This balance between the 
soluble and HPSG-bound isoforms helps maintain the VEGF gradient, which is 
vital for coordinated vessel sprouting, but also affects VEGFR-integrin/neuropilin 
engagement and the spatial distribution of VEGFR signalling [22,64-66]. The 
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most commonly produced VEGF isoforms are VEGF121, VEGF165, and VEGF189, 
although knockout studies in mice suggest that VEGF165 is the most efficacious 
[53]. Indeed, VEGF165, which despite its solubility can bind heparin, has increased 
signalling potential over the non-heparin binding VEGF121, potentially due to its 
ability to promote NRP1-VEGFR2 complex formation [67-69]. More recently, 
further VEGF splice variants denoted VEGF-A(xxx)b have been discovered, 
although they appear to be anti-angiogenic (reviewed in [70]). 
 
Interestingly, there is disparity between the actions of paracrine VEGF on ECs 
and autocrine VEGF produced by ECs. Whereas paracrine VEGF induces EC 
sprouting, autocrine VEGF is more involved in maintaining vessel homeostasis 
[58,71]. 
 
1.3.2.2.2 VEGFR2 
VEGFR2, also known as KDR (kinase domain receptor) in the human and Flk1 
(fetal liver kinase-1) in the mouse, is the main VEGFR in ECs [65]. Like the other 
VEGFRs, it is made up of seven extracellular immunoglobulin (Ig)-like domains, a 
transmembrane (TM) domain, a regulatory juxtamembrane domain, an 
intracellular tyrosine kinase domain, a kinase insert domain, and a carboxy(C)-
terminal domain [55]. VEGF binds VEGFR2 at Ig-like domains 2-3 to induce its 
dimerisation and allow trans/autophosphorylation of intracellular tyrosine (Y) 
residues, which include Y951, Y1054, Y1059, Y1175 and Y1214 [65]. These 
phosphorylated tyrosines serve as binding sites for downstream signalling 
mediators containing SRC homology 2 (SH2) domains. For example, 
phosphorylation of Y1175, located at the C-terminal domain, results in the 
recruitment of signalling mediators like phospholipase Cγ (PLCγ), the adapter 
proteins SHB and SCK, and SHCA and GRB2, which in turn recruit SOS [65]. 
Various signalling cascades follow to initiate different cellular events involved in 
the angiogenic response including cell proliferation, migration, survival, and 
permeability (Figure 1.5B) [65]. 
 
EC proliferation is mainly induced by VEGF via activation of the 
RAS/RAF/MEK/ERK (mitogen activated protein kinase (MAPK)) pathway [65,72]. 
Signals are directed through this pathway via phosphorylated PLCγ, which 
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hydrolyses phosphatidylinositol bisphosphate (PIP2) at the membrane to DAG 
and IP3. DAG subsequently activates PKC, which is believed to propagate the 
signal through the MAPK pathway partly via sphingosine kinase (SPK) 
phosphorylation of RAS [73], but PKC can also feed in independently of RAS 
[65,74]. 
 
The VEGFR2-dependent migration of ECs can be dictated through signalling 
transducers that bind phosphorylated(p) Y951, Y1175, and Y1214 [65]. For 
example, pY1175-mediated SHB recruitment results in SRC-dependent SHB 
phosphorylation [75]. In turn, SHB binds focal adhesion kinase (FAK), resulting in 
its phosphorylation [65,76]. FAK is then able to influence migration through its 
role in regulating the turnover of focal adhesions and actin organisation [55]. 
Another stimulator of migration, Rac, which generates ‘ruffles’ in the membrane, 
is activated in response to GAB1-mediated PI3K production of 
phosphatidylinositol trisphosphate (PIP3), although GAB1’s VEGFR2-binding site 
is yet to be determined [65,77]. Additionally, pY1214 recruits a NCK/FYN 
complex, which mediates the activation of migration enhancers Cdc42 and 
p38MAPK via phosphorylation of PAK2 [78]. Various other inducers of migration 
are activated through VEGFR2 signalling, including IQGAP1, HSP27, and TSAd 
[65]. 
 
The production of PIP3 via VEGFR2-activated PI3K also leads to the activation of 
Akt, which is one of the molecules involved in inhibiting apoptosis and therefore 
promoting cell survival [65]. VEGFR2’s mediation of vessel permeability involves 
signalling through eNOS, and the phosphorylation or endocytosis of VE-cadherin 
[32,65,79].  
 
VEGFR2 signalling output can be modulated by clustering, heterodimerisation, 
phosphatases, its co-receptors, integrins and neuropilins, as described later, and 
also by its subcellular location. Indeed, although VEGFR-2 was previously 
thought to exclusively signal at the plasma membrane, it is now known to 
additionally signal from early or recycling endosomes [80-85]. Moreover, the 
endocytosis of cell surface receptors like VEGFR2 is widely reported to enhance 
downstream signalling (e.g. via ERK1/2) and angiogenesis [86,87]. In resting 
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ECs, a significant proportion of VEGFR2 is stored in intracellular vesicles, but is 
delivered to the plasma membrane in a SRC-dependent manner upon VEGF 
stimulation [88]. Meanwhile, VEGF also initiates VEGFR2 membranal 
internalisation into endosomes, which is regulated by ephrinB2, VE-cadherin, and 
the phosphatase DEP1 [65,83,85,89-91]. Subsequently, VEGFR2 is either 
degraded following its ubiquitination, or recycled to the membrane, allowing it to 
continue signalling. This recycling process is dependent on VEGFR2’s interaction 
with NRP1, and will therefore be discussed in more detail later.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Structure and signalling of VEGF receptors. A VEGFs can bind different variants of 
type III receptor tyrosine kinases, VEGF receptors 1, 2 and 3 (VEGFR1/2/3), causing them to homo- 
or hetero-dimerise. VEGF-A signals mainly through VEGFR2. VEGF-B and PlGF bind VEGFR1. 
VEGF-C binds VEGFR2 weakly, but mainly activates VEGFR3, and VEGF-D also binds both 
VEGFR2 and VEGFR3, although not the former in mice. VEGFRs consist of extracellular 
immunoglobulin (Ig)-like domains, a transmembrane domain (TMD), a regulatory juxtamembrane 
domain (JMD), an intracellular tyrosine kinase domain (TKD), a kinase insert domain (KID), and a 
carboxy(C)-terminal domain. B VEGF-A activates VEGFR2, resulting in the phosphorylation of its 
intracellular tyrosine (Y) residues. For example, Y1175 phosphorylation results in activation of the 
RAS-RAF-MEK-ERK pathway, and SRC/FAK, to promote cell proliferation and migration, 
respectively. Y1214 phosphorylation activates p38 MAPK- and Cdc42-mediated cell migration. The 
VEGFR2 phosphorylation site that mediates the Akt cell survival pathway is currently unknown. 
Figures adapted from [65] and [276].
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1.4 Angiogenesis in disease 
Unfortunately, insufficient or excessive angiogenesis can contribute to the 
development of a range of pathological conditions. For example, too little can 
lead to ischemic diseases such as stroke and coronary artery disease, whilst too 
much is associated with psoriasis, arthritis, diabetic blindness, and cancer [17]. 
This thesis is concerned with the latter. 
 
1.4.1 Cancer 
The term cancer encompasses a group of diseases characterised by the 
abnormal growth of cells into malignant neoplasms, or tumours, which are 
capable of spreading (metastasising) to different tissues around the body. It has 
been proposed that there are six ‘hallmarks’ of cancer that can be acquired to 
contribute to the progression of tumour cell growth and metastasis [92,93]. These 
are: 1) Sustaining proliferative signalling; 2) Evading growth suppressors; 3) 
Resisting cell death (apoptosis); 4) Enabling replicative immortality; 5) Inducing 
angiogenesis; 6) Activating invasion and metastasis [92,93]. 
 
1.4.1.1 Tumour Angiogenesis 
Angiogenesis is critical for cancer progression as tumours are limited in growth 
and cannot metastasise until they acquire their own blood supply [23,94]. This led 
J. Folkman to propose, as early as 1971, that inhibiting tumour angiogenesis 
might be a valuable therapy against cancer [28,95]. When a tumour exceeds a 
few millimetres in diameter, hypoxia and nutrient-deprivation trigger, and in this 
case sustain, the angiogenic switch, meaning pro-angiogenic growth factors are 
persistently released in the tumour microenvironment [96,97]. This results in the 
induction of the same angiogenic signalling pathways as in normal angiogenesis, 
but due to their dysregulation, the arising vasculature is continuously remodelled, 
and is therefore leaky, tortuous and fragile [97,98]. Where mural cells have 
detached to expose the degrading BM, platelets become activated to release 
more angiogenic and permeability factors that enhance the response [97,98]. 
Tumour-associated fibroblasts (TAFs) then aberrantly deposit ECM, which is 
continuously remodelled by proteases to expose more growth factors [97,99]. To 
further escalate matters, even more stimulatory factors are released by TAFs, 
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infiltrating inflammatory cells (e.g. tumour-associated macrophages (TAMs) and 
neutrophils (both bone-marrow-derived myeloid cells)), and bone-marrow derived 
EPCs [97]. Tumour vessels additionally lack functional mural cells, meaning they 
can never fully reach quiescence and are more prone to regression [23]. Notably, 
in tumour angiogenesis, not only can blood vessels sprout from pre-existing 
ones, as in normal angiogenesis, but tumour cells can also co-opt the existing 
vasculature, and vessels can even form from differentiating tumour stem cells 
(vascular mimicry) [24,97,100]. Unsurprisingly, this does not stabilize the 
vasculature, but rather increases the likeliness of metastasis [97]. See Figure 
1.6. 
 
Clearly, tumour angiogenesis is a complex process whose aberrance is 
dependent on the contribution of multiple cell types. In fact, although once 
disregarded, the tumour microenvironment, or stroma, is now seen as similarly 
important for tumour progression and angiogenesis as the tumour (parenchymal) 
cells are themselves. Stromal cells include ECs, mural cells, TAFs, TAMs, EPCs, 
and lymphatic ECs, all of which can produce and/or respond to VEGF [58,101]. 
Below I have highlighted examples of how tumour and stromal cells contribute to 
the enhanced and aberrant tumour angiogenesis phenotype.  
 
Tumour cells: 
As we know, tumour cells signal to cells in their microenvironment in a paracrine 
manner to initiate angiogenesis in response to hypoxia. However, due to the 
abnormal and poorly perfused tumour vasculature that results, ‘pockets’ of 
hypoxia and acidosis persist throughout the tumour, creating a hostile 
environment in which pro-angiogenic factors are sustainably released to promote 
a vicious cycle of events [29]. Tumour cells not only produce VEGF, but respond 
to it to enhance their own survival, migration, proliferation, metastasis and 
epithelial-to-mesenchymal transition (EMT), and thus promote tumourigenesis 
[58]. Aside from VEGF, tumour cells additionally release many other pro-
angiogenic factors that contribute to tumour growth and angiogenesis, including 
PlGF, VEGF-C, VEGF-D, PDGF-C, FGF1 or FGF2, ANG1, and ephrins A1 and 
A2 [58]. 
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Tumour endothelial cells: 
Pathologically high and persistent levels of VEGF and other growth factors have 
numerous consequences for ECs and angiogenesis, but ultimately they lead to 
hypersprouting and abnormal vessels [10,58]. Activated tumour ECs lose their 
polarity, and can detach from the BM and stack on top of each other, impeding 
blood flow [10]. They hypersprout, probably by increasing tip cell formation via 
DLL4, and become leaky through increasing their number of fenestrations, and 
widening their junctions, partly through a loss in differential VE-cadherin mobility 
[10,102]. This increase in permeability builds interstitial hypertension, impairs 
perfusion, and allows for leukocyte extravasation and tumour cell invasiveness 
[58,101]. Recently, EC metabolism has been pinpointed as a regulator of 
angiogenesis that is also influential in the context of a tumour. ECs rely on 
glycolysis for their metabolism, which is enhanced in response to VEGF via the 
upregulation of PFKFB3 [103,104]. This provides energy to increase EC 
proliferation and tip cell locomotion through inducing rapid actin remodelling in 
filopodia and lamellipodia [103,104]. The pharmacological inhibition of PFKFB3 
has been shown to block tumour growth in vivo [104,105]. 
 
Mural cells: 
Like in the physiological situation, tumours and their microenvironment release 
PDGF-B to recruit pericytes, but frequently tumour vessels have loose EC-
pericyte associations and inadequate pericyte coverage, possibly due to a VEGF-
dependent increase in ANG2 [58,106,107]. Those pericytes that do attach to the 
endothelium may have an abnormal shape, extend their processes into the 
stroma, and express less contractile markers [10]. Interestingly, it has been 
shown that breast cancer cell-derived VEGF enhances mural cell migration 
through a VEGFR1/NRP1/Akt-dependent pathway, although how this impacts on 
tumour vessel mural cell coverage is unclear [58,108]. Pericyte abnormalities 
ultimately ensure tumour vessels keep remodelling and never reach maturity, and 
thus disrupt blood flow and increase tumour cell intravasation and metastasis, for 
example [10,109]. 
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Tumour associated fibroblasts (TAFs): 
Signalling from tumour cells promotes the differentiation of tissue-resident 
fibroblasts into myofibroblasts and then into TAFs [110]. In contrast to 
myofibroblasts, TAFs can no longer revert to normal fibroblasts, are anti-
apoptotic, and are generally more pro-tumourigenic [110]. TAFs are important 
regulators of tumour angiogenesis as they produce pro-angiogenic growth 
factors, allow them to be stored within the ECM they lay down, and release 
MMPs that make them available [110]. They have also been implicated in the 
recruitment of EPCs and stimulation of tumour growth through their secretion of 
stromal cell-derived factor (SDF)1 (CXCL12) [111]. 
 
Bone marrow-derived cells (BMDCs): 
VEGF recruits bone-marrow derived EPCs (non-haematopoietic) and CXCR4+ 
myeloid cells (haematopoietic) to the hypoxic tissue, where their CXCR4 receptor 
is bound by SDF1-α from perivascular myofibroblasts [58,112,113]. This enables 
EPCs to differentiate into contributing ECs (postnatal vasculogenesis), and pro-
angiogenic monocytes and macrophages to become residents of the perivascular 
space, respectively [58,112,113]. Indeed, inflammatory cells, which additionally 
include mast cells, eosinophils, neutrophils, and dendritic cells, have an important 
role in tumour angiogenesis, having been initially ineffective at fighting the tumour 
[110]. By this point, they have been shown to release pro-angiogenic factors and 
ECM proteinases, and even suppress cytotoxic T-cell activity [110]. As an 
example, TAMs that resemble M2-type macrophages promote tumour growth and 
metastasis through their release of PlGF [114]. Given that inflammatory cells are 
now promoting, rather than suppressing, tumour growth and angiogenesis, 
tumours have rather bleakly been described as ‘wounds that do not heal’ [115]. 
 
 
 
 
 
 
 
 
Figure 1.6: Tumour angiogenesis. In comparison to blood vessels in healthy tissues, those in 
tumours are leaky, tortuous, and fragile, due to dysregulated angiogenesis that is continuously 
remodelled. For example, excess growth factor release from tumour cells, platelets, 
tumour-associated fibroblasts, and infiltrating inflammatory cells (e.g. tumour-associated 
macrophages,TAMs)) maintains elevated angiogenesis. Persistently activated endothelial cells 
(ECs) begin to lose their polarity, stacking on top of each other to obstruct blood flow. Basement 
membrane coverage is disrupted and pericytes have looser and sparser associations with the 
endothelium. Widened endothelial junctions promote leakiness and therefore an increase in 
interstitial pressure, and a greater chance of leukocyte extravasation and tumour cell intravasation. 
Figure adapted from [10].
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1.4.1.2 Metastasis 
Metastasis is the spreading of tumour cells from the primary tumour neoplasm to 
one or more secondary locations around the body. It is reliant on tumour cells 
developing the ability to invade into a surrounding blood/lymphatic vessel 
(intravasation), travel through and survive in the bloodstream, and exit the 
circulation to colonise a distant site (extravasation) (reviewed in [116]). Relatively 
few tumour cells will eventually colonise given the difficulty in overcoming all of 
these barriers, but over time they may accumulate and grow to ultimately cause 
organ dysfunction. It is this reason that metastasis is seen as the primary cause 
of morbidity and mortality in most cancer patients. Different cancers are 
characterised by their differing metastatic potential, and the differential locations 
at which metastases form, thus partly explaining why particular cancer types are 
more aggressive and less treatable than others. The variability in metastatic 
outcome can be explained by a long-standing concept in cancer research known 
as ‘seed and soil’, theorised by Stephen Paget in 1889 [117]; the idea being that 
tumour cells or ‘seeds’ are spread around but can only survive and grow if they 
arrive in the optimum environment or ‘soil’ [116]. The type of cancer cell and the 
microenvironment at potential secondary sites will thus determine the degree of 
metastasis. This again highlights the importance of the stroma in coordinating 
tumour progression, as tumour cells are more likely to thrive in a more 
accommodating secondary environment, now termed the metastatic niche, which 
is dependent on the stromal components. Tumour cells are known to interact with 
this niche, releasing ECM molecules such as periostin and tenascin C, and 
inducing their sustained release from stromal cells, to ultimately promote 
colonisation [118]. A distinct population of tumour cells with stem cell properties, 
known as cancer stem cells (CSCs), are likely initiators of metastatic colonisation, 
given their ability to adapt to new environments [118]. Interestingly, in support of 
the seed and soil hypothesis, a ‘pre-metastatic niche’ may be primed for 
colonisation even before the tumour cells arrive. For example, VEGFR1+α4β1-
integrin+ BMDCs were found to home to future metastatic sites of B16 melanoma 
and Lewis lung carcinoma (LLC) cells 4-6 days prior to them, clustering on 
fibronectin to facilitate tumour cell attachment and liberate stimulatory growth 
factors such as VEGF [119]. 
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Metastasis, requiring blood vessels for intra- and extra-vasation, is heavily 
dependent on tumour angiogenesis at both primary and secondary sites. Not only 
do tumour cells have a nearby blood supply through angiogenesis, vessel co-
option and vascular mimicry, but they also have a greater chance of intravasation 
due to the inherent leakiness of the vessels in this context. Clearly, the fact that 
angiogenesis is directly linked to metastasis, both of which are hallmarks of 
cancer, highlights the importance of angiogenesis and its potential as a target in 
cancer therapy. 
 
1.4.1.3 Anti-angiogenic cancer therapy 
Since J. Folkman [95] first proposed that targeting tumour angiogenesis might be 
a therapeutically beneficial strategy to treat cancer, a number of anti-angiogenic 
drugs have been clinically approved for the treatment of different tumour types, all 
of which disrupt the VEGF pathway [120,121]. This is unsurprising, given VEGF’s 
key role in driving angiogenesis, its increased expression in most solid tumours, 
and the various successes of its inhibition in animal models to suppress tumour 
growth [122]. The drugs include: bevacizumab (Avastin®), ziv-aflibercept 
(Zaltrap®), sunitinib (Sutent®), sorafenib (Nexavar®), pazopanib (Votrient®), 
axitinib (Inlyta®), vandetanib (Caprelsa®), everolimus (Afinitor®), regorafenib 
(Stivarga®), and cabozantinib (Cometriq®) [58,121,123]. As an example, 
bevacizumab, the most widely used of these, is a humanised monoclonal 
antibody targeted against VEGF that has improved survival in patients with 
metastatic colorectal cancer and non–small-cell lung cancer when combined with 
chemotherapy [57,121]. It has also been approved for use with interferon-α to 
treat metastatic renal cancer, in the treatment of breast and ovarian cancers, and 
as a monotherapy for the treatment of patients with recurrent glioblastoma 
[38,58,120,121]. The rest of the approved antagonists can inhibit VEGF signalling 
by acting as a decoy receptor for VEGF family members, targeting tyrosine 
kinases or reducing VEGF production by blocking the mammalian target of 
rapamycin (mTOR) pathway [121]. 
Unfortunately, the results obtained with these drugs have been modest, with 
overall patient survival increasing by only a few months at best, and in some 
cases tumour growth and metastasis actually becomes more aggressive after 
administration [57,120]. Moreover, somewhat predictably given VEGF’s ubiquity, 
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severe side effects such as renal toxicity, bleeding, arterial thromboembolic 
events, wound healing complications, gastrointestinal perforation and vessel 
regression in organs have been reported [124]. The ineffectiveness of these 
therapies has mainly been attributed to different mechanisms of resistance that 
tumours and their vasculature either have intrinsically or acquire to ‘escape’ 
treatment. Intrinsic resistance is likely observed in vasculature that has already 
matured, since VEGF-targeted therapies are more effective in newly forming 
vessels in pre-clinical models [122,125,126]. The tumour microenvironment that 
is inherently insensitive to VEGF targeting may also already have a high degree 
of redundancy of other pro-angiogenic signals, may not be dependent on 
angiogenic vessel growth, or the vessels might have already undergone 
invasive/metastatic co-option [125]. Acquired resistance may take the form of: an 
increase in tumour hypoxia causing increased growth factor release, enhanced 
tumour cell survival under stress, alternative mechanisms of tumour 
vascularisation (e.g. vessel co-option, vascular mimicry, intussusception), an 
upregulation of ECM components that can sequester active VEGF around the 
tumour microenvironment, a change in the dominant VEGF isoform, an increase 
in infiltrating pro-angiogenic BMDCs and stromal cells, increased pericyte 
coverage for vessel maturation, and a decrease in VEGF-dependence through an 
upregulation of other pro-angiogenic pathways [58,120-122,125-128].  
 
Recently, it has been proposed that simultaneously blocking multiple pro-
angiogenic pathways might be an effective strategy for overcoming these 
compensatory mechanisms; a concept that that has been upheld in various pre-
clinical studies that co-target pathways such as VEGF/VEGFR, PDGFR, ANG2, 
FGF, DLL4/NOTCH, β3-integrin and neuropilin-1 [38,129-135]. As a 
consequence, new drugs against other angiogenic targets (e.g. integrin 
antagonists) have been in clinical trials, and may prove to be effective co-
therapies that produce fewer side effects in the future. Additionally, R. K. Jain 
[136] has proposed that angiogenic therapy could be used to correct abnormal 
tumour vessel structure and function in order to improve the delivery and efficacy 
of chemotherapeutic drugs [24,124]. Indeed, this may be why the use of 
angiogenesis inhibitors in combination with chemotherapy has improved survival 
in many cases, although similar successes of the drugs used alone leave this 
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open to debate [122]. The therapeutic outcome with anti-angiogenic inhibitors is 
dependent on a multitude of other factors, including the type of cancer being 
treated, the stage of disease, the setting of drug administration (neo-adjuvant or 
adjuvant), the specificity and dose of inhibitor, and the physiology of the patient 
[122]. Clearly, to produce more therapeutically beneficial results in the future, all 
of these factors must be considered carefully to meet the requirements of each 
individual case. 
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1.5 More Molecular players in angiogenesis 
1.5.1 Integrins 
Integrins are a family of heterodimeric transmembrane (TM) glycoproteins, 
expressed in virtually every cell, that act as cell adhesion receptors for ECM 
proteins and immunoglobulin superfamily molecules [137,138]. They are involved 
in the promotion of cell attachment and migration on the surrounding ECM, as 
well as the regulation of cell proliferation, differentiation, and survival [137,139]. 
There are at least 24 distinct integrin α-β heterodimers that form from one of 18 α 
and one of 8 β subunits, each of which consist of an extracellular domain, a 
single TM region, and a short cytoplasmic tail [140,141] (Figure 1.7). Different 
integrins have different ligand specificity; some bind a single ligand, others bind 
several, and many recognise short peptide sequences in their ligands. For 
example, αvβ3, α5β1, αIIbβ3, αvβ6 and α3β1, all recognise the Arginine-
Glycine-Aspartic acid tripeptide, or RGD motif [137,142]. Typically, when integrins 
are ligated they exist in an unbent active conformation to promote a high avidity 
state, but when they are unligated they are in a bent inactive low avidity state, 
and can initiate apoptosis [137,143,144]. Integrins are capable of bi-directional 
signalling, meaning they can respond to intracellular stimuli, which initiate 
conformational changes that influence how the extracellular heads interact with 
ligands in their environment (‘inside-out’ signalling), and they can also mediate 
the transmission of extracellular signals across the plasma membrane to the 
intracellular signalling machinery (‘outside-in’ signalling) [140,141]. Although they 
have no intrinsic enzymatic or kinase activity, integrins can cluster at the plasma 
membrane and recruit scaffolding, adapter, and signalling proteins, including 
kinases, which feed through different signalling pathways to regulate different 
cellular processes. Through this mechanism, and by more direct interactions, 
integrins can enhance the activity of receptor tyrosine kinases, such as those 
activated by VEGF, FGF, and epidermal growth factor (EGF) [143]. The recruited 
scaffolding and adapter proteins at integrin adhesion sites form a clustered 
network known as a focal adhesion (FA), which links to the actin cytoskeleton to 
regulate cell migration in response to the environment [145]. 
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Integrins regulate many physiological processes, but they also play an important 
role in promoting cancer through their functioning in different cells of the tumour 
microenvironment. Tumour cell proliferation, migration, survival, and invasion are 
all regulated by integrins, thereby affecting neoplasm growth and metastasis. 
Indeed, expression of integrins αvβ3, αvβ5, α5β1, α6β4, α4β1 and αvβ6, in 
several tumour cell types correlates with disease progression and decreased 
patient survival [139]. In addition, tumour-supporting processes such as 
angiogenesis, lymphangiogenesis, desmoplasia (fibrous/connective tissue 
growth) and inflammation are all regulated by integrins expressed in cells 
including ECs, mural cells, fibroblasts, BMDCs, inflammatory cells, and platelets 
[139]. Through their interactions with their extracellular ligands, integrins also 
regulate proteases and control ECM remodelling, which is essential for these 
processes [139,143]. The targeting of integrins in the tumour microenvironment is 
therefore viewed as a promising potential therapeutic approach for cancer 
treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BA
Figure 1.7: Integrin subunits and structure. A Diagram showing the different mammalian integrin 
subunits and their associations. There are at least 24 distinct integrin α-β heterodimers that form 
from one of 18 α and one of 8 β subunits. Different integrins have different ligand specificity. For 
example, αvβ3-integrin and α5β1-integrin recognise the Arginine-Glycine-Aspartic acid tripeptide, or 
RGD motif. Figure adapted and redrawn from [141]. B Integrin subunits consist of an extracellular 
domain (ECD), a single transmembrane (TM) region, and a short cytoplasmic tail. Figure adapted 
from [137].
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1.5.1.1 Integrins and their ligands 
The extracellular heads of activated integrins are capable of binding one or more 
ECM components or counter-receptors on adjacent cell surfaces [140]. The 
number of integrin ligands is extensive, but their recognition depends on the 
context of their location and integrin expression and activation. In blood vessels, 
integrins may, for example, be expressed on the luminal and abluminal side of 
ECs, where they may bind different ECM proteins, or on the surface of circulating 
blood cells, where they may recognise endothelial molecules like intercellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) 
to mediate blood cell transmigration [138]. Cells in the tumour microenvironment 
that bind the ECM express integrins that recognise ECM proteins such as 
collagen, fibronectin, vitronectin, laminin, von Willebrand factor (vWF), fibrinogen, 
fibrillin, and thrombospondins [138,140]. Integrins have specificity for their ligands 
through recognising distinct peptide sequences in different ligands, such as the 
RGD motif already mentioned, and others such as EILDV, REDV, and LDV-type 
motifs [139,140]. This enforces cells expressing certain integrin heterodimers to 
reside within the ECM at locations rich in their specific ligand components [143]. 
As well as integrins being able to recognise multiple ligands, many ligands also 
display multivalency for their integrin counterparts, and often comprise several 
subunits that contain at least one recognition site [138]. For example, fibronectin 
binds α4β1-, α5β1-, and αvβ3-integrins among others [138,140]. See Figure 1.8. 
This may result in a high avidity scenario, where a dense ECM simultaneously 
crosslinks and clusters many integrins to enhance signalling potential [138]. The 
spatial dynamics of integrin associations ultimately determines how cells sense 
and respond to their environment, and thus dictates their migratory and invasive 
capacity [143]. Integrins therefore have a profound influence on angiogenesis 
and tumour cell invasion and metastasis, even helping determine the metastatic 
niche through their ligand specificity for particular ECM environments [143,146]. 
Integrin-ligand interactions also regulate cell survival; those that are ligated relay 
survival signals, and those that are not help initiate apoptotic pathways through 
anoikis (apoptosis occurring in response to cellular detachment) or integrin-
mediated death (IMD - apoptosis occurring in response to unligated integrin 
recruitment and activation of caspase-8) [139]. Integrins therefore dynamically 
respond to their environment to manage this balance. Important to tumour 
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progression and ineffective therapeutic targeting, some tumour cells are resistant 
to IMD through loss of caspase-8, or an anchorage-independent αvβ3-integrin-
SRC-mediated survival pathway [147,148]. Finally, integrin ligation can regulate 
cell proliferation by, for example, controlling the expression of cell cycle proteins 
like cyclin D1 and cyclin-dependent kinase inhibitors [139,149]. Again, integrin-
mediated proliferation can contribute to tumour progression, as shown in a study 
where αvβ3-integrin overexpression promoted anchorage-dependent heregulin-
induced breast cancer cell proliferation [150]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: Integrin ligands. As well as integrins being able to recognise multiple ligands, many ligands also 
display multivalency for their integrin counterparts. The diagram shows the major integrin-ligand  
combinations. Figure adapted from [140].
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1.5.1.2 Integrin activation - ‘inside-out’ signalling 
Integrins are activated for ligand binding by inside-out signalling, which causes a 
conformational change that allows integrin extracellular domains to expose the 
ligand-binding site. This conformational change is known as ‘affinity modulation’ 
for a single integrin molecule as its affinity for its ligand is increased, but when 
multiple integrins and ligands are involved, as is predominantly the case in 
biological systems, ‘avidity modulation’ is the preferred term [138]. Structurally, 
activation begins when the non-covalently associated cytoplasmic tails and TM 
helices of the α and β subunits are unclasped and separated. Subsequently, the 
extracellular head of the integrin, which is typically bent towards the cell 
membrane in a closed conformation, is moved away from the membrane in a 
‘switchblade motion’ through a conformational change in the extracellular 
domains that causes the two ‘legs’ to elongate. This ‘intermediate’ state can be 
opened further to permit access to larger ligands by swinging out the headpiece 
[138]. These transient conformational states are in equilibrium, dynamically 
changing in response to the environment (Figure 1.9). Reviewed in more 
molecular detail in [151,152]. 
 
Two major proteins that interact with, and activate, integrins via their cytoplasmic 
tails are worth mentioning here: talin and kindlin. Briefly, both talin and kindlins 
(there are three) are required for complete integrin activation by binding mainly to 
the membrane proximal NPxY peptide motif or the membrane distal NxxY motif 
respectively on the β integrin cytoplasmic tail via one of their FERM sub-domains, 
and thus displacing the β subunit’s complex with the α subunit [138,153]. Talin 
itself is an actin-binding protein (ABP), but it also binds focal adhesion proteins 
including vinculin and the Rap1-interacting adapter molecule (RIAM), which 
interacts with the GTPase Rap1 to promote talin’s binding to, and activation of, 
the β integrin cytoplasmic tail [138,153]. Talin is further primed for integrin 
activation through binding PIP2 near the membrane, which shifts talin’s inhibitory 
rod domain to expose its FERM-domain-containing head domain [138,153]. Like 
talin, kindlin contains three FERM sub-domains, but the F2 domain is interrupted 
by a Pleckstrin Homology (PH) domain [153]. Kindlin binding to integrins is 
thought to enhance the effect of talin-binding and promote the fully open and 
extended conformation, although this is not the case for kindlin1/2 binding of β1-
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integrin [153,154]. It is also important to note that growth factors, particularly 
VEGF, have been implicated in integrin activation [155]. Interestingly, inside-out 
integrin activation can be inhibited by proteins such as Dok1, ICAP1, and filamin, 
which compete with talin for its integrin binding site, potentially to release talin 
from the integrin cytoplasmic tail to promote outside-in signalling [153,156]. 
 
1.5.1.3 Integrins and focal adhesion complexes 
As the main intermediaries between the ECM and the intracellular actin 
cytoskeleton, integrins are essential for the transduction of biochemical and 
biophysical signals in the external environment to actin-myosin-mediated force 
generation [145]. This profoundly affects cell migration, which is governed by 
tightly regulated adhesions forming to cause actin-directed leading edge 
protrusion, and releasing to allow cell contraction at the rear [156]. Integrins 
indirectly link with, and polymerise, actin at adhesion sites through the recruited 
and clustered scaffolding and adapter proteins that make up focal adhesion (FA) 
complexes. FA complexes are dynamic; they constantly assemble and 
disassemble (turn over) in response to their external environment, at a rate that 
dictates the dynamics of cell adhesion and migration [157]. Several hundred FA 
proteins can be additively recruited at integrin-ECM adhesion sites, all of which 
are collectively referred to as the integrin ‘adhesome’ [158]. Some examples 
include those that directly bind both integrins and actin (actin-binding proteins, 
ABPs), such as talin, filamin, tensin, and α-actinin, and those that indirectly link 
integrins to actin, such as vinculin and Integrin Linked Kinase (ILK) [159]. In these 
cases, vinculin is an ABP that links to integrins via talin or paxillin, and ILK is an 
integrin-binding protein that links to actin via PINCH and parvin [156,159].  
 
FA complexes do not just regulate physical properties of cells and tissues by 
building and severing this mechanical integrin-actin linkage; they also coordinate 
different cellular responses through signalling, including acto-myosin-mediated 
force generation required for migration, as many of the constituent proteins are 
kinases or other signalling molecules [160]. Some signalling pathways in the 
context of FA complexes will be discussed below, but the complexity of the 
integrin adhesome will be discussed in more detail later. 
 
Figure 1.9: Integrin inside-out activation. Schematic of an example integrin (αxβ2) in its bent and 
upright conformations. Activation begins when the non-covalently associated cytoplasmic tails and 
transmembrane helices of the α and β subunits are unclasped and separated. Subsequently, the 
extracellular head of the integrin, which is typically bent towards the cell membrane in a closed 
conformation, is moved away from the membrane in a ‘switchblade motion’ through a conformational 
change in the extracellular domains that causes the two ‘legs’ to elongate. This ‘intermediate’ state 
can be opened further to permit access to larger ligands by swinging out the headpiece. These 
transient conformational states are in equilibrium, dynamically changing in response to the 
environment. Figure adapted from [152].
β-propeller
51
52 
1.5.1.4 Integrin ‘outside-in’ signalling 
As those activated integrins with an open conformation and high affinity for their 
ligands engage in ECM binding, they become stabilised and clustered to promote 
the high avidity state for more binding, but also increase outside-in signalling 
potential [153]. Clustered integrins recruit FA proteins to their cytoplasmic tails to 
form nascent adhesions, which may either disassemble or mature into more 
stable FAs [153]. Many of the different FA proteins are able to function in various 
signalling pathways that influence processes including cell migration, 
proliferation, differentiation, and survival [153], but for the purpose of this thesis 
we will concentrate on some of the roles of just a few. 
 
A major signalling protein in FA complexes is the non-receptor tyrosine kinase, 
FAK, which is recruited to integrins early in outside-in signalling. It is activated 
after binding integrins directly, or via talin or paxillin, through autophosphorylation 
of its Y397 [159]. This creates a binding site for the SH2 domain of SRC, another 
non-receptor tyrosine kinase, which further phosphorylates and activates this 
SRC-FAK complex [159,161]. The activated SRC-FAK complex can potentiate 
lots of signalling pathways, but of particular interest is its role in activating the 
Rho family GTPases Rac1 and Cdc42 by modulating the balance of activity of 
particular GTPase activating proteins (GAPs) and guanine nucleotide exchange 
factors (GEFs) [156]. Active Rac1 is involved in promoting the protrusion of 
lamellipodia, which are actin projections at the leading edge of cells, whilst active 
Cdc42 is more involved in the extension of filopodia, the ‘microspike’ actin 
projections that extend beyond lamellipodia [153]. Rac1 and Cdc42 work through 
activating the Arp2/3 complex via different effector proteins (including N-WASP 
and WAVE1, respectively), causing it to nucleate and polymerise actin in the 
lamellipodia and filopodia [162]. They are therefore major drivers of cell 
spreading and migration. As well as the SRC-FAK complex, a number of other 
FA signalling proteins, including paxillin and p130 CRK-associated substrate 
(p130Cas), can also ultimately affect Rac1- and Cdc42-regulated actin 
remodelling [153,156,159]. It is also worth noting that SRC, and other SRC-family 
kinases, can additionally directly bind the cytoplasmic tail of integrins via its SH3 
domain to activate downstream signalling molecules [156,161]. The other most 
common Rho family GTPase, RhoA, is actually suppressed by Rac and SRC-
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FAK in leading edge protrusions, but is activated elsewhere by other means, 
whilst Rac1 is inhibited, to promote FA assembly and the formation of contractile 
acto-myosin fibres (stress fibres), which are more associated with contracting the 
rear of the cell during migration [153,162]. Clearly, this antagonistic relationship 
between the Rho family GTPases highlights the need for their proper 
spatiotemporal regulation by integrin outside-in signalling in order to effectively 
coordinate migration [153]. For a recent more detailed review on their relationship 
in this context, see [163]. See Figure 1.10. 
 
Many of the above integrin-regulated FA signalling proteins can feed into other 
signalling pathways that influence other cellular processes. Of noteworthy 
mention is their synergistic effect with growth factor receptors. For example, FAK, 
SRC and other adapters like SHC and GRB2 are involved in enhancing growth 
factor receptor signalling cascades such as the MAPK or PI3K-Akt pathways 
[143,161]. Integrins have also been reported to directly interact with, and 
reciprocally cross-activate, growth factor receptors [138]. A major example of this 
is the interaction between αvβ3-integrin and VEGFR2, which will be discussed in 
more detail later. The indirect and direct cross-talk between integrins and growth 
factor receptors in different cells of the tumour microenvironment is hugely 
important for the enhanced signalling that contributes to tumour progression 
[139]. 
 
1.5.1.5 Integrin trafficking 
It is important to note that integrin function is dependent on its levels on the cell 
surface available for ligand binding, which is determined by the degree of its 
expression and trafficking. Indeed, proteomics data have revealed that there are 
many proteins associated with receptor trafficking mechanisms present in the 
integrin adhesome, indicating the importance of trafficking to adhesion function 
[164]. The different processes involved in trafficking: integrin endocytosis, sorting, 
recycling, and degradation, must therefore be carefully regulated to optimise 
integrin signalling and function. Otherwise, disrupted integrin trafficking may 
contribute to cancer progression. The molecular detail of integrin trafficking goes 
beyond the scope of this thesis, but for a recent review, see [165]. 
 
Figure 1.10: Integrin outside-in signalling. Activated and ligated integrins are able to recruit focal 
adhesion proteins that function in different signalling pathways. For example, a SRC-FAK complex 
can be recruited and activated at the integrin cytoplasmic tail, which potentiates signalling through 
Rac and Cdc42. Rac and Cdc42 in turn activate the Arp2/3 complex via different effector proteins, 
causing it to nucleate and polymerise actin, and therefore promote cell migration. FAK, SRC and 
other adapters like SHC and GRB2 are also involved in enhancing growth factor receptor signalling 
cascades, such as the RAS-RAF-MEK-ERK pathway. Figure adapted from [137].
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1.5.1.6 Integrins in angiogenesis 
The importance of certain integrins in angiogenesis can be highlighted by their 
differential expression in angiogenic and quiescent vessels, and their functional 
significance in various angiogenesis in vitro and in vivo models [166]. Integrins 
regulate angiogenesis through their expression in multiple contributing cell types, 
including ECs, pericytes, BMDCs, and fibroblasts. Those implicated in 
angiogenesis (with their canonical ligands in brackets) include: α1β1 and α2β1 
(collagen), α4β1 and α5β1 (fibronectin), α6β1 and α6β4 (laminin), α9β1 
(osteopontin), αvβ3 and αvβ5 (vitronectin), all of which are expressed by ECs, 
and αvβ8, which is expressed by glial cells in the brain [24,137,167]. With the 
exception of α6β4, this divides angiogenic integrins into two categories: αv-
integrins and β1-integrins. As well as angiogenic sprouting being controlled by 
endothelial integrins dynamically adhering to the ECM, it is also affected by other 
integrin-dependent mechanisms. Very briefly, integrins can additionally regulate 
the expression and activity of different pro- and anti-angiogenic growth factors, 
receptors, cytokines, and proteases, affecting processes such as cell migration, 
proliferation, cell-cell interactions, and ECM remodelling [166]. Their ability to 
influence so many angiogenic factors has led to the suggestion that they act as 
‘hubs’ that coordinate a variety of signalling pathways [166]. Once newly formed 
blood vessels have invaded their microenvironment, integrins also play a role in 
their maturation through regulating interactions between ECs, pericytes and the 
BM [24]. Furthermore, especially in tumour angiogenesis, integrins promote the 
adhesion of infiltrating BMDCs to the ECs [24]. 
 
1.5.1.6 αvβ3-integrin 
αvβ3-integrin (αvβ3) is an RGD motif-recognising integrin that can bind a whole 
range of ECM ligands including fibronectin, fibrinogen, fibrillin, tenascin, 
osteopontin, vWF, and thrombospondin, but its major ECM ligand is vitronectin 
[137,140,146]. Important for research involving αvβ3, the β3 subunit can only pair 
with αv and αIIb, the latter of which is not expressed in ECs, meaning the αvβ3 
heterodimer alone is influenced by manipulations in β3 in ECs [141]. This 
contrasts with the αv subunit, which can pair with both β3 and β5 in ECs, and β1, 
β6, and β8 elsewhere [141]. 
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αvβ3 has probably received the most attention of the endothelial integrins in the 
angiogenesis field, ever since it was found to be upregulated in ECs in 
neoangiogenic vessels, yet expressed at low levels in quiescent vasculature 
[168]. Indeed, it is found widely expressed on blood vessels of human tumour 
biopsies, but not on vessels in normal tissues [137]. This finding alone not only 
highlighted αvβ3’s importance in angiogenesis, but also hinted at its potential as 
a more specific anti-angiogenic target than the more ubiquitous VEGF pathway. 
Indeed, early studies demonstrated the effectiveness of the LM609 function-
blocking monoclonal antibody against αvβ3, and the RGDfV (EMD66203) cyclic 
peptide antagonist of both αvβ3 and αvβ5, in inhibiting neovascularisation in 
different in vivo models, including tumour angiogenesis in a human breast cancer 
model [168-172]. These promising findings led to the development of another 
antagonistic RGD-mimetic cyclic peptide of αvβ3 and αvβ5, EMD121974, which 
also suppressed angiogenesis in vitro [173,174] and in vivo [175,176], and 
entered clinical trials as an anti-angiogenic drug under the commercial name of 
cilengitide [177]. Whilst cilengitide was well tolerated in patients and produced 
some anti-tumour efficacy, unfortunately in 2013 it failed its Phase III clinical trial 
when used in combination with standard chemo/radio-therapy for the treatment of 
the highly vascularised and aggressive brain cancer, glioblastoma multiforme, 
having failed to improve overall patient survival [178,179]. This, along with 
various pre-clinical data highlighted below suggested that αvβ3 may have both 
pro-and anti-angiogenic roles depending on its context, and its inhibition may 
induce counteracting mechanisms of resistance [180]. 
 
1.5.1.6.1 αvβ3-integrin as a pro-angiogenic molecule 
The early antagonistic studies described above certainly implicate αvβ3 as a pro-
angiogenic factor, their successes attributed in part to an increase in EC 
apoptosis following the unligation of αvβ3 and αvβ5 to vitronectin [181-184]. Also, 
aside from the well-documented roles of integrins in regulating different 
processes that contribute to angiogenesis, αvβ3 can be singled out in particular 
as a positive regulator of the main angiogenesis receptor, VEGFR2 [185-191]. 
Specifically, Soldi et al. [189] discovered that in HUVECs when αvβ3 is bound to 
vitronectin, and in the presence of VEGF, it can co-immunoprecipitate with, and 
cross-activate VEGFR2, enhancing phosphorylation of its intracellular tyrosine 
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residues to increase signalling through PI3K and promote EC migration and 
proliferation. Masson-Gadais et al. [188] confirmed these results, additionally 
finding elevated downstream activation of p38MAPK and FAK in response to 
αvβ3 cross-talk with VEGFR2, but specifically when αvβ3 was clustered and 
activated, which was not required in Soldi et al.’s study. Interestingly, Byzova et 
al. [155] additionally found a reverse scenario, where VEGF-stimulation activated 
αvβ3 via VEGFR2 and its PI3K activity. This prompted Byzova’s laboratory to 
make use of knock-in ‘DiYF’ mice which expressed β3-integrin containing 
mutations in its Y747 and Y459 cytoplasmic tail residues, located in the integrin-
activating motifs NPxY and NxxY, respectively [186]. Despite having normal 
embryogenesis and adult vasculature, these DiYF mice had significantly impaired 
tumour growth and angiogenesis in both prostate and melanoma subcutaneous 
cancer models. Furthermore, the defective β3 tyrosine phosphorylation in DiYF 
ECs resulted in the loss of VEGF-dependent β3-VEGFR2 interactions on 
vitronectin, and a significant reduction in both VEGFR2 phosphorylation and β3 
activation, as well as decreased EC adhesion and migration [186]. In a 
subsequent study, the same laboratory identified that the VEGF-induced β3-
VEGFR2 cross-talk was mediated by Src, which is activated downstream of 
VEGFR2 to cause β3 tyrosine phosphorylation, promoting a high avidity state, 
and β3-VEGFR2 complex formation, which in turn enhances VEGFR2 
phosphorylation [187]. Moreover, they more recently found that the interaction 
between β3 and VEGFR2 is a direct one between their cytoplasmic tails, which is 
enhanced by β3 Y747 phosphorylation [191]. Gong et al. [192] have since shown 
the importance of Sprouty4 in regulating β3-VEGFR2 cross-activation, finding its 
overexpression to inhibit Src’s phosphorylation of β3. Furthermore, a recent study 
by Ravelli et al. [193] implicated gremlin, a bone morphogenic protein antagonist, 
as a novel non-canonical ligand for VEGFR2, finding it stimulated the formation of 
VEGFR2-αvβ3 complexes to promote an angiogenic phenotype. These studies 
suggest that there is a reciprocal, and synergistic, relationship between β3 and 
VEGFR2, which is pro-angiogenic in vitro and in the context of a tumour (Figure 
1.11). Indeed, the combination of cilengitide and a VEGFR2 antagonist in a pre-
clinical cancer model inhibited tumour angiogenesis and progression significantly 
more than either antagonist alone [194]. This has led to the development of a 
dual-specific inhibitor that simultaneously binds αvβ3 and VEGFR2 and inhibits 
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angiogenesis in vitro and in vivo to a greater degree than mono-specific 
inhibitors, although it has not entered clinical trials [195]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: αvβ3-integrin cross-talk with VEGFR2. When endothelial β3-integrin is engaged with 
vitronectin in the presence of VEGF, VEGFR-2 and αvβ3 cross-activate each other by means of 
tyrosine (Y) phosphorylation, enhancing pro-angiogenic intracellular signalling cascades. Diagram 
adapted from [190].
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1.5.1.6.2 αvβ3-integrin as an anti-angiogenic molecule 
In contrast to these studies implicating αvβ3 as a pro-angiogenic factor, global β3 
knock-out (β3-NULL) mice, although not displaying obvious developmental 
vascular defects [196], had significantly enhanced tumour growth and 
angiogenesis compared to wild-type (WT) littermates following subcutaneous 
injection of melanoma and lung carcinoma cells [197]. Interestingly, the β3-NULL 
ECs overexpressed VEGFR2, and in a follow-up study by Hodivala-Dilke’s 
laboratory [134], the increased tumour growth and angiogenesis in the β3-NULL 
mice, as well as enhanced EC migration and proliferation, were deemed 
dependent on elevated VEGFR2 signalling. Similarly, in a separate study they 
showed an increase in VEGF-dependent blood vessel permeability, another facet 
of angiogenesis, in β3-NULL mice, which was also reversible by VEGFR2 
inhibition [198]. The same laboratory later additionally implicated Rac1 in a 
potential compensatory pathway, as its induced endothelial depletion was only 
effective in inhibiting tumour growth and angiogenesis in β3-NULL mice [199]. 
Together, all this work implies that the global and constitutive loss of β3 
enhanced angiogenesis through a developmental compensatory mechanism 
involving elevated VEGFR2 signalling and possibly an increased dependence on 
Rac1. Adding further complexity, however, the group later discovered that low 
doses (ie. nanomolar concentrations) of cilengitide also stimulated tumour growth 
and angiogenesis in a VEGFR2-dependent manner, and specifically promoted 
Rab4a-mediated VEGFR2 recycling and increased αvβ3’s presence in peripheral 
FAs in ECs [200]. Furthermore, Alghisi et al. [201] found that cilengitide actually 
induced αvβ3 activation in HUVECs adhered to β1 ligands. This therefore 
showed that angiogenic compensation was not restricted to constitutive genetic 
β3 ablation, but also dependent on the dose of αvβ3 antagonist and its effects on 
non-canonical ligands. A further potential mechanism of compensation was 
observed by Robinson et al. [202], who showed that, in β3-NULL ECs, the VEGF 
co-receptor, NRP1, increased its expression and association with VEGFR2 to 
enhance signalling through ERK1/2. The inhibition of NRP1 when β3 was present 
at normal levels had a minimal effect on angiogenesis, but in the β3-NULL model, 
and when β3 was targeted by cilengitide, NRP1 inhibition became effective at 
reducing ex vivo VEGF-mediated aortic ring microvessel sprouting, and/or EC 
migration, and VEGFR2-mediated signalling [202]. Furthermore, the authors 
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reported co-immunoprecipitation between αvβ3 and NRP1, suggesting a 
mechanism whereby αvβ3 normally sequesters NRP1 away from VEGFR2 to 
prevent its enhancement of pro-angiogenic signalling [202]. A mutant form of β3 
lacking part of its cytoplasmic tail (β3Δ722), though still able to dimerise and 
engage ligands, hindered the interaction between β3 and NRP1, but increased 
NRP1-VEGFR2 associations, promoting the potential importance of β3’s 
cytoplasmic tail in this regulatory mechanism. The study therefore showed that 
angiogenesis in constitutive β3-NULL, constitutive β3-EC-NULL and cilengitide-
treated models were dependent on NRP1 and its interactions with VEGFR2. 
However, a more detailed analysis of β3-NRP1 interplay is required to find out 
how β3 regulates NRP1; something that this thesis attempts to address.  
 
Overall, one can conclude from the findings outlaid so far that it appears αvβ3 
plays pro- and anti-angiogenic roles depending on its context [180]. The 
constitutive global removal of β3 enhances angiogenesis, suggesting an anti-
angiogenic role, but is probably due to developmental compensation involving, at 
the least, VEGFR2, NRP1, and Rac1. Global removal of β3 complicates matters, 
as we are unable to determine whether β3 removal in different contributing cell 
types (e.g. pericytes, BMDCs, platelets, tumour cells) differentially affects 
angiogenesis [180]. Furthermore, we are not able to dissect out the specific 
contribution of the αIIbβ3 heterodimer, highly expressed by platelets, in 
angiogenesis, which, like αvβ3, would also be affected by β3 removal in a global 
knockout model [180]. In more clinically relevant models exploring the effect of 
αvβ3 antagonists on angiogenesis, further dichotomy in αvβ3’s angiogenic role 
has arisen. Whilst cilengitide inhibited angiogenesis in some pre-clinical models 
[173-176,202], its use at low doses produced the opposite effect, which was 
dependent on VEGFR2 activity [200]. The dose of inhibitor therefore also has 
some bearing on αvβ3’s angiogenic role. αvβ3’s cross-activation of VEGFR2 
positively regulates angiogenesis, an effect that is reversed in the DiYF model 
containing globally mutated integrin-activating tyrosine phosphorylation sites on 
β3’s cytoplasmic tail, and by phosphorylated peptides that mimic the same site 
[186,191]. The DiYF model therefore contrasts with the β3-NULL model in 
angiogenic outcome and its lack of compensation through VEGFR2 
overexpression, maybe because the integrin is still present and can still function 
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to some degree [202,203]. However, there is no evidence for this, except for the 
fact that the DiYF mutants do not display severe platelet defects and extended 
bleeding times like the β3-NULL mice [196,203]. The difference between the two 
models could also be partly related to cell survival; cells with unligated αvβ3 can 
undergo apoptosis through anoikis or IMD, which may contribute to the reduction 
in angiogenesis in DiYF mice, but, paradoxically, a reduction in β3 expression 
can decrease apoptosis, and so increased cell survival may play a part in the β3-
NULL phenotype [144,203,204]. The potential mechanisms of resistance 
observed in the β3-NULL model involving NRP1 and VEGFR2 suggest that β3’s 
interactions with other molecules might be influential in governing angiogenic 
outcome (ie. β3-VEGFR2 interactions seem pro-angiogenic, whilst β3-NRP1 
interactions appear anti-angiogenic) [180]. It therefore may be important to further 
explore the significance of β3 interactions with conventionally pro- or anti-
angiogenic molecules. Indeed, it has already been reported that the anti-
angiogenic activity of tumstatin, a proteolytic fragment of collagen IV in the ECM, 
in tumour growth is dependent on interactions with αvβ3 [205], which may be a 
factor in promoting the anti-angiogenic DiYF phenotype [203]. A potential 
compensatory pathway through the increased angiogenic function of other 
integrins must also be carefully studied as a mechanism of resistance in 
response to different forms of β3 targeting [203]. 
 
1.5.1.6.3 Cell-specific functions of αvβ3-integrin 
Given that the context of αvβ3 targeting seems so important, and due to the 
emergence of research on more specific drug targeting methods (e.g. the use of 
nanoparticles as delivery vehicles [206]), more emphasis has been placed on 
dissecting out the cell-specific contributions of αvβ3 to angiogenesis. Taverna et 
al. [207], for example, discovered that transplanting WT bone marrow into β3-
NULL mice restored normal tumour growth and angiogenesis, promoting the 
importance of BMDCs in the β3-NULL phenotype [180]. Through transplanting 
β3-NULL bone marrow into β3-WT mice, it was later discovered that the lack of 
β3 in bone marrow may lead to enhanced angiogenesis through a greater degree 
of EPC mobilisation from the bone marrow, although most of the new vessels 
were non-functional [208]. Feng et al. [209] also demonstrated the significance of 
β3 expression by BMDCs in angiogenesis, finding WT bone marrow to rescue the 
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defective angiogenesis displayed by DiYF mice. Here, suppressed angiogenesis 
in the DiYF mice correlated with impaired CXCR4+ myeloid BMDC recruitment 
and retention at angiogenic sites via their improper adhesion and transmigration, 
rather than a change in release from the bone marrow  [209]. This therefore, 
again, highlights the polarisation of αvβ3 angiogenicity in different contexts. More 
careful analysis of specific types of BMDCs is required to interpret these results 
properly, although Feng et al. did rule out a significant contribution of platelets to 
the DiYF phenotype [209]. In this regard, tissue-specific genetic targeting of β3 
using the Cre-Lox system has progressed our understanding of myeloid and 
platelet expression of β3 [210]. Specifically, Morgan et al. [210] found that the 
depletion of β3 in platelets, despite disrupting hemostasis, had no effect on 
tumour growth, whereas a deficiency of β3 in myeloid cells enhanced tumour 
growth, although not necessarily due to angiogenesis. The endothelial 
contribution of αvβ3 to tumour growth and angiogenesis was reported by our 
laboratory in a publication released in 2014 (see List of publications) [211]. 
Here, we used β3-floxed mice crossed to two different endothelial-specific Cre 
lines: Tie1-Cre, in which floxed targets are constitutively deleted in Tie1+ cells 
(β3-EC-NULL); and Pdgfb-iCreERT2, in which floxed targets are depleted in 
Pdgfb+ cells in an inducible fashion by the administration of 4-hydroxy-tamoxifen 
(OHT) (β3-EC-inducible depletion (ID)). This enabled us to compare the effects of 
a long-term reduction of β3 in ECs (an EC-specific imitation of the β3-NULL 
model) with an acute endothelial β3 depletion induced at a particular time (a 
genetic mimic of antagonist administration). We found that whilst the constitutive 
loss of β3 in ECs had no effect, an acute depletion successfully reduced tumour 
growth and angiogenesis when induced preventatively, but not in pre-established 
tumours. However, the suppressed responses were only observed for a transient 
period of time before longer-term depletion became ineffective. Our study 
therefore concluded that the timing of targeting, as well as the length of inhibition, 
were further critical factors in determining the effectiveness of targeting β3. 
Importantly, though, long-term endothelial β3 targeting did not result in increased 
tumour growth and angiogenesis, suggesting that enhanced pathological 
angiogenesis in the β3-NULL model is due to the contribution of non-ECs [211]. 
Therefore, due to an initial benefit in targeting β3 that was eventually overcome, it 
appears that there is still scope for the use of β3 as an effective anti-angiogenic 
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target, especially if we specifically target it in ECs, but only if we can prevent the 
acquisition of resistance. In our paper, we found that long-term targeting 
correlated with increased VEGFR2 surface levels, decreased expression of β5, 
reduced levels of FAK, and a misbalance in FAK phosphorylation, the latter two 
of which have been implicated in enhanced tumour growth and angiogenesis 
recently [212]. However, more work is required to properly decipher common 
mechanisms of escape to genetic and pharmacological long-term endothelial β3 
targeting [213,214]. 
 
It is imperative not to forget the role of αvβ3 in tumours when considering 
targeting it in anti-angiogenic cancer therapy. Indeed, there is evidence to 
suggest that it may function differently in different tumours. For example, although 
it is upregulated in the vasculature of most tumours, in angiosarcomas endothelial 
β3 expression decreases during malignant transformation [180]. Moreover, there 
are conflicting reports over the contribution of β3, as expressed by tumour cells, 
to tumour growth and angiogenesis. For example, Lorger et al. [215] found that 
αvβ3 activation in tumour cells enhanced tumour angiogenesis and metastasis in 
the brain, whilst Kaur et al. [216], showed that the expression of αvβ3 in ovarian 
cancer cells reduced tumour growth and metastasis. Additionally, De et al. [217] 
discovered that active and clustered αvβ3 on tumour cells promoted the 
production of VEGF via p66 Shc phosphorylation to enhance tumour 
angiogenesis in prostate and breast cancers. This study is particularly relevant to 
the failure of αvβ3 therapies, as the effect was observed even in response to the 
LM609 αvβ3 function-blocking antibody. Furthermore, an adhesion-independent 
role of αvβ3 in tumour progression was discovered by Desgrosellier et al. [147]. 
Here, unligated αvβ3 in IMD-resistant tumour cells increased anchorage-
independent tumour cell survival and metastasis via Src. Thus, the potential 
adverse effects of αvβ3 targeting in different patients and cancer types must be 
properly scrutinised in order to make informed decisions about the correct use of 
antagonists. For comprehensive reviews on αvβ3 and other integrins in tumour 
cells, see [139,143,146]. 
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1.5.1.6.4 Conclusions on αvβ3-integrin 
Careful consideration of the multiple factors that influence αvβ3’s role in 
angiogenesis is essential for us to improve the therapeutic results achieved with 
antagonists. Such improvements may rely on enhancing the specificity of 
antagonists to certain parts of the αvβ3 molecule in particular cell types at the 
optimal time, using the correct dose, and simultaneously targeting other 
compensatory pathways to counter therapy resistance. With regard to the latter, 
which may prove most therapeutically effective, co-targets must be carefully 
chosen based on how significant and common their mode of resistance is in 
different clinically relevant models, how they interplay with αvβ3 and other 
pathways, and whether their targeting produces unwanted adverse effects. This 
thesis will be further exploring the joint roles of αvβ3 and NRP1 to pathological 
angiogenesis, with a view to determining whether NRP1 would present itself as 
one such candidate.  
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1.5.2 Revisiting the integrin adhesome 
Since the recent proteomic profiling of the integrin adhesome in human and 
mouse fibroblasts [218-220], mesenchymal stem cells [221], and chronic 
myelogenous leukemia cells [222,223], we have gained greater insight into its 
cell-, integrin- or ECM-specific molecular complexity, but still have limited 
understanding about its functional significance in different contexts, how it is 
dynamically assembled, disassembled, and regulated, and how its composition 
differs in vivo, and in different cell types and conditions [164]. Moreover, there is 
still some confusion over the specific terms for different focal adhesion 
complexes. Proteins that make up the adhesome have in this thesis hitherto been 
referred to as FA proteins, and their clustered arrangement at integrin adhesion 
sites has been described as a FA complex. However, this is a simplification, as 
the general consensus is that the proteins can be arranged in four classical types 
of adhesion complex: nascent adhesions, focal complexes, focal adhesions and 
fibrillar adhesions, as well as the less conventional podosomes and invadopodia 
(Figure 1.12) [156,224]. These classical types vary in their location, lifespan, and 
composition. Nascent adhesions are the smallest type that form at the 
lamelliopodial side of the cell to promote membrane protrusion; they either rapidly 
disassemble or mature into focal contacts, which have a slightly slower rate of 
turnover [156,157]. Focal contacts in turn can mature into larger, more elongated 
focal adhesions, which have a slower turnover still. FAs can support forward 
movement through their linkage to actin stress fibres that propagate contractile 
force, but can also disassemble at the rear of the cell to aid cell retraction [218]. 
Fibrillar adhesions are long, stable structures found parallel to bundles of 
fibronectin, mainly in fibroblasts [156,157]. To achieve coordinated cell migration, 
there must be a cooperative balance in the workings of these complexes, which 
depends on the specific adhesion conditions. For example, Schiller et al. [220] 
found that cells with restricted expression of either αv- or β1-integrins formed 
distinct adhesion complexes that regulated different mechanical transduction 
events. α5β1-integrins induced the formation of nascent adhesions, activated the 
Rac1/Wave/Arp2/3 pathway at membrane protrusions, and generated 
actomyosin force through the RhoA-ROCK-myosin II pathway, whereas αv-
integrins accumulated in areas of high tension and promoted the formation of 
large FAs that were more involved in mediating the structural reinforcement of 
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actin stress fibres via GEF-H1, the formin mDia, and RhoA [164,220]. Indeed, 
work from Rossier et al. [225] showing that activated β3-integrins are immobilised 
in large FAs, whilst activated β1-integrins are capable of rearward movement, 
may imply a similar distinction in αvβ3 and α5β1 specifically, even though they 
are both fibronectin-binding integrins. On this matter, Roca-Cusachs et al. [226] 
found that α5β1 clusters were important in maintaining the strength of adhesion 
to fibronectin under high forces, whereas αvβ3 had a weaker association with 
fibronectin, but was more involved in the structural reinforcement of linkages to 
the cytoskeleton and enabling mechanotransduction. Regardless, it seems that 
both integrins are required to cooperatively enable cells to adapt cellular 
contractility to the rigidity of the ECM [145]. 
 
The proteomics data for the adhesome from different sources have expanded the 
pre-existing adhesome database, consisting of 232 proteins accumulated by 
microscopy and protein interaction assays, by two- to three-fold [164]. However, 
a large proportion of the additional proteins from each proteomics study are a 
context-specific subset related to the cell type, ECM substrate and integrin 
components, that need to be dissected further [164,227]. This suggests that there 
may be a group of canonical adhesome components, and many more additional 
non-canonical proteins that are more labile [164]. However, it is important to 
emphasise that protein associations within the adhesome are dynamic, or 
‘switchable’, and not necessarily universal [157,228]. Furthermore, much of the 
work on the adhesome has been carried out on cells adhered to 2D surfaces, and 
so is not entirely representative [157]. A major discovery from adhesome 
proteomics studies is that many proteins recruited to maturing integrin adhesions 
do so in a myosin II-dependent manner, and contain LIN-11, Isl1, and MEC- 3 
(LIM) domains (e.g. zyxin and paxillin), which are believed to be important for 
force mechanotransduction in stress fibres [164,218,219]. More recently, 
Robertson et al. [229] proteomically profiled the phospho-adhesome and found a 
number of known and novel phosphorylated proteins that contribute to adhesion 
signalling, including cyclin-dependent kinase 1 (CDK1), whose inhibition reduces 
adhesion complex formation. Interestingly, the activity of CDK1 has been shown 
to be enhanced by increased αvβ3-integrin expression to promote migration, and 
members of the CDK family are known to regulate proteins such as paxillin and 
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filamin-A [229-232]. These proteomics studies, combined with super-resolution 
microscopy and higher resolution mass spectrometry imaging in the future should 
build us a clearer picture of adhesion complex structure and dynamics in different 
cells and adhesion types [164]. 
 
For the sake of clarity, a summary of the mechanotransductive role of integrin-
mediated-cell-ECM adhesions, including examples of canonical adhesome 
proteins, is as follows: integrins activated by talin and kindlins attach to the ECM 
to form adhesions. At the leading edge of a cell, these engaged integrins recruit a 
small number of proteins in a myosin II-independent fashion, including FAK, 
SRC, paxillin, and p130Cas to form nascent adhesions, where signalling is 
generally directed through Rac1 and Cdc42 to promote cell motility via Arp2/3-
mediated actin polymerisation in lamellipodia and filopodia [145,157,159,218]. 
Nascent adhesions keep turning over quickly during membrane protrusion, but 
they may also undergo a tension-dependent maturation into larger focal 
complexes that reside at the interface between the lamellipodia and the lamella, 
and subsequently focal adhesions, which endure longer and are more associated 
with high RhoA activity and the generation of contractile force through their 
stabilised connection to the actin cytoskeleton [145,163]. Adhesion complex 
maturation involves the recruitment of additional proteins such as vinculin, which 
stabilises the link between talin and actin, and the RhoA-mDia-mediated 
elongation of actin, which is bundled by α-actinin, and further complexed with the 
adapter proteins zyxin, tensin, and VASP [218]. The integrin adhesion machinery 
is mechanosensitive to tension generated intracellularly by myosin II activity or by 
external forces (e.g. the rigidity of the ECM) [157]. In response to these forces, 
tension-sensitive FA proteins change conformation to expose binding sites for 
non-tension-sensitive proteins, and thus promote adhesion maturation [218]. 
Tension further amplifies maturation through the activation of FAK and SRC, 
which can phosphorylate paxillin and p130Cas to form binding sites for SH2-
containing proteins [218]. Cells therefore modulate FA composition and signalling 
for a spatially and temporally regulated mechanotransductive response to applied 
forces [145]. A stiff ECM, or high myosin II activity, will promote adhesion 
maturation and therefore the generation of RhoA-ROCK-dependent acto-myosin 
contractile force, but a more compliant ECM will block this to enhance nascent 
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adhesion-mediated membrane protrusion [145,157]. Myosin II and ECM rigidity 
therefore have key roles in coordinating a balance between the protrusive and 
contractile activity of a cell [145]. FA-mediated contractile force reflects back on 
the ECM, pulling on it to alter its structure and organisation, and thus allowing 
cells to continue mechanosensing their environment [145]. Actomyosin 
contractility also contributes to FA disassembly by presenting FAs with 
disassembly factors, and ultimately retracts the cell rear to complete the 
migration cycle [233]. FA disassembly may also be regulated by other factors, 
such as PIP2 levels, but, like FA assembly, is still a poorly understood process 
[234]. 
 
Aside from those mentioned, other ‘core’ canonical FA components that frequent 
proteomics data are believed to include filamin, ILK, LASP, and IQGAP, although 
we still do not know if these components differ in other cell types under different 
conditions [164]. Unsurprisingly, improper functioning of adhesome proteins is 
characteristic of different diseases, particularly cancer, and increasing evidence 
suggests that components of the adhesome may be interesting novel therapeutic 
targets. See [160] for a review. More detailed sub-chapters on some FA 
components relevant to this thesis follow below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12: Classical focal adhesion structures. The general consensus is that proteins of the 
adhesome can be arranged in four classical types of adhesion complex: nascent adhesions, focal 
complexes, focal adhesions and fibrillar adhesions. These structures localise to different areas of the 
cell, and are characterised by their size and rate of turnover, which is determined by the rates of their 
maturation and disassembly. The hierarchy of maturation (green arrows) and disassembly (red 
arrows) are depicted. Figure adapted from [156].
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1.5.2.3 Filamin A 
Filamin A, belonging to the family of filamins, is a multi-domain homodimeric 
protein that cross-links actin, and contributes to its anchorage to the ECM 
[235,236]. Indeed, not just ABPs, filamins can bind a range of other molecules 
including receptors, ion channels, transcription factors, and scaffolding, 
signalling, and adhesion proteins [236]. In response to tension, filamins, like other 
FA proteins, can undergo conformational changes that can change their affinity 
for binding partners and expose binding sites for other components [236]. This 
has led to the speculation that filamins play a role in mechanosensing the 
environment to confer cells with mechanical properties and influence processes 
like cell spreading and migration [236,237]. 
 
In non-muscle cells, filamin A is known to co-localise with filamentous(F)-actin 
along, and at the end of, stress fibres, and can also concentrate at filopodia and 
lamellopodia during cell spreading, and at adhesion sites following force 
application to cells [235,236,238] 
 
As mentioned briefly earlier, filamins compete with talin, and also kindlins, for 
their binding site on integrins, inhibiting their activation [159]. However, migfilin, a 
LIM-domain-containing protein can reverse this effect [159,239]. Filamins 
increase their binding to integrins in response to myosin II-dependent force 
production and external shear, which can expose the integrin binding site in 
filamins, but also cause the release of the filamin A-associated Rho GAP 
(FilGAP), a Rac inactivator [159,240,241]. This is important, for example, for the 
suppression of Rac1 activity at later stages of adhesion, as, here, activated 
FilGAP can inhibit the formation of Rac-dependent lamellipodia [163,242]. 
Interestingly, filamin A can also inhibit Rac at the latter stages of adhesion 
through a pathway involving IQGAP and RacGAP1 [163,243]. Presumably, since 
it takes myosin II-dependent force for filamins to bind integrins, and the 
recruitment of LIM-domain-containing proteins like migfilin is also dependent on 
myosin II, the inhibitory effect of filamins on integrin activation may be offset. 
 
 
 
72 
1.5.2.4 Non-muscle myosin II (NM-II) 
Members of the non-muscle myosin II (NM-II) family are conventional F-actin-
based molecular motors involved in regulating the organisation and force-
generation of the cytoskeleton [244]. Their name is actually a misnomer since 
members are expressed in cardiac, skeletal, and smooth muscle cells, but in 
much smaller amounts than sarcomeric myosins [244]. There are three NM-II 
isoforms in vertebrates: myosin IIA, myosin IIB, and myosin IIC, which consist of 
two copies each of heavy chains, essential light chains, and regulatory light 
chains [245]. Myh9, Myh10, and Myh14 genes encode the heavy chains of 
myosin IIA, IIB, and IIC, respectively, which contain binding sites for both ATP 
and actin in their N-terminal globular domain [245]. Phosphorylation of the 
regulatory light chains by Ca2+-MLCK or Rho-ROCK pathways triggers NM-II 
activation and its higher-order assembly into a bipolar complex, which slides 
between actin filaments of opposing polarity towards their plus-ends via ATP 
hydrolysis to generate tension and contractile forces and cross-link them [244]. 
Myosin IIA and IIB appear to have slightly different, yet overlapping, roles in cell 
migration. Myosin IIA is mainly localised at the front of cells and in protrusions, 
although not at their leading edge, as nascent adhesion formation is NM-II-
independent, whilst myosin IIB is missing from protrusions, but more associated 
with the centre and rear of migrating cells [244]. Loosely, myosin IIA supports FA 
formation and protrusion at the front, and the formation of actomyosin stress 
fibres at the rear. Myosin IIB is more involved in the stabilisation and contraction 
of these stress fibres [244]. These isoforms therefore work in tandem to 
coordinate cell adhesion and directional migration. They are, however, involved in 
many other processes, including vesicular transport, endocytosis, exocytosis, and 
cytokinesis, and can contribute to different diseases when functioning improperly 
[244]. 
 
1.5.2.5 Paxillin 
Paxillin is a multi-domain signalling scaffold protein recruited to integrin 
adhesions early on [246]. It is capable of promoting FA formation through binding 
an array of different scaffolding and signalling proteins via its many modules, 
which includes four LIM domains, in a manner that is regulated by 
phosphorylation of its multiple tyrosine, threonine and serine phosohorylation 
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sites [247,248]. Specifically, phosphorylated tyrosine is known to provide 
additional docking sites for protein binding [248]. Key interactants of paxillin 
include the kinases FAK, Src, and ILK, phosphatases, ABPs like vinculin, and 
GAPs and GEFs of the Rho GTPases [156,246,248]. The diversity in paxillin’s 
interactions likely suggests an ability to dynamically regulate FA turnover and 
migration [246]. Of noteworthy mention is that the phosphorylation of paxillin (Y31 
and Y118) enhances its association with FAK in nascent adhesions, which 
significantly increases FA formation and size, and keeps FA turnover in check 
[249]. Like that of FAK, paxillin’s regulation of Rho GTPases via various GAPs 
and GEFs has also been deemed greatly important for cell motility, having been 
described as a ‘Rac hub’ [248,250]. Also, in addition to its role in FA formation 
and signalling, paxillin has been shown to be important for the disassembly of 
FAs, as paxillin-deficient fibroblasts have significantly impaired FA disassembly 
[251]. 
 
Recently, German et al. [252] discovered that reduced expression of paxillin 
increased the migration of human umbilical vein ECs (HUVECs), and stimulated 
angiogenesis during development and in response to tumour-derived factors in 
vivo. This effect correlated with, and was mimicked by, reduced NRP2 
expression, and overexpression of NRP2 prevented the effect [252]. Interestingly, 
this study contrasts with work by Yang et al. [253], who showed a reduction in 
VEGF-induced HUVEC migration and in vitro tube formation in paxillin-
knockdown cells. However, although Yang et al.’s tube formation assay was 
performed in matrigel, it appears as though their HUVECs were cultured on poly-
L-lysine, which promotes integrin-independent adhesion. This contrasts with 
German et al.’s HUVEC culturing on 1% gelatin, and so might explain these 
dichotomous findings. 
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1.5.3 Neuropilins 
The neuropilins (NRPs), consisting of neuropilin-1 (NRP1) and neuropilin-2 
(NRP2), are single-pass TM glycoproteins that are primarily involved in the 
nervous and cardiovascular systems [27]. Although originally identified as 
adhesion molecules, NRPs also act as receptors for class 3 semaphorins (a 
family of secreted polypeptides with major roles in axon guidance), and for 
members of the VEGF family [69,254]. However, they are more specifically 
referred to as co-receptors as they lack their own catalytic activity but mediate 
signalling responses when complexed with other receptors (ie. plexins in the case 
of semaphorins; VEGF receptors in the case of VEGFs) [27,255,256]. NRP1 and 
NRP2 share a similar domain structure and have an overall amino acid homology 
of 44%, but can generally be divided by their functional significance in different 
processes, as highlighted by mutant mouse studies. These have shown that 
whilst NRP1 is essential for neural and cardiovascular development, NRP2 is 
dispensable for blood vessel patterning, but more associated with neuronal path-
finding and lymphangiogenesis [27,255-259]. NRPs play roles in other 
physiological and pathological processes, and, aside from their regulation of the 
above receptors, are also notable for their influence on cell migration, adhesion, 
and permeability. Importantly, they are highly expressed in different tumours, and 
have been implicated in tumour growth and angiogenesis in vivo [69,133,255]. 
 
1.5.3.1 Structure and isoforms of neuropilins 
NRPs are made up of an N-terminal extracellular domain, a TM domain, and a 
small cytoplasmic tail. Their extracellular domain consists of a1/a2 domains that 
can bind semaphorins, b1/b2 domains that can bind VEGF165, heparin, and 
semaphorins to some extent, and a c domain that mediates oligomerisation 
[27,69,260]. The cytoplasmic tail, consisting of 44 and 43 amino acids for NRP1 
and NRP2, respectively, contains an SEA amino acid motif at its C-terminus (in 
NRP1 and the NRP2a isoform) which recognises the PSD-95/DIg/ZO-1 (PDZ) 
domain of synectin, otherwise known as GAIP-interacting protein (GIPC1) 
(Figure 1.13) [27,69,260,261]. 
 
 
 
Figure 1.13: Neuropilin domain organisation. Neuropilins are made up of an N-terminal 
extracellular domain, a transmembrane (tm) domain, and an intracellular domain. The extracellular 
domain consists of a1/a2 domains that can bind semaphorin-3 (SEMA), b1/b2 domains that are 
involved in adhesion and can bind VEGF-A165 and heparin/heparan sulfate, and a C domain that 
mediates interactions with other receptors. The last three amino acids of the cytoplasmic domain 
(SEA) confer binding to the PDZ domain-containing protein synectin. Figure adapted from [260].
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The NRP1 gene comprises 17 exons that code for the full-length protein of 933 
amino acids. Alternative splicing of the gene results in one membrane-bound 
isoform (Δexon16) that retains normal functionality, and four mRNA isoforms that 
lack the c domain and cytoplasmic tail, and, although only two of these have 
been reported to translate into soluble(s)NRP1 protein isoforms, likely act as 
decoy receptors [69]. There are two major NRP2 membrane-bound forms, 
NRP2a and NRP2b, the latter of which only shares 11% homology in its TM 
domain and cytoplasmic tail with that of the former, and sNRP2 also exists [69]. 
Both NRPs are post-translationally glycosylated at varying degrees depending on 
the cell type. A high-molecular-weight glycosylated species of NRP1 (>250 kDa) 
is known to exist in addition to the normal species in some tumour cell lines, 
vSMCs and ECs [69]. 
 
1.5.3.2 The neuropilin ligands 
Of the semaphorins, Sema3A binds NRP1 with the highest affinity, whilst 
Sema3F is the best-characterised NRP2 ligand [69]. VEGF165 can bind both 
NRPs, and, as discussed previously, has the most signalling potential of the 
VEGFs, possibly due to its ability to promote NRP1-VEGFR2 complex formation 
[68,69]. Whilst the other major VEGF-A isoforms are theoretically capable of 
binding NRP1, VEGF121 cannot promote NRP1-VEGFR2 complex formation, and 
VEGF189 and VEGF206 are sequestered in the ECM [68,69]. VEGF165’s affinity for 
NRP1 is enhanced by the presence of heparin, NRP1 density, and CS-GAG 
glycosylation of NRP1 [69,262]. Other VEGF family members have additionally 
been shown to bind NRP1, including VEGF-B, VEGF-E, and PlGF-2 for NRP1, 
and VEGF-C and VEGF-D for both NRPs [69]. 
 
1.5.3.3 Neuropilin-1 
NRP1 plays an essential role in vascular development, highlighted by the fact 
that NRP1-knockout (NRP1-NULL) mice die in utero with severe vascular 
defects, and NRP1 overexpression, also embryonic lethal, causes the excessive 
growth of leaky, haemorrhagic blood vessels [27,263,264]. Moreover, NRP1 is 
highly expressed in the endothelium of growing blood vessels, and in other cell 
types of the angiogenic microenvironment, such as neural progenitor cells and 
macrophages in the hindbrain [27,265]. Interestingly, early on in endothelial tip 
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cell research, Gerhardt et al. [266] used NRP1-NULL mice to demonstrate that 
NRP1 is required for tip cell guidance in the developing hindbrain. More recently, 
Fantin et al. [265] found, through the use of constitutive and OHT-inducible cell-
specific knockout mice, that while the specific expression of NRP1 in neural 
progenitors and macrophages was redundant for normal embryonic brain 
angiogenesis, endothelial NRP1 was essential, even though its EC depletion was 
inefficient due to inadequate Cre recombination. The impairment in Cre 
recombinase efficiency was actually favourable, though, as it resulted in 
remaining NRP1+ ECs to preferentially adopt the tip cell position, thus suggesting 
that endothelial NRP1 cell autonomously promotes tip cell function [265]. The 
specific role of NRP1’s cytoplasmic tail has also been investigated in blood 
vessel development through the use of mice that lack this portion of the NRP1 
molecule (NRP1Δcyto). Fantin et al. [267] showed that NRP1’s cytoplasmic tail is 
dispensable for developmental angiogenesis, but important for the spatial 
separation of retinal arteries and veins, as the NRP1Δcyto mice displayed 
increased artery-vein crossings. This therefore suggests that NRP1’s membrane-
anchored extracellular domain alone is sufficient for regulating blood vessel 
development [267]. Lanahan et al. [268] additionally reported a redundancy of the 
cytoplasmic tail in pathological angiogenesis using oxygen-induced retinopathy 
and skin wounding mouse models, but instead found it to be required for 
arteriogenesis. More recently, two separate groups discovered that mice 
expressing NRP1 unable to bind VEGF overcame embryonic lethality but had 
defective postnatal angiogenesis, suggesting NRP1’s binding of VEGF is non-
essential for embryonic blood vessel development, but important later on 
[269,270]. 
 
These studies have therefore all shown NRP1 to be important for blood vessel 
formation during development in one form or another. However, the exact 
molecular mechanism of NRP1 action in adult vascular endothelium during 
physiological and pathological angiogenesis is not yet clear. We have seen from 
earlier that Robinson et al. [202] reported no effect on ex vivo microvessel 
sprouting when targeting NRP1 alone, and that pathological angiogenesis in 
Lanahan et al.’s [268] study was independent of NRP1’s cytoplasmic tail, 
therefore suggesting NRP1’s role in these processes is negligible. However, 
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Raimondi et al. [271] recently found that inducible endothelial NRP1 depletion 
inhibited oxygen-induced retinopathy in pups, and Fantin et al. [269] implicated 
the VEGF-binding domain of NRP1 as important for this pathological 
neovascularisation of the retina in pups as well, but also for angiogenesis-
dependent tumour growth, thus putting us into doubt over NRP1’s exact role in 
pathological angiogenesis. Research over the last 10 years or so has broadly 
split NRP1’s endothelial function into two categories; its role in regulating 
VEGFR2 biology, and its VEGFR2-independent role, which is partly related to its 
roots as an adhesion molecule. These categories will be explored further below. 
 
1.5.3.3.1 VEGFR2-dependent roles of neuropilin-1 
NRP1 can form a receptor complex with VEGFR2 upon VEGF165 binding, and 
also reciprocally enhance the affinity of VEGF-A165 for VEGFR2, thereby 
altogether enhancing VEGFR2 phosphorylation and signalling, and promoting EC 
migration [68,256,272-279]. The VEGF-NRP1-VEGFR2 tri-partite complex likely 
forms through VEGF165 bridging between the two receptors, binding VEGFR2’s 
core VEGF homology region via its cysteine knot motif and NRP1’s b domain via 
its C-terminal moiety [69,256]. However, Prahst et al. [280] have reported that the 
VEGFR2-NRP1 association is also dependent on NRP1’s cytoplasmic tail, 
suggesting that intracellular interactions may also be important [69]. In HUVECs, 
NRP1 enhances VEGF-mediated VEGFR2 Y1175 phosphorylation, as shown by 
a significant reduction in phosphorylation following NRP1 siRNA-mediated 
knockdown in two separate studies, although ERK1/2 phosphorylation was 
unaffected [272,273]. However, a NRP1-directed antibody, which specifically 
inhibits VEGF binding to NRP1, the expression of a NRP1 Y297A mutant 
deficient in VEGF binding, and the expression of a mutant NRP1 lacking its 
cytoplasmic tail (NRP1Δcyto), all had no such effect on VEGFR2 
phosphorylation, suggesting that the NRP1-VEGFR2 interaction and the role of 
the NRP1 cytoplasmic tail does not directly affect VEGFR2 activation in HUVECs 
[133,272,273]. Both NRP1 knockdown and the expression of NRP1Δcyto did 
abrogate p130Cas phosphorylation and endothelial migration, however, 
suggesting a VEGF-dependent role for NRP1 in regulating migration via FA 
function [272]. This involvement of NRP1 in the phosphorylation of p130Cas was 
mediated by Pyk2 phosphorylation, but was independent from the 
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phosphorylation of FAK at its major phosphorylation site, Y397 [69,272]. Instead, 
NRP1 knockdown and the expression of the NRP1 Y297A mutant suppressed the 
VEGF-induced phosphorylation of FAK at Y407, which is also known to be 
regulated by Pyk2 [69,273,281]. This suggests that NRP1 potentially mediates 
signalling through a Pyk2/FAK407/p130Cas pathway, although how much this 
depends on VEGFR2 activation is unclear [256]. The VEGF165-induced 
association of NRP1 with VEGFR2 has additionally been implicated in activating 
p38MAPK, another known positive regulator of migration [133,275]. NRP1’s 
effect on EC migration is striking, as targeting NRP1 in different ways has 
consistently reduced EC migration to a high degree in a number of different 
studies, but, interestingly, VEGF-induced HUVEC proliferation and survival, as 
regulated through the PLCγ/ERK and Akt signalling cascades, appear to be 
largely independent of NRP1 and its association with VEGFR2 in these cells 
[69,133,272-275,282]. However, more recently, Raimondi et al. [271] reported 
reduced VEGF-induced phosphorylation of PLCγ/ERK and Akt in human dermal 
microvascular ECs (HDMECs) upon NRP1 siRNA knockdown, indicating a 
discrepancy between EC types. Furthermore, arterial ECs and heart tissue from 
NRP1Δcyto mice were shown to exhibit dampened phosphorylation of VEGFR 
Y1175 and ERK1/2 in response to VEGF, though this is more congruent with 
NRP1’s role in arteriogenesis, as mentioned above, which appears to require a 
greater degree of ERK1/2 signalling [268]. Overall, consistent results in HUVECs 
show that NRP1 regulates VEGF-induced EC migration and signalling through 
p38MAPK, p130Cas, and FAK407 in a manner that is dependent on its 
interaction with VEGF and VEGFR2, and its cytoplasmic tail, but not necessarily 
on VEGFR2 activation (Figure 1.14A). It is also worth mentioning that NRP1 has 
additionally been implicated in VEGF/VEGFR-2-mediated endothelial 
permeability [283]. 
 
There is now mounting evidence to suggest that a major role for NRP1 is to 
mediate the endocytosis and trafficking of VEGFR2, and therefore regulate its 
signalling in this way. In primary murine aortic ECs, Salikhova et al. [284] showed 
that VEGF165 induced the clathrin-mediated endocytosis of NRP1 and VEGFR2 
together, and that NRP1 trafficking to EEA1+ early endosomes was dependent 
on the presence of its cytoplasmic binding partner, synectin, which is known to 
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drive receptor internalisation via the molecular motor, myosin VI [285]. Lanahan 
et al. [82] subsequently found that synectin and myosin VI were also required for 
VEGF-induced VEGFR2 trafficking to EEA1+ early endosomes in these cells. 
Without the synectin-myosin VI complex, VEGFR2 Y1175 phosphorylation and 
downstream signalling through ERK1/2 and Akt was impaired due to delayed 
VEGFR2 trafficking away from the phosphatase PTP1b at the plasma membrane, 
but was, interestingly, here, not related to associations with NRP1 [82]. The 
synectin-myosin VI-dependent trafficking of VEGFR2 was additionally shown to 
be important for arterial morphogenesis [82]. Ballmer-hofer et al. [80] then, 
through the use of overexpressed VEGFR2, NRP1 and fluorescently-tagged-Rab 
proteins in porcine aortic ECs (PAEs), which lack endogenous VEGFR 
expression, found that VEGF165 stimulated NRP1-VEGFR2 complexes to recycle 
to the plasma membrane through Rab5, Rab4, and Rab11 vesicles. However, 
without the NRP1-VEGFR2 association, VEGFR2 was shuttled down a 
degradation pathway through Rab7 vesicles, and without NRP1’s C-terminal 
synectin-binding motif (SEA), VEGFR2 no longer trafficked through Rab11 
vesicles and was degraded faster [80]. The presence of NRP1 resulted in 
elevated phosphorylation of VEGFR2 Y1175, PLCγ, and p38MAPK. PLCγ and 
p38MAPK phosphorylation was impaired by loss of NRP1’s cytoplasmic tail, and 
full p38MAPK phosphorylation was even dependent on NRP1’s SEA synectin-
binding motif [80]. Consistent with these results, the defective arteriogenesis and 
VEGFR2/ERK phosphorylation observed previously in NRP1Δcyto mice in 
Lanahan et al. [268]’s study was ascribed to the lack of a link between NRP1-
VEGFR2 and synectin that resulted in delayed VEGFR2 trafficking from Rab5 to 
EAA1+ endosomes and therefore prolonged exposure to PTP1b. Interestingly, a 
recent study by Koch et al. [286] showed that if NRP1 is presented to VEGFR2 in 
trans (ie. from one EC to another), then VEGFR2 endocytosis was arrested, and 
its signalling via ERK was delayed, compared to NRP1 expressed on the same 
cell. 
Together, this work therefore points to a role for NRP1 in enhancing VEGF-
induced VEGFR2 endocytosis and recycling, and thus signalling, via its 
cytoplasmic tail’s interaction with the PDZ domain of synectin (Figure 1.14B). 
Indeed, we know from earlier that VEGFR2 can continue signalling from 
endocytic vesicles, which enhances signalling responses [80-86,91]. However, 
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since these studies were carried out in aortic/arterial ECs, which did not 
necessarily endogenously express NRP1 and VEGFR2, it is not clear how 
physiologically relevant these results are, and whether they translate to HUVECs 
or microvascular ECs. Given Fantin et al.’s [267] and Lanahan et al.’s [268] in 
vivo results with NRP1Δcyto mice, it has been proposed that NRP1-mediated 
VEGFR2 trafficking, and therefore high levels of ERK1/2 signalling, are only 
required for arteriogenesis, and not for angiogenesis [287]. Exactly how NRP1 
influences VEGF-induced signalling overall is still unclear, especially as there 
appears to be differences between that in HUVECs, microvascular ECs and 
aortic/arterial ECs that may also be related to angiogenic vs arteriogenic effects 
[268]. We also do not know the exact function of NRP1’s cytoplasmic tail in either 
angiogenic or arteriogenic contexts. Can it directly or indirectly activate VEGFR2? 
Does it universally regulate VEGFR2 signalling by promoting its trafficking? Does 
it have additional binding partners other than synectin? And how does its 
VEGFR2-dependent role integrate with its other functions? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14: Neuropilin-1’s VEGFR2-dependent roles. Neuropilin-1 (NRP1) can form a receptor 
complex with VEGFR2 upon VEGF-A165 binding, and also reciprocally enhance the affinity of 
VEGF-A165 for VEGFR2. A As a result, NRP1 can regulate VEGF-induced EC migration and 
signalling through p38MAPK, p130Cas, and FAK407. B Also, when in this complex, NRP1 can 
enhance VEGF-induced VEGFR2 endocytosis and recycling through Rab11-positive vesicles, and 
thus enhance ERK1/2 signalling, via its cytoplasmic tail’s interaction with the PDZ domain of 
synectin. Figure adapted from [276].
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1.5.3.3.2 VEGFR2-independent roles of neuropilin-1 
Fantin et al. [269] recently investigated the significance of VEGF binding to NRP1 
for angiogenesis in vivo using mice with a Y297 mutation in the VEGF-binding 
pocket of NRP1’s b1 domain. Though this resulted in NRP1 hypomorphism, and 
therefore reduced NRP1 expression, NRP1-VEGF binding was successfully 
perturbed, and, importantly, the NRP1 Y297 mice were able to overcome the mid-
gestation lethality of NRP1-NULL mice [269]. More recently, a different NRP1 
VEGF-binding-deficient mutant mouse line that expressed normal levels of NRP1 
also survived, and with normal vasculature, therefore meaning NRP1 does not 
appear to influence embryonic blood vessel formation through binding VEGF 
[270]. The mice did, however, display defects in postnatal angiogenesis in the 
retina [270].  In further support of a VEGF-independent role for NRP1 in 
embryonic blood vessel formation, the vascular phenotype in mutant mice that 
only express their equivalent of the non-NRP1-VEGFR2 complex-inducing VEGF, 
VEGF121, was also less severe than NRP1-NULL mice, although this phenotype 
was more attributed to differential VEGF-ECM binding ability than the loss of 
NRP1 binding [27,66]. Regardless, these studies prove that NRP1 can function 
independently of its binding to VEGF to regulate embryonic blood vessel 
formation in vivo, though NRP1-VEGF binding is more required for postnatal 
angiogenesis. 
 
The original discovery of NRP1 as an adhesion receptor is suggestive of its 
VEGF-independent endothelial role partly being related to adhesion [254]. 
Indeed, siRNA knockdown of NRP1, but not of VEGFR2, impaired HUVEC 
adhesion to gelatin, fibronectin and laminin, suggesting NRP1 regulates EC 
attachment in a VEGFR2-independent manner [282]. Consistent with this 
hypothesis to some degree, Valdembri et al. [288] showed that NRP1 promoted 
human umbilical artery EC (HUAEC) adhesion to fibronectin, although not type I 
collagen, vitronectin or laminin, in a manner that was dependent on NRP1’s SEA 
synectin-binding motif, and the fibronectin-binding integrin, α5β1, and was, 
importantly, independent of VEGF [288]. The authors specifically found that this 
function of NRP1 was mediated through its interaction with α5β1 via its 
extracellular domain at adhesion sites, and its promotion of α5β1 trafficking via 
synectin (which can interact with both NRP1 and α5β1) and subsequent recycling 
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to the membrane [288]. This could have profound implications for angiogenesis, 
particularly given NRP1’s significance in tip cells, and the importance of a fast 
turnover of α5β1-positive nascent FAs for EC migration [266,288]. 
In agreement with NRP1’s involvement with integrin function, as discussed 
earlier, it is possible that αvβ3 normally interacts with NRP1 to prevent its pro-
angiogenic interactions with VEGFR2, which may be why the loss of β3 
increases NRP1-VEGFR2 interactions and elevates angiogenesis [202]. 
However, this does not take into account NRP1’s clear VEGFR2-independent 
role. It is therefore important to properly evaluate both NRP1’s VEGR2-
dependent and -independent functions when αvβ3 is targeted to have a greater 
insight into its endothelial mechanism of action. 
 
Recently, there has been further support for NRP1’s function in adhesion. 
Seerapu et al. [289] immunoprecipitated NRP1 from murine heart ECs and used 
proteomics to identify binding partners. They found, for example, the heavy 
chains of NM-IIA and NM-IIB to associate with NRP1 with and without the 
presence of VEGF, and filamin A and α-enolase to co-associate only when VEGF 
was present [289]. NRP1 co-localised with filamin A in vesicles in response to 
VEGF in a manner dependent on its cytoplasmic tail, and additionally associated 
with another FA protein, p130Cas, but in vesicular punctae, and not FAs, 
suggesting it was a recycling fraction of p130Cas [289]. NRP1Δcyto ECs 
migrated slower than WT ECs in a VEGF-induced wound-closure model, and FA 
assembly and disassembly were impaired in NRP1Δcyto ECs, as viewed by live 
TIRF imaging mCherry-tagged-kindlin-2 dynamics [289]. This therefore 
suggested that in heart ECs, NRP1, via its cytoplasmic tail, interacts with FA 
proteins mainly along their trafficking pathway, and resides in FAs only 
transiently, but regulates FA turnover, and thus EC migration [289]. The authors 
speculated that NRP1 may be regulating FA turnover by promoting the trafficking 
of FA components via its cytoplasmic link to synectin and myosin VI [289]. 
NRP1’s role in FA dynamics may also be supported by its VEGF-induced 
phosphorylation of FAK407 and p130Cas, which may or may not be mediated by 
VEGFR2. 
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In a separate study, Raimondi et al. [271] discovered that, independent of 
VEGF/VEGFR2, NRP1 promoted fibronectin-stimulated actin remodelling and 
phosphorylation of paxillin Y118 via the non-receptor tyrosine kinase, ABL1. In 
response to fibronectin, NRP1 formed a complex with ABL1, which was required 
for ABL1’s phosphorylation of paxillin, and for the promotion of HMDEC, HUVEC 
and mouse lung EC migration on fibronectin. NRP1 itself also co-associated with 
phosphorylated paxillin at peripheral cell areas resembling FAs, further 
supporting a potential role for NRP1 in FAs [271]. Concordant with these results, 
both physiological and pathological angiogenesis in the perinatal retina were 
inhibited by treatment with an ABL1 inhibitor, Imatinib; pathological angiogenesis 
was affected in a similar manner to that observed in inducible EC-specific NRP1 
knockout murine pups [271]. The authors hypothesised that, given NRP1’s 
cytoplasmic tail is not required for angiogenesis, its extracellular domain likely 
influences ABL1’s effect on paxillin, but possibly in an indirect manner through 
interactions with fibronectin-binding integrins [271]. 
 
Fantin et al. [290] most recently found that NRP1, again independent of VEGF 
stimulation, promoted fibronectin-stimulated Cdc42-dependent actin remodelling 
and filopodia formation in endothelial tip cells, thereby supporting angiogenic 
sprouting. This fit with Raimondi et al.’s [271] work nicely, as fibronectin-
stimulated Cdc42 activation was dependent on ABL1 activity, suggesting that a 
NRP1-ABL1 complex directly activates Cdc42 [290] (Figure 1.15). The authors 
additionally proved that NRP1 was not required for genetic tip cell identity, 
meaning NRP1 purely promoted tip cell function by promoting Cdc42 activation 
[290]. 
 
Other VEGFR2-independent roles for NRP1 aside from adhesion have also been 
reported. For example, its fusion to the EGFR promoted EC migration in 
response to VEGF [278]. NRP1 mediated VEGF-induced, but VEGFR2-
independent EC survival via synectin, which activated Akt and subsequently 
inactivated p53 pathways and FoxOs, and activated p21 [291]. NRP1 also 
reportedly binds VEGFR1, potentially to compete against its binding with 
VEGFR2 [292]. Furthermore, we must not forget the role of NRP1 in other cell 
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types, as PDGF-BB-stimulated migration and signalling via p130Cas was 
significantly decreased when NRP1 was inhibited in vSMCs [293]. 
 
The aforementioned studies have provided substantial evidence for VEGFR2-
independent roles for NRP1 in regulating angiogenesis that is mainly related to its 
role in EC adhesion. Though NRP1’s VEGF binding capability was not required 
for embryonic blood vessel formation, it is likely that generally both NRP1’s 
VEGFR2-dependent and -independent functions are required to work together to 
coordinate effective EC activity to meet the requirements of a particular scenario. 
However, again, the studies were predominantly performed in developmental 
angiogenesis models, meaning further physiological and pathological 
angiogenesis analyses are required in adult mice to properly distinguish NRP1’s 
function in these different contexts. Similarly, NRP1’s projected role in regulating 
focal adhesions must be pursued further in different cell types and under different 
conditions, before we can fully understand the mechanisms behind this alleged 
function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15: Projected model of neuropilin-1’s adhesion-dependent role. Fantin et. al. [ref] have 
proposed that neuropilin-1 (NRP1) mediates the extracellular matrix (ECM)- dependent activation of 
ABL1 and Cdc42, thereby promoting filopodia formation and actin remodelling in endothelial tip  
cells. Figure adapted from [290].
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1.5.3.3.3 NRP1 in cancer 
NRP1 is seen as a potentially good target in cancer therapy; not only is it 
overexpressed in a wide range of cancer cell lines and human tumours, but 
targeting NRP1 with monoclonal antibodies, siRNAs, inhibitory peptides, soluble 
NRP1, and small molecule inhibitors of the NRP1-VEGF interaction, inhibits pro 
cancer phenotypes such as tumor cell migration, adhesion, and survival, as well 
as tumour growth and angiogenesis in various pre-clinical models 
[69,124,133,294-304]. In rectal carcinoma patients, treatment with bevacizumab 
increased NRP1 expression in cancer cells, suggesting NRP1 may be involved in 
a compensatory escape mechanism following VEGF targeting [124,305]. In 
support of this, blocking the VEGF-binding domain of NRP1 with a monoclonal 
antibody, whilst only mildly affecting VEGFR2 signalling, strongly reduced tumour 
growth and vessel organisation in an additive manner when combined with anti-
VEGF antibody therapy [133]. Interestingly, this effect was not dependent on 
NRP1’s expression in the tumour cells, but rather due to an inhibition of the 
tumour vasculature, although other studies have contested the notion that 
NRP1’s role in tumour growth is solely related to vascularisation [69,133]. 
Nevertheless, the study further implicates the importance of VEGFR2-
independent roles for NRP1, but in pathological angiogenesis [69]. In agreement, 
NRP1 expression was found to promote invasiveness of melanoma cells through 
both VEGFR2-dependent and -independent mechanisms [306]. Also, NRP1 
promoted pancreatic cancer cell growth, survival, and invasion via its interaction 
with β1-integrin, [307] and, in another study, NRP1 stimulated tumour growth by 
increasing fibronectin fibril assembly in the tumour microenvironment via 
associations with synectin and ABL to augment α5β1 activity [308]. Clearly, 
NRP1’s VEGFR2-independent functions cannot be overlooked when deciding on 
NRP1-based cancer therapies. 
 
The use of small molecule inhibitors that target the NRP1-VEGF interaction may 
have promise as a novel cancer therapeutic strategy [69,299]. EG00229 and 
EG3287 are current peptidomimetics of portions of the VEGF165 molecule, which 
have demonstrated efficacy in inhibiting VEGFR2 phosphorylation and EC 
migration, and EG3287 has additionally been shown to inhibit cancer cell 
adhesion and migration, and even enhance chemosensitivity by interfering with 
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integrin-dependent survival pathways [274,299,300]. Promisingly, they have 
provided a basis for the design of further inhibitors that may have clinical efficacy 
in the future, especially when used in combination with antagonists against other 
molecules [69,299]. 
 
1.5.3.3.4 Conclusions on neuropilin-1 
We have gained great insight into the roles of NRP1 in the endothelium, the 
significance of its cytoplasmic tail, its VEGF-binding ability, and its potential 
promise as an anti-cancer target. However, the mass of information on NRP1’s 
contribution to blood vessel formation is complex, given NRP1’s differential 
effects in different contexts. Though the global and endothelial expression of 
NRP1 is essential for vascular development and endothelial tip cell function, 
NRP1’s cytoplasmic tail is dispensable for developmental angiogenesis, and its 
role in VEGF binding is not required for embryonic blood vessel formation, but 
more involved in postnatal angiogenesis. NRP1’s synectin-dependent promotion 
of VEGFR2 trafficking and prolonged ERK signalling appears to be important for 
arteriogenesis, but not developmental angiogenesis, which is likely more 
influenced by a combination of other VEGFR2-dependent and -independent 
functions of NRP1. It has been proposed that during angiogenesis, given that 
endothelial tip cells express very high levels of VEGFR2 and are exposed to high 
VEGF concentrations, they likely do not require prolonged NRP1-mediated 
VEGFR2/ERK signalling, but are rather more reliant on a VEGFR2-dependent 
and -independent induction of migration [287]. On the other hand, arteriogenesis, 
which involves luminal expansion, for example, may be more limited in VEGF 
availability, and so requires NRP1 to enhance and prolong VEGFR2 signalling by 
inceasing its recycling [287]. This may partly explain the overall differences 
observed in NRP1-mediated signalling properties between EC types (ie. due to 
their inherent predisposition for regulating different blood vessel formation 
processes), though this whole theory needs exploring further. More clarity is also 
needed on how NRP1’s VEGFR2-dependent and adhesion-dependent functions 
cooperate to regulate angiogenesis. Moreover, information on the roles of NRP1 
in adult physiological and pathological angiogenesis is still lacking. There is 
therefore a requirement for further work on NRP1’s significance and mechanisms 
of action in these contexts. 
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1.6 Research Aims and Objectives 
 
Following the discovery that NRP1’s role in angiogenesis becomes more 
influential, and thus targetable, in the complete absence of β3 [202], this project 
was developed to examine whether the same phenomenon exists in a more 
physiologically relevant model than β3-NULL mice, and whether it impacts on 
tumour progression and angiogenesis. Coupled with this major objective, since 
αvβ3 was reported to associate with NRP1 and potentially control its function in 
ECs, this project also aimed to elucidate whether, and how, αvβ3-integrin might 
regulate neuropilin-1’s role in this new model. Any data collected would help us 
determine whether targeting both molecules together might be a promising anti-
angiogenic therapeutic approach in the future. 
 
In line with the above, more specific aims are outlined below: 
1. Determine the effect of an endothelial-specific NRP1 depletion on tumour 
growth, angiogenesis and metastasis in WT and β3-integrin-heterozygous 
(β3-HET) mice 
2. Determine the effect of the loss of NRP1’s cytoplasmic tail on tumour 
growth, angiogenesis and metastasis in WT and β3-HET mice 
3. Assay for potential differences in EC behaviour following the targeting of 
β3 and/or NRP1 
4. Elucidate a molecular mechanism of how β3 and NRP1 interplay, and 
how β3 regulates NRP1’s function, in ECs 
5. Determine whether simultaneously targeting both β3 and NRP1 inhibits 
tumour growth and angiogenesis in mice 
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2. Materials and methods 
2.1 Reagents (and antibodies) 
VEGF-A164 (the mouse equivalent of human VEGF-A165), used for stimulating 
mouse lung microvascular ECs, was made in-house according to the protocol 
published by Krilleke et al. [309]. All chemicals were from Sigma-Aldrich (Poole, 
UK) unless otherwise indicated. All primary and secondary antibodies used are 
presented in Table 2.1 and Table 2.2, respectively. 
 
 
2.2 Animals 
All animals were on a mixed C57BL6/129 background. β3-integrin-heterozygous 
(β3-HET) mice, which have one β3-NULL allele [196], were acquired from β3-WT 
X β3-HET breeding pairs. Neuropilin-1 (NRP1)-floxed mice [258], which contain 
loxP sites flanking exon 2 of the Nrp1 gene, were purchased from The Jackson 
Laboratory (Bar Harbor, Maine, USA). The β3-integrin-floxed allele was 
generated by gene target insertion of embryonic stem cells that resulted in the 
insertion of loxP sites flanking exon 1 of the itgb3 (β3-integrin) gene [210]. Pdgfb-
iCreERT2 mice [310] were provided by Marcus Fruttiger (UCL, London, UK). 
NRP1-floxed/floxed (fl/fl), β3fl/fl, and NRP1/β3-doublefl/fl mice were bred with Pdgfb-
iCreERT2 mice in order to generate each different floxed Cre-positive (and Cre-
negative) animal. Mice lacking NRP1’s cytoplasmic tail (NRP1Δcyto) [267] were 
provided by Christiana Ruhrberg (UCL, London, UK), and were crossed with β3-
WT and β3-HET mice to acquire β3-WT-NRP1Δcyto and β3-HET-NRP1Δcyto 
animals. Littermate controls were used for all in vivo experiments. All experiments 
were performed in accordance with UK Home Office regulations and the 
European Legal Framework for the Protection of animals used for scientific 
purposes (European Directive 86/609/EEC). 
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Table 2.1 List of primary antibodies: 
Anti-   Clone/Cat. #   Conjugate   Host   Reactivity used   Source   Application  
 α1-integrin   HMα1 / 142603   PE   Hamster (IgG)   Mouse   Cambridge Bioscience   FC  
 α2-integrin   DX5 / 12-5971-63   PE   Rat (IgM)   Mouse   eBioscience   FC  
 α5-integrin   eBioHMα5-1 / 12-0493-81   PE   Hamster (IgG)   Mouse   eBioscience   FC  
 α5-integrin   #4705     Rabbit   Mouse   Cell Signalling Technology   WB  
 αV-integrin   RMV-7 / 12-0512-81   PE   Rat (IgG1)   Mouse   eBioscience   FC  
 β1-integrin   eBioHMb1-1 / 12-0291-81   PE   Hamster (IgG)   Mouse   eBioscience   FC  
 β3-integrin   2C9.G3 / 12-0611-82   PE   Hamster (IgG)   Mouse   eBioscience   FC  
 β3-Integrin   #4702     Rabbit   Mouse   Cell Signalling Technology   WB  
 β5-integrin   KN52 / 12-0497-41   PE   Mouse (IgG1, κ)   Mouse   eBioscience   FC  
 Akt   #9272     Rabbit   Mouse   Cell Signalling Technology   WB  
 Phospho Akt   #4060     Rabbit   Mouse   Cell Signalling Technology   WB  
 Biotin   3D6.6     Mouse   Mouse   Jackson Immunoresearch   IP  
 BS1-lectin    L2895   FITC     Mouse   Sigma   ARA  
 CD31   ER-MP12     Rat   Mouse   Abd Serotec   ECS  
 CD31   390 / 12-0311-82   PE   Rat (IgG2a, κ)   Mouse   eBioscience   FC  
 CD146   EPR3208     Rabbit   Mouse   Abcam, Cambridge, UK   IHC  
 Endomucin   V.7C7     Rat   Mouse   Santa Cruz Biotechnology   IHC  
 ERK1/2 (p44/42 MAPK)   137F5 / #4695     Rabbit   Mouse   Cell Signalling Technology   WB  
 Phospho ERK1/2   D13.14.4E #4370     Rabbit   Mouse   Cell Signalling Technology   WB  
 VEGFR2   AVAS 12α1   PE   Rat (IgG2a, κ)   Mouse   BD Pharmingen   FC  
 FAK   #3285     Rabbit   Mouse   Cell Signalling Technology   WB  
 Phospho FAK (Y407)   #OPA1-03887     Rabbit   Mouse   Thermo Scientific   WB  
 Filamin A   ab76289     Rabbit   Mouse   Abcam   WB  
 GAPDH   14C10 / #2118     Rabbit   Mouse   Cell Signalling Technology   WB  
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 Histone H3   D1H2 / #4499     Rabbit   Mouse   Cell Signalling Technology   WB  
 HSC-70   B-6 / sc-7298     Mouse   Mouse   Santa Cruz Biotechnology   WB  
 ICAM-2   #MCA2295EL     Rat   Mouse   AbD Serotec   ECS  
 ICAM-2   3C4 (mlc2/4) / 53-1021-80   Alexa®-488    Rat (IgG2a, κ)   Mouse   eBioscience   FC  
 IgG Isotype control   eBio299 Arm / 12-4888-81   PE   Hamster   Mouse   eBioscience   FC  
 IgG1 isotype control   M1-14D12   PE   Rat   Mouse   eBioscience   FC  
 IgG1, κ isotype control   P3.6.2.8.1   PE   Mouse   Mouse   eBioscience   FC  
 IgG2a, κ isotype control   G155-178   PE   Mouse   Mouse   BD Biosciences   FC  
 IgM isotype control   eBRM / 12-4341-81   PE   Rat   Mouse   eBioscience   FC  
 Myosin 9   #3403     Rabbit   Mouse   Cell Signalling Technology   WB  
 Neuropilin 1   D62C6 / #3725     Rabbit   Mouse, Human   Cell Signalling Technology   WB, IP  
 Neuropilin 1   AF566     Goat   Mouse   R&D Systems   ICC, IP  
 p130cas   #610271     Mouse   Mouse   BD Biosciences   WB  
 Phospho p130cas   #4011     Rabbit   Mouse   Cell Signalling Technology   WB  
 p38 MAPK   #9212     Rabbit   Mouse   Cell Signalling Technology   WB  
 Phospho p38 MAPK   3D7 / #9215     Rabbit   Mouse   Cell Signalling Technology   WB  
 Paxillin   ab32084     Rabbit   Mouse   Abcam   ICC, WB  
 Phospho Paxillin (Y118)   #2541     Rabbit   Mouse   Cell Signalling Technology   ICC, WB  
 SP-1   #5931     Rabbit   Mouse   Cell Signalling Technology   WB  
 VE-Cadherin   eBioBC13 / 12-1441-80   PE   Rat (IgG1)   Mouse   eBioscience   FC  
 VEGFR2   AVAS 12α1   PE   Rat (IgG2a, κ)   Mouse   BD Biosciences   FC  
 VEGFR2   55B11 / #2479     Rabbit   Mouse, Human   Cell Signalling Technology   WB, IP  
 Phospho VEGFR-2 (Y1175)   19A10 / #2478     Rabbit   Mouse   Cell Signalling Technology   WB  
 Vimentin   D21H3 / #5741     Rabbit   Mouse   Cell Signalling Technology   WB  
 
Table 2.1: Abbreviations - Aortic ring assay (ARA), EC sorting (ECS), Flow cytometry (FC), Immunocytochemistry (ICC), Immunohistochemistry (IHC), 
Immunoprecipitation (IP), and Western blotting (WB). 
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Table 2.2 List of secondary antibodies: 
Anti- Cat. # Conjugate Host Source Application 
Goat A-21222 Alexa®-488  Rabbit Invitrogen ICC 
Goat A-21223 Alexa®-594  Rabbit Invitrogen ICC 
Mouse 715-035-151 HRP Donkey Jackson Immunoresearch WB 
Rabbit A-21206 Alexa®-488  Donkey Invitrogen IHC, ICC 
Rabbit 711-035-152 HRP Donkey Jackson Immunoresearch WB 
Rat 11035 Dynabeads Sheep Invitrogen ECS 
Rat A-21209 Alexa®-594  Donkey Invitrogen IHC 
 
Table 2.1: Abbreviations - EC sorting (ECS), Immunocytochemistry (ICC), Immunohistochemistry 
(IHC), Immunoprecipitation (IP), and Western blotting (WB). 
 
 
2.3 Mouse genotyping 
2.3.1 PCR genotyping 
Ear or tail snips from mice were digested overnight (o/n) at 56°C in 100 μL 
ear/tail snip lysis buffer (50 mM Tris-HCl pH 8.5, 10 mM EDTA pH 8.0, 100 mM 
NaCl, 0.2% SDS) supplemented with 100 μg/mL proteinase K in separate wells of 
a 96-well PCR plate (Fisher Scientific). DNA was subsequently precipitated by 
adding 100 μL isopropanol to each well, shaking the plate to mix, and 
centrifuging the plate at 1400 × g for 30 mins. Isopropanol was removed by gently 
inverting the plate, and the DNA pellet was dried at 37°C for about 2 hrs. DNA 
was then resuspended in 200 μL TE buffer (10 mM Tris-HCl pH7.5, 1 mM EDTA) 
and left to solubilise o/n at room temperature (RT). 
 
PCR reactions were then performed for the relevant transgenic mice in a 96-well 
block thermal cycler PCR machine (Bioer Technology, Binjiang, China), as 
detailed below. 
 
2.3.1.1 β3-integrin-knockout PCR 
PCR analysis of the β3-NULL allele, which was originally created by replacing a 
1.4 kb HindIII fragment of the β3 gene (in exons I and II) with a 1.7 kb targeting 
construct containing a PGK-neomycin (neo)-resistance cassette [196], was 
carried out using the following oligonucleotide primers: 
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Common forward primer 1:  5’ – CTTAGACACCTGCTACGGGC – 3’ 
Reverse primer 2:   5’ – CACGAGACTAGTGAGACGTG – 3’ 
Reverse primer 3:   5’ – CCTGCCTGAGGCTGAGTG – 3’ 
 
The forward primer 1, which recognises DNA 5’ of the PGK-neo cassette, was 
used in two separate PCR reactions with each of the other reverse primers (2 and 
3). Primer 2 is neo-specific and primer 3 is wild-type specific, meaning an 
amplification product of a reaction involving primers 1 and 2 corresponds to the 
β3-NULL allele, whilst that of a reaction involving primers 1 and 3 corresponds to 
the β3-WT allele. PCR amplified products produced in both reactions therefore 
corresponds to DNA from β3-HET mice. 
 
For each PCR reaction involving primers 1 and 2, 0.4 μL of DNA was mixed with 
10 μL MegaMix-Blue (Microzone, Haywards Heath, UK), and primers 1 and 2 
(used at a final concentration of 1 μM). For each PCR reaction involving primers 
1 and 3, 0.4 μL of DNA was mixed with 10 μL MegaMix-Blue, and primers 1 and 
3 (used at a final concentration of 0.4 μM). PCR reaction conditions were as 
follows: initialisation step at 95°C for 15 min; followed by 35 amplification cycles 
of denaturation at 95°C for 30 sec, extension at 60°C for 45 sec, and annealing at 
72°C for 90 sec; and terminated with a final elongation step at 72°C for 10 min. 
PCR products are 538 base pairs (bp) long (β3-NULL allele) and 446-bp (wild-
type).  
 
2.3.1.2 β3-integrin-floxed PCR 
PCR analysis of the β3-floxed allele was carried out using the following 
oligonucleotide primers: 
 
Forward primer: 5’ – TTGTTGGAGGTGAGCGAGTC – 3’ 
Reverse primer: 5’ – GCCCAGCGGATCTCCATCT – 3’ 
 
For each PCR reaction, 0.8 μL of DNA was mixed with 10 μL MegaMix-Blue, and 
the forward and reverse primers (used at a final concentration of 0.8 μM). PCR 
reaction conditions were as follows: initialisation step at 95°C for 2 min; followed 
by 35 amplification cycles of denaturation at 95°C for 30 sec, extension at 56°C 
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for 30 sec, and annealing at 72°C for 30 sec; and terminated with a final 
elongation step at 72°C for 8 min. PCR products are 182-bp (β3-WT), 272-bp 
(β3fl/fl). 
 
2.3.1.3 NRP1-floxed PCR 
PCR analysis of the NRP1-floxed allele was carried out using the following 
oligonucleotide primers: 
 
Forward primer: 5’ – AGGTTAGGCTTCAGGCCAAT – 3’ 
Reverse primer: 5’ – GGTACCCTGGGTTTTCGATT – 3’ 
 
For each PCR reaction, 0.8 μL of DNA was mixed with 10 μL MegaMix-Blue, and 
the forward and reverse primers (used at a final concentration of 0.8 μM). PCR 
reaction conditions were as follows: initialisation step at 94°C for 3 min; followed 
by 35 amplification cycles of denaturation at 94°C for 30 sec, extension at 65°C 
for 1 min, and annealing at 72°C for 1 min; and terminated with a final elongation 
step at 72°C for 2 min. PCR products are 550-bp (NRP1-WT), 738-bp (NRP1fl/fl). 
 
2.3.1.4 Pdgfb.CreER PCR  
PCR analysis of the Pdgfb.CreER allele was carried out using the following 
oligonucleotide primers: 
 
Forward primer: 5’ – GCCGCCGGGATCACTCTC – 3’ 
Reverse primer: 5’ – CCAGCCGCCGTCGCAACT – 3’ 
 
For each PCR reaction, 0.8 μL of DNA was mixed with 10 μL MegaMix-Blue, and 
the forward and reverse primers (used at a final concentration of 1 μM). PCR 
reaction conditions were as follows: initialisation step at 94°C for 4 min; followed 
by 34 amplification cycles of denaturation at 94°C for 30 sec, extension at 57.5°C 
for 45 sec, and annealing at 72°C for 1 min; and terminated with a final 
elongation step at 72°C for 10 min. PCR product is 443-bp if positive for 
Pdgfb.CreER. 
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2.3.1.5 NRP1Δcyto PCR 
PCR analysis of the NRP1Δcyto allele was carried out using the following 
oligonucleotide primers: 
 
Forward primer:  5’ – CCTTTTGATGGACATGTGACCTGTAGC – 3’ 
Reverse primer:  5’ – CACCAGGTCTGATTGAAGAGAAGG – 3’ 
Δcyto reverse primer:  5’ – ATGGTACCTTGAGCATCTGACTTCTG – 3’ 
 
For each PCR reaction, 1 μL of DNA was mixed with 8 μL MegaMix-Blue, forward 
primer (used at a final concentration of 1 μM), reverse primers (used at a final 
concentration of 0.5 μM), and betaine (used at a final concentration of 0.4 M). 
PCR reaction conditions were as follows: initialisation step at 94°C for 2 min; 
followed by 34 amplification cycles of denaturation at 94°C for 40 sec, extension 
at 60°C for 45 sec, and annealing at 72°C for 1 min; and terminated with a final 
elongation step at 72°C for 10 min. PCR products are 550-bp (NRP1-WT) or 660-
bp (NRP1Δcyto). 
 
2.3.2 Agarose gel electrophoresis 
PCR products were separated on a 1.8% agarose gel, apart from those from the 
NRP1Δcyto PCR, which were separated on a 2% agarose gel. To make these 
gels, the corresponding agarose (Fisher Scientific, Loughborough, UK) amounts 
to a final volume of 200 mL were weighed in grams and dissolved in 100 mL 
distilled water (dH2O) by microwaving for 2-3 mins. Another 96 mL distilled water 
was then added to this dissolved agarose to aid faster cooling, along with 4 mL of 
50X TAE buffer (0.5 M Tris, 1 M acetic acid, 50 mM EDTA pH 8.0) and 10 μL of 
ethidium bromide (Fisher Scientific). This gel solution was poured into a large gel 
tank (Alpha Laboratories, Eastleigh, UK) containing well-forming combs that meet 
the demand for the number of PCR samples. The entire PCR product (~10 μL) 
from each reaction was loaded into each well of the gel and separated at 100 V 
for ~1 hr. Gel bands were visualised under UV light and photographed using a 
BioDoc-It Transiluminator (UVP, Cambridge, UK). 
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2.4 In vivo tumour growth assays 
Syngeneic mouse melanoma (B16F0, ATCC; mycoplasma free) or mouse lung 
carcinoma (CMT19T, CR-UK Cell Production; mycoplasma free) cells (1×106) 
were injected subcutaneously in the flank of age-matched experimental and 
littermate control mice.  12-20 days after injection mice were sacrificed by 
cervical dislocation, tumour sizes were measured in two dimensions using a 
digital caliper, and tumour samples were fixed in 4% paraformaldehyde (PFA) o/n 
for histological analysis. For prevention studies in Pdgfb-iCreERT2 mice (Figure 
3.2, Appendix Figure 1), slow release (5 mg, 21-day release) tamoxifen pellets 
(Innovative Research of America, Sarasota, Florida, USA) were implanted 
subcutaneously into the scruff of the neck 3 days prior to tumour cell injection.  
For intervention studies (Figure 3.7), pellets were implanted after 10 days of 
initial tumour growth.  Tumour volumes (mm3) were calculated according to the 
formula: length × width2 × 0.52 [311]. 
 
 
2.5 Immunohistochemical analyses 
2.5.1 Tumour samples 
Post-fixation, tumours were washed in PBS for a further 24 hrs, and then 
bisected at the midline. Samples were dehrydrated by successively placing them 
through ethanol solutions of increasing concentrations (50-100%), followed by 
Histoclear (Sigma), and were then embedded in paraffin. Paraffin blocks were 
sectioned using a microtome (HM 355 S, Microm, Bicester, UK) into 5 μm 
sections (with the cut tumour face toward blade), which were mounted onto glass 
slides and dried at 37°C o/n. Prior to immuno-staining, sections were de-
paraffinised in Histoclear, and rehydrated through successive solutions of ethanol 
of decreasing concentrations (100%-50%) and left in PBS. Heat-mediated 
antigen retrieval was performed by boiling sections in sodium citrate buffer (10 
mM tri-sodium citrate, 0.05% Tween®-20, pH 6) for 20 mins. They were then 
allowed to cool, washed in PBLEC (1 mM CaCl2, 1 mM MgCl2, 0.1 mM MnCl2, 1% 
Tween-20) (3X15 mins), and blocked using drops of serum-free protein block 
solution (Dako, Ely, UK) at 37°C in a humidified chamber for 30 mins. Sections 
were incubated with primary antibody (Ab) (diluted in PBLEC) at 4°C o/n, washed 
in PBS 0.1% Triton X-100 (Sigma, Dorset, UK) (3X15 mins), and then incubated 
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with secondary Ab (diluted in PBLEC) at RT for 2 hrs. After 2X15 mins washes in 
PBS 0.1% Triton, 1X15 min wash in PBS, sections were stained with 0.1% Sudan 
Black (Sigma) for 10 mins, rinsed in water, and mounted with Prolong Gold 
containing DAPI (Life Technologies, Warrington, UK). Images were acquired on 
an Axioplan (Zeiss, Cambridge, UK) epifluorescent microscope and tissue area 
was quantified using Image JTM software available at the National Institutes of 
Health website. Primary antibodies: rat anti-endomucin (clone V.7C7, used at 
1:500, Santa Cruz Biotechnology, Santa Cruz, CA, USA); rabbit anti-CD146 
(clone EPR3208, used at 1:500, Abcam, Cambridge, UK). Secondary antibodies: 
donkey anti-rat Alexa®-594 and donkey anti-rabbit Alexa®-488 conjugates 
(Invitrogen, Paisley, UK), both used at 1:500. 
 
Blood vessel density was assessed by counting the total number of endomucin-
positive vessels per mm2 across entire midline tumour sections from age-
matched, size-matched tumours. For tumour sections from the intervention 
studies (Figure 3.7) vessels around the perimeter of the sections were counted in 
order to avoid the necrotic centres of tumours. 
 
2.5.2 Lung samples from metastasis experiment 
Lungs were embedded in paraffin post-fixation as described above for tumour 
samples, except lungs were not bissected, and 10 μm sections were prepared 
instead of 5 μm. Prior to hematoxylin and eosin (H&E) staining, sections were de-
paraffinised in Histoclear, and rehydrated through successive solutions of ethanol 
of decreasing concentrations (100%-50%) and left in dH2O. Sections were then 
stained with haematoxylin for 2 mins, rinsed with running tap water, and 
submerged in a solution of 1% HCl in 70% EtOH for 30 sec. After washing in 
dH2O for 10 mins, sections were then placed in 2% sodium bicarbonate for 2 
mins, dH2O for 2 mins, and stained with eosin for 30 sec. Then, sections were 
dehydrated in 70% EtOH for 10 sec, 2X95% for 2 mins, 2X100% for 2 mins, and 
placed in Histoclear for 10 mins, before mounting with DePeX (BDH Laboratory 
Supplies, Poole, UK). Images were acquired on an Axioplan (Zeiss) 
epifluorescent microscope using the colour camera (AxioCam HRc, Zeiss). 
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2.6 Ex vivo aortic ring assay 
This assay was performed by following the protocol outlined by Baker et al. [312]. 
In summary, thoracic aortae were dissected from 6- to 9-week-old adult mice, cut 
into rings approximately 0.5 mm in width, and incubated in serum-free media 
(Opti-MEM™, Invitrogen) at 37°C o/n. Each ring was then embedded in separate 
wells of a 96-well plate containing 1 mg/mL of collagen I (Millipore, Watford, UK), 
which was polymerised by leaving the plate at 37°C for 30 mins. Rings were fed 
with fresh Opti-MEM™ supplemented with 2.5% FBS and VEGF (30 ng/mL) 
(where indicated) at 37°C every 3 days. After 6-10 days, rings were fixed with 4% 
PFA, permeabilised with 0.2% Triton and stained with FITC-conjugated BS-1 
lectin. A Zeiss inverted microscope (Zeiss Axiovert 40 CFL) was used to count 
sprouting microvessels and obtain images of the rings. Endothelial protein 
depletion in aortic rings from Pdgfb-iCreERT2 mice was induced in culture with 1 
μM 4-hydroxytamoxifen (OHT). For the intervention study (Figure 3.6), protein 
depletion in ECs was induced in culture with 1 μM OHT 4 days after VEGF-
induced sprouting had been established, and the microvessel sprouts were 
quantified after an additional 4 days of VEGF-stimulation. 
 
 
2.7 In vivo metastasis experiment 
2.7.1 Attempt at Luciferase-tagging CMT19TF1 cells 
2.7.1.1 Lentivirus production in HEK293 cells 
HEK-293 cells were seeded at 1×106 cells per well in 6-well plates in DMEM high 
glucose + 10% FBS (without penicillin/streptomycin) and left o/n at 37°C. The 
following day cells were transfected with 1 μg pLenti-II-CMV-Luc-IRES-GFP 
lentiviral vector (Abm, Huntingdon, cat no. V010127), 750 ng of the packaging 
plasmid psPAX (Addgene, Teddington, UK), and 250 ng of the envelope plasmid 
pMD2.G (Addgene), using lipofectamine 2000 (Thermo Scientific). For 
transfection, these reagents were first mixed in serum-free OptiMEM® for 30 
mins at RT and then applied slowly to the cells, before leaving them at 37°C for 
12-15 hrs. The media was then replaced with DMEM high glucose + 10% FBS + 
100 units/mL penicillin/streptomycin. The following day, lentivirus was harvested 
by collecting the conditioned media and storing at 4°C o/n, whilst replenishing the 
media for the cells. A second harvest was collected the following day, pooled with 
101 
that from the previous day, and centrifuged at 1400 × g to remove cell debris. The 
conditioned media was then aliquoted into cyrovials (Thermo Scientific) and 
stored at −80°C until use. 
 
2.7.1.2 Lentiviral transduction of CMT19TF1 cells 
Mouse lung carcinoma cells enriched for their ability to metastasise to the lung 
(CMT19TF1) were seeded at 2×104 cells per well in 6-well plates, and a volume 
of lentivirus predicted to give 100% transduction efficiency was added to the 
media (DMEM high glucose + 10% FBS + 100 units/mL penicillin/streptomycin), 
along with 8 μg/mL hexadimetherine bromine (polybrene, Sigma). After leaving 
cells at 37°C for 48 hrs, the media was replaced and successful transduction was 
confirmed by observed green fluorescent cells under an inverted Axiovert (Zeiss) 
microscope. These cells were then trypsinised and expanded in culture under 
antibiotic selection (500 μg/mL G418). 
 
2.7.1.3 Reverse transcription PCR to detect luciferase expression 
Lentiviral-transduced-CMT19TF1 cells, and non-transduced cells (as a control), 
were pelleted, resuspended in RNAbee (Amsbio, Abingdon, UK), and stored at 
−80°C until use. RNA was the extracted using a SV Total RNA isolation kit 
(Promega, Southampton, UK).  cDNA was created by reverse transcription using 
Superscript II (Thermo Scientific) following the manufacturer’s supplied protocol. 
 
PCR analysis of luciferase was carried out on the cDNA using the following 
oligonucleotide primers: 
 
Forward primer: 5’ – GTTCGTCACATCTCATCTACCTCC – 3’ 
Reverse primer: 5’ – CTTTAGGCAGACCAGTAGATCCAG – 3’ 
For each PCR reaction, 50 ng of DNA was mixed with 10 μL MegaMix-Blue, and 
the forward and reverse primers (used at a final concentration of 0.8 μM). PCR 
reaction conditions were as follows: initialisation step at 95°C for 3 mins; followed 
by 39 amplification cycles of denaturation at 95°C for 10 sec, extension at 55°C 
for 30 sec, and annealing at 72°C for 30 sec; and terminated with a final 
elongation step at 72°C for 1 mins. PCR products were separated by gel 
electrophoresis on a 1.8% agarose gel. 
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2.7.1.4 Bioluminescence imaging 
To confirm luciferase tagging of CMT19TF1 cells in vivo, 1×106 lentiviral-
transduced CMT19TF1 cells, and B6-LV1 cells (previously tagged with luciferase) 
were injected subcutaneously in the flank of WT mice. After a few days of growth, 
mice were injected i.p. with 0.1 cc of a 1 mg/mL luciferin (Promega) and 
bioluminescence was detected in the mice using the In vivo Xtreme BI 4MP 
machine (Bruker, Coventry, UK). 
 
2.7.2 In vivo metastasis experiment 
CMT19TF1 cells (1×106) were injected subcutaneously in the flank of age-
matched experimental and littermate control mice. 20 days after injection, 
tumours were resected, and slow release (5 mg, 21-day release) tamoxifen 
pellets were implanted subcutaneously into the scruff of the neck. After 12 further 
days, mice were sacrificed by cervical dislocation, and their lungs were inflated 
with 4% PFA, and left in 4% PFA o/n prior to histological analysis by H&E (see 
2.5.2 Lung samples from metastasis experiment). 
 
 
2.8 Mouse tumour endothelial cell isolation 
Tumours were dissected and placed in Hank’s Balanced Salt Solution (HBSS) 
(Thermo Scientific). They were minced and enzymatically digested for 1 hr at 
37°C under gentle agitation in HBSS containing 0.2% collagenase IV (Invitrogen), 
0.01% hyaluronidase and 0.01% DNase I. The cellular digests were passed 
through 19 gauge needles, filtered through a 70 μm mesh (Fisher Scientific), and 
centrifuged for 5 mins at 400 x g. After centrifugation, cells were resuspended in 
HBSS containing 2% bovine serum albumin (BSA) and 0.6% sodium citrate. Cell 
yield was determined in a hemocytometer and viability assessed by trypan blue 
exclusion. Anti-CD31 (AbD Serotec, Oxford, UK) -coupled Dynabeads® 
(Invitrogen) were incubated at a ratio of 30 beads per target cell (estimated at 1% 
of total cell count) at 4°C for 25 mins with occasional agitation. Bound cells were 
separated from unbound cells on a magnet and were washed 3X in HBSS 
containing 0.1% BSA and 0.6% sodium citrate. Bound cells were lysed in 
electrophoresis sample buffer (ESB; 65 mM Tris-HCl, pH 7.4, 60 mM sucrose, 
3% SDS) and prepared for Western blot analysis. 
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2.9 Cell isolation and/or culture 
2.9.1 Mouse lung microvascular endothelial cell culture 
Primary mouse lung ECs were cultured in MLEC media: a 1:1 mix of Ham’s F-
12:DMEM medium (low glucose) (Invitrogen) supplemented with 20% fetal bovine 
serum (FBS) (HyClone, Invitrogen), 100 units/mL penicillin/streptomycin 
(Invitrogen), 2 mM glutamax (Invitrogen), 50 µg/mL heparin (Sigma), and 25 mg 
of endothelial mitogen (AbD Serotec). To induce target gene deletion in Pdgfb-
iCreERT2-floxed cell lines, cells were grown for 48 hrs in medium supplemented 
with 500 nM OHT. 
 
Immortalised mouse lung ECs were cultured in IMMLEC media, which is identical 
to MLEC media, except for the exclusion of endothelial mitogen and that FBS 
was supplemented only to 10%. Tissue culture flasks for routine sub-culture were 
always pre-coated with 0.1% gelatin (type A from porcine skin, ~300g bloom). 
Immortalised ECs were used between passages 5-20, and were routinely 
checked by flow-cytometry for surface expression of ICAM2, CD31, and VECAD 
(see 2.12 Flow Cytometry, and Figure 4.1) to ensure they retained their normal 
EC characteristics. For experimental analyses, tissue culture plates and flasks 
were coated overnight at 4°C with one or more of the following, as specified 
below: 0.1% gelatin, Purecol (COLI) (Nutacon B.V., the Netherlands), human 
plasma fibronectin (FN) (Millipore) and mouse multimeric vitronectin (VN) 
(Patriecell Ltd, Nottingham, UK).  
 
2.9.2 Mouse lung microvascular endothelial cell isolation and 
immortalisation 
Primary mouse lung endothelial cells were isolated from adult mice as described 
previously by Reynolds & Hodivala-Dilke [313]. In summary, lungs were removed 
aseptically from adult mice and collected in Ham’s F12 medium. They were then 
rinsed in 70% ethanol, minced with scalpels, and enzymatically digested in PBS 
containing 0.1% collagenase I (Invitrogen) at 37°C for 1 hr. The cellular digests 
were passed through 19 gauge needles three times, filtered through sterile 70 µm 
filters (Fisher Scientific), and centrifuged for 5 mins at 300 × g. Cells were 
resuspended in MLEC media by gentle pipetting, plated into a well of a 6-well-
plate previously coated with a mixture of COLI (30 μg/mL) and gelatin (0.1%), 
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and incubated at 37°C o/n. The following day, cells were washed two times with 
PBS to remove red blood cells. Intracellular adhesion molecule-2 (ICAM-2)-
positive ECs were then selected for by magnetic activated cell sorting (MACS): 
Cells were incubated with rat-anti-mouse ICAM-2 (Abd Serotec) (1:1000 in PBS) 
for 30 mins at 4°C, washed with PBS and then incubated with sheep-anti-rat IgG 
coated magnetic beads (2 µl bead/mL of MLEC medium) for another 30 mins at 
4°C. After 3XPBS washes to remove unbound beads, cells were detached with 
0.25% trypsin:EDTA (Invitrogen), resuspended in MLEC media, collected in an 
eppendorf™ tube and put on a magnet.  The supernatant was discarded and the 
ECs attached to the beads were resuspended in fresh medium and plated into a 
new well of a previously coated (as above) 6-well-plate. When cells neared 
confluency, a second positive sort was performed in order to enhance EC purity. 
 
For immortalisation, ECs were treated with polyoma-middle-T-antigen (PyMT) 
retroviral transfection as described previously by Robinson et al. [09]. Briefly, 
PyMT conditioned medium was collected from cultured packaging GgP+E cells, 
filter sterilised using a 0.45 μm filter, and stored at −80°C until use. Following two 
rounds of ICAM-2-positive selection, primary ECs in six-well plates were treated 
with the preserved PyMT conditioned medium supplemented with 8 μg/mL 
polybrene for 6 hrs at 37°C. PyMT conditioned medium was removed and 
replaced with complete growth medium. This same procedure was repeated the 
following day. Cells were observed and passaged for 4 weeks to ensure their 
immortalisation.  
 
2.9.3 Human umbilical vein endothelial cell culture 
HUVECs were cultured in EBM-2 media supplemented with the SingleQuotsTM kit 
(Lonza, Slough, UK). 
 
2.9.4 Other cell culture 
CMT19T, CMT19TF1, B16F0, and B6-LV1 cancer cells, and HEK293 cells were 
cultured in high glucose DMEM (Invitrogen) supplemented with 10% FBS and 
100 units/mL penicillin/streptomycin. 
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2.10 Flow-cytometry 
For flow-cytometric analysis, cells were trypsinised, resuspended in fluorescence-
activated cell sorting (FACS) buffer (1% FBS in PBS + 1 mM CaCl2 + 1 mM 
MgCl2), and labelled with one of the following antibodies (all used at 1:200 and, 
unless stated otherwise, purchased from eBioscience, Hatfield, UK): PE-anti-
mouse Flk1/VEGFR2 (BD Biosciences, Oxford, UK), PE-anti-mouse CD49a 
(Cambridge Bioscience, Cambridge, UK); PE-anti-mouse CD49b; PE-anti-mouse 
CD49e; PE-anti-mouse CD51; PE-anti-mouse CD29; PE-anti-mouse CD61; PE-
anti-mouse integrin beta 5; PE-anti-mouse CD31; FITC-anti-mouse ICAM2; PE-
anti-mouse VECAD; appropriate PE/FITC labelled isotype-matched controls were 
from eBioscience. In the case of VEGFR2 analysis, cells were stimulated with 30 
ng/mL VEGF at 37°C over a timecourse before trypsinisation. 
 
 
2.11 Western blot analysis 
For the analysis of VEGFR2, NRP1, β3-integrin, ERK1/2, p130cas, FAK, Akt, and 
p38MAPK in MLECs, cells were seeded at 2×105 cells per well in 6-well plates 
coated with 0.1% gelatin, 10 μg/mL FN, 10 μg/mL COLI, and 2 μg/mL VN. For 
paxillin analysis, ECs were seeded at the same density, but on plates coated with 
only 10 μg/mL FN in PBS. 24 hrs later, cells were starved for 3 hrs in serum-free 
OptiMEM®. VEGF was then added to a final concentration of 30 ng/mL cells 
were lysed at the indicated times (see relevant figures) in ESB. Lysed cells were 
scraped off their plates using rubber policeman, transferred to eppendorfTM tubes 
containing acid-washed glass beads (Sigma), homogenised in a Tissue Lyser 
(Qiagen, Sussex, UK) at 50 Hz for 2 mins, and centrifuged at 12,000 × g for 10 
mins at RT. Lysates were analysed for protein concentration using the BioRad 
DC protein assay (BioRad, Hemel Hempstead, UK). NB: see other method 
sections for sample preparation for other assays that required Western blot 
analysis. 15–30 μg of protein from each sample was loaded onto 8–10% 
polyacrylamide gels and subjected to SDS-PAGE. For paxillin analysis, samples 
were loaded onto a 4-12% gradient gel for better resolution. The protein was 
transferred to a nitrocellulose membrane (Whatman® Protran®, Sigma) and 
incubated for 1 hr in 5% milk powder/PBS plus 0.1% Tween-20 (PBSTw), 
followed by an overnight incubation in primary Ab diluted 1:1000 in 5% 
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BSA/PBSTw at 4°C. The blots were then washed 3X with PBSTw and incubated 
with the relevant horseradish peroxidase (HRP)-conjugated secondary Ab (Dako) 
diluted 1:2000 in 5% milk/PBSTw, for 1 hr at RT. Chemiluminescence was 
detected on a Fujifilm LAS-3000 darkroom (Fujifilm UK Ltd, Bedford, UK). 
Antibodies (all used at 1:1000 and purchased from Cell Signalling Technology, 
unless noted otherwise): anti-phospho (Y1175) VEGFR2 (clone 19A10); anti-
VEGFR-2 (clone 55B11); anti-Neuropilin-1 (cat no. 3725); anti-β3-integrin (cat no. 
4702); anti-phospho (Thr202/Tyr204) p44/42 MAPK Erk1/2 (clone D13.14.4E); 
anti-total p44/42 MAPK Erk1/2 (clone 137F5); anti-phosho (Y410) p130cas (cat 
no. 4011); anti-p130cas (Cat no. 610271, BD Biosciences); anti-phospho (Y407) 
FAK (#OPA1-03887, Fisher Scientific); anti-FAK (cat no. 3285); anti-HSC70 
(clone B-6, Santa Cruz Biotechnology); anti-phospho (Y118) paxillin (cat no. 
2541); anti-paxillin (ab32084; Abcam); anti-GAPDH (14C10, cat no. 2118); anti-
SP1 (cat no. 5931); anti-histone H3 (D1H2, cat no. 4499); anti-vimentin (D21H3, 
cat no. 5741); anti-phospho p38 MAPK (cat no. 9215); anti-p38 MAPK (cat no. 
9212); anti-phospho Akt (cat no. 4060); anti-Akt (cat no. 9272); anti-myosin 9 (cat 
no. 3403); anti-filamin a (ab76289; Abcam); anti-α5-integrin (cat no. 4705).  
 
Densitometric readings of band intensities for Western blots were obtained using 
Image JTM. Band densities for total protein were normalized to HSC-70/GAPDH 
levels, and densities for phosphorylated protein were normalised to the 
corresponding total protein levels to make quantitative measurements of protein 
expression levels. 
 
 
2.12 Cell surface biotinylation assay 
Cells were plated o/n at a density of 8 × 105 in 6 cm dishes, coated with 0.1% 
gelatin, 10 μg/mL FN, 10 μg/mL COLI, and 2 μg/mL VN. After starvation, cells 
were moved to an ice bath, washed twice with ice-cold SBS (Soerensen Buffer, 
14.7 mM KH2PO4, 2 mM Na2HPO4 and 120 mM Sorbitol pH 7.8), and left in the 
second wash for 10 mins. All of the SBS was then removed before adding 1 mL 
of ice-cold SBS pH 7.8 containing 0.3 mg/mL EZ-Link NHS-SS-biotin (Fisher 
Scientific) per dish for 30 mins. After a further two washes in ice-cold SBS pH 7.8, 
the unreacted biotin was quenched for 10 mins by incubation with ice-cold SBS 
pH 7.8 containing 100 mM glycine. Cells were then washed twice with ice-cold 
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SBS pH 7.8 and left in Opti-MEMTM supplemented with 2 µg/mL heparin for 5 
mins before stimulation with 30 ng/mL VEGF for 5, 15, 30 and 60 minute time-
points at 37°C to allow internalisation of biotinylated plasma membrane proteins. 
Internalisation was stopped by bringing the cells back to the ice bath, washing 
twice in ice-cold SBS pH 8.2, and leaving them in the second wash for 5 mins. 
The biotin still present on cell-surface molecules was cleaved off by incubating 
the cells with 50 mM of membrane impermeable disulphide reducing agent TCEP 
(tris-(2-carboxyethyl)phosphine; Sigma) in ice-cold SBS pH 8.2 for 25 mins. 
Unstimulated cells not treated with TCEP were used as controls. Cells were 
washed twice with ice-cold SBS pH 8.2 and then lysed in 0.2 mL/dish of RIPA 
buffer (20 mM Tris pH 7.4, 50 mM NaCl, 0.1% SDS, 1% Triton, 1% Deoxycholate, 
1% NP40) containing phenylmethanesulfonylfluoride (PMSF, Sigma) (~1 mM) 
and Halt® Protease and Phosphatase inhibitor (1:100) (Fisher Scientific). Cells 
were scraped off their dishes using rubber policeman, transferred to eppendorfTM 
tubes containing acid-washed glass beads, homogenised in a Tissue Lyser at 50 
Hz for 2 mins, and centrifuged at 12,000 × g for 10 mins at 4°C. Biotinylated 
proteins were then immunoprecipitated by incubating them with 3 µg of a mouse-
anti-mouse-biotin Ab (Jackson Immunoresearch, Newmarket, UK) coupled to 
magnetic dynabeads (using the Dynabeads® Ab Coupling Kit (Invitrogen)) on a 
rotator o/n at 4°C. Immunoprecipitated complexes were washed three times with 
0.2 mL of RIPA buffer, and once in PBS, before being added to, and boiled in, 1X 
NuPAGE® LDS sample buffer containing reducing agent (Invitrogen), ready for 
separation on an 8% acrylamide gel and Western blotting. 
 
 
2.13 Immunoprecipitation assays 
Cells were grown to 80-90% confluency in 15 cm dishes, coated with 10 μg/mL 
FN in PBS. After starvation in OptiMEM® for 3 hrs, cells were stimulated with 30 
ng/mL VEGF for 10 mins (+VEGF), or for the indicated times, at 37°C. Cells were 
then placed on ice, washed two times with PBS, and lysed in 0.5 mL/plate of 
RIPA buffer (20 mM Tris pH 7.4, 50 mM NaCl, 0.1% SDS, 1% Triton, 1% 
Deoxycholate, 1% NP40) containing PMSF (~1 mM) and Halt® Protease and 
Phosphatase inhibitor (1:100). Lysates were centrifuged at 12,000 × g for 10 
mins at 4°C. 400 μg of total protein from each sample was IP’d by incubating 
them with protein-G Dynabeads® (Invitrogen) coupled to the relevant Ab on a 
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rotator o/n at 4°C. IP’d complexes were washed three times with 0.2 mL of RIPA 
buffer, and once in PBS, before being added to, and boiled in, 1X NuPAGE® 
sample reducing agent (Life Technologies), ready for SDS-PAGE prior to 
Western blotting (to detect co-associations (co-IP)), silver staining, or mass 
spectrometry analysis (first experiment). A rabbit-anti-mouse-VEGFR2 Ab (clone 
55B11, Cell Signalling Technology) was used for the VEGFR2 IP. The NRP1 IP 
that was initially used to detect β3-co-association and for the first mass 
spectrometry experiment was carried out using a rabbit-anti-mouse-Neuropilin-1 
(cat no. 3725) Ab. A rabbit-anti-mouse-β3-integrin (cat no. 4702) was used for 
the β3 IP. The NRP1 IP for the second mass spectrometry experiment and the 
other NRP1 co-IPs was carried out using a goat-anti-mouse Neuropilin-1 Ab 
(AF566, R&D Systems). Prior to subjecting the NRP1 IP’d samples to mass 
spectrometry analyses, a fraction of them were separated by SDS-PAGE on a 
10% polyacrylamide gel, which was subsequently silver stained using the 
Pierce® Silver Stain Kit (Fisher Scientific) to confirm uniform IP efficiency 
between samples. 
 
 
2.14 Adhesion Assays 
2.14.1 Static adhesion 
96-well plates were coated overnight at 4°C with 10 μg/mL COLI, 10 μg/mL FN, 
10 μg/mL laminin-I (LN), or 2 μg/mL VN in PBS, or a mixture (MIX) containing 10 
μg/mL COLI, 10 μg/mL FN, and 2 μg/mL VN in 0.1% gelatin was also used. The 
wells were then washed with PBS, and blocked for 1 hr at RT with 1% BSA in 
PBS, before a final wash in PBS.  Prior to seeding, cells were starved for 3 hrs in 
Opti-MEM®, trypsinised, and resuspended in serum-free OptiMEM®. They were 
then seeded in serum–free OptiMEM® at a concentration of 1×104 cells/well for 
90 mins at 37°C.  Plates were washed three times gently by immersion in a 
bucket of PBS, and any excess volume was removed.  Cells were fixed with 4% 
formalin for 10 mins, stained with methylene blue for 30 mins, washed for 15 
mins under running water and air-dried.  Dye was extracted with 
50%ethanol:50% 0.1N HCl and the absorbance of each well was measured at 
610 nm. 
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2.14.2 Adhesion on various matrix concentrations 
96-well plates were coated overnight at 4°C with serial dilutions of VN or FN.  The 
wells were then washed with PBS, and blocked for 1 hr at RT with 1% BSA in 
PBS.  Prior to seeding, cells were starved for 3 hrs in Opti-MEM®, trypsinised, 
and resuspended in serum-free OptiMEM®. They were then seeded in serum–
free OptiMEM® at a concentration of 3×104 cells/well for 90 mins at 37°C.  Plates 
were tapped vigorously on the bench top and wells were washed thoroughly 
using a multi-channel pipette. Cells were fixed with 4% formalin, stained with 
methylene blue for 30 mins, washed for 15 mins under running water and air-
dried.  Dye was extracted with 50%ethanol:50% 0.1N HCl and the absorbance of 
each well was measured at 610 nm. 
 
2.14.3 Cell spreading assay 
6-well plates were coated overnight at 4°C with 10 μg/mL FN. The wells were 
then washed with PBS, and blocked for 1 hr at RT with 1% BSA in PBS.  Prior to 
seeding, cells were starved for 3 hrs in Opti-MEM®, trypsinised, and 
resuspended in serum-free OptiMEM®. They were then seeded in serum–free 
OptiMEM® at a concentration of 70×105 cells/well for 6 hours at 37°C. Plates 
were washed three times gently by immersion in a bucket of PBS, and any 
excess volume was removed.  Cells were fixed with 4% formalin for 10 mins, 
stained with methylene blue for 30 mins, washed for 15 mins under running water 
and air-dried.  Phase contrast photographs were taken using an inverted Axiovert 
(Zeiss) microscope and cell surface areas were measured using ImageJTM 
software.  
 
 
2.15 Migration assays 
2.15.1 Random migration assay 
ECs were starved in OptiMEM® for 3 hrs, trypsinised and seeded at 1.5×104 
cells/well in 24-well plates coated with 10 μg/mL FN in PBS, and allowed to 
adhere for 3 hrs. The media was then replaced with OptiMEM® + 2% FBS, and 
half of the wells were supplemented with 30 ng/mL VEGF. One phase-contrast 
image/well was taken live every 10 mins in a fixed field of view using an inverted 
Axiovert (Zeiss) microscope for 15 hrs at 37°C and 4% CO2. Individual cells were 
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then manually tracked using the ImageJTM cell tracking plugin, and the speed of 
random migration was calculated in μm moved/hr. 
 
2.15.2 Wound closure assay 
ECs were seeded at 4×105 cells/well in 6-well plates coated with 10 μg/mL FN in 
PBS, and cultured until the next day, by which time they had reached confluency. 
Cells were serum starved for 3 hrs in OptiMEM® before scratching the confluent 
monolayer with a P200 pipette tip. Phase contrast images of scratches were then 
captured and the media was changed to OptiMEM® containing 30 ng/mL VEGF. 
After 24 hrs, cells were fixed for 10 mins with 4% formaldehyde and scratches 
were imaged again. The degree of scratch wound closure was quantified by 
measuring the gap between cells in three areas per field using Axiovision (Zeiss) 
software, taking an average, and calculating the length change between time 
points. 
 
 
2.16 Cell fractionation assay 
ECs were seeded in plates coated with 0.1% gelatin, 10 μg/mL FN, 10 μg/mL 
COLI, and 2 μg/mL VN. 24 hrs later, cells were starved for 3 hrs in serum-free 
OptiMEM®, and either stimulated with 30 ng/mL VEGF or not. Cells were then 
trypsinised and centrifuged at 500 × g. Cell fractionation was carried out following 
the ‘Subcellular protein fractionation kit for cultured cells’ (Fisher Scientific) 
protocol exactly, and samples were prepared for Western blotting. 
 
 
2.17 Immunocytochemistry 
Either primary or immortalised ECs were seeded at 1.5×105 cells/well in six-well 
plates on acid-washed and oven-sterilised glass coverslips, coated with 10 μg/mL 
FN in PBS and cultured until the next day. Cells were starved for 3 hrs in serum-
free OptiMEM®, and either stimulated with 30 ng/mL VEGF at 37°C for 10 mins 
(+VEGF), or not at all (−VEGF). Cells were then fixed in 4% formaldehyde for 10 
mins, washed in PBS, permeabilised with 0.5% NP40 in PBS, blocked in 0.1% 
BSA+0.2% Triton in PBS, and incubated with primary antibody diluted 1:100 in 
PBS for 1 hr at RT. After further PBS washes, cells were incubated with the 
relevant Alexa-Fluor®-conjugated secondary antibody (Invitrogen) diluted 1:500 
111 
in PBS for 45 min at RT. Coverslips were washed in PBS again before they were 
mounted on slides with Prolong® Gold containing DAPI (Invitrogen). To stain for 
filamentous-(F) actin, Alexa-Fluor®-568–phalloidin (Invitrogen) was used 1:300 in 
PBS at the secondary-antibody incubation stage. To look at β3-integrin 
fluorescently, 1×106 ECs were transfected with a GFP-tagged β3-integrin cDNA 
expression construct (provided by Dr Maddy Parsons, King’s College London, 
London, UK) by nucleofection prior to seeding on coverslips at 1.5×105 cells/well. 
Antibodies (all used at 1:100) were: anti-phospho (Y118) paxillin (Cell Signaling 
Technology, cat. no. 2541); anti-paxillin (ab32084, Abcam); anti-neuropilin-1 
(AF566, R&D Systems). NRP1-PXN co-localisation was quantified using the 
Coloc2 ImageJTM plugin to determine the Pearson’s correlation coefficient. Focal 
adhesion sizes were measured using ImageJTM software. 
 
 
2.18 Mass spectrometry analyses 
Mass spectrometry experiments were carried out by the Fingerprints Proteomics 
Facility, Dundee University, Dundee, UK. In the first experiment, after NRP1 IP’d 
samples were confirmed for their uniform NRP1 IP efficiency by silver staining 
(see above), the remainder of the samples were again separated by SDS-PAGE 
and sent off to the facility as gel fragments lane by lane. They were then 
subjected to 1D nano liquid chromatography tandem mass spectrometry (1D 
nLC-MS/MS) using an LTQ Orbitrap analysis.  In the second experiment, after 
NRP1 IP’d samples were confirmed for their uniform IP efficiency by silver 
staining, the remainder of the NRP1-IP’d dynabead samples were boiled in ESB 
buffer and separated on a magnet. The samples in ESB buffer were then sent off 
to the facility for label-free quantitative mass spectrometry. Peptides were 
identified and quantified using MaxQuant software using the Andromeda peptide 
database.  To achieve label-free quantitative results, 3 biological repeats were 
pooled and each of these pooled samples was analysed via 3 technical repeats 
through the spectrometer. Peptides present in at least 2 samples were 
hierarchically clustered by clustering median log(LFQ) values by city-block 
distance using Cluster 3.0 software (available for download from 
http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm), and presented with 
Java TreeView (available from http://jtreeview.sourceforge.net). 
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2.19 Focal adhesion enrichment 
ECs were starved in serum-free OptiMEM® for 3 hrs and seeded at 6×106 
cells/plate in 10 cm plates that were previously coated with 10 μg/mL FN in PBS 
o/n at 4°C and blocked in 1% BSA in PBS for 1 hr at RT. Cells were allowed to 
adhere for 90 mins to allow for mature FAs to form and either stimulated with 30 
ng/ml VEGF at 37°C for 10 mins (+VEGF) or not at all (−VEGF). Cells were 
washed in PBS + 1 mM CaCl2 + 1 mM MgCl2 (PBS++) and incubated with 0.5 
mM Dithiobis(succinimidyl propionate) (DSP) and 0.05 mM 1,4-di-[30-(20-
pyridyldithio)-propionamido] butane (DPP) diluted in PBS++ for 5 mins to cross-
link FAs to the plate. This reaction was quenched with 1 M Tris-HCl pH 7.5 before 
cells were lysed in RIPA for 30 mins on ice with occasional agitation. RIPA was 
collected without scraping, and the plates were blasted with a high-sheer flow jet 
of distilled water to remove cell debris. Cross-linked proteins were eluted with 2 
mL dithiothereitol (DTT) buffer (25 mM Tris-HCl pH 7.5, 10 mM NaCl, 0.1% SDS, 
100 mM DTT) for 1 hr at 60°C in a sealed and humidified chamber. 8 mL of 
acetone was added to this solution and left overnight at −20°C to allow the 
proteins to precipitate. Samples were then centrifuged at 13,000 × g for 40 mins, 
and the acetone layer removed. The pellet was resuspended in ESB ready for 
Western blot analysis (or mass spectrometry analysis in a separate project). 
 
 
2.20 Focal adhesion tracking 
1×106 ECs were transfected with a GFP-tagged paxillin cDNA-expression-
construct (kindly provided by Dr Maddy Parsons, KCL, London, UK) and a 
fraction of these were seeded on acid-washed and oven-sterilised glass 
coverslips, coated with 10 μg/mL FN in PBS, in wells of a 6-well plate. Cells were 
cultured for ~48 hrs before they were starved in serum-free OptiMEM® for 3 hrs. 
In turn, individual coverslips were separately transferred to OptiMEM® + 2% FBS 
+ 30 ng/mL VEGF was added. An Axiovert (Zeiss) inverted microscope was then 
used to take live images of the GFP-paxillin-positive focal adhesions in a selected 
field of view every 2 mins for 1 hr at 37°C + 4% CO2. Assembly and disassembly 
was quantified by manually tracking leading and trailing edges of focal adhesions 
using the MTrackJ plugin for Image JTM. 
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2.21 Statistical analysis 
Significant differences between means were evaluated by Student’s-t-test. 
P<0.05 was considered statistically significant. For flow cytometric analysis of 
integrins, relative differences were deemed significant if they were greater than 2-
fold. 
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3. Investigating the dual importance of αvβ3-
integrin and neuropilin-1 in tumour growth 
and angiogenesis 
 
3.1 Like β3-integrin-knockout mice, β3-integrin-heterozygous mice have 
significantly increased angiogenesis and tumour growth relative to their 
wild-type littermates 
As described earlier, it was previously shown that tumour growth and 
angiogenesis were significantly enhanced in β3-integrin-knockout (β3-NULL) 
mice [134,197,202]. Though these results were surprising at the time, given 
αvβ3’s upregulation in neo-angiogenic vasculature and various successes with 
αvβ3 antagonists in pre-clinical models, it has since become clear that 
angiogenic phenotypes that arise in response to αvβ3 targeting are determined 
by the context in which αvβ3 is targeted [180]. It was postulated that the β3-
NULL phenotype was caused, in part, by a developmental upregulation of 
VEGFR2, and increased NRP1-VEGFR2 associations [134,202]. Since 
interactions between αvβ3 and VEGFR2 are important for angiogenesis, the 
results obtained from a model in which β3 is completely absent and VEGFR2 
levels are elevated are not physiologically relevant and difficult to interpret 
[186,191]. We therefore moved our analyses to β3-integrin-heterozygous (β3-
HET) mice, which express roughly half the normal level of β3 (see Chapter 4), 
hypothesising that this would circumvent developmental changes arising from the 
complete loss of the protein, whilst at the same time maintaining, at least to a 
degree, interactions between β3 and VEGFR2 and/or NRP1. Using VEGF-
induced aortic ring microvessel sprouting as a means of measuring angiogenesis 
in these models, we found that angiogenesis in the β3-HET model was enhanced 
compared to that in wild-type (WT) aortic rings, though not as markedly as in the 
β3-NULL model (Figure 3.1). Similarly, we also observed an increase in 
subcutaneous B16F0 melanoma allograft tumour growth in β3-HET mice, but 
again this effect was dampened compared to the increase seen in β3-NULL 
mice. Unsurprisingly, these data suggest that mechanisms of resistance to 
genetic β3 targeting still feature in the β3-HET model, though their effects are not 
as pronounced as when β3 is missing. 
 
Figure 3.1: Like β3-integrin-null (β3-NULL) mice, β3-integrin-heterozygous (β3-HET) mice 
have significantly increased angiogenesis and tumour growth relative to their wild-type          
(β3-WT) littermates. Microvessel sprouting of aortic ring explants of the indicated genotypes. The 
bar chart shows the total number of microvessel sprouts per aortic ring after 6 days of 
VEGF-stimulation (mean +SEM from 3 independent experiments; n≥40 rings per genotype). 
Asterisks indicate statistical significance: ***, P<0.001; nsd = not significantly different.  Unpaired 
two-tailed t test. The bottom panel shows representative images of aortic rings stained with 
FITC-conjugated BS1-lectin (an endothelial marker) from each genotype. The panel on the right 
shows representative examples of B16F0 melanoma allograft tumours from each genotype after 12 
days of growth.
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3.2 Tumour growth and angiogenesis in β3-integrin-heterozygous mice are 
sensitive to endothelial neuropilin-1 depletion 
Robinson et al. [202] previously reported that targeting NRP1 with inhibitory 
peptides or siRNA inhibited angiogenesis in the β3-NULL model more 
substantially than when β3 was uninterrupted. However, we do not know if this 
phenomenon applies in the β3-HET model. Endothelial neuropilin-1 has been 
shown to be essential for normal embryonic brain angiogenesis [265], and its 
depletion inhibits postnatal pathological neovascularisation of the retina [271]. 
However, its significance in angiogenesis in adult models has never been 
investigated. We therefore wanted to combine these two objectives and 
determine the effect of an acute EC-specific depletion of NRP1 (NRP1-EC-ID) on 
tumour growth and angiogenesis in both β3-WT and β3-HET mice. 
 
We crossed β3-WT and β3-HET mice to tamoxifen (OHT)-inducible Pdgfb-
iCreERT2/NRP1-floxed mice [258,310] and examined subcutaneous allograft 
tumour growth using both CMT19T cells (Figure 3.2) and B16F0 cells (Appendix 
Figure 1), as well as aortic ring sprouting (Figure 3.3). EC-NRP1 depletion, 
which was induced with OHT prior to tumour growth and aortic ring sprouting 
(meaning NRP1 was targeted in a preventative manner), had no effect on β3-WT 
responses, but significantly inhibited tumour growth and VEGF-induced 
microvessel sprouting in β3-HET mice. Tumour angiogenesis was also only 
significantly inhibited in β3-HET mice by depleting endothelial NRP1, although 
vessel morphology and pericyte coverage were normal (Figure 3.2B). These 
results are reminiscent of the increased angiogenic sensitivity to NRP1 targeting 
in the β3-NULL model reported previously [202], but additionally suggest that 
NRP1 function is perturbed by a reduction in, and not absence of, β3 expression, 
and that, as a result, specifically endothelial NRP1 becomes more targetable in 
the context of pathological angiogenesis. Compensation to long-term β3 targeting 
may therefore partly take the form of an increased importance for endothelial 
NRP1, meaning that NRP1 is normally regulated by β3, but only when β3 is 
properly expressed in ECs. 
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Figure 3.2: Tumour growth and tumour angiogenesis in β3-integrin-heterozygous mice are 
sensitive to endothelial neuropilin-1 depletion. A Tumour growth was measured in animals of the 
indicated genotypes. Mice were given subcutaneous injections of CMT19T tumour cells. To induce 
depletion of endothelial NRP1 (NRP1-EC-ID), 21-day slow-release OHT pellets were administered 
3-days prior to tumour cell injection. OHT-treated Cre-negative (NRP1-EC-WT) littermates served as 
controls. Tumour volumes were measured after 12 days of growth (mean +SEM of 3 independent 
experiments; n≥10 animals per genotype). Representative pictures of tumour macroscopic 
appearances are shown. Scale bar = 10 mm. B Blood vessel density was assessed in tumours of the 
indicated genotypes by counting the total number of endomucin-positive vessels across tumour 
sections (mean +SEM; n≥10 sections per genotype). Representative micrographs of 
immunofluorescence staining for endomucin, an endothelial cell marker (Endo, red) and CD146, a 
pericyte marker (green) in tumour sections from each genotype are shown. DAPI (blue) was used as 
a nuclear counterstain. Scale bar = 100 μm. Asterisks indicate statistical significance: *, P<0.05; **, 
P<0.01; nsd = not significantly different.  Unpaired two-tailed t test.
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Figure 3.3: Angiogenesis in β3-integrin-heterozygous mice is sensitive to endothelial 
neuropilin-1 depletion. Microvessel sprouting of aortic ring explants of the indicated genotypes. To 
induce depletion of endothelial NRP1 (NRP1-EC-ID), 1 μM OHT was supplemented in culture.  
OHT-treated Cre-negative (NRP-EC-WT) rings served as controls.  The bar chart shows the total 
number of microvessel sprouts per aortic ring after 6 days of VEGF-stimulation (mean +SEM from 3 
independent experiments; n≥40 rings per genotype). Asterisks indicate statistical significance: **, 
P<0.01; nsd = not significantly different.  Unpaired two-tailed t test.
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3.3 Tumour growth and angiogenesis in β3-integrin-heterozygous mice are 
sensitive to the loss of neuropilin-1’s cytoplasmic tail 
NRP1’s cytoplasmic tail is known to be dispensable for developmental and 
pathological angiogenesis, but more involved in arteriogenesis and arteriovenous 
patterning  [267,268]. However, a potentially cooperative role between the 
cytoplasmic tail of NRP1 and β3 has never been studied in angiogenesis, or 
elsewhere. To narrow our mechanistic focus, we wanted to explore whether 
pathological angiogenesis in β3-HET mice is sensitive to the removal of NRP1’s 
cytoplasmic tail. 
 
We therefore crossed β3-WT and β3-HET animals with mice carrying a global 
deletion of NRP1’s cytoplasmic tail (NRP1Δcyto) [267] and examined CMT19T 
subcutaneous allograft tumour growth (Figure 3.4) and aortic ring sprouting 
(Figure 3.5), as before.  CMT19T tumour growth and microvessel sprouting were 
unaltered in β3-WT mice by the introduction of the NRP1Δcyto mutation, but both 
were inhibited in β3-HET-NRP1Δcyto mice. Although the loss of NRP1’s 
cytoplasmic tail had a minor effect on tumour angiogenesis in β3-WT mice 
(Figure 3.4B), this did not translate to an overall difference in tumour growth 
(Figure 3.4A). As in EC-NRP1-ID tumours, pericyte coverage of tumour 
vasculature was not affected by a NRP1 cytoplasmic deletion (Figure 3.4B). We 
conclude from these results that NRP1’s cytoplasmic tail is normally dispensable 
for pathological angiogenesis, but its role becomes significant when β3 
expression is reduced. Thus, it is possible that β3 normally keeps the pro-
angiogenic functioning of NRP1’s cytoplasmic tail in check, but is unable to when 
insufficiently expressed. 
 
 
 
 
 
 
 
 
 
 
 
AB
Figure 3.4: Tumour growth and tumour angiogenesis in β3-integrin-heterozygous mice are 
sensitive to the loss of neuropilin-1’s cytoplasmic tail. A CMT19T tumour growth and 
angiogenesis were measured in animals of the indicated genotypes.  In addition to their β3-integrin 
genetic status, mice were negative (NRP1WT) or positive (NRP1Δcyto) for the loss of NRP1’s 
cytoplasmic tail.  Mice were given subcutaneous injections of CMT19T cells and tumour volumes 
were measured 12 days later. The bar chart shows tumour volumes (mean +SEM of 3 independent 
experiments; n≥10 animals per genotype). B Blood vessel density was assessed by endomucin (red) 
and CD146 (green) staining (mean +SEM; n≥10 sections per genotype). DAPI was used as a 
nuclear counterstain (blue).  Scale bar = 100 μm.  Asterisks indicate statistical significance: *, 
P<0.05; **, P<0.01; ***, P<0.001; nsd = not significantly different.  Unpaired two-tailed t test.
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Figure 3.5: Angiogenesis in β3-integrin-heterozygous mice is sensitive to the loss of 
neuropilin-1’s cytoplasmic tail. Microvessel sprouting of aortic ring explants of the indicated 
genotypes. The bar chart shows the total number of microvessel sprouts per aortic ring after 6 days 
of VEGF-stimulation (mean +SEM from 3 independent experiments; n≥40 rings per genotype). 
Asterisks indicate statistical significance: **, P<0.01; nsd = not significantly different.  Unpaired 
two-tailed t test.
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3.4 Simultaneous depletion of both endothelial β3-integrin and neuropilin-1 
blocks pre-established tumour growth and angiogenesis 
Whilst the data presented so far convincingly show that tumour growth and 
angiogenesis become sensitive to NRP1 disruption when there is reduced β3 
expression, it is difficult to claim that targeting β3 and NRP1 together would be an 
effective anti-cancer strategy on this evidence alone. The β3-HET and 
NRP1Δcyto models do not accurately simulate β3/NRP1 targeting in a clinical 
scenario, as they feature a global and constitutive reduction, or perturbation, in 
β3 and NRP1, respectively. Furthermore, in the endothelial NRP1-targeted 
model, NRP1 depletion was induced before tumour growth and angiogenesis 
were established. These targeting methods are therefore preventative, and so 
are not representative of the clinical situation, where tumour growth and 
angiogenesis are already in motion. We therefore wanted to examine the effect of 
simultaneously targeting both β3 and NRP1 on already established tumour 
growth and angiogenesis, as a proof-of-concept for clinical intervention, using 
β3/NRP1-double-floxed mice crossed to those with OHT-inducible-Pdgfb-
iCreERT2 transgenics. 
 
First, we assessed the effect of such an intervention on angiogenesis in the aortic 
ring assay. VEGF-induced microvessel sprouting was initiated in aortic rings 
isolated from: 1) β3-floxed mice with (Cre-positive) and without (Cre-negative) 
Pdgfb-iCreERT2; 2) NRP1-floxed mice with (Cre-positive) and without (Cre-
negative) Pdgfb-iCreERT2; or 3) double-floxed mice with (Cre-positive) and 
without (Cre-negative) Pdgfb-iCreERT2. OHT was administered to all rings after 4 
days of sprouting to induce endothelial depletion (EC-ID) in Cre-positive rings, 
and microvessels were quantified 4 days later. Only in rings from double-floxed 
Pdgfb-iCreERT2-positive animals was further sprouting significantly inhibited 
(Figure 3.6). We then examined intervention in established vascularised tumours 
in mice of these same genotypes. CMT19T allografts were grown in the animals, 
as previously, but this time OHT was administered after 10 days of growth, before 
allowing the tumours to continue growing for another 10 days. In concordance 
with the intervention aortic ring studies, further tumour growth and angiogenesis 
were significantly inhibited in double-floxed Pdgfb-iCreERT2-positive animals, but 
not in any of the other genotypes (Figure 3.7). These results therefore constitute 
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key pre-clinical evidence that suggests simultaneously targeting β3 and NRP1 
may be a viable anti-angiogenic intervention strategy in cancer therapeutics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Simultaneous depletion of both endothelial β3-integrin and neuropilin-1 blocks 
pre-initiated microvessel sprouting. Microvessel sprouting of aortic ring explants of the indicated 
genotypes. To induce depletion of endothelial β3 and/or NRP1 (EC-ID), 1 μM OHT was 
supplemented in culture 4 days after VEGF-induced sprouting had been established.  The bar chart 
shows the total number of microvessel sprouts per aortic ring after an additional 4 days of 
VEGF-stimulation (mean +SEM from 3 independent experiments; n≥40 rings per genotype).  
Asterisks indicate statistical significance: ***, P<0.001; nsd = not significantly different.  Unpaired 
two-tailed t test.
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BFigure 3.7: Simultaneous depletion of both endothelial β3-integrin and neuropilin-1 blocks 
pre-established tumour growth and angiogenesis. Tumour growth and angiogenesis were 
measured in animals of the indicated genotypes.  A Model schematic: Mice were injected 
subcutaneously with CMT19T cells and 10 days later OHT was administered to induce depletion of 
endothelial β3 and/or NRP1 (EC-ID). After an additional 10 days (20 days in total) tumours were 
harvested. B The bar chart shows mean tumour volumes measured at days 10 and 20 (+SEM of 2 
or more independent experiments; n≥10 animals per genotype). C Blood vessel density in 20-day 
tumours was assessed by counting the total number of endomucin-positive vessels around the 
periphery (within 150 μm of the edge of the tumour) of midline bisected tumour sections. The bar 
chart shows mean vessel number per mm2 (+SEM). Representative micrographs of endomucin 
staining (red) are shown along the bottom.  Scale bar = 50 μm. D Western blot showing 
representative depletion of β3-integrin and NRP1 in tumour endothelial cells (TEC) isolated from 
Cre-positive animals, compared to Cre-negative littermate controls. Asterisks indicate statistical 
significance: *, P<0.05;  ***, P<0.001; nsd = not significantly different.  Unpaired two-tailed t test.
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3.5 The investigation of the dual importance of β3-integrin and neuropilin-1 
in metastasis was unsuccessful 
Our data show that targeting both β3 and NRP1 inhibits the growth and 
angiogenesis of tumours, but tumour progression also encompasses metastasis, 
which invariably is the cause of mortality in cancer patients. We therefore sought 
to determine whether a joint β3/NRP1 targeting strategy could also negatively 
regulate metastasis, and thus potentially improve patient survival in this way if 
used in the clinic. Our plan was to grow subcutaneous allografts, as before, but 
using a variant of the CMT19T cancer cell line, CMT19TF1, which we had 
previously shown to metastasise to the lung (not shown). We attempted to 
transduce this cell line with luciferase (Luc) in order to monitor the progress of 
metastasis formation using bioluminescence. However, although RT-PCR of the 
Luc gene appeared to show the presence of Luc cDNA in the transduced cells 
(Appendix Figure 2A), no bioluminescence signal was ever detected in mice 
injected with the alleged CMT19TF1-Luc cells (Appendix Figure 2B). 
Nevertheless, we pursued with the untagged CMT19TF1 cells, injecting them into 
mice of all the genotypes used in the intervention experiment, and allowing 20 
days of growth. Tumours were then resected, and OHT was administered at this 
point to simulate β3 and/or NRP1 targeting in the adjuvant setting. After 12 more 
days, lungs from the animals were harvested and processed for 
immunohistochemical analysis. Surprisingly, no metastases were observed in 
lungs from any of the animals in two separate repeats of this experiment 
(Appendix Figure 2D). Since work from our laboratory previously identified lung 
metastases in both Cre-negative and Cre-positive Tie.Cre/β3-floxed mice 
(example shown in Appendix Figure 2D), we therefore conclude that this 
metastasis experiment did not work in our hands on these occasions. However, 
since the Tie1-Cre/β3-floxed mice display a constitutive deletion of β3, no 
administration of OHT is required in this case. It is therefore possible that the 
OHT used in our experiments may have inhibited the formation of metastases, 
though further investigation into this, and other reasons why our model failed, is 
required to avoid disappointment in the future. 
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3.6 Discussion 
In a previous publication, we showed that the acute depletion of endothelial β3 
only transiently inhibits tumour growth and angiogenesis, suggesting that specific 
mono-targeting strategies, though initially effective, are not so in the long-term, 
and therefore may benefit from the additional targeting of a compensatory 
pathway [211]. Unfortunately, although long-term endothelial β3 targeting in this 
particular study correlated with increased VEGFR2 surface levels, decreased 
expression of β5, reduced levels of FAK, and a misbalance in FAK 
phosphorylation, a conclusive mechanism of escape is yet to be elucidated in this 
case [211]. However, Robinson et al. [202] formerly showed that the total loss of 
β3 expression sensitises angiogenesis to NRP1 inhibition by siRNA or small 
peptides, suggesting that NRP1 may play a compensatory role when β3 has 
been missing for a long time, and pre-empting the idea that co-targeting αvβ3 
and NRP1 might offer greater anti-angiogenic efficacy than their individual 
targeting. Though encouraging, these results were limited by the potential 
physiological irrelevance of a situation where β3 is globally and constitutively 
absent, and the complication of a developmental upregulation in VEGFR2 in the 
β3-NULL model. In order to gain a deeper mechanistic understanding of how β3 
and NRP1 cooperate, and of the effect of their joint targeting in a more 
physiologically relevant model, we decided to move from β3-NULL mice to β3-
HET mice, which feature a more subtle, albeit global, reduction in β3 expression. 
Like their knockout counterparts [134,197,202], β3-HET mice display enhanced 
tumour growth and angiogenesis, though not to such an elevated extent. This 
suggests that a compensatory resistance mechanism arises in this context in 
response to a constitutive reduction in β3, but not as aggressively as when β3 is 
constitutively absent. This contrasts with the long-term endothelial depletion of 
β3, which, despite not preventing mechanisms of escape, does not result in an 
elevated pathological response. Thus it is logical to assume that enhanced 
pathological angiogenesis in β3-HET mice is mainly due to the contribution of 
non-ECs. Even so, tumour growth and angiogenesis in β3-HET, but not WT, mice 
are sensitive to both the endothelial depletion of NRP1, and the global deletion of 
its cytoplasmic tail. This corroborates what Robinson et al. [202] previously 
showed in β3-NULL mice, but applies it to a more physiologically relevant model, 
extends the effect of targeting NRP1 to pathological angiogenesis, and implicates 
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NRP1’s cytoplasmic tail as a major contributor to the effect. That both NRP1’s 
endothelial depletion and lack of cytoplasmic tail had no effect on WT responses 
are also progressive findings. Endothelial NRP1 has previously been shown to be 
essential for embryonic brain angiogenesis [265] and postnatal pathological 
neovascularisation of the retina [271], but here we report a redundancy for 
endothelial NRP1 in VEGF-stimulated microvessel sprouting and pathological 
angiogenesis in adult mice, unless β3 is insufficiently expressed. Endothelial 
NRP1 is therefore non-essential for angiogenesis after development, at which 
point it may be held under control by β3, but if β3 levels drop, angiogenesis 
becomes dependent on NRP1 in ECs. Although our finding that NRP1’s 
cytoplasmic tail is normally dispensable for angiogenesis is in agreement with 
previous studies [267,268], again we now report that its function becomes 
significant when β3 expression is reduced. Whilst we cannot rule out the effect of 
the deletion of NRP1’s cytoplasmic tail in other cell types, this result implicates 
the cytoplasmic tail of NRP1 as a factor that dictates a significant pro-angiogenic 
response when β3 levels are reduced in ECs. The mechanistic basis behind β3’s 
potential regulation of NRP1 in ECs must therefore be carefully analysed for 
greater clarity on this issue. 
 
Our previous work has already shown that the acute endothelial depletion of β3 
alone is unable to inhibit tumour growth and angiogenesis in pre-established 
tumours [211]. Now we report that the acute depletion of either β3 or NRP1 in 
ECs has no effect on tumour growth and angiogenesis, or on aortic ring 
microvessel sprouting, but when both β3 and NRP1 are simultaneously depleted, 
further tumour growth and angiogenesis, and microvessel sprouting, are blocked. 
This reinforces the notion that specifically targeting β3 in ECs is an effective anti-
angiogenic approach, but that its results can be substantially improved by 
additionally targeting endothelial NRP1, which may otherwise contribute to an 
escape mechanism. That tumour growth can be inhibited by intervention is 
particularly exciting, as it strongly suggests that an anti-angiogenic approach 
involving the targeting of both molecules might offer improved therapeutic results 
in patients with advanced solid cancers over other strategies that have failed. The 
effect of β3/NRP1 dual targeting on metastasis in an adjuvant-like setting has so 
far proved elusive, but is the source of ongoing research in our laboratory. If co-
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targeting the molecules additionally produces anti-metastastic effects, then the 
case for their further clinical investigation is strengthened. However, before 
antagonists can enter clinical trials as a joint therapy, a greater mechanistic 
understanding of how the two molecules cooperate is needed. Such an 
understanding might further implicate novel master regulators of the effect we 
have seen, or highlight particular portions of the molecules that should be 
targeted. Only then can we assuredly experiment with antagonists that impair the 
important processes involved. In the meantime, small molecule inhibitors directed 
against NRP1 are under development [274,299,300], which could be tested 
alongside existing or new αvβ3-integrin antagonists, although their effect on non-
ECs that also contribute to tumour growth and angiogenesis must be considered 
carefully, as our results suggest that specifically targeting the molecules in ECs 
would be the most effective form of therapy. The small molecule inhibitors that 
have been produced so far target the VEGF-binding portion of NRP1, which, 
unlike the cytoplasmic tail, we do not know the significance of in pathological 
angiogenesis, although it would be interesting to find this out. We can also further 
explore the durability of a dual-targeted approach; it may be that additional 
mechanisms of escape arise in response to the long-term targeting of both 
molecules. 
 
Nevertheless, our main priority in this project was to discover the mechanistic 
basis behind why NRP1 becomes more sensitive to perturbation with reduced β3 
expression. This will now be explored in the following two chapters, which focus 
on NRP1’s VEGFR2-dependent and VEGFR2-independent roles, respectively, 
both of which have been shown to be influenced by NRP1’s cytoplasmic tail. 
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4. Investigating how αvβ3-integrin regulates 
neuropilin-1’s VEGFR2-dependent role in 
endothelial cells 
 
4.1 Polyoma-middle-T-antigen immortalised endothelial cells maintain their 
endothelial identity 
In order to investigate the underlying molecular mechanisms associated with the 
phenotypes presented in the previous chapter, and specifically determine how β3 
expression levels differentially affect NRP1 function, we employed polyoma-
middle-T-antigen (pMT) immortalised murine lung microvascular ECs (MLECs) 
isolated from β3-WT, β3-WT.NRP1Δcyto, β3-HET and β3-HET-NRP1Δcyto 
mice. These pMT MLECs, which are well suited for assays that require large 
numbers of cells, have previously been utilised as models to study angiogenesis 
to great effect [202,211,314], but to confirm they maintain endothelial identity in 
our hands, we routinely analysed their surface levels of the EC markers VE-
Cadherin, CD31, and ICAM-2 by flow cytometry. We consistently found them to 
display a significant enrichment in these markers compared to isotype controls 
(Figure 4.1). 
 
4.2 VEGFR-2 expression levels are marginally elevated in β3-integrin-
heterozygous endothelial cells 
β3-NULL ECs display significantly upregulated VEGFR2 expression, a 
characteristic that may arise during development in response to the absence of 
β3, and may partly explain the enhanced tumour growth and angiogenesis seen 
in β3-NULL animals [134,197,202]. We therefore assessed total VEGFR2 levels 
in the four genotypes. In comparison to β3-NULL ECs, we noted only a small (not 
significant) trend of increased VEGFR2 levels in both β3-HET and β3-HET-
NRP1Δcyto ECs (Figure 4.2). Since tumour growth and angiogenesis is reduced 
in β3-HET-NRP1Δcyto compared to β3-HET mice, this suggests that upregulated 
VEGFR2 is not necessary for elevated tumour growth and angiogenesis in β3-
HET mice. 
 
 
Figure 4.1: Polyoma-middle-T-antigen immortialised endothelial cells maintain their 
endothelial identity. Lung microvascular endothelial cells (ECs) were isolated and immortalised 
(polyoma-middle-T-antigen) from β3-WT and β3-HET mice. ECs were trypsinised and analysed by 
flow cytometry for surface levels of the EC markers VE-Cadherin, CD31, and ICAM-2.  Median 
fluorescence intensity was measured after forward versus side scatter data were tightly gated 
around, and normalised to, an isotype control. Representative flow-cytometric histogram profiles of 
β3-WT and β3-HET ECs are shown.
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Figure 4.2: VEGFR-2 expression levels are elevated in β3-integrin-heterozygous endothelial 
cells. Lung microvascular endothelial cells (ECs) were isolated and immortalised 
(polyoma-middle-T-antigen) from β3-WT and β3-HET mice that were expressing either normal 
(WTNRP1) or cytoplasmic-tail deleted NRP1 (NRP1Δcyto). Multiple EC lysates of each genotype 
were Western blotted (WB) to examine total cellular levels of VEGFR2 and β3-integrin.  HSC-70 was 
used as a loading control.  Bar charts of densitometric analysis of mean (+SEM) changes between 
the four genotypes are shown below.   Asterisks indicate statistical significance: *, P<0.05.
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4.3 VEGFR2 activation and degradation patterns are no different between 
wild-type and β3-integrin heterozygous endothelial cells with and without 
neuropilin-1’s cytoplasmic tail 
Given that NRP1 is widely recognised as a regulator of VEGFR2 function 
[68,272-275,277,278], we wanted to determine whether β3 expression levels 
differentially affect known NRP1-mediated VEGFR2 responses. NRP1’s 
cytoplasmic tail is important for driving VEGFR2 trafficking, which increases 
VEGFR2 phosphorylation and downstream signalling through ERK. Although this 
effect has only been observed in aortic/arterial ECs before, and been projected to 
be more associated with arteriogenesis than angiogenesis, we wondered whether 
it featured in our MLECs with normal or reduced β3 expression. 
 
We started to address this objective by immunoblotting for changes in VEGFR2 
phosphorylation, ERK1/2 phosphorylation, and total VEGFR2 levels over a time 
course of VEGF stimulation between β3-WT and β3-HET ECs with and without 
NRP1’s cytoplasmic tail. Both extended (Figure 4.3A) and shortened (Figure 
4.3B) time courses were used so we were able to discern subtle changes in 
timing patterns (4.3A) and, once we had this information, to simultaneously 
compare all four genotypes at the most crucial time points (4.3B). Importantly, 
like all other assays that require EC adhesion in this chapter, prior to their VEGF 
stimulation, ECs were allowed to adhere to a complex matrix containing gelatin, 
collagen I (COLI), fibronectin (FN), and vitronectin (VN), to ensure we were not 
perturbing VEGFR2 function by denying its interaction with β3, which relies on 
VN [ref]. Apart from the previously mentioned upregulation of VEGFR2 in the β3-
HET ECs, no differences in patterns of VEGFR2 expression over the timecourses 
were observed between the ECs, with VEGFR2 levels steadily decreasing over 
time after VEGF stimulation in each case (Figure 4.3A). This suggests that the 
VEGFR2 protein is degraded over time in all four genotypes in a similar manner 
to that previously reported [88,200,315], indicating that VEGFR2 degradation was 
not affected by the loss of NRP1’s cytoplasmic tail even with reduced β3 
expression. Although VEGF-induced VEGFR2 phosphorylation was slightly 
elevated in β3-HET ECs, VEGFR2 phosphorylation, like degradation, was not 
significantly changed by the introduction of the NRP1Δcyto mutation in either β3-
WT or β3-HET ECs. In contrast, VEGF-induced ERK1/2 phosphorylation was 
133 
sensitive to NRP1 cytoplasmic deletion in β3-HET ECs but not β3-WT ECs 
(Figure 4.3B). This may be suggestive of a slight disruption in NRP1 cytoplasmic 
tail-mediated VEGFR2 trafficking in β3-HET-NRP1Δcyto ECs, although we still 
cannot be sure that this change in ERK1/2 phosphorylation is not regulated 
independently from VEGFR2, especially given the lack of difference in VEGFR2 
phosphorylation. Moreover, differences seem to be too subtle to fully explain the 
high degree of sensitivity of angiogenesis in β3-HET mice (relative to WT 
counterparts) to NRP1’s cytoplasmic tail removal. Of additional noteworthy 
mention, NRP1 expression, like that of VEGFR2, was found to be slightly 
elevated in both β3-HET ECs, but also was increased in the Δcyto ECs (in both 
β3-WT and β3-HET cells) relative to those that expressed normal NRP1, arguing 
against the idea that in vivo phenotypes are influenced by changes in NRP1 
expression. 
 
Taken together, these results show that certain facets of previously recognised 
NRP1-mediated VEGFR2 trafficking are seemingly not dependent on NRP1’s 
cytoplasmic tail in microvascular MLECs. However, as slightly enhanced ERK1/2 
phosphorylation in β3-HET ECs is sensitive to the loss of NRP1’s cytoplasmic 
tail, VEGFR2 trafficking will be further investigated later. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: VEGFR2 degradation patterns and signalling through ERK are no different 
between wild-type and β3-integrin heterozygous endothelial cells with and without 
neuropilin-1’s cytoplasmic tail. Lung microvascular endothelial cells (ECs) were isolated and 
immortalised (polyoma-middle-T-antigen) from β3-WT and β3-HET mice that were expressing either 
normal (WTNRP1) or cytoplasmic-tail deleted NRP1 (NRP1Δcyto). ECs were seeded overnight on a 
complex matrix containing gelatin, collagen, fibronectin and vitronectin, and were then stimulated 
with VEGF over: A an extended time course to examine protein degradation and signalling kinetics; 
B a shorter time course to enable comparison between all genotypes. ECs were lysed and blotted 
for levels of phosphorylated (‘p’...) and total VEGFR2, NRP1, β3-integrin, and phosphorylated and 
total ERK1/2. HSC-70 was used as a loading control. Data are representative of 3 independent 
experiments.
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4.4 Neuropilin-1-regulated VEGFR2 signalling is no different between wild-
type and β3-integrin heterozygous endothelial cells with and without 
neuropilin-1’s cytoplasmic tail 
Besides investigating NRP1’s reported regulation of VEGFR2/ERK signalling, we 
wanted to examine its role in other VEGF-induced signalling pathways in β3-WT 
and β3-HET microvascular MLECs to continue determining whether β3 levels 
differentially affect NRP1-mediated VEGFR2 function. Of particular interest was 
NRP1’s involvement in the regulation of p130Cas phosphorylation, which, in 
HUVECs, is dependent on NRP1’s cytoplasmic tail, and may be part of a NRP1-
mediated signalling pathway that additionally involves FAK Y407 phosphorylation 
[272,273]. However, immunoblotting for phosphorylated and total p130Cas and 
FAK after ECs were stimulated with VEGF over extended (Figure 4.4A) and 
shortened (Figure 4.4B) time courses revealed no relative changes in 
phosphorylation of either molecule upon NRP1 cytoplasmic tail removal, even 
when β3 expression was reduced. It did appear, however, as though both total 
and phosphorylated levels of p130Cas and FAK were slightly reduced by the loss 
of NRP1’s cytoplasmic tail in β3-WT and β3-HET ECs to a similar degree. Thus, 
although this does not translate to differences in phosphorylation relative to the 
amounts of total protein, NRP1’s cytoplasmic tail may have some influence on 
these molecules, yet not in a way that explains the differential sensitivity of β3-
WT and β3-HET mice to NRP1 targeting. 
 
A mild reduction in p38MAPK activity following the prevention of NRP1’s VEGF-
binding ability in HUVECs and PAEs [133,275], and in PAEs expressing mutant 
NRP1 lacking its cytoplasmic tail [80], have previously been reported. Also, there 
have been reports of reduced Akt phosphorylation upon NRP1 siRNA knockdown 
in HDMECs [271], but not HUVECs [133,272,275] (except by a small molecule 
NRP1 inhibitor [274]). We therefore additionally examined phosphorylation of 
these molecules over a VEGF time course by immunoblotting, but again saw no 
changes that might explain why β3-HET mice are sensitive to NRP1 perturbation, 
whereas β3-WT mice are not (Appendix Figure 3). We therefore conclude that 
β3 levels do not differentially affect NRP1-mediated VEGF-induced signalling. 
 
 
Figure 4.4: Neuropilin-1-regulated VEGFR2 signalling via p130Cas and FAK is no different 
between wild-type and β3-integrin heterozygous endothelial cells with and without 
neuropilin-1’s cytoplasmic tail. Lung microvascular endothelial cells (ECs) were isolated and 
immortalised (polyoma-middle-T-antigen) from β3-WT and β3-HET mice that were expressing either 
normal (WTNRP1) or cytoplasmic-tail deleted NRP1 (NRP1Δcyto). ECs were seeded overnight on a 
complex matrix containing gelatin, collagen, fibronectin and vitronectin, and were then stimulated 
with VEGF over: A an extended time course to examine signalling kinetics; B a shorter time course 
to enable comparison between all genotypes. ECs were lysed and blotted for levels of 
phosphorylated (‘p’...) and total p130cas, and phosphorylated (tyrosine 407) and total FAK. HSC-70 
was used as a loading control. Data are representative of 3 independent experiments.
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4.5 Cell surface biotinylation internalisation assays do not reliably measure 
VEGFR2 trafficking in pMT MLECs, but VEGFR2 surface levels do not 
appear different in β3-HET ECs with or without NRP1’s cytoplasmic tail by 
flow cytometry 
Whilst we saw no changes in VEGFR2 activation or degradation in NRP1Δcyto 
ECs with normal or reduced β3 expression, we did see a slight change in ERK1/2 
phosphorylation between β3-HET and β3-HET-NRP1Δcyto ECs, which may 
reflect changes in VEGFR2 trafficking. It was therefore necessary to continue 
looking at different aspects of VEGFR2 trafficking in our MLECs. Our first 
approach was to monitor internalised VEGFR2 and NRP1 using a cell surface 
biotinylation assay that was previously used successfully by Remacle et al. [316]. 
In this assay, surface proteins are biotinylated and internalised with VEGF for 
different time points before the remaining biotin on cell surface proteins is 
stripped off using a membrane-impermeable reducing agent. Cells are then lysed 
and immunoprecipitated (IP’d) for biotin, and these IPs are immunoblotted for 
VEGFR2 and NRP1 to see their degree of internalisation at the different VEGF 
time points. Unfortunately, in our pMT ECs we were not able to achieve 
consistent results with the reducing agent MESNA, as shown by its inability to 
strip off remaining biotin in the ‘stripped’ internal control in pMT ECs, but not 
HUVECs (Figure 4.5B). This did not improve after continuous attempts to 
optimise the protocol, which involved trialling the temperature at which it was 
performed, the concentration of biotin, the timing of different incubation steps, the 
washing buffer, the lysis buffer, and the surface protein being examined. 
However, changing the reducing agent to TCEP did result in successful biotin 
stripping, though still not altogether reliably. We therefore cannot read too much 
into VEGFR2 and NRP1 internalisation results obtained with TCEP. An example 
of such an experiment is shown in Figure 4.5C, and the quantified degree of 
internalisation is presented in Figure 4.5D. Here, whilst biotin stripping in the 
control is somewhat effective in β3-HET ECs, it is not so in WT ECs, reducing the 
impact of this data. If one were to analyse this data, though, it looks as though 
VEGFR2 and NRP1 are internalised very quickly in WT ECs before their signal 
disappears, which may suggest their complete degradation or recycling, or more 
likely a combination of both. In β3-HET ECs, however, VEGFR2 and NRP1 are 
more slowly internalised, and their signals are lost more slowly, in a manner 
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similar to the degradation pattern observed before, although recycling may play a 
role here as well. In both β3-WT and β3-HET ECs lacking NRP1’s cytoplasmic 
tail, NRP1 internalisation is again difficult to comment on due to the inefficiency of 
biotin stripping in the control. However, VEGFR2 is not internalised in either case, 
suggesting that NRP1’s cytoplasmic tail is important for VEGFR2 endocytosis, 
although it is possible that the assay is too insensitive to pick up subtle signal 
changes. Due to the unreliability of this assay in pMT ECs, we were also not able 
to use it to specifically analyse VEGFR2/NRP1 recycling, despite attempts using 
the recycling inhibitor, primaquine (not shown).  
 
As we were unable to accurately measure VEGFR2 trafficking by cell surface 
biotinylation, we turned to the analysis of VEGFR2 surface levels in trypsinised 
pMT LMECs over a time course of VEGF stimulation by flow cytometry (Figure 
4.5E). Surface levels were similar between the four genotypes, with each 
showing an initial increase in surface levels upon stimulation that likely reflects 
the previously reported VEGFR2 mobilisation from an internal pool [88], and 
subsequently a general decrease over time, in line with various internalisation 
studies [88,89,200,315]. This therefore suggests that, ultimately, perturbing 
NRP1 function when there are normal or reduced β3 expression levels does not 
majorly affect net changes in VEGFR2 internalisation and recycling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Cell surface biotinylation internalisation assays do not reliably measure VEGFR2 
trafficking in pMT MLECs, but VEGFR2 surface levels do not appear different in β3-HET ECs 
with or without NRP1’s cytoplasmic tail by flow cytometry. Lung microvascular endothelial cells 
(ECs) were isolated and immortalised (polyoma-middle-T-antigen) from β3-WT and β3-HET mice 
that expressed either normal or cytoplasmic-tail-deleted NRP1 (NRP1Δcyto).                                            
A Biotinylation assay schematic (adapted from [316]): Cell surface proteins of ECs seeded on a 
complex matrix containing gelatin, collagen, fibronectin and vitronectin, were biotinylated, 
internalised with VEGF for different time points, and the remaining biotin on cell surface proteins was 
‘stripped’ off using a membrane-impermeable reducing agent (MESNA/TCEP). Cells were lysed and 
immunoprecipitated (IP’d) for biotin. B Western blot (WB) of biotin-pulldowns show MESNA 
effectively strips biotin off VEGFR2 and NRP1 in HUVECs, but not in pMT ECs. C WB of biotin IPs 
showing internalised VEGFR-2 and NRP1 over time of VEGF stimulation between the different 
transgenic pMT ECs. ‘Total’ surface protein (from cells not stimulated and not stripped), and protein 
from cells not stimulated with VEGF, but ‘stripped’ with TCEP, are shown as controls. D Graphs 
showing the internalisation of VEGFR2 and NRP1 over time stimulated with VEGF (mins) between 
the different ECs from C. Internalisation is quantified as a percentage of the ‘total’ surface protein 
level from a densitometric analysis. E Following a VEGF time course, pMT ECs were trypsinised and 
analysed by flow cytometry for surface levels of VEGFR2.  Median fluorescence intensity was 
measured, and normalised to, an isotype control. The graph shows the relative surface level of 
VEGFR2 (means ±SEM) relative to the 0 (non-stimulated) time point from 3 independent 
experiments.
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4.6 There are no relative differences in neuropilin-1-VEGFR2 interactions 
between wild-type and β3-heterozygous endothelial cells 
VEGF-induced interactions between VEGFR2 and NRP1 are elevated in β3-
NULL ECs, and contribute to increased angiogenesis and ERK signalling in this 
model [202]. We therefore next examined this interaction in response to VEGF in 
β3-WT and β3-HET ECs by co-immunoprecipitation, first comparing different 
isolates to one another (Figure 4.6A), and then comparing association kinetics 
over a time course (Figure 4.6B). No significant changes in VEGFR2-NRP1 
associations were observed in β3-HET ECs compared to β3-WT ECs, despite 
their upregulated expression of both proteins. In contrast to a previously 
published study [280], we saw that the VEGF-induced association between the 
two molecules was preserved in both β3-WT-NRP1Δcyto and β3-HET-
NRP1Δcyto ECs (Figure 4.6C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: There are no relative differences in neuropilin-1-VEGFR2 interactions between 
wild-type and β3-heterozygous endothelial cells. Lung microvascular endothelial cells (ECs) 
were isolated and immortalised (polyoma-middle-T-antigen) from β3-WT and β3-HET mice that were 
expressing either normal (WTNRP1) or cytoplasmic-tail deleted NRP1 (NRP1Δcyto). ECs were 
seeded overnight on a complex matrix containing gelatin, collagen, fibronectin and vitronectin and 
stimulated with VEGF for the indicated amounts of time and then lysed and immunoprecipitated for 
VEGFR2 (VEGFR2 IP), before being blotted for NRP1 association. A Western blot showing 
VEGFR2-NRP1 associations in 2 separate isolates of β3-WT and β3-HET ECs either stimulated (10 
mins) with VEGF or unstimulated (0 mins). Total cell lysates taken before the IP (pre-IP) and after the 
IP (post-IP) are shown as controls to confirm the efficiency of the IP. B Western blot showing 
VEGFR2-NRP1 associations over a VEGF time course. A total cell lysate (TCL) is shown for 
comparison. C Western blot showing VEGFR2-NRP1 associations from β3-WT and β3-HET ECs 
lacking NRP1’s cytoplasmic tail.
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4.7 Discussion 
Since elevated tumour growth and angiogenesis in β3-NULL mice was 
dependent on upregulated VEGFR2 expression [134], and NRP1 has been 
shown to positively regulate VEGFR2, including via its cytoplasmic tail 
[68,80,268,272-275,277,278], we sought to determine whether β3 expression 
levels differentially regulate NRP1-mediated VEGFR2 function, and therefore 
explain why tumour growth and angiogenesis are sensitive to NRP1 perturbation 
in β3-HET, but not β3-WT mice. 
 
In contrast to the β3-NULL model, we observed a relatively small upregulation in 
VEGFR2 expression in both β3-HET and β3-HET-NRP1Δcyto ECs. This 
suggests that enhanced VEGFR2 expression in ECs is not required for elevated 
tumour growth and angiogenesis in β3-HET mice. Moreover, it means that the 
reduction in tumour growth and angiogenesis in β3-HET-NRP1Δcyto mice occurs 
in spite of slightly enhanced VEGFR2 levels in ECs. Whilst we cannot rule out the 
role of VEGFR2 in other cell types that contribute to our in vivo phenotypes in β3-
HET mice, there was no change in VEGFR2 expression in the acute EC-depleted 
β3 model in our previous publication, which displayed transiently reduced tumour 
growth and angiogenesis [211], and joint β3/NRP1 EC targeting inhibits pre-
established tumour growth and angiogenesis, both implying that ECs can majorly 
influence our phenotypes.  
 
In aortic/arterial ECs, NRP1 is known to complex with VEGFR2 in the presence of 
VEGF and enhance its trafficking away from a degradative pathway, but rather 
through recycling endosomes via NRP1’s cytoplasmic tail’s linkage to 
synectin/myosin VI [80,268]. This keeps VEGFR2 away from the phosphatase 
PTP1b and results in enhanced VEGFR2 and ERK1/2 phosphorylation 
[80,82,268]. Since NRP1’s cytoplasmic tail was previously shown to be 
dispensable for angiogenesis, but more involved in arteriogenesis [268], NRP1’s 
mediation of VEGFR2 recycling and enhanced ERK signalling has been 
proposed to be specific for arteriogenesis [287]. However, this role of NRP1 had 
never been examined in microvascular ECs, and we wondered whether it 
featured differentially between β3-WT and β3-HET ECs. No differences in 
VEGFR2 phosphorylation, surface levels, or degradation patterns were found 
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when NRP1 lacked its cytoplasmic tail in either β3-WT or β3-HET ECs. 
Moreover, there was no difference in VEGF-induced NRP1-VEGFR2 association 
between β3-WT and β3-HET ECs. However, whilst VEGF-induced ERK1/2 
phosphorylation was not dependent on NRP1’s cytoplasmic tail in β3-WT ECs, it 
was in β3-HET ECs. Overall, this implies that NRP1-mediated VEGFR2 
trafficking does not occur to a significant extent in WT microvascular ECs, 
agreeing, perhaps, with the notion that it is more of an archetype of 
arteriogenesis, at least when β3 is sufficiently expressed. However, that there 
was a minor difference in ERK1/2 phosphorylation between β3-HET and β3-HET-
NRP1Δcyto ECs may be indicative of a subtle increase in NRP1-dependent 
VEGFR2 recycling in β3-HET ECs that could not be detected in our analyses. 
Our biotinylation data may support this, given slight changes in VEGFR2 
internalised signal between β3-WT and β3-HET ECs, although the unreliability of 
the assay in pMT ECs, and our unsuccessful attempts at extending it to monitor 
recycling, leaves this open to debate. As differences in ERK signalling were only 
minor, and we observed no other VEGFR2 trafficking-related changes, and 
furthermore, the change in ERK1/2 phosphorylation may have been mediated 
independent of VEGFR2, we did not pursue further with VEGFR2 recycling 
analyses. If we were to do so in the future, then perhaps it would be most 
worthwhile to use immunocytochemistry to monitor potential differences in 
VEGFR2 co-localisation with different Rab GTPase markers of recycling 
endosomes over a VEGF-stimulated timecourse between β3-WT and β3-HET 
ECs. 
The lack of an effect on VEGF-induced ERK phosphorylation in β3-WT-
NRP1Δcyto ECs is in agreement with other studies that saw no effect in 
response to different forms of NRP1 targeting in HUVECs, including using anti-
NRP1 monoclonal antibodies [133], NRP1 siRNA knockdown [272], and a NRP1 
mutant defective in VEGF binding [273]. However, there have been contradictions 
in this matter. Whilst the differences mentioned in aortic/arterial ECs that feature 
enhanced VEGFR2 trafficking may be explained by their inherent tendencies 
towards supporting arteriogenesis, minor reductions in ERK activation have also 
been observed in HUVECs in response to another NRP1 siRNA [282] or a small 
molecule NRP1 antagonist [274], and in HDMECs following NRP1 siRNA 
knockdown [271]. Clearly, the role that NRP1 plays in mediating VEGF-induced 
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ERK phosphorylation is dependent on the EC type and the method of NRP1 
inhibition, and so the mechanistic basis behind these discrepancies must be 
further scrutinised. 
As shown previously in HUVECs [272], but not arterial ECs or heart tissue [268], 
we observed no difference in VEGF-induced VEGFR2 Y1175 phosphorylation in 
ECs lacking NRP1’s cytoplasmic tail, again suggesting a division in different cell 
types’ predispositions for different processes, but this warrants further 
investigation. Nevertheless, in our microvascular ECs, this portion of NRP1 does 
not influence VEGFR2 activation under conditions of both normal and reduced β3 
expression. 
 
Since both total and phosphorylated levels of p130Cas and FAK were marginally 
reduced by the loss of NRP1’s cytoplasmic tail in β3-WT and β3-HET ECs to a 
similar degree, this does not support the previously reported relative reduction in 
phosphorylation of each molecule in response to NRP1 targeting in HUVECs 
[272,273]. Nor does it explain the differential sensitivity of tumour growth and 
angiogenesis in β3-WT and β3-HET mice to NRP1 targeting. Furthermore, unlike 
previous studies in other cell types [80,133,271,274,275], we observed no 
obvious changes in Akt or p38MAPK activation in either β3-WT or β3-HET 
microvascular ECs. 
 
Perhaps partly explaining the absence of differences in NRP1-mediated VEGFR2 
trafficking and signalling in our different ECs, unlike β3-NULL ECs, we found no 
change in VEGF-induced NRP1-VEGFR2 interactions in β3-HET ECs compared 
to β3-WT ECs. The interactions we detected were also not dependent on NRP1’s 
cytoplasmic tail in our cells, unlike results published by Prahst et al. [280], which 
showed that the PDZ domain of NRP1 was required for NRP1-VEGFR2 
interactions in PAEs and HUVECs. Again, this may point to distinctions in NRP1’s 
role between EC types, and should be a matter for further investigation. 
 
Overall, although our cultured transgenic microvascular ECs are not perfect 
mimics of ECs in pathological angiogenesis, results garnered from them indicate 
that the increased sensitivity of tumour growth and angiogenesis to perturbations 
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in NRP1 in β3-HET mice cannot be explained by NRP1’s VEGFR2-dependent 
function, despite potential subtle changes in VEGFR2 trafficking. 
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5. Investigating how αvβ3-integrin regulates 
neuropilin-1’s VEGFR2-independent role in 
endothelial cells 
 
5.1 Examining adhesion and cell spreading properties of β3-integrin-wild-
type and heterozygous endothelial cells with and without neuropilin-1’s 
cytoplasmic tail 
Intriguingly, recent studies have shown that NRP1’s contribution to angiogenesis 
is not limited to its binding of VEGF [269,270], and that its regulation of the 
process can be mediated by FN [271,290]. Indeed, prior to its description as a 
VEGF co-receptor, NRP1 was identified as a surface protein mediating cell 
adhesion [254], and Valdembri et al. [288] later found it to promote HUVEC 
adhesion to FN, but not COLI, VN or LN, in a manner dependent on NRP1’s SEA 
synectin-binding motif and α5β1 [288]. As our transgenic models included 
manipulations of both NRP1 and αvβ3, whose canonical ligand is VN, we 
examined adhesion of our β3-WT, β3-WT.NRP1Δcyto, β3-HET and β3-HET-
NRP1Δcyto pMT ECs to a range of concentrations of VN or FN (Figure 5.1A). 
Unsurprisingly, compared to β3-WT and β3-WT-NRP1Δcyto ECs, β3-HET and 
β3-HET-NRP1Δcyto ECs showed reduced adhesion to VN over a range of 
concentrations tested, although, in this assay, the same was also true for their 
adhesion to FN, indicating that the heterozygous expression of β3 reduces 
adhesion to both its VN and FN ligands, regardless of a deletion in NRP1’s 
cytoplasmic tail. In contrast to Valdembri et al’s [288] study, the loss of NRP1’s 
cytoplasmic tail had no obvious effect on microvascular EC adhesion to FN, with 
normal or reduced β3 expression. Having established working concentrations of 
ECM components, we tested the ECs’ adhesion to saturating concentrations of a 
range of matrices, normalising the data to the degree of adhesion to FN (which 
universally bound the most cells), since we would later be analysing other EC 
processes that we did not want to be influenced by differences in adhesion to low 
concentrations of ECM components (Figure 5.1B). The only clear difference 
noted on saturating matrix concentrations in these types of assays was the 
expected reduction in adhesion of β3-HET and β3-HET-NRP1Δcyto ECs to 
matrices containing VN. Since ECs were only allowed to adhere over a short time 
(90 minutes) in these assays, we also examined long-term cell spreading of our 
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four cell lines to 10 μg/ml FN, a saturating concentration which effectively 
promotes adhesion and migration of a number of cell types (Figure 5.1C) [317-
319]. Cell spreading on FN after 6 hours was similar in all four genotypes, 
meaning the subtle differences in adhesion between genotypes were negligible if 
the ECs were allowed enough time to adhere to saturating FN concentrations. 
Importantly, this gives us the opportunity to measure EC migration on this 
component over a longer period of time without the added complexity of 
differences in EC adhesion (see later). 
 
5.2 Examining surface levels of integrins in β3-integrin-wild-type and 
heterozygous endothelial cells with and without neuropilin-1’s cytoplasmic 
tail 
Although there were only relatively subtle differences in adhesion of our four 
transgenic cell lines to VN and FN, we still wondered whether reduced β3 
expression levels cause changes in other integrins. Since NRP1 is known to 
interact with a number of integrins [202,288,307], they may be involved in 
allowing NRP1 to be more sensitive to perturbation in β3-HET ECs.  
 
We therefore used flow cytometry to examine the surface expression of various 
EC integrin subunits in our pMT ECs (Figure 5.2 and Appendix Figure 4). 
Consistent with the adhesion data, αv- and β3-integrin levels were significantly 
higher in β3-WT and β3-WT-NRP1Δcyto ECs compared to their β3-HET 
counterparts. Whilst α1, β1 and β5 surface levels were unchanged, we observed 
a small increase in α2 surface expression in β3-HET ECs. Most notably, 
however, α5 surface levels were lower in ECs expressing reduced levels of β3-
integrin, which might partially account for their reduced adhesion to FN. The 
molecular consequences of these changes in integrin surface levels in β3-HET 
ECs on NRP1 function would therefore be interesting to dissect to further 
ascertain whether they contribute in any way to our in vivo phenotypes. 
 
 
 
 
 
Figure 5.1: Examining adhesion and cell spreading properties of β3-integrin-wild-type and 
heterozygous endothelial cells with and without neuropilin-1’s cytoplasmic tail. A ECs of the 
indicated genotypes were plated on increasing concentrations of FN or VN.  After 90 minutes plates 
were washed and remaining cells were fixed and stained. Dye was extracted and measured 
spectophotometrically.  The graph shows mean (±SEM) number of cells that remained attached to 
the plate after the procedure. B ECs of the indicated genotypes were seeded on collagen type I 
(COLI), fibronectin (FN), laminin (LN), vitronectin (VN), or a complex mixture of COLI, FN, VN and 
gelatin (MIX) for 90 minutes. Unattached cells were washed off, and the remaining cells were fixed 
and stained. Dye was extracted and measured spectophotometrically. The bar chart shows the 
percentage of cell adhesion to each component relative to FN (means +SEM from 3 independent 
experiments). C 70×105 cells of the indicated genotypes were plated for 6 hours on 10 μg/ml FN in 
6-well plates.  Phase contrast photographs were taken and cell surface areas were measured using 
ImageJTM software.  The bar chart represents mean (+SEM) surface area quantified from multiple 
images (n ≥ 50 cells per genotype). Asterisks indicate statistical significance: *, P<0.05; **, P<0.01; 
***, P<0.001; nsd = not significantly different.  Unpaired two-tailed t test.
A
β3-WT
β3-WT.NRP1∆cyto
β3-HET
β3-HET.NRP1∆cyto
0
50
100
150
%
 A
dh
es
io
n
COLI FN LN VN MIX
Matrix Component/s
*** *
0
0.5
1.0
1.5
2.0
0 1 2 3 4 5
VN concentration (µg/ml)
Re
la
tiv
e 
Ad
he
si
on
 (A
U)
β3-WT
β3-WT.NRP1∆cyto
β3-HET
β3-HET.NRP1∆cyto
0.5
1.0
1.5
2.0
0 2 4 6 8 10
FN concentration (µg/ml)
Re
la
tiv
e 
Ad
he
si
on
 (A
U)
1000
Ce
ll 
su
rfa
ce
 a
re
a 
(µ
m
2 )
200
400
600
800
0
nsd
B
β3-WT
β3-WT.NRP1∆cyto
β3-HET
β3-HET.NRP1∆cyto
C
148
Figure 5.2: Examining surface levels of integrins in β3-integrin-wild-type and heterozygous 
endothelial cells with and without neuropilin-1’s cytoplasmic tail. ECs of the indicated 
genotypes were measured for their surface expression of endothelial integrin subunits by 
flow-cytometry.  Median fluorescence intensity (MFI) was measured after forward versus side scatter 
data were tightly gated around, and normalised to, an isotype control. The bar chart shows the 
relative change in MFI of β3-HET compared to β3-WT ECs or of β3-HET.NRP1Δcyto ECs compared 
to β3-WT.NRP1Δcyto ECs (means +SEM from 3 independent experiments). *Relative changes were 
deemed significant with a 2-fold change. Representative flow-cytometric histogram profiles are 
shown below for significantly changed integrins.
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5.3 VEGF-induced migration in β3-integrin-heterozygous endothelial cells 
is dependent on neuropilin-1 
It has been widely reported that targeting NRP1 in different ways reduces the 
migration of multiple EC types [68,272-275]. As EC migration is a key part of 
angiogenesis, we wanted to determine the effect of reduced β3 expression levels 
on EC migration in response to VEGF stimulation. Importantly, we wondered 
whether β3-WT and β3-HET EC migration are differentially affected by the loss of 
NRP1’s cytoplasmic tail, as was the case for ERK1/2 phosphorylation, and 
therefore help explain our in vivo phenotypes. 
 
Since NRP1, α5β1-integrin and αvβ3 all promote adhesion to FN [141,288], we 
set out to measure the migration of our four pMT EC lines on this matrix 
component, confident that our results would not be complicated by differences in 
cell spreading (see earlier). We examined both random (Figure 5.3A) and 
directed (Figure 5.3B) migration in cells following their long-term (ie. overnight) 
adhesion to a saturating concentration of FN. Both types of migration assays 
revealed enhanced baseline and VEGF-induced migration in β3-HET ECs, 
compared to β3-WT ECs. Unlike β3-WT ECs, β3-HET ECs were sensitive to 
NRP1 disruption, in a manner reminiscent of the tumour growth and angiogenesis 
phenotypes in mice of these genotypes. This therefore suggests that aberrant 
integrin-directed migration contributes to pathological angiogenesis in our 
models. Migration appears to be regulated by β3 expression levels, but, at least 
in these transgenic pMT microvascular ECs, is only dependent on NRP1’s 
cytoplasmic tail when β3 levels are reduced. 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: VEGF-induced migration in β3-integrin-heterozygous endothelial cells is 
dependent on neuropilin-1. A ECs were firmly attached to FN coated dishes and then imaged live 
for 15 hours in low serum medium ±VEGF.  Individual cells were tracked every 10 minutes over this 
period using ImageJTM. The bar chart shows the EC migration speed of each of the indicated 
gentoypes (mean +SEM from 3 independent experiments; n=50 cells per condition). B ECs were 
plated onto FN coated dishes overnight. After 3 hours of starvation a scratch wound was created and 
cells were incubated in low serum medium ± VEGF for 24 hours. The bar chart shows the percentage 
closure of the scratch ‘wound’ as a result of directed cell migration (means +SEM from 3 independent 
experiments; n=27 for each condition). Representative images of scratch wound closure at 24 hours 
are shown below. Scale bar = 200μm.  Asterisks indicate statistical significance: *, P<0.05; **, 
P<0.01; ***, P<0.001; nsd = not significantly different. Unpaired two-tailed t test.  
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5.4 Neuropilin-1’s sub-cellular localisation is proportionally similar between 
β3-integrin-wild-type and heterozygous endothelial cells 
Taking steps towards deciphering how β3 expression levels influence the 
sensitivity of EC migration to NRP1 perturbations, we first examined NRP1’s 
distribution in subcellular compartments in β3-WT and β3-HET ECs after cell 
fractionation, looking for obvious signs of changes in NRP1 localisation (Figure 
5.4). Immunoblotting for NRP1 and markers of the different fractions revealed no 
clear differences in NRP1 sub-cellular localisation between the ECs, other than 
the previously noted trend toward overexpression of the protein in β3-HET ECs. 
 
5.5 Neuropilin-1’s localisation at the ends of actin filaments is altered in 
stimulated β3-integrin-depleted endothelial cells 
NRP1 is known to localise at adhesion sites, and co-associate with FA-
associated proteins [271,288,289]. We therefore next immunolocalised NRP1 
alongside filamentous (F)-actin staining in cells plated on FN overnight. These 
cells included our pMT β3-WT and β3-HET MLECs (Figure 5.5A) and primary 
MLECs that were isolated from β3-floxed-Pdgfb-iCreERT2-negative (β3-WT) and -
positive animals (Figure 5.5B), which were supplemented with OHT in culture to 
induce the depletion of β3 in the Cre-positive ECs (β3-EC-ID). In all of these ECs, 
the lack of VEGF-stimulation resulted in NRP1 localised to mature FA-like 
structures, which were found at the plus-ends of F-actin fibres. Whilst this 
localisation was maintained after VEGF stimulation in the pMT and primary β3-
WT ECs, in VEGF-stimulated β3-HET and primary β3-EC-ID ECs, NRP1 only 
very rarely localised to these sites. These changes therefore intriguingly highlight 
a potential mechanism whereby β3 expression levels control NRP1’s localisation 
to FA-like structures in a manner sensitive to VEGF stimulation. 
 
 
 
 
 
 
 
 
Figure 5.4: Neuropilin-1’s sub-cellular localisation is proportionally similar between                   
β3-integrin-wild-type and heterozygous endothelial cells. β3-WT and β3-HET ECs were 
subjected to a cell fractionation experiment following ±VEGF treatment for 10 minutes. Fractionated 
samples were then analysed by Western blot (WB) for the indicated proteins. 1=cytoplasmic extract; 
2=membrane extract; 3=soluble nuclear extract; 4=chromatin-bound nuclear extract; 5=cytoskeletal 
extract. Protein markers for each sub-cellular compartment were included as controls. Data are 
representative of 2 independent experiments. The bar charts represent the relative proportion (%) of 
VEGFR2 or NRP1 present in each fraction determined by ImageJTM densitometry. 
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Figure 5.5: Neuropilin-1’s localisation at the ends of actin filaments is altered in stimulated     
β3-integrin-depleted endothelial cells. ECs of the indicated genotypes were seeded overnight 
onto FN-coated glass coverslips, starved for 3 hours in serum-free medium, and stimulated with 
VEGF for 10 minutes. Cells were fixed and stained with phalloidin for filamentous actin (F-actin - 
green), and immunostained for neuropilin-1 (NRP1- red). White arrows point to the ends of actin 
filaments. A The above was carried out on β3-WT and β3-HET 
polyoma-middle-T-antigen-immortalised lung microvascular ECs. Scale bar = 20 μm. B The above 
was carried out on primary lung microvascular ECs that were isolated from                                                  
β3-floxed-Pdgfb-iCreERT2-negative and -positive animals.  Tamoxifen (OHT) was administered after 
pure EC-populations were achieved to induce β3-integrin depletion (β3-EC-ID). Scale bar = 20 μm. 
The bar chart shows the percentage of cells within the population showing NRP1 staining at the end 
of actin filaments (mean +SEM; n≥50 cells per condition).  
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5.6 β3-integrin and neuropilin-1 co-localise in the same structures, but their 
interaction is weak 
Given this β3-regulated effect on NRP1 localisation we wondered whether β3 is 
also present in the same FA-like structures, so we set about immunolocalising β3 
and NRP1 in our ECs. Unfortunately, antibodies raised against β3 produced a lot 
of background signal (even in β3-NULL cells, not shown), so instead we 
transfected β3-WT ECs with a GFP-tagged β3-integrin cDNA expression 
construct and plated them on FN overnight (Figure 5.6A). NRP1 did indeed co-
localise with β3 in FA-like structures in these ECs. 
 
β3 and NRP1 were previously shown to co-associate in HUVECs in a manner 
that was enhanced by VEGF stimulation [202]. Here, we examined their co-
association in β3-WT and β3-HET pMT ECs using an IP of NRP1 (Figure 5.6B) 
and of β3 (Figure 5.6C) to detect co-immunoprecipitation (co-IP) in both 
directions. Using the NRP1 IP we detected an association with β3, albeit a weak 
one, which did not appear to change in β3-WT ECs with VEGF stimulation or 
between unstimulated β3-WT and β3-HET ECs, taking the overexpression of 
NRP1 and reduced expression of β3 in β3-HET ECs into account. However, 
NRP1-β3 co-IP looks slightly reduced in the β3-HET sample following VEGF 
stimulation. When the β3 IP was used, we observed a slight increase in β3’s 
association with NRP1 following VEGF stimulation in β3-WT ECs, but again 
found VEGF to cause a reduced association between the molecules in β3-HET 
samples. These results are suggestive of a VEGF-dependent reduction in 
interactions between β3 and NRP1 only in β3-HET ECs, and are therefore in 
synchronisation with our immunolocalisation studies. However, IP co-association 
of the molecules was weak in both directions and changes were only subtle, 
suggesting that the interaction between them is not direct. Moreover, trends 
between β3-WT and β3-HET samples are difficult to interpret given the 
overexpression of NRP1 in β3-HET ECs.  
 
 
 
 
 
Figure 5.6: β3-integrin and neuropilin-1 co-localise in the same structures, but their 
interaction is weak. A β3-WT ECs were transfected with a β3-integrin-GFP construct (green) and 
seeded on FN-coated coverslips. 48 hours later, cells were fixed and immunostained for NRP1 (red). 
Split channel close-ups are shown to depict β3-integrin/NRP1 co-localisation.  Scale bars = 10 μm. 
B,C β3-WT and β3-HET ECs were seeded overnight on a complex matrix containing gelatin, 
collagen, fibronectin and vitronectin, and were then stimulated with VEGF and lysed and 
immunoprecipitated for: B NRP1 (NRP1 IP), before blotting for β3 association, or C β3 (β3 IP), 
before blotting for NRP1 association. Total cell lysates (TCLs) are shown as controls, and HSC-70 
served as a loading control. NB: In B, β3 was immunoblotted before NRP1, which explains why the 
β3, and β3 background, bands are present on the NRP1 WB. In C, 2 separate isolates of β3-HET 
ECs stimulated with VEGF were IP’d (HET 1 and 2).
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5.7 Myosin 9 co-associates with neuropilin-1 less in β3-heterozygous 
endothelial cells 
Due partly to the weakness of β3-NRP1 associations, which may suggest an 
indirect interaction between the two molecules, and partly to our desire to explore 
NRP1’s protein associations when there are different β3 expression levels, we 
decided to use proteomics to examine NRP1’s binding partners in β3-WT and β3-
HET EC samples in an unbiased way. We wondered whether we could identify 
proteins whose association with NRP1 changes between the samples upon 
VEGF stimulation in a way that reflects β3’s supposed regulation of NRP1 
localisation to FA-like structures. Using an anti-NRP1 antibody (raised against 
NRP1’s cytoplasmic tail), we immunoprecipitated NRP1 in unstimulated (-V) and 
VEGF-stimulated (+V) β3-WT and β3-HET ECs and, after confirming the uniform 
efficiency of the IPs between samples by silver staining them following their 
separation by SDS-PAGE (Figure 5.7A), we subjected these samples to 1D 
nano liquid chromatography tandem mass spectrometry (1D nLC-MS/MS). To 
compare the effect of VEGF stimulation on NRP1’s protein associations between 
β3-WT and β3-HET ECs, we ordered our results by the fold change between the 
ratios of β3-WT+V/-V and β3-HET+V/-V Mascot protein scores (Table 5.1). 
Though this is not quantitative data, we still get a general idea of the number of 
peptide hits in each sample. Unexpectedly, we did not find many NRP1-binding 
proteins that are associated with focal adhesions. However, after we had carried 
out this experiment, Seerapu et al. [289] published a study in which LC-MS/MS 
was used to identify NRP1’s protein associations in murine heart ECs. Here, a 
different anti-NRP1 antibody (raised against NRP1’s extracellular portion) was 
used to IP NRP1, and FA proteins were identified, such as filamin a, which 
directly interacted with NRP1 via its cytoplasmic tail [289]. We therefore surmised 
that by using an anti-NRP1 antibody targeted against the cytoplasmic tail, 
interactions at this part of the molecule may be masking the ability of the antibody 
to bind NRP1, especially as we had previously used the anti-NRP1 antibody that 
Seerapu et al. [289] used to immunolocalise NRP1 in FA-like structures. We 
therefore decided to repeat our experiment with this other antibody (NB: proteins 
in bold in Tables 5.1 and 5.2 are present in both experiments). However, before 
attempting this, we did note that, like in Seerapu et al.’s [289] study, our NRP1-
associated protein data included the NM-IIA and NM-IIB heavy chain proteins, 
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myosin 9 and myosin 10, both of which had very high Mascot scores that were 
not only reduced in the β3-HET samples relative to those of β3-WT, but were 
raised after VEGF stimulation to a much lower degree in the β3-HET sample 
compared to the β3-WT sample. This trend in NRP1-myosin 9 association was 
subsequently confirmed by co-IP (Figure 5.7B). Since NM-II proteins are 
involved in the force generation associated with mature FAs, the reduction in 
NRP1-myosin 9 assocation in VEGF-stimulated β3-HET ECs compared to 
stimulated β3-WT ECs does loosely connect with NRP1’s change in localisation 
away from FA-like structures in the stimulated β3-HET cells. However, since the 
level of NRP1-myosin 9 association does not change much between unstimulated 
and stimulated β3-HET ECs, this phenomenon does not appear to tell the whole 
story. 
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Table 5.1: Mass spectrometry results of neuropilin-1-immunoprecipitated β3-WT and 
β3-HET endothelial cell samples (first experiment). Mass spectrometry Mascot score normalised to that of NRP1 
   
Gene Protein WT-V WT+V HET-V HET+V WT+V/WT-V 
HET+V/ 
HET-V 
Fold 
change 
HET/WT 
Sfpq Splicing factor, proline- and glutamine-rich 0.46 0.07 0.49 0.38 0.15 0.78 5.06 
Rnp1 RNA recognition motif, RNP-1; Heterogeneous nuclear ribonucleoprotein M 0.52 0.14 0.56 0.48 0.27 0.86 3.18 
Nono Isoform 1 of Non-POU domain-containing octamer-binding protein 0.32 0.08 0.37 0.26 0.26 0.69 2.65 
Ei3e Eukaryotic translation initiation factor 3 subunit E 0.17 0.09 0.25 0.36 0.54 1.43 2.64 
Ei4g1 Isoform 1 of Eukaryotic translation initiation factor 4 gamma 1 0.60 0.28 0.86 0.94 0.47 1.08 2.31 
Ei3c Eukaryotic translation initiation factor 3 subunit C 0.44 0.33 0.42 0.58 0.75 1.41 1.89 
Hnrnph1 Heterogeneous nuclear ribonucleoprotein H 0.43 0.26 0.31 0.34 0.60 1.10 1.83 
Dhx9 Isoform 1 of ATP-dependent RNA helicase A 0.17 0.14 0.23 0.32 0.80 1.39 1.73 
Pcbp2 poly(rC)-binding protein 2 isoform 4 0.13 0.08 0.24 0.23 0.63 0.97 1.53 
G3bp1 Ras GTPase-activating protein-binding protein 1 0.39 0.31 0.46 0.57 0.80 1.22 1.52 
Ddx1 ATP-dependent RNA helicase DDX1 0.38 0.33 0.56 0.72 0.87 1.29 1.49 
Ei3h Eukaryotic translation initiation factor 3 subunit H 0.27 0.22 0.22 0.27 0.82 1.21 1.47 
Prrc2a protein PRRC2A isoform 2 0.17 0.10 0.25 0.20 0.56 0.82 1.45 
Rps3 40S ribosomal protein S3 0.30 0.27 0.27 0.35 0.91 1.31 1.44 
Rpsa 40S ribosomal protein SA 0.22 0.22 0.16 0.22 0.99 1.41 1.42 
Fam120a Constitutive coactivator of PPAR-gamma-like protein 1 0.54 0.47 0.53 0.65 0.87 1.23 1.41 
Myl12a myosin light chain, regulatory B-like 0.27 0.38 0.07 0.14 1.40 1.91 1.37 
Fam83d Isoform 1 of Protein FAM83D 0.27 0.29 0.17 0.25 1.07 1.46 1.36 
Hnrnpa1 Isoform Long of Heterogeneous nuclear ribonucleoprotein A1 0.20 0.17 0.17 0.19 0.82 1.10 1.34 
Ybx1 Nuclease-sensitive element-binding protein 1 0.33 0.21 0.29 0.25 0.64 0.85 1.33 
Gulp1 Isoform 1 of PTB domain-containing engulfment adapter protein 1 0.25 0.26 0.20 0.27 1.03 1.36 1.33 
Hsp90ab1 Heat shock protein HSP 90-beta 0.17 0.20 0.09 0.14 1.20 1.58 1.32 
Caprin1 caprin-1 isoform c 0.35 0.30 0.46 0.51 0.85 1.10 1.30 
Eps15 Isoform 1 of Epidermal growth factor receptor substrate 15 0.52 0.67 0.17 0.29 1.29 1.66 1.29 
Rplp0 60S acidic ribosomal protein P0 0.18 0.19 0.10 0.13 1.06 1.35 1.28 
Fxr1 Isoform C of Fragile X mental retardation syndrome-related protein 1 0.71 0.54 0.67 0.65 0.76 0.97 1.27 
Rnp1 
RNA recognition motif, RNP-1; Poly-adenylate binding protein, unique 
domain 0.61 0.55 0.74 0.85 0.90 1.15 1.27 
Igf2bp2 Isoform 1 of Insulin-like growth factor 2 mRNA-binding protein 2 0.23 0.24 0.28 0.37 1.06 1.33 1.26 
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Ei3b Eukaryotic translation initiation factor 3 subunit B 0.23 0.24 0.29 0.38 1.05 1.32 1.26 
Usp10 Isoform 1 of Ubiquitin carboxyl-terminal hydrolase 10 0.25 0.19 0.33 0.30 0.73 0.91 1.24 
Mov10 Putative helicase MOV-10 0.40 0.34 0.53 0.55 0.84 1.04 1.23 
Rps15a 40S ribosomal protein S15a 0.13 0.23 0.13 0.28 1.70 2.09 1.23 
Dhx29 ATP-dependent RNA helicase Dhx29 0.13 0.11 0.32 0.34 0.89 1.08 1.22 
Prrc2b protein PRRC2B isoform 1 0.24 0.24 0.24 0.29 0.99 1.19 1.21 
Ei2s1 Eukaryotic translation initiation factor 2 subunit 1 0.18 0.18 0.20 0.25 1.04 1.26 1.21 
Rtcb tRNA-splicing ligase RtcB homolog 0.35 0.37 0.50 0.64 1.06 1.28 1.21 
Elavl1 ELAV-like protein 1 0.24 0.27 0.31 0.41 1.11 1.33 1.20 
Eif3i Eukaryotic translation initiation factor 3 subunit I 0.15 0.17 0.15 0.19 1.12 1.30 1.17 
Pabp1 Polyadenylate-binding protein 1 1.20 1.07 1.28 1.31 0.89 1.03 1.16 
Rhamm1, 
Hmmr Isoform RHAMM1 of Hyaluronan mediated motility receptor 0.37 0.53 0.29 0.46 1.46 1.59 1.09 
Ddx5 Probable ATP-dependent RNA helicase DDX5 0.26 0.31 0.28 0.36 1.19 1.28 1.08 
Paics Multifunctional protein ADE2 1.47 1.60 0.78 0.90 1.09 1.15 1.06 
Upf1 Isoform 1/2 of Regulator of nonsense transcripts 1 0.96 0.89 1.05 1.02 0.92 0.98 1.06 
Tubb5 Tubulin beta-5 chain 0.18 0.27 0.14 0.21 1.51 1.56 1.03 
Ap1b1 AP-1 complex subunit beta-1 0.80 1.21 0.52 0.81 1.52 1.55 1.02 
Nrp1 Neuropilin-1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Ap2a1 Isoform B of AP-2 complex subunit alpha-1 1.93 2.44 1.02 1.28 1.27 1.25 -1.02 
Hspa5, 
Grp78 78 kDa glucose-regulated protein 0.17 0.21 0.19 0.24 1.27 1.24 -1.02 
Rps19 40S ribosomal protein S19 0.12 0.12 0.19 0.18 0.99 0.93 -1.07 
Eif2s2 Eukaryotic translation initiation factor 2 subunit 2 0.15 0.21 0.18 0.24 1.42 1.33 -1.07 
Ap2b1 Isoform 1 of AP-2 complex subunit beta 1.78 2.54 1.21 1.61 1.43 1.33 -1.07 
Nufip2 Isoform 1 of Nuclear fragile X mental retardation-interacting protein 2 0.50 0.39 0.50 0.36 0.77 0.72 -1.07 
Rps17 40S ribosomal protein S17 0.10 0.10 0.18 0.16 0.97 0.90 -1.08 
Eif3d Eukaryotic translation initiation factor 3 subunit D 0.32 0.40 0.34 0.40 1.26 1.15 -1.09 
Ddx6 Probable ATP-dependent RNA helicase DDX6 0.14 0.23 0.27 0.39 1.60 1.45 -1.10 
Eif3m Eukaryotic translation initiation factor 3 subunit M 0.20 0.27 0.17 0.20 1.35 1.20 -1.12 
Eif3l Eukaryotic translation initiation factor 3 subunit L 0.31 0.38 0.43 0.48 1.25 1.11 -1.12 
Cltc Clathrin heavy chain 1 1.00 1.13 0.46 0.45 1.13 0.99 -1.14 
Tbk1 Serine/threonine-protein kinase TBK1 0.48 0.68 0.27 0.33 1.43 1.25 -1.14 
Reps1 Isoform 1 of RalBP1-associated Eps domain-containing protein 1 0.49 0.82 0.25 0.35 1.68 1.41 -1.19 
Ddx3x ATP-dependent RNA helicase DDX3X 0.37 0.50 0.52 0.56 1.34 1.09 -1.23 
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Arhgap29 Isoform 1 of Rho GTPase-activating protein 29 0.18 0.39 0.13 0.22 2.09 1.68 -1.25 
Ap2m1 AP-2 mu 0.87 1.38 0.54 0.68 1.59 1.27 -1.25 
Tbkbp1 Isoform 2 of TANK-binding kinase 1-binding protein 1 0.17 0.18 0.16 0.12 1.01 0.78 -1.29 
C14orf166 UPF0568 protein C14orf166 homolog 0.16 0.25 0.30 0.35 1.55 1.17 -1.33 
Hnrnpf Isoform 1 of Heterogeneous nuclear ribonucleoprotein F 0.26 0.31 0.24 0.21 1.22 0.87 -1.39 
Ap2a2 AP-2 complex subunit alpha-2 1.39 2.29 0.82 0.90 1.65 1.09 -1.51 
Rps3a 40S ribosomal protein S3a 0.22 0.33 0.30 0.29 1.46 0.95 -1.54 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 0.23 0.37 0.21 0.20 1.56 0.93 -1.67 
Carm1 Isoform 2 of Histone-arginine methyltransferase CARM1 0.19 0.27 0.13 0.11 1.43 0.80 -1.79 
Actg1 Actin, cytoplasmic 2 1.61 3.52 0.81 0.98 2.19 1.21 -1.80 
Myh9 Myosin-9 4.40 13.92 1.81 3.06 3.17 1.69 -1.87 
Shank3 SH3 and multiple ankyrin repeat domains protein 3 0.16 0.36 0.10 0.11 2.16 1.08 -1.99 
Tardbp, 
Tdp43 TAR DNA-binding protein 43 0.17 0.30 0.17 0.15 1.81 0.88 -2.05 
FLJ45252 Uncharacterized protein FLJ45252 homolog 0.35 0.38 0.23 0.11 1.09 0.49 -2.21 
Myh10 Myosin-10 1.10 5.08 0.40 0.72 4.61 1.83 -2.53 
Msn Moesin 0.13 0.42 0.12 0.15 3.34 1.25 -2.67 
Fscn Fascin 0.07 0.26 0.13 0.16 3.46 1.29 -2.67 
Myo1c Isoform 1 of Myosin-Ic 0.61 1.66 0.38 0.35 2.70 0.92 -2.94 
Rasip1 Ras-interacting protein 1 0.17 0.40 0.13 0.08 2.32 0.63 -3.67 
Ckap4 Cytoskeleton-associated protein 4 0.08 0.31 0.07 0.06 3.79 0.95 -4.01 
Gsn Isoform 2 of Gelsolin 0.09 0.68 0.05 0.04 7.73 0.74 -10.38 
Aak1 Isoform 1 of AP2-associated protein kinase 1 0.50 0.84   0.30 1.68   
 Ago2 Protein argonaute-2   0.16 0.36 0.41   1.12 
 Anxa2 Annexin A2   0.35 0.13 0.15   1.21 
 Ap2s1 AP-2 complex subunit sigma 0.19 0.23 0.11   1.21   
 Ascc3 Activating signal cointegrator 1 complex subunit 3 isoform 2 0.08   0.19 0.14   0.76 
 Atxn2l Isoform 2 of Ataxin-2-like protein 0.24   0.36 0.29   0.80 
 Ddx17 Isoform 1 of Probable ATP-dependent RNA helicase DDX17 0.22   0.21 0.27   1.26 
 
DHX15 
putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 
isoform 1 0.11   0.20 0.19   0.93 
 Eif2s3x Eukaryotic translation initiation factor 2 subunit 3, X-linked     0.23 0.25   1.09 
 Eif3a Eukaryotic translation initiation factor 3 subunit A 0.38   0.63 0.77   1.23 
 Eif4a1 Eukaryotic initiation factor 4A-I 0.19   0.19 0.33   1.71 
 Eif4a2 Isoform 1 of Eukaryotic initiation factor 4A-II 0.19   0.17 0.25   1.46 
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Eif4a3 Eukaryotic initiation factor 4A-III 0.25   0.23 0.26   1.15 
 Eif4g2 Eukaryotic translation initiation factor 4 gamma 2 isoform 2 0.23 0.16   0.53 0.69   
 Eif4g3 Isoform 4 of Eukaryotic translation initiation factor 4 gamma 3 0.15   0.42 0.41   0.99 
 Eps15l1 Isoform 3 of Epidermal growth factor receptor substrate 15-like 1 0.26     0.16     
 FAM98A Protein FAM98A 0.08   0.28 0.38   1.35 
 Fmr1 Isoform ISO3 of Fragile X mental retardation protein 1 homolog   0.27 0.36 0.48   1.33 
 G3bp2 Isoform A of Ras GTPase-activating protein-binding protein 2 0.27   0.31 0.35   1.12 
 Gnb2l1 Guanine nucleotide-binding protein subunit beta-2-like 1     0.15 0.19   1.25 
 Hdlbp Vigilin     0.20 0.11   0.53 
 Hnrnpa2b1 Isoform 3 of Heterogeneous nuclear ribonucleoproteins A2/B1 0.15   0.24 0.30   1.25 
 Hnrnph2 Heterogeneous nuclear ribonucleoprotein H2 0.32   0.20 0.23   1.14 
 Larp1 Isoform 1 of La-related protein 1 0.17   0.32 0.39   1.20 
 Larp4 La-related protein 4     0.23 0.20   0.86 
 Mmrn2 Isoform 1 of Multimerin-2 0.34 0.49     1.46   
 Prrc2c Isoform 5 of Protein PRRC2C 0.19   0.29 0.33   1.13 
 Pura Transcriptional activator protein Pur-alpha 0.20   0.15 0.09   0.63 
 Rbm14 Isoform 1 of RNA-binding protein 14 0.17   0.19 0.10   0.51 
 Rps18 40S ribosomal protein S18   0.20 0.22 0.28   1.27 
 Rps5 40S ribosomal protein S5 0.22   0.18 0.20   1.10 
 Rps6 40S ribosomal protein S6 0.07   0.22 0.15   0.68 
 Rps8 40S ribosomal protein S8 0.20   0.25 0.27   1.07 
 Rrbp1 Isoform 3 of Ribosome-binding protein 1 0.20   0.16 0.12   0.75 
 Spag9 Isoform 2 of C-Jun-amino-terminal kinase-interacting protein 4 0.36 0.48     1.31   
 Synj1 Synaptojanin-1 isoform a 0.27 0.30     1.10   
 Tdrd3 Isoform 2 of Tudor domain-containing protein 3 0.25 0.11   0.30 0.42   
 Tmod3 Tropomodulin-3 0.06 0.35     5.51   
 Top3b DNA topoisomerase 3-beta-1     0.26 0.29   1.13 
 Tpm3 Isoform 2 of Tropomyosin alpha-3 chain 0.07 0.72   0.08 10.44   
 Tpm4 Tropomyosin alpha-4 chain 0.06 0.38     6.08   
 Ybx3 Y-box-binding protein 3 0.14   0.19 0.20   1.06 
 Zc3h7a Zinc finger CCCH-type containing 7A 0.21   0.21       
 Zo1 Tight junction protein ZO-1 isoform 2   0.30 0.03       
  
NB: Genes/proteins in bold = also present in second NRP1 IP mass spectrometry experiment. Genes/proteins underlined = of special interest. 
Figure 5.7: Myosin 9 confirmed to co-associate with neuropilin-1 less in β3-heterozygous 
endothelial cells. A β3-WT and β3-HET ECs were seeded overnight on fibronectin, treated ±VEGF, 
and lysed and immunoprecipitated for NRP1 (NRP1 IP). IP’d samples were separated by 
SDS-PAGE for A Silver staining, and B Western blotting. Total cell lysates taken before the IP 
(pre-IP) and after the IP (post-IP) are shown as controls to confirm the efficiency of the IP.
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5.8 Many of the proteins that are appear differentially associated with NRP1 
between β3-wild-type and β3-heterozygous endothelial cells are related to 
the cytoskeleton 
We set about repeating the proteomic analysis of NRP1-associated proteins by 
immunoprecipitating NRP1 in unstimulated (-V) and VEGF-stimulated (+V) β3-
WT and β3-HET ECs using the anti-NRP1 antibody from Seerapu et al.’s [289] 
study. This time, after confirming the uniform efficiency of the IPs between 
samples by silver staining (not shown), the samples were subjected to label-free 
quantitative mass spectrometry in order to more accurately compare data 
between samples. Results were ordered by the fold change between the ratios of 
β3-WT+V/-V and β3-HET+V/-V label-free quantification (LFQ) values to compare 
the effect of VEGF stimulation on NRP1’s protein associations between β3-WT 
and β3-HET ECs (Table 5.2). LFQ values were also hierarchically clustered to 
group NRP1-associated proteins that appeared between samples in similar 
trends (Figures 5.8 and 5.9). 
 
In contrast with our previous mass spectrometry experiment, this time we were 
able to detect many of the proteins reported to associate with NRP1 by Seerapu 
et al. [289], including myosin 9, myosin 10, filamin a, α-enolase, and eukaryotic 
elongation factor 1 α1 (underlined in Table 5.2). We also identified NRP1-
associated proteins that were present in both of our mass spectrometry 
experiments that used different anti-NRP1 antibodies for NRP1 
immunoprecipitation, noting similar trends between samples for almost all of them 
(Table 5.3). 
 
From the hierarchical clustering analysis we noticed that many of the proteins 
that appear differentially associated with NRP1 between β3-WT and β3-HET ECs 
are functionally related to the cytoskeleton (Figures 5.9A-E). To our surprise, in 
complete contrast with the first experiment, myosin 10 appeared to associate with 
NRP1 more in the β3-HET samples (Figure 5.9A). However, the trend in myosin 
9-NRP1 associations between samples was similar to that observed previously, 
and clustering revealed a number of other proteins associating with NRP1 in a 
similar pattern (ie. reduced NRP1 associations in β3-HET ECs) (Figure 5.9B). 
These included some that we identified in the previous experiment, such as Ras 
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interacting protein 1, actin cytoplasmic 2, unconventional myosin 1c, and 
tropomodulin-3, as well as various other actin- and myosin-related proteins. 
 
Of particular interest to us were clustered groups that show proteins that appear 
to associate with NRP1 much less in VEGF-stimulated β3-HET ECs (Figures 
5.9C-D). This included the FA protein filamin a, a result that is congruent with 
NRP1’s localisation away from FA-like structures in stimulated β3-HET ECs. Also 
reduced in stimulated β3-HET EC samples was IQGAP1, which, along with 
filamin a, has previously been implicated in Rac1 deactivation at β1-integrin 
activation sites to regulate cell migration [243]. 
 
We further noted NRP1-associated proteins that were different upon VEGF 
stimulation in both β3-WT and β3-HET ECs (Figures 5.9F-H). Amongst these 
was α-enolase, which, like that previously reported, more prevalently bound to 
NRP1 in stimulated ECs [289], although this effect was slightly dampened in β3-
HET samples. 
 
We conclude that reduced β3 expression causes changes in NRP1’s association 
with many proteins and is further influenced by VEGF stimulation. Almost all of 
the proteins identified associate with NRP1 less in β3-HET ECs, and most that 
have a clear trend in reduced NRP1 associations in both β3-HET samples are 
actin- and myosin-related proteins. Myosin 10 and myosin 9 are part of different 
NM-II molecules that play distinct, but complementary roles in coordinating cell 
migration [244]. Since myosin 10, which is involved in the stabilisation and 
contraction of actin stress fibres, is increased in β3-HET samples, whilst myosin 
9, which is more involved in FA formation, is decreased, it is possible that this 
misbalance in association with NRP1 contributes to the enhanced migration of 
β3-HET ECs that is sensitive to NRP1 disruption. However, the change in myosin 
10 was opposite to that observed in the previous experiment, and the lack of a 
clear difference in NRP1’s association with these molecules between 
unstimulated and stimulated β3-HET samples does not reflect NRP1’s 
immunolocalisation phenotype. The FA proteins filamin a and IQGAP1 associate 
with NRP1 in a way more fitting with NRP1’s localisation away from FA-like 
structures in stimulated β3-HET ECs, since they are both reduced in these 
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samples. As both filamin a and IQGAP1 are involved in regulating cell migration 
through Rac1 deactivation [243], it is possible that NRP1’s association with them 
is important in dictating EC migration outcome, thus presenting a possible reason 
why NRP1 becomes more targetable when β3 expression is reduced. Overall, 
these observations, coupled with the changes in NRP1’s mobilisation away from 
the ends of actin filaments upon VEGF-stimulation, suggest that β3 regulates 
NRP1’s localisation to, and association with, components of the cytoskeleton. 
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Table 5.2: Quantitative mass spectrometry results of neuropilin-1-
immunoprecipitated β3-WT and β3-HET endothelial cell samples (second 
experiment). 
LFQ value normalised to that of 
NRP1 
   
Gene Protein WT-V WT+V HET-V HET+V WT+V/WT-V 
HET+V/ 
HET-V 
Fold 
change 
HET/WT 
Gng5 Guanine nucleotide-binding protein  0.23 0.12 0.03 0.05 0.50 1.53 3.06 
Tpm4  Tropomyosin alpha-4 chain 0.54 0.21 0.11 0.13 0.38 1.12 2.94 
Tpm3  Tropomyosin alpha-3 chain 1.82 1.33 0.34 0.58 0.73 1.73 2.37 
Zo2  Tight junction protein ZO-2 0.33 0.11 0.08 0.06 0.33 0.74 2.23 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 0.50 0.53 0.36 0.70 1.07 1.94 1.81 
Myl6  Myosin light polypeptide 6 1.97 1.60 0.68 0.99 0.81 1.45 1.79 
Tpm1  Tropomyosin alpha-1 chain 0.39 0.36 0.09 0.13 0.93 1.43 1.55 
Myh14  Isoform 2 of Myosin-14 5.54 3.86 4.62 4.78 0.70 1.04 1.49 
Grn  Granulins 0.73 0.60 0.47 0.52 0.83 1.13 1.35 
Rpl13a  60S ribosomal protein L13a 0.10 0.06 0.04 0.03 0.61 0.77 1.27 
Plec  Plectin 3.64 2.26 1.86 1.39 0.62 0.75 1.20 
Krt71  Keratin, type II cytoskeletal 71 0.03 0.03 0.02 0.03 0.98 1.14 1.17 
Sipa1  Signal-induced proliferation-associated protein 1 0.04 0.02 0.02 0.01 0.58 0.65 1.11 
Capza2  Capza2 F-actin-capping protein subunit alpha 2 0.64 0.56 0.38 0.37 0.88 0.97 1.10 
Myo1c  Unconventional myosin-Ic 0.78 0.71 0.38 0.37 0.90 0.99 1.09 
Serpinh1  Serpin H1 0.13 0.09 0.18 0.13 0.67 0.71 1.07 
Rasip1  Ras-interacting protein 1 0.06 0.05 0.04 0.03 0.76 0.81 1.07 
Rplp0  60S acidic ribosomal protein P0 0.26 0.24 0.15 0.14 0.93 0.96 1.03 
Myh10  Myosin-10 3.97 3.97 6.32 6.52 1.00 1.03 1.03 
Rpl6 60S ribosomal protein L6 0.05 0.04 0.03 0.02 0.79 0.81 1.02 
Cald1  Caldesmon 1 1.48 1.19 0.57 0.46 0.80 0.82 1.02 
Tmod3  Tropomodulin-3 0.29 0.31 0.18 0.19 1.07 1.08 1.01 
Dbn1  Isoform E2 of Drebrin 0.09 0.08 0.05 0.05 0.92 0.93 1.01 
Nrp1 Neuropilin-1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Actg1  Actin, cytoplasmic 2 166.25 172.15 109.54 110.31 1.04 1.01 -1.03 
Myl12a Myosin light chain, regulatory B-like 1.53 2.25 0.58 0.82 1.47 1.42 -1.03 
Capza1  Capza1 F-actin-capping protein subunit alpha 1 0.25 0.26 0.21 0.21 1.05 1.01 -1.04 
Flii  Protein flightless-1 homolog 0.22 0.18 0.15 0.12 0.81 0.77 -1.05 
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Actc1  Actin, alpha cardiac muscle 1 2.37 3.72 0.65 0.96 1.57 1.47 -1.07 
Actbl2  Beta-actin-like protein 2 38.52 41.16 21.77 20.61 1.07 0.95 -1.13 
Capzb  F-actin-capping protein subunit beta 0.30 0.33 0.22 0.21 1.10 0.94 -1.18 
Myh9  Myosin-9 226.75 246.90 159.30 146.76 1.09 0.92 -1.18 
Myo6  Unconventional myosin-VI 0.05 0.05 0.05 0.04 0.95 0.77 -1.24 
Rpl18  60S ribosomal protein L18 0.05 0.03 0.04 0.02 0.65 0.52 -1.25 
Myo1b  Unconventional myosin-Ib 0.11 0.12 0.08 0.07 1.12 0.89 -1.26 
Myo1e Unconventional myosin-Ie 0.10 0.11 0.08 0.07 1.13 0.88 -1.28 
Rpl7 60S ribosomal protein L7 0.07 0.06 0.05 0.03 0.91 0.63 -1.44 
Rps3  40S ribosomal protein S3 0.11 0.18 0.05 0.05 1.70 1.17 -1.46 
Flna  Filamin a 0.12 0.11 0.11 0.07 0.93 0.58 -1.59 
Spnb2  Spectrin beta chain, non-erythrocytic 1 0.08 0.06 0.08 0.04 0.78 0.47 -1.66 
Spna2  Spectrin alpha chain, non-erythrocytic 1 0.22 0.23 0.21 0.14 1.07 0.64 -1.67 
Myo18a  Unconventional myosin-XVIIIa  0.48 0.47 0.54 0.28 0.97 0.52 -1.88 
Iqgap1  Ras GTPase-activating-like protein IQGAP1 0.04 0.06 0.04 0.03 1.45 0.69 -2.09 
Hspa5 78 kDa glucose-regulated protein 0.15 0.38 0.17 0.17 2.48 1.00 -2.47 
Hspa8  Heat shock cognate 71 kDa protein 0.20 0.65 0.15 0.16 3.18 1.13 -2.82 
Gsn Gelsolin 0.02 0.09 0.03 0.02 3.68 0.85 -4.33 
Tuba1b  Tubulin alpha-1B chain 0.15 0.68 0.16 0.17 4.46 1.02 -4.36 
Eno1  Alpha-enolase 0.02 1.18 0.02 0.20 58.82 13.03 -4.51 
Tubb5  Tubulin beta-5 chain 0.04 0.16 0.06 0.04 3.75 0.69 -5.40 
Anxa2 Annexin A2 0.20 1.34 0.15 0.16 6.61 1.03 -6.40 
Mtap4  Microtubule-associated protein 4 0.03 0.04 0.17 0.03 1.38 0.18 -7.54 
Hsp90aa1  Heat shock protein HSP 90-alpha 0.03 0.31 0.03 0.03 8.97 1.18 -7.59 
Eef1a1  Eukaryotic elongation factor 1-alpha 1 0.26 1.32 0.27 0.18 5.10 0.64 -7.93 
Cfl1 Cofilin-1 0.01 0.16 0.01 0.01 12.15 1.07 -11.38 
Lmna  Prelamin-A/C 0.02 0.81 0.01 0.02 32.79 2.01 -16.34 
Jup  Junction plakoglobin 0.30 5.31 0.53 0.53 17.43 1.01 -17.29 
Eef2  Elongation factor 2 0.03 0.51 0.03 0.03 19.87 1.13 -17.52 
Uba52  Ubiquitin-60S ribosomal protein L40 0.17 1.82 0.26 0.13 11.01 0.48 -22.91 
Dsp  Desmoplakin 0.42 8.94 0.50 0.46 21.46 0.92 -23.44 
Calm2;Calm1;Calm3  Calmodulin 0.02 1.12 0.01 0.01 66.65 1.32 -50.37 
Actn4  Alpha-actinin-4 0.06 0.29     5.18     
Ahnak  Ahnak Desmoyokin 0.04 0.08     2.09     
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Aldoa  Fructose-bisphosphate aldolase A 0.12 1.10   0.60 9.10     
Arpc4  Actin-related protein 2/3 complex subunit 4 0.01 0.09   0.01 7.01     
Atp5b  ATP synthase subunit beta, mitochondrial   0.08   0.02       
Cltc  Clathrin heavy chain 1 0.04 0.07     1.88     
Eppk1  Epiplakin 0.07 1.30   0.03 17.59     
Hal  Histidine ammonia-lyase 0.02 0.14   0.02 5.93     
Hist1h2al  Histone H2A type 2-C   0.44   0.04       
Hist1h4a Histone H4   1.31   0.03       
Hspa1a  Heat shock 70 kDa protein 1A   0.33   0.05       
Ldha  L-lactate dehydrogenase A chain   0.31   0.17       
Lima1  LIM domain and actin-binding protein 1 0.06   0.05 0.04   0.91   
Lrrfip1  Leucine-rich repeat flightless-interacting protein 1 0.06 0.04   0.03 0.70     
Naca  Nascent polypeptide-associated complex subunit alpha 0.01 0.03     3.16     
Pgk1  Phosphoglycerate kinase 1   0.20   0.06       
Pkm2  Pyruvate kinase PKM 0.03 0.39   0.11 11.37     
Ptbp1  Polypyrimidine tract-binding protein 1 0.02 0.05     3.03     
Rpl10a  Ribosomal protein   0.05 0.04 0.04   0.91   
Rpl12 60S ribosomal protein L12 0.03 0.03     1.09     
Rpl4  60S ribosomal protein L4 0.05   0.03 0.03   0.87   
Slc25a4 Plakophilin-1   0.16 0.03         
Tgm1  Protein-glutamine gamma-glutamyltransferase K   0.06   0.01       
Tpi1  Triosephosphate isomerase   0.40 0.02 0.10   6.30   
Tpm1  Tropomyosin alpha-1 chain 0.09   0.03 0.03   1.04   
 
NB: Genes/proteins in bold = also present in first NRP1-IP mass spectrometry experiment. Genes/proteins underlined = of special interest. 
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Table 5.3: Comparison of common hits from mass 
spectrometry of neuropilin-1-immunoprecipitated   
β3-WT and β3-HET EC samples between first and 
second experiments. 
LFQ value normalised to that of 
NRP1 (second experiment) 
Mass spectrometry Mascot score 
normalised to that of NRP1 (first 
experiment) 
Gene Protein WT-V WT+V HET-V HET+V WT-V WT+V HET-V HET+V 
Tpm4  Tropomyosin alpha-4 chain 0.54 0.21 0.11 0.13 0.06 0.38     
Tpm3  Tropomyosin alpha-3 chain 1.82 1.33 0.34 0.58 0.07 0.72   0.08 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase 0.50 0.53 0.36 0.70 0.23 0.37 0.21 0.20 
Myo1c  Unconventional myosin-Ic 0.78 0.71 0.38 0.37 0.61 1.66 0.38 0.35 
Rasip1  Ras-interacting protein 1 0.06 0.05 0.04 0.03 0.17 0.40 0.13 0.08 
Rplp0  60S acidic ribosomal protein P0 0.26 0.24 0.15 0.14 0.18 0.19 0.10 0.13 
Myh10  Myosin-10 3.97 3.97 6.32 6.52 1.10 5.08 0.40 0.72 
Tmod3  Tropomodulin-3 0.29 0.31 0.18 0.19 0.06 0.35     
Nrp1 Neuropilin-1 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Actg1  Actin, cytoplasmic 2 166.25 172.15 109.54 110.31 1.61 3.52 0.81 0.98 
Myl12a Myosin light chain, regulatory B-like 1.53 2.25 0.58 0.82 0.27 0.38 0.07 0.14 
Myh9  Myosin-9 226.75 246.90 159.30 146.76 4.40 13.92 1.81 3.06 
Rps3  40S ribosomal protein S3 0.11 0.18 0.05 0.05 0.22 0.33 0.30 0.29 
Gsn Gelsolin 0.02 0.09 0.03 0.02 0.09 0.68 0.05 0.04 
Tubb5  Tubulin beta-5 chain 0.04 0.16 0.06 0.04 0.18 0.27 0.14 0.21 
Anxa2 Annexin A2 0.20 1.34 0.15 0.16   0.35 0.13 0.15 
Cltc  Clathrin heavy chain 1 0.04 0.07     1.00 1.13 0.46 0.45 
  
	   	   	   	   	   	   	   	   	  
	  
NB: Genes/proteins in bold = those with	     : relatively high value in group of comparison 
  similar trends between experiments.   : relatively low value in group of comparison 
β3-WT β3-WT β3-HET β3-HET
-VEGF +VEGF -VEGF +VEGF
Figure 5.8: Quantitative mass spectrometry analysis of neuropilin-1-immunoprecipitated 
samples highlights differential neuropilin-1 associations between β3-wild-type and                    
β3-heterozygous endothelial cells. β3-WT and β3-HET ECs were seeded overnight on 
fibronectin, treated ±VEGF, and lysed and immunoprecipitated for NRP1. Samples were subjected 
to label-free quantitative mass spectrometry analysis. Peptides present in at least 2 samples were 
hierarchically clustered by clustering median log(LFQ) values by city-block distance. The analysis is 
further dissected in Figures 9A-H. Particular clusters subsequently focussed on are highlighted in 
red on the right side.
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Figure 5.9: Quantitative mass spectrometry analysis of neuropilin-1-immunoprecipitated 
samples highlights differential neuropilin-1 associations between β3-wild-type and                    
β3-heterozygous endothelial cells. β3-WT and β3-HET ECs were seeded overnight on 
fibronectin, treated ±VEGF, and lysed and immunoprecipitated for NRP1. Samples were subjected 
to label-free quantitative mass spectrometry analysis. Peptides present in at least 2 samples were 
hierarchically clustered by clustering median log(LFQ) values by city-block distance. A Top 2 
proteins highlighted have enhanced NRP1 associations in β3-HET ECs. B Predominantly 
cytoskeletal proteins have enhanced NRP1 associations in β3-WT ECs and decreased associations 
in β3-HET ECs. NB: Genes in bold = protein also present in first NRP1 IP mass spectrometry 
experiment. Genes underlined = of special interest. 
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Figure 5.9: Quantitative mass spectrometry analysis of neuropilin-1-immunoprecipitated 
samples highlights differential neuropilin-1 associations between β3-wild-type and                    
β3-heterozygous endothelial cells. β3-WT and β3-HET ECs were seeded overnight on 
fibronectin, treated ±VEGF, and lysed and immunoprecipitated for NRP1. Samples were subjected 
to label-free quantitative mass spectrometry analysis. Peptides present in at least 2 samples were 
hierarchically clustered by clustering median log(LFQ) values by city-block distance. C Proteins 
highlighted have enhanced NRP1 associations in β3-WT ECs -VEGF, but decreased associations in 
β3-HET ECs +VEGF. D Predominantly cytoskeletal proteins have decreased NRP1 associations 
specifically in β3-HET ECs +VEGF. E Predominantly cytoskeletal proteins have strongly enhanced 
associations in β3-WT ECs and strongly decreased associations in β3-HET ECs. F Proteins have 
enhanced associations in β3 WT ECs +VEGF and reduced associations in β3-HET ECs +VEGF. 
NB: Genes in bold = protein also present in first NRP1 IP mass spectrometry experiment. 
Genes underlined = of special interest.   
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Figure 5.9: Quantitative mass spectrometry analysis of neuropilin-1-immunoprecipitated 
samples highlights differential neuropilin-1 associations between β3-wild-type and                    
β3-heterozygous endothelial cells. β3-WT and β3-HET ECs were seeded overnight on 
fibronectin, treated ±VEGF, and lysed and immunoprecipitated for NRP1. Samples were subjected 
to label-free quantitative mass spectrometry analysis. Peptides present in at least 2 samples were 
hierarchically clustered by clustering median log(LFQ) values by city-block distance. G Proteins have 
strongly enhanced NRP1 associations in β3 WT ECs +VEGF and strongly reduced associations in 
β3-HET ECs +VEGF. Hα-enolase has enhanced associations in both β3-WT and β3-HET ECs 
stimulated with VEGF. NB: Genes in bold = protein also present in first NRP1 IP mass 
spectrometry experiment. Genes underlined = of special interest.  
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5.9 Examining neuropilin-1’s associations within the endothelial adhesome 
Since mass spectrometry revealed that many of the proteins that changed their 
associations with NRP1 between β3-WT and β3-HET ECs were related to FAs 
and the cytoskeleton, we further investigated the association of NRP1 with such 
proteins that might be relevant to our phenotypes by co-IP. Following the IP of 
NRP1 using the same antibody as the second mass spectrometry experiment, we 
initially looked again at associations with myosin 9, as well as with filamin a, and 
α5-integrin (Figure 5.10Ai). We decided on α5-integrin as NRP1 is known to 
interact with α5β1 and control its trafficking in ECs [288], because the surface 
expression of α5 is reduced in β3-HET ECs, and because filamin a and IQGAP1, 
which we have established to associate with NRP1, are known to be recruited to 
active β1 sites [243]. We additionally examined NRP1’s associations with the FA 
proteins FAK and p130Cas (Figure 5.10Aii), whose phosphorylation is known to 
be regulated by NRP1 [272,273]. p130Cas is also known to co-localise with 
NRP1 in vesicular punctae [289]. Unfortunately, these co-IP experiments were 
not consistent, meaning the effect of VEGF stimulation and/or reduced β3 
expression does not conclusively alter NRP1’s associations with these 
molecules. In the experiments shown in Figure 5.10A, NRP1 was IP’d in both 
pMT immortalised and primary β3-WT and β3-HET MLECs, although not 
uniformly between unstimulated and VEGF-stimulated pMT EC samples, for 
reasons unknown. Taking this into account, there were no obvious differences in 
NRP1 co-association between samples for any of the molecules tested. This 
includes myosin 9-NRP1 association, which we previously showed was reduced 
in β3-HET ECs, although a different anti-NRP1 antibody was used for the IP. 
However, myosin 9-NRP1 association was reduced in stimulated primary β3-HET 
ECs, suggesting that results with myosin 9 may be inherently variable. Repeats 
of the NRP1-filamin a co-IP experiment are shown in Figure 5.10B to confirm 
that no differences in NRP1 co-association were observed for this molecule per 
amount of NRP1 IP’d. However, experimental repeats with the other molecules 
were even more inconsistent (not shown). Whilst we found NRP1’s association 
with myosin 9 and filamin a to not change in the way predicted from mass 
spectrometry, we can confirm that NRP1 does associate with a range of FA 
molecules, including α5-integrin, filamin a, FAK, and p130Cas [288,289]. To 
further support NRP1’s placement within the endothelial adhesome, we used a 
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method previously employed by Schiller et al. [219,220] in fibroblasts to establish 
and enrich mature integrin-dependent FAs in β3-WT and β3-HET ECs. Eluted 
FA-enriched samples were analysed for NRP1 content by Western blotting 
(Figure 5.10C). We detected similar amounts of NRP1 in the adhesomes from 
unstimulated and VEGF-stimulated β3-WT and β3-HET ECs. This therefore 
confirms that NRP1 is present in the endothelial adhesome, but does not provide 
further insight into the difference in NRP1 localisation in stimulated β3-HET ECs. 
A more detailed analysis of the FA-enriched samples has been conducted in a 
separate project, but we can confirm here that the samples have been validated 
for their enrichment for FA components as expected (not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Examining neuropilin-1’s associations within the endothelial adhesome. A,B        
β3-WT and β3-HET primary (1°) and polyoma-middle-T-antigen immortalised lung microvascular 
ECs were seeded overnight on fibronectin (FN), treated ±VEGF, and lysed and immunoprecipitated 
for NRP1 (NRP1 IP). IP’d samples were separated by SDS-PAGE for Western blotting. Total cell 
lysates taken before the IP (pre-IP) and after the IP (post-IP) are shown as controls to confirm the 
efficiency of the IP. C ECs were allowed to adhere to FN-coated dishes for 90 minutes to establish 
‘mature’ integrin-dependent focal adhesions (FAs). FAs were chemically crosslinked to the plates 
and cells were lysed with RIPA buffer.  Non-crosslinked proteins and other cellular components were 
rinsed away under high-sheer flow. FA-enriched complexes were eluted and subjected to 
SDS-PAGE for Western blot analysis. A total cell lysate (TCL) is shown for comparison. Data are 
representative of 3 independent experiments.
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5.10 Neuropilin-1’s co-localisation with paxillin-positive focal adhesions is 
lost upon stimulation with VEGF in only β3-heterozygous endothelial cells 
Whilst the examination of NRP1 associations in β3-WT and β3-HET ECs by co-
IP/Western blot was inconclusive, and could not explain NRP1’s localisation 
away from the ends of actin filaments in stimulated β3-HET ECs, the consistent 
link between NRP1 and the adhesome led us to speculate that there may be 
NRP1-regulated changes in FA dynamics that are too subtle to be detected by 
co-IP. Indeed, NRP1 has previously been implicated in FA turnover [289], as well 
as FN-stimulated paxillin (PXN) phosphorylation [271]. We therefore turned our 
attention to examining NRP1 alongside PXN, first by immunolocalising them in 
β3-WT and β3-HET ECs both with and without NRP1’s cytoplasmic tail to further 
dissect the differences in EC migration observed previously (Figure 5.11A). 
 
Immunocytochemistry of ECs plated overnight on FN showed a predicted         
co-localisation of total PXN and NRP1 in mature FAs in unstimulated β3-WT ECs. 
This co-localisation was maintained after 10 minutes of VEGF-stimulation. 
NRP1/PXN co-localisation in mature FAs was also apparent in unstimulated β3-
HET ECs, but it was lost upon VEGF-stimulation, with NRP1 co-localising with 
PXN in vesicular structures instead. A similar pattern was observed in β3-HET-
NRP1Δcyto ECs, except NRP1 also no longer co-localised with PXN in vesicles. 
β3-WT-NRP1Δcyto ECs displayed a relatively small loss of NRP1/PXN co-
localisation in mature FAs after VEGF-stimulation (Figure 5.11B). 
 
The sizes of paxillin-positive FAs were measured in all of the cell types to gain a 
static representation of the ramifications of FA turnover in the different ECs 
(Figure 5.11C). We noted that both β3-WT-NRP1Δcyto and β3-HET-NRP1Δcyto 
ECs contained slightly proportionally larger FAs than their counterparts with intact 
NRP1. 
 
 
 
 
 
 
Figure 5.11: Neuropilin-1’s co-localisation with paxillin-positive focal adhesions is lost upon  
stimulation with VEGF in only β3-heterozygous endothelial cells. A ECs of the indicated 
genotypes were seeded overnight on FN-coated glass coverslips. After 3 hours of starvation, cells 
were treated ±VEGF for 10 minutes in serum-free medium, then fixed and immunostained for total 
paxillin (PXN - green) and neuropilin-1 (NRP1 - red).  Split channel close-ups are shown to depict 
PXN/NRP1 co-localisation in mature focal adhesions. White arrowheads in β3-HET close-up 
highlight PXN/NRP1 co-localisation in vesicles. Scale bar = 20 μm.
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Figure 5.11: Neuropilin-1’s co-localisation with paxillin-positive focal adhesions is lost upon  
stimulation with VEGF in only β3-heterozygous endothelial cells. ECs of the indicated 
genotypes were seeded overnight on FN-coated glass coverslips. After 3 hours of starvation, cells 
were treated ±VEGF for 10 minutes in serum-free medium, then fixed and immunostained for total 
paxillin and neuropilin-1. B The box and whisker plot shows Pearson’s correlation coefficient of 
PXN/NRP1 colocalisation in each of the indicated genotypes in the indicated regions as determined 
using the ImageJTM coloc2 plugin (means ± interquartile ranges and extreme values; n≥5 cells per 
genotype). C The size of FAs was quantified by using ImageJ to measure the area of PXN-positive 
FAs. The graph shows plotted values of FA size for each cell genotype (n≥10 cells per genotype, 
1800 FAs per genotype in total). The percentage of FAs in different size ranges are indicated in red.  
Asterisks indicate statistical significance: *, P<0.05; **, P<0.01; nsd = not significantly different.  
Unpaired two-tailed t test.  
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5.11 Paxillin activation is sensitive to neuropilin-1 disruption in                                              
β3-integrin-heterozygous endothelial cells 
We next pursued a potential β3-integrin-regulated NRP1 link with PXN activation 
by analysing the phosphorylation of PXN through Y118 by immunoblotting 
(Figures 5.12A,B) and immunocytochemistry (Figure 5.12C). PXN 
phosphorylation was substantially reduced in β3-HET-NRP1Δcyto ECs, but not 
β3-WT-NRP1Δcyto ECs, suggesting that PXN activation is only NRP1-dependent 
when β3-integrin levels are suppressed. This therefore reflects the tumour 
angiogenesis, and EC migration phenotypes observed previously, but unlike the 
mobilisation of NRP1 away from PXN-positive FAs, reduced PXN 
phosphorylation in β3-HET-NRP1Δcyto ECs was apparent in both non-VEGF-
stimulated and VEGF-stimulated ECs. 
 
5.12 Focal adhesion turnover is more sensitive to neuropilin-1 disruption in 
β3-integrin-heterozygous endothelial cells 
Finally, through the live tracking of GFP-PXN in transfected cells, we monitored 
FA turnover by measuring the rates of FA assembly and disassembly (Figure 
5.13). We noted that compared to β3-WT ECs, which displayed similar rates of 
FA assembly and disassembly, β3-HET ECs contained FAs that overall 
assembled and disassembled at a faster rate, thereby corresponding to an 
overall increase in FA turnover in these cells. However, in β3-WT-NRP1Δcyto 
and β3-HET-NRP1Δcyto ECs, whilst FA assembly rates were enhanced 
compared to that in β3-WT ECs, the corresponding rates of FA disassembly were 
significantly reduced, meaning net FA turnover is perturbed by the loss of NRP1’s 
cytoplasmic tail. This effect was most pronounced in β3-HET-NRP1Δcyto ECs, 
and therefore the combination of β3 expression reduction and the absence of 
NRP1’s cytoplasmic tail impairs FA turnover most efficaciously. Indeed, whilst FA 
disassembly rates between β3-WT and β3-WT-NRP1Δcyto ECs were not quite 
significantly reduced, the rates between β3-HET and β3-HET-NRP1Δcyto ECs 
were reduced significantly. These data reflect the differences in size of FAs 
between the cells reported earlier (ie. the small increase in FA size in the 
NRP1Δcyto ECs, which was greatest in the β3-HET-NRP1Δcyto ECs, is 
congruent with a net reduction in FA turnover). It is logical to connect the 
abnormally localised NRP1 away from mature FAs in VEGF-stimulated β3-HET 
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ECs, and the increased sensitivity of β3-HET ECs to NRP1-mediated PXN 
activation and FA turnover, to the EC migration phenotypes observed previously, 
since FA dynamics are inextricably linked to cell motility. Our data suggest that, in 
the presence of β3-integrin, EC migration is NRP1-independent; β3-integrin 
maintains NRP1 in mature FAs, thus ensuring a controlled migratory response to 
VEGF-stimulation. However, reduced levels of β3-integrin lead to changes in FA 
turnover and cell migration that are NRP1-dependent. Extrapolating further, these 
phenomena may help explain the enhanced sensitivity of tumour growth and 
angiogenesis to NRP1 perturbation when β3 expression is reduced, as well as 
the blockade of established tumour growth and angiogenesis in response to 
simultaneous endothelial β3/NRP1 inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: Paxillin activation is sensitive to neuropilin-1 disruption in                                              
β3-integrin-heterozygous endothelial cells. A ECs of the indicated genotypes were seeded 
overnight on FN.  They were then starved for 3 hours and treated ±VEGF for 10 minutes in serum 
free medium. Cells were lysed and Western blotted (WB) for levels of phosphorylated (p) and total 
(t) PXN. GAPDH served as a loading control. Data are representative of 3 independent experiments. 
B The graph shows densitometry of pPXN relative to tPXN, as determined by Western blot, over an 
extended VEGF time course (means ±SEM from ≥3 independent experiments). C ECs that were 
seeded overnight onto FN-coated glass coverslips and stained for pPXN.  ECs were starved for 3 
hours and treated ±VEGF for 10 minutes in serum free medium. Cells were fixed and immunostained 
for pPXN (green). Scale bar = 10 μm.
A
70
40
β3-WT β3-HET
WT
NRP1
NRP1
∆cyto
pPXN
Y118
GAPDH
WT
NRP1
NRP1
∆cyto
70 tPXN
Re
la
tiv
e
pP
XN
 (Y
11
8)
 le
ve
l
+V
E
G
F
- V
E
G
F
β3-WT
T.Wβ3-
NRP1∆cyto β3-HET
β3-HET.
NRP1∆cyto
C
0
1.0
2.0
3.0
4.0
0 10 20 30 40 50 60 0 10 20 30 40 50 60
β3-WT Tβ3-W .NRP1∆cyto
β3-HET Tβ3-HE .NRP1∆cyto
- +VEGF: - + - + - +
VEGF (min):
pPXN
Mr (kDa)
B
183
Figure 5.13: Focal adhesion turnover is more sensitive to NRP1 disruption in                                   
β3-integrin-heterozygous endothelial cells. ECs were transfected with a PXN-GFP construct and 
seeded at a low density on FN-coated coverslips. 72 hours later cells were starved and then treated 
with VEGF in reduced serum medium. Representative cells were then imaged live (every 2 minutes) 
on an inverted fluorescence microscope for 1 hour to monitor focal adhesion (FA) turnover. The front 
and back ends of individual FAs were tracked over this period to measure FA assembly and 
disassembly using the ImageJTM MTrack2 plugin. The box and whisker plot shows the rate of FA 
assembly or disassembly for each of the indicated genotypes (means ± interquartile ranges and 
extreme values; n≥20 FAs per genotype). The table below highlights the significance of net changes 
in FA assembly vs disassembly (turnover) for each EC genotype. Asterisks indicate statistical 
significance: *, P<0.05; **, P<0.01. ***, P<0.001; nsd = not significantly different. Unpaired two-tailed 
t test.
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5.13 Discussion 
Following our conclusion that disrupting NRP1 in β3-HET ECs did not sufficiently 
change VEGFR2 biology to account for the reduction in tumour growth and 
angiogenesis in β3-HET mice, we turned to the analyses of other NRP1 
functions. Firstly, the adhesion of β3-HET pMT LMECs to αvβ3’s canonical 
ligand, vitronectin, was reduced as expected, and was supported by a reduction 
in αv and β3 levels on the surface of these cells. Similarly, the adhesion of these 
β3-HET ECs to fibronectin was reduced, and may be related to their reduction in 
α5 surface levels as FN is a prominent ligand of α5β1, although β1 surface levels 
were unchanged. Contrary to previous findings in HUAECs [288], the absence of 
NRP1’s cytoplasmic tail had no obvious effect on the adhesion of microvascular 
MLECs to FN when β3 was expressed at normal and reduced levels. This 
discrepancy may be related to the EC type, and possibly a disparity between 
tendencies toward either angiogenesis or arteriogenesis, as predicted for 
VEGFR2 function previously. Surface levels of α5 and β1 in β3-WT and β3-HET 
ECs lacking NRP1’s cytoplasmic tail reflected those in the equivalent ECs 
expressing full-length NRP1. Though Valdembri et al. [288] showed that NRP1 
internalises and recycles with α5β1 in ECs, they found no differences in α5β1 
surface levels in ECs with NRP1 expression knocked-down, meaning our data is 
in agreement in this case. However, given the reduction in α5 surface levels in 
β3-HET ECs, it remains possible that α5β1 recycling may be perturbed in these 
cells. Like Valdembri et al.’s [288] study, no obvious differences in EC adhesion 
to VN, COLI or LN, were found in the absence of NRP1’s cytoplasmic tail. 
 
Whilst differences in EC adhesion were not especially enlightening, both random 
and directed migration of β3-HET, but not β3-WT, ECs were sensitive to NRP1 
perturbation, thereby phenocopying the tumour growth and angiogenesis in vivo 
data from animals of the same genotypes. As angiogenesis is heavily dependent 
on EC migration, this suggests that migration significantly contributes to the in 
vivo phenotypes. Indeed, as β3-HET EC migration was elevated, enhanced 
tumour angiogenesis in the corresponding mice is likely not only due to the 
contribution of non-ECs. In contrast with a study by Seerapu et al. [289], who 
showed that NRP1Δcyto heart ECs had an impeded rate of scratch wound 
closure, β3-WT microvascular ECs lacking NRP1’s cytoplasmic tail did not 
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migrate differently from those with full-length NRP1. This dichotomy again may be 
related to the EC type, as our results are more fitting with the normal EC 
migration observed in the angiogenic postnatal retina of NRP1Δcyto mice [267]. 
Although EC migration can be regulated by VEGFR2-dependent signalling, our 
previous analysis of VEGFR2 signalling pathways showed no obvious changes, 
other than NRP1-sensitive ERK1/2 signalling in β3-HET ECs, and so our 
attention was diverted towards NRP1’s purported regulation of migration via its 
involvement with FA proteins [271,289]. 
 
We found that NRP1 is normally able to localise at mature PXN-positive FAs at 
the plus-ends of actin filaments and is retained at these sites following VEGF 
stimulation. Moreover, through the enrichment of FA complexes, we have, for the 
first time, placed NRP1 in the endothelial adhesome of both unstimulated and 
VEGF-stimulated β3-WT and β3-HET ECs. However, in β3-HET ECs with normal 
and cytoplasmic-tail-deleted NRP1, and to a lesser extent in β3-WT-NRP1Δcyto 
ECs, we found that VEGF-stimulation mobilises NRP1 away from mature FAs. 
This was also true in primary ECs with an induced depletion of β3, therefore 
highlighting a novel ability of β3 to regulate NRP1 by controlling its retention 
within mature FAs upon VEGF-stimulation. This regulation may occur through an 
indirect interaction between β3 and NRP1 in FAs, as although the two molecules 
co-localised in the same structures, their association by co-IP was weak, and β3 
was not present in the mass spectrometry data of NRP1-immunoprecipitated 
samples. The slight reduction in NRP1’s retention in mature FAs in β3-WT ECs 
missing NRP1’s cytoplasmic tail suggests that the cytoplasmic portion of NRP1 is 
also important for the localisation of NRP1 at mature FAs. Though NRP1 has 
previously been shown to localise at both α5β1-positive adhesion sites and 
intracellular vesicles in HUAECs [288], Seerapu et al. [289] reported that in heart 
ECs NRP1 associated with FAs transiently, but was rather more associated with 
recycling FA components in vesicles following VEGF stimulation, and may 
regulate the trafficking of these proteins via its cytoplasmic tail’s link to synectin. 
Since we found NRP1 still localised to mature FAs, and relatively little NRP1-PXN 
co-localisation in vesicles, following VEGF stimulation in β3-WT ECs, it seems 
possible that, in contrast to that in heart ECs, NRP1’s regulation of FA proteins in 
vesicles does not readily occur when β3 is adequately expressed in 
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microvascular ECs. However, when β3 expression is reduced, NRP1 is mobilised 
from mature FAs in response to VEGF, and becomes co-localised with PXN in 
vesicles. NRP1 may therefore be much more involved in regulating the trafficking 
of FA components in β3-HET ECs, though this hypothesis is yet to be tested. The 
presence of NRP1 in Rab-11-positive recycling vesicles, and its association with 
FA proteins, was previously shown to be dependent on NRP1’s cytoplasmic tail 
[268,289]. Here, although NRP1 without its cytoplasmic tail is mobilised away 
from mature FAs to some extent following VEGF stimulation, it also does not co-
localise with PXN in vesicles, so this may agree with previous reports. Therefore, 
upon VEGF stimulation NRP1 may have different functions between β3-HET and 
β3-WT-NRP1Δcyto ECs that explain their differential migration. It would therefore 
be interesting to determine whether NRP1 differentially co-localises with Rab 
vesicle markers and FA proteins between the ECs after VEGF stimulation to gain 
further insight into this matter. On a related note, one thing we know from earlier 
is that NRP1 does not appear to be degraded differently over a VEGF timecourse 
between the ECs. 
 
In further support of β3’s regulation of actin/FA-localised NRP1, mass 
spectrometry identified mainly cytoskeletal, FA- and myosin-based proteins that 
associated with NRP1 to a lesser degree in β3-HET ECs. Of particular interest 
was NRP1’s mis-balanced association with myosin 9/10 in β3-HET ECs, and the 
specific reduction in NRP1’s association with filamin a and IQGAP1 in VEGF-
stimulated β3-HET ECs. It is possible that, since myosin 9 and 10 are part of the 
NM-IIA and NM-IIB proteins that regulate distinct FA-related processes [244], 
NRP1’s differential association with them in β3-HET ECs may result in their 
uncoordinated elevated migration, though this would be difficult to clarify in our 
transgenic ECs. In agreement with Seerapu et al.’s [289] mass spectrometry 
data, myosin 9 and myosin 10 associated with NRP1 in both unstimulated and 
VEGF-stimulated ECs, and α-enolase was more prevalently associated in VEGF-
stimulated ECs. However, filamin a was equally associated with NRP1 in β3-WT 
unstimulated and VEGF-stimulated ECs, unlike the VEGF-dependent association 
previously reported [289]. As filamin a and IQGAP1, which are known to be 
involved in Rac1 deactivation at active β1 sites, had reduced associations with 
NRP1 in stimulated β3-HET ECs, this may fit with NRP1’s localisation away from 
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mature FAs. NRP1 was previously identified to localise with α5β1 at adhesion 
sites, and regulate α5β1 trafficking via NRP1’s cytoplasmic tail [288]. Together, 
these results point towards the possibility that reduced β3 expression inhibits 
NRP1 from associating with α5β1 (which might explain β3-HET ECs’ reduction in 
α5 surface levels and adhesion to FN, possibly through defective α5β1 
recycling), filamin a, and IQGAP1, thereby impacting on Rac1 activation and 
hence cell migration. Indeed, NRP1 has previously been shown to regulate 
Cdc42 activation, and thereby filopodia formation and actin remodelling in 
endothelial tip cells [290], so it would be interesting to additionally assess Rac1 
activity in our ECs. Though we have recently established that total Rac1 levels do 
not change between β3-WT and β3-HET ECs (not shown), we are yet to examine 
Rac1 phosphorylation. NRP1’s co-localisation with filamin a was previously 
shown to be dependent on NRP1’s cytoplasmic tail in heart ECs [289], a finding 
that may be supported by our results showing NRP1 localised away from mature 
FAs in stimulated β3-WT-NRP1Δcyto ECs. Unfortunately, the co-association of 
NRP1 with α5, filamin a, myosin 9, FAK, and p130Cas in β3-WT and β3-HET 
ECs was too variable and/or inconclusive by co-IP to follow up our mass 
spectrometry data with any certainty. Though it is possible that the variability in 
myosin 9-NRP1 associations pertains to the ‘stickiness’ of the myosin molecule, 
we ultimately reasoned that NRP1’s associations may be too dynamic in nature 
to be able to detect differences by co-IP, so we moved to the assessment of FA 
dynamics through paxillin activation and FA turnover, both of which have 
previously been reported to be regulated by NRP1 [271,289]. In the future, 
however, it would be interesting to further investigate NRP1’s protein associations 
identified in the mass spectrometry data by immunocytochemistry. 
 
Reflecting our EC migration phenotype, paxillin phosphorylation and FA 
disassembly were only impaired in β3-HET-NRP1Δcyto ECs. Compared to β3-
WT ECs, net FA turnover was increased in β3-HET ECs, but decreased in β3-
HET-NRP1Δcyto ECs, thus suggesting that EC migration is mainly dependent on 
FA turnover here. β3-WT-NRP1Δcyto ECs also displayed defective FA turnover, 
in agreement with Seerapu et al.’s [289] work, but not to the same extent as β3-
HET-NRP1Δcyto ECs, and this did not translate to differences in migration in our 
microvascular ECs. This may be because paxillin phosphorylation was not 
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inhibited in β3-WT-NRP1Δcyto ECs, and therefore may still promote Cdc42 
activation and concomitant EC migration in the way projected by Fantin et al. 
[290]. As NRP1’s role in Cdc42 activation was reported recently (after this project 
had been completed), we have not yet clarified whether Cdc42 activation is 
regulated by NRP1-mediated PXN phosphorylation in our microvascular MLECs, 
but it would be interesting to do so in the future. Nevertheless, the inhibition of 
PXN phosphorylation in β3-HET-NRP1Δcyto ECs, and lack thereof in in β3-WT-
NRP1Δcyto ECs, is in agreement with Raimondi et al. [271]’s prediction that 
NRP1’s extracellular portion is responsible for ABL1-mediated paxillin activation 
via interactions with FN-binding integrins. It is therefore possible that β3 is one 
such FN-binding integrin that regulates NRP1-ABL1-mediated PXN 
phosphorylation (though we have yet to examine ABL1 activation in our ECs). 
However, since PXN phosphorylation is unaltered in β3-HET ECs, there appears 
to be redundancy built into the system such that the presence of either β3 or full-
length NRP1 is sufficient to mediate adequate PXN activity. Perhaps another 
molecule can compensate for reduced β3 levels to regulate this function of NRP1 
in a way dependent on NRP1’s cytoplasmic tail. Indeed, α5β1-integrin, as a 
major FN-binding integrin that is regulated by NRP1’s cytoplasmic tail, may be 
one such candidate, though the reduction in α5 surface levels in β3-HET ECs 
may argue against this. We do not yet know how NRP1’s VEGF-induced 
mobilisation away from mature FAs and towards PXN-positive vesicles in β3-HET 
ECs links with FA turnover and PXN phosphorylation, but it could be that NRP1’s 
role in regulating FA protein trafficking via its cytoplasmic tail is enhanced in β3-
HET ECs, and results in faster FA turnover that, along with concomitant PXN 
phosphorylation [271], is sensitive to the removal of NRP1’s cytoplasmic tail. 
Since NRP1’s associations with filamin a and IQGAP1 were less prevalent in 
stimulated β3-HET ECs in the mass spectrometry data, this would mean that 
these FA-proteins are not trafficked by NRP1 in β3-HET ECs. They could even 
rather be blocked from deactivating Rac1 at active β1 sites, thereby further 
enhancing uncontrolled EC migration. To prove this theory, NRP1, filamin a, 
IQGAP1, and PXN would need to be co-localised with recycling vesicles and 
imaged over a time course, and Rac1 activation should be scrutinised, in our 
ECs. Moreover, it would be interesting to further explore the functional 
relationship between NRP1 and α5β1-integrin. 
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Overall, the increased sensitivity of β3-HET EC migration to the loss of NRP1’s 
cytoplasmic tail may be caused by a number of factors, but it seems to be 
strongly related to β3-integrin’s regulation of NRP1 function at FAs. When β3 is 
expressed at normal levels, NRP1 is stabilised in mature FAs, and has a 
negligible role in EC migration. On the other hand, when β3 expression is 
reduced, NRP1 is mobilised from mature FAs and EC migration becomes 
dependent on NRP1 via its involvement in FA turnover and concomitant PXN 
activation. This may therefore help explain the increased sensitivity of tumour 
growth and angiogenesis in β3-HET, but not β3-WT, mice to NRP1 perturbation. 
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6. Final Discussion and Future Work 
 
6.1 Final Discussion 
In this project we have shown that, in angiogenesis, NRP1 becomes more 
targetable, not only in the complete absence of β3-integrin (β3-NULL), as 
previously reported [202], but in a more physiologically relevant model that 
displays a more subtle, albeit global, reduction in β3 expression (β3-HET). This 
phenomenon additionally extends to pathological angiogenesis, as only in β3-
HET mice does an endothelial depletion of NRP1, or the removal of NRP1’s 
cytoplasmic tail, inhibit tumour growth and angiogenesis. Although NRP1 
depletion in ECs in WT mice may affect embryonic brain angiogenesis [265] and 
postnatal pathological neovascularisation of the retina [271], that we observed no 
effect on β3-WT angiogenic responses suggests that the role of endothelial 
NRP1 in pathological angiogenesis is redundant in adult mice. The lack of an 
effect of the removal of NRP1’s cytoplasmic tail on adult angiogenesis in β3-WT 
mice is, however, in agreement with that previously reported across the board 
[267,268]. Our in vivo and ex vivo angiogenic phenotypes correlated with the 
rates of random and directed migration of lung microvascular ECs isolated from 
mice of the same genotypes; only in β3-HET ECs was migration sensitive to the 
loss of NRP1’s cytoplasmic tail. EC migration may therefore have a profound 
influence on tumour growth and angiogenesis in our models. Indeed, although the 
lack of a difference in tumour growth and angiogenesis in mice with a constitutive 
endothelial deletion of β3 [211] suggests that elevated tumour growth and 
angiogenesis in β3-HET mice is due to the role of non-ECs, β3-HET EC 
migration was enhanced in a similar manner to angiogenesis, and so endothelial 
migration cannot be ignored as a major contributor to our in vivo phenotypes. 
That there was no difference in the migration of β3-WT ECs lacking NRP1’s 
cytoplasmic tail compared to WT ECs with full-length NRP1 came in contrast to 
the previously reported slower rate of migration exhibited by NRP1Δcyto heart 
ECs [289]. However, this discrepancy is likely explained by differences between 
lung microvascular ECs and heart ECs, which may reflect the dispensable role of 
NRP1’s cytoplasmic tail in angiogenesis and significant role of this portion of 
NRP1 in arteriogenesis, respectively [267,268]. Since the knock-down of NRP1 
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has consistently impaired EC migration in the past [133,272], it stands to reason 
that the extracellular portion of NRP1 plays an important part in migration. In 
contrast to β3-NULL animals, increased angiogenesis in β3-HET mice does not 
occur through overt changes in VEGFR2 expression or VEGFR2-NRP1 
interactions. Moreover, although ERK1/2 phosphorylation in β3-HET ECs was 
slightly reduced without NRP1’s cytoplasmic tail, and there may be subtle 
changes in VEGFR2 recycling between β3-WT and β3-HET ECs, the increased 
sensitivity of β3-HET EC migration to the loss of NRP1’s cytoplasmic tail does not 
appear to be wholly related to differences in VEGFR2 signalling or trafficking, 
which have previously been reported to be regulated by NRP1 
[68,80,272,273,275,284]. Rather, we have identified a novel function for β3-
integrin whereby it regulates the retention of NRP1 within mature FAs upon 
VEGF-stimulation. NRP1’s involvement in EC migration, at least in microvascular 
ECs, is thereupon regulated by β3. When β3 is expressed at normal levels, 
NRP1 is stabilised in PXN-positive mature FAs, even following VEGF stimulation, 
and its cytoplasmic tail is dispensable for EC migration. However, when β3 
expression is reduced, NRP1 is mobilised from mature FAs upon VEGF 
stimulation, and instead, unless it is missing its cytoplasmic tail, preferentially 
localises to PXN-positive vesicles. Though likely not through a direct interaction, 
β3 regulates NRP1’s molecular associations with proteins within the adhesome, 
including filamin a and IQGAP1, whose associations with NRP1 become 
decreased in VEGF-stimulated β3-HET ECs, thus concurring with NRP1’s 
localisation away from mature FAs. β3 also regulates NRP1’s role in FA turnover 
and PXN activation. Whilst the loss of NRP1’s cytoplasmic tail slightly impairs FA 
turnover, it does not affect PXN phosphorylation, and therefore may not perturb 
Cdc42-dependent migration [290]. β3-HET ECs display fast FA turnover, but 
without NRP1’s cytoplasmic tail both FA turnover and PXN phosphorylation are 
strongly impaired. Thus, EC migration in β3-HET ECs is dependent on NRP1 via 
its involvement in FA turnover and PXN activation. 
 
Since αvβ3-integrin is known to immobilise in static FAs [224], we hypothesise a 
mechanism in microvascular ECs whereby, when adequately expressed, αvβ3-
integrin prevents NRP1 from fully participating in FA dynamics by sequestering it 
at these mature FAs even after VEGF stimulation. When αvβ3 expression is 
193 
reduced, however, VEGF stimulation mobilises NRP1 from these sites, allowing 
NRP1 to regulate the rapid vesicular recycling of FA components and 
concomitant FA turnover and PXN activation. PXN activation and concomitant 
Cdc42 activation can be adequately mediated by either unaltered αvβ3 or NRP1, 
but not when both are perturbed. Though not yet proven, NRP1 may also 
contribute to an increase in VEGFR2 recycling when β3 expression is reduced, 
thus accounting for an increase in ERK1/2 phosphorylation that is sensitive to the 
loss of NRP1’s cytoplasmic tail. As a result of all this, whilst the role of NRP1’s 
cytoplasmic tail in WT tumour growth and angiogenesis, and EC migration, is 
redundant, these processes become dependent on it when αvβ3 levels are 
reduced (see Figure 6.1). 
 
This mechanism may also explain why simultaneously targeting both αvβ3 and 
NRP1 in ECs blocks the growth and angiogenesis of already established 
tumours. Accordingly, our work provides proof-of-concept that a dual-combative 
αvβ3-integrin/NRP1 targeting approach offers a clinically beneficial way of 
treating advanced solid cancers. Indeed, since β3-integrin’s regulation of NRP1 
function is dependent on the presence of VEGF, even when NRP1’s regulation of 
VEGFR2 is largely unchanged, this approach may improve upon the efficacy of 
current strategies that mainly focus on manipulating the VEGF-VEGFR2 pathway, 
which are linked with significant side-effects and prone to treatment resistance 
[120].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Model mechanism. Schematic representation of the hypothesised participation of 
neuropilin-1 (NRP1) in focal adhesion (FA) turnover and migration in β3-integrin-wild-type (β3-WT) 
(left) and β3-suppressed (right) endothelial cells (EC)s. See text for full details. ITGN, integrin. FN, 
fibronectin.
FN
NRP1 αvβ3-ITGN α5β1-ITGN
mature FA
+ VEGF
β3-dependent
NRP1-independent
EC migration
WT β3-ITGN
β3-independent
NRP1-dependent
EC migration
 
β3-ITGN
+ VEGF
NRP1-
mediated
FA turnover
F-actin
P
Cdc42 GDP
GDP
P
GDP
GDP
Faster
NRP1-VEGFR2
recycling?
ERK1/2
P
paxillin
194
195 
6.2 Future Work 
Despite achieving the overall aims of this project, there are a number of areas 
that can be developed further in the future. Firstly, since our investigation into the 
effect of β3/NRP1 dual targeting on tumour metastasis was unsuccessful, this 
experiment remains a priority for us to better understand the longer-term 
implications of this type of intervention therapy. As our attempts using CMT19T 
cancer cells did not result in metastases, we propose to subcutaneously inject a 
different resectable cell-line, such as the Lewis lung carcinoma (LLC) cell-line, 
and carry on the experiment as before. Alternatively, we could also employ an 
orthotopic bone metastasis model that is currently being further developed in our 
laboratory. This model makes use of a C57BL/6 MMTV-PyMT-derived transplant 
cell-line (B6 LV-1) established by Prof Katherine Weilbaecher (Washington 
University, St Louis, USA), which selectively metastasises to bone following an 
orthotopic injection into mammary fat pads of mice. With this model, an adjuvant 
form of therapy can be simulated by administering OHT to induce endothelial 
depletion of β3 and/or NRP1 in our Cre-transgenic mice at the time of 
mastectomy. Subsequently, the formation of metastases in long bones can be 
monitored in vivo by bioluminescent/fluorescent imaging, as the B6 LV-1 cells are 
both GFP- and luciferase-tagged. If, like tumour growth, metastasis is reduced in 
the β3/NRP1 dual-targeted model, then the case for their joint targeting in the 
clinic is strengthened. 
 
To expand on our proposed mechanism of αvβ3-regulated NRP1 function in FAs, 
a number of areas can be further clarified. As previously mentioned, to gain a 
clearer idea of potentially differential associations between NRP1 and particular 
FA proteins that were detected by mass spectrometry, but not reliably by co-IP, in 
our transgenic MLECs, we could use immunocytochemistry to co-localise NRP1 
and these molecules, which include filamin a, IQGAP1, myosin 9, and α5β1-
integrin, over a VEGF time course. Extending this further, to determine whether 
NRP1 does differentially recycle FA proteins in vesicles between EC genotypes, 
and thus explain NRP1-dependent differences in FA turnover, we would like to 
additionally co-localise these molecules with Rab4 or Rab11 markers of recycling 
vesicles. NRP1-PXN-Rab11 co-localisation in vesicles in β3-HET ECs, for 
example, which dynamically changes over a time course of VEGF stimulation, 
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may help prove that FA turnover is elevated in these cells as a result of faster 
NRP1-mediated PXN recycling. To further clarify whether there are subtle 
changes in NRP1-mediated VEGFR2 recycling between β3-WT and β3-HET ECs 
that explains their differential ERK1/2 activity, we could also monitor co-
localisation between VEGFR2, Rab11 and NRP1 over time after stimulation in 
this way. As we wondered whether Cdc42 and Rac1 activation may be 
differentially activated via NRP1 in our ECs, we would to like to test this by using 
a PAK pull-down assay. If we detect differences in Cdc42 activation, it would also 
be worth looking at ABL1 activation to see if there is a β3/NRP1-regulated ABL1-
mediated activation of PXN and Cdc42, as partly predicted by Raimondi et al. 
[271] and Fantin et al. [290]. Since these two previous studies were stimulating 
ECs by adhering them to FN, as opposed to VEGF-stimulating ECs already 
adhered to FN as we did, it might be interesting to try this alternative approach to 
seek potential differences. Moreover, we could also see if other growth factors 
besides VEGF have the same overall effect on NRP1 and its downstream effects 
in our ECs (or, indeed, on NRP1 localisation). If there are differences in Rac1 
activation, we could initially determine whether NRP1 regulates this through 
filamin a and IQGAP1 by knocking down NRP1 and examining filamin a/IQGAP1 
associations with Rac1. 
 
Perhaps a more pertinent question regarding αvβ3’s regulation of NRP1 is how 
does αvβ3-integrin control NRP1 localisation? To answer this we suggest 
transfecting different mutant β3 cDNA constructs into β3-NULL ECs in order to 
establish the particular functional properties of αvβ3 that exert control over 
NRP1’s localisation to mature FAs. Specifically, we could make use of the DiYF 
β3 mutant developed by Phillips et al. [320], and previously used by 
Mahabeleshwar et al. [186], which contains mutations in the cytoplasmic tail 
residues Y747 and Y459, located in the NPxY and NxxY motifs, respectively, and 
thus is unable to be activated at these sites. Also available is the β3Δ722 mutant 
used by Robinson et al. [202], which lacks the end residues 723-787 of β3’s 
cytoplasmic tail, and though still able to dimerise and engage ligands of the ECM, 
has impaired outside-in signalling. Another β3 mutant, β3Δ744, which is similar 
to β3Δ722 but less able to engage the ECM, could also be used. These 
constructs can be transfected into β3-NULL ECs alongside full-length β3 and an 
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empty vector as controls to compare NRP1 localisation between them by 
immunocytochemistry. This would additionally clarify whether the absence of β3 
in β3-NULL ECs affects NRP1 localisation in the same way as in β3-HET ECs. 
 
Having a clearer idea of the functionally relevant parts of the β3 and NRP1 
molecules that contribute to our phenotypes should allow for the design of 
antagonists that are better suited to reducing tumour growth and angiogenesis in 
a dual-targeting strategy. Currently, small molecule inhibitors directed against 
NRP1 are under development [274,299,300], which target the VEGF-binding 
portion of NRP1. It would be interesting to initially determine whether these 
inhibitors have the same effect on EC migration in β3-HET ECs, or in ECs 
additionally targeted with existing αvβ3 antagonists, as the loss of NRP1’s 
cytoplasmic tail has in β3-HET ECs. Similarly, we could examine EC migration in 
a reverse scenario, where αvβ3 is targeted with antagonists in β3-WT and β3-
WT-NRP1Δcyto ECs, to determine whether the acute targeting of αvβ3, like long-
term genetic targeting in the β3-HET model, also renders EC migration 
dependent on NRP1’s cytoplasmic tail. One αvβ3 antagonist we would like to trial 
in particular is the RGDfV (EMD66203) cyclic peptide compound, which has 
greater specificity for αvβ3 compared to cilengitide, which more equally targets 
boh α5β1 and αvβ3. If these antagonists are similarly effective in inhibiting EC 
migration as our genetic approach, then this would pave the way for their joint 
use in clinically relevant tumour models, and ultimately in clinical trials. However, 
we suspect that inhibitors targeted against the cytoplasmic tail of NRP1 may 
meet with greater success than those currently under development, given the 
importance of this portion of NRP1 in regulating both FA proteins and VEGFR2. 
Moreover, until we have a better idea of what portion of the αvβ3 molecule 
regulates NRP1, we cannot decisively recommend an antagonist that would work 
most efficaciously alongside NRP1 inhibition. As both molecules are expressed 
by multiple cell types that contribute to tumour growth and angiogenesis, we must 
also carefully consider the off-target effects of antagonists on cell types other 
than ECs. Overall, a dual-targeted αvβ3/NRP1 pharmacological approach must 
be properly scutinised in the future in order to fulfil its potential for clinically 
beneficial and durable results. 
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German et al. [252] recently found that reducing PXN expression also reduced 
NRP2, thereby increasing HUVEC migration and angiogenesis. NRP2 has also 
separately been shown to regulate α6β1-integrin in the formation of FAs on 
laminin in breast cancer cells [321]. Another possible area for future research 
would therefore be to examine the relationship between αvβ3 and NRP2. Does 
β3 expression regulate NRP2 localisation in the same way as NRP1? Is NRP2 
involved in directing FA turnover in ECs? Are tumour growth, angiogenesis, and 
EC migration sensitive to NRP2 targeting in β3-depleted models? These are 
some of the questions that would be interesting to attempt to answer in this 
regard. 
 
Our findings that β3-integrin changes NRP1’s associations within the adhesome, 
and that both molecules are implicated in directing FA dynamics and EC 
migration, warrant a wider investigation into how αvβ3 influences the endothelial 
adhesome. We would therefore like to conduct detailed further analyses of the 
adhesome by mass spectrometry with a view to observing how the composition 
of the adhesome changes following different αvβ3 targeting methods in ECs. FA 
proteins that change consistently between different approaches of targeting αvβ3 
might offer themselves as novel candidates that contribute to differential 
adhesion dynamics, and thus could potentially be co-targeted with αvβ3 to 
manipulate angiogenic responses. We can additionally assess the role of myosin 
II-generated force and externally applied forces in changes in NRP1 and the 
adhesome, as well as examining changes following myosin II inhibition with 
blebbistatin. 
 
Finally, results from this project have hinted at the possible involvement of α5β1-
integrin in a β3/NRP1-related mechanism. We would therefore like to begin to 
decipher how these three molecules behave together in ECs, with a view to 
continue developing the search for a novel anti-angiogenic therapeutic approach. 
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Appendix Figure 1: B16F0 Tumour growth and tumour angiogenesis in                                               
β3-integrin-heterozygous mice are sensitive to endothelial neuropilin-1 depletion. A Tumour 
growth was measured in animals of the indicated genotypes. Mice were given subcutaneous 
injections of B16F0 tumour cells. To induce depletion of endothelial NRP1 (NRP1-EC-ID), 21-day 
slow-release OHT pellets were administered 3-days prior to tumour cell injection. OHT-treated 
Cre-negative (NRP1-EC-WT) littermates served as controls. Tumour volumes were measured after 
12 days of growth (mean +SEM of 3 independent experiments; n≥10 animals per genotype). 
Representative pictures of tumour macroscopic appearances are shown below. Scale bar = 10 mm. 
B Blood vessel density was assessed in tumours of the indicated genotypes by counting the total 
number of endomucin-positive vessels across tumour sections (mean +SEM; n≥10 sections per 
genotype). Representative micrographs of immunofluorescence staining for endomucin, an 
endothelial cell marker (Endo, red) in tumour sections from each genotype are shown below. DAPI 
(blue) was used as a nuclear counterstain. Scale bar = 100 μm. Asterisks indicate statistical 
significance: *, P<0.05; **, P<0.01; nsd = not significantly different.  Unpaired two-tailed t test.
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Appendix Figure 2: The investigation of the dual importance of β3-integrin and neuropilin-1 in 
metastasis was unsuccessful. A RT-PCR of the luciferase (Luc) gene from CMT19TF1 cells 
transduced with a lentiviral-luciferase construct and control cells that were not transduced. B 
Bioluminescence image of mice previously injected with the alleged CMT19TF1-Luc cells and 
another cell-line known to be tagged with Luc (B6 LV1-Luc). No bioluminescence was detected in the 
CMT19TF1-Luc-injected mice. C Metastasis model schematic: Mice were injected subcutaneously 
with CMT19TF1 cells and 20 days later tumours were resected and OHT was administered to induce 
depletion of endothelial β3 and/or NRP1 (EC-ID). After an additional 12 days (32 days in total) lungs 
were harvested and processed to detect metastases. D Representative H&E images of all lungs from 
this experiment showing no metastases (left) and of lungs from Cre-negative Tie.Cre/β3-floxed mice 
in another experiment from our laboratory that do display metastases (right). 
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Appendix Figure 3: Neuropilin-1-regulated VEGFR2 signalling via Akt and p38MAPK is no 
different between wild-type and    β3-integrin heterozygous endothelial cells with and without 
neuropilin-1’s cytoplasmic tail. Lung microvascular endothelial cells (ECs) were isolated and 
immortalised (polyoma-middle-T-antigen) from β3-WT and β3-HET mice that were expressing either 
normal (WTNRP1) or cytoplasmic-tail deleted NRP1 (NRP1Δcyto). ECs were seeded overnight on a 
complex matrix containing gelatin, collagen, fibronectin and vitronectin, and were then stimulated 
with VEGF over an extended time course to examine signalling kinetics. ECs were lysed and blotted 
for levels of phosphorylated (‘p’...) and total Akt, and phosphorylated p38MAPK and total p38MAPK. 
HSC-70 was used as a loading control. Data are representative of 3 independent experiments.
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Appendix Figure 4: Examining surface levels of integrins in β3-integrin-wild-type and 
heterozygous endothelial cells with and without neuropilin-1’s cytoplasmic tail. ECs of the 
indicated genotypes were measured for their surface expression of endothelial integrin subunits by 
flow-cytometry.  Flow-cytometric histogram profiles were generated after forward versus side scatter 
data were tightly gated around, and normalised to, an isotype control. Representative profiles are 
shown from 3 independent experiments.
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Suppression of β3-integrin in mice triggers a neuropilin-1-
dependent change in focal adhesion remodelling that can
be targeted to block pathological angiogenesis
Tim S. Ellison1, Samuel J. Atkinson1, Veronica Steri1, Benjamin M. Kirkup1, Michael E. J. Preedy1,
Robert T. Johnson1, Christiana Ruhrberg2, Dylan R. Edwards1, Jochen G. Schneider3,
Katherine Weilbaecher4 and Stephen D. Robinson1,*
ABSTRACT
Anti-angiogenic treatments against αvβ3-integrin fail to block
tumour growth in the long term, which suggests that the tumour
vasculature escapes from angiogenesis inhibition through αvβ3-
integrin-independent mechanisms. Here, we show that suppression
of β3-integrin in mice leads to the activation of a neuropilin-1 (NRP1)-
dependent cell migration pathway in endothelial cells via amechanism
that depends on NRP1’s mobilisation away from mature focal
adhesions following VEGF-stimulation. The simultaneous genetic
targeting of both molecules significantly impairs paxillin-1 activation
and focal adhesion remodelling in endothelial cells, and therefore
inhibits tumour angiogenesis and the growth of already established
tumours. These findings provide a firm foundation for testing drugs
against thesemolecules in combination to treat patientswith advanced
cancers.
KEY WORDS: Integrin, Neuropilin-1, Angiogenesis, Tumour,
Focal adhesion
INTRODUCTION
Angiogenesis, the formation of new blood vessels from pre-existing
vasculature, is essential to support both primary and metastatic
tumour growth (Hanahan and Weinberg, 2011). It occurs when
hypoxia causes tumour cells to release growth factors such as
vascular endothelial growth factor (VEGF), which stimulate nearby
endothelial cells (ECs) to activate appropriate growth factor
receptors, e.g. VEGF-receptor-2 (VEGFR2). New blood-vessel
formation ensues as ECs proliferate and migrate through the
extracellular matrix (ECM) toward the tumour in an integrin-
dependent fashion (Robinson and Hodivala-Dilke, 2011). This
process of tumour angiogenesis frequently offers a route to
metastasis by providing an increased density of highly permeable
blood vessels. Thus, anti-angiogenic strategies form a key
component of the current cancer-targeting arsenal. Because of its
central role in the process, many of the existing anti-angiogenic
strategies target the VEGF-VEGFR2 pathway, but these approaches
are linked to a plethora of unwanted side effects and the
development of treatment resistance (Ebos and Kerbel, 2011).
Integrins are the main ECM adhesion receptors. They sense,
integrate and disseminate ECM and growth factor signals to co-
ordinate EC responses during angiogenesis (Silva et al., 2008).
αvβ3-integrin has emerged as a key anti-angiogenic therapeutic
target because it is upregulated in the vasculature of solid tumours,
but its expression is low in quiescent vasculature (Brooks et al.,
1994). Unlike current FDA-approved anti-angiogenic drugs,
αvβ3-integrin antagonists are well-tolerated, likely owing to the
fact that αvβ3-integrin expression is restricted to neo-angiogenic
vessels (Hariharan et al., 2007). However, the synthetic inhibitors
directed against αvβ3-integrin have so far failed to improve overall
survival in patients (Marelli et al., 2013). Moreover, although we
have shown that suppressing endothelial αvβ3-integrin in the early
stages of tumour growth has an inhibitory growth effect, its long-
term suppression leads to ‘treatment’ resistance (Steri et al., 2014).
We do not yet understand what the mechanisms of resistance are, or
how to overcome them. In order to improve therapeutic outcomes
when targeting this key molecule, we need to rethink how to best
use anti-angiogenic strategies based on αvβ3-integrin antagonism.
A promising approach to overcome resistance to anti-angiogenic
treatment is to identify pathways of resistance and to co-target them
alongside the original target. Such approaches are emerging in a
number of cancer types as viable therapeutic strategies to improve
upon existing treatments (Sennino and McDonald, 2012). In 2009,
an αvβ3-integrin co-target candidate emerged: the VEGF co-
receptor, neuropilin-1 (NRP1) (Robinson et al., 2009). However, we
do not yet fully understand how these two molecules cooperate
mechanistically to regulate pathological angiogenesis, nor do we
know whether their interaction can be manipulated to alter
outcomes.
NRP1 is a single-pass transmembrane molecule found, for
example, in neurons and ECs. Originally identified as an adhesion
molecule (Takagi et al., 1995), attention shifted to its VEGF-
dependent role in binding and regulating the signalling and
trafficking of VEGFR2 in ECs (Ballmer-Hofer et al., 2011;
Herzog et al., 2011). NRP1’s short cytoplasmic tail is crucial for
the regulation of VEGFR2 trafficking because its SEA motif binds
the PDZ domain of synectin, linking the complex to the inward
trafficking motor myosin VI (Ballmer-Hofer et al., 2011; Cai and
Reed, 1999). Recent work has returned to its original role as
an adhesion molecule. Valdembri et al. (2009) showed that
NRP1 binds and regulates α5β1-integrin trafficking, again via its
cytoplasmic tail, and thus promotes EC spreading on lowReceived 13 January 2015; Accepted 7 July 2015
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concentrations of fibronectin (FN), whereas Raimondi et al. (2014)
demonstrated an essential role for NRP1 in promoting FN-
dependent signalling in ECs. In support of VEGF-independent
roles for NRP1 in ECs, Fantin et al. (2014) found that mice with a
mutant NRP1 defective in VEGF binding overcome the mid-
gestation lethality of full NRP1-knockout mice (Kawasaki et al.,
1999). Indeed, there is mounting evidence that links VEGF-
independent roles for NRP1 to focal adhesion (FA) function
(Raimondi et al., 2014; Seerapu et al., 2013). What we do not yet
know is how and when, and in what cell types, NRP1 contributes to
the assembly and maintenance of these large and dynamic
macromolecular assemblies that link the ECM to the cytoskeleton
and through which both mechanical force and regulatory signals are
transmitted (Zamir and Geiger, 2001).
That NRP1 plays a crucial role in developmental angiogenesis
and arteriogenesis is undeniable (Fantin et al., 2014, 2011; Gerhardt
et al., 2004; Kawasaki et al., 1999; Lanahan et al., 2013), but its role
in pathological angiogenesis is not clear. Although a number of
papers allude to it having no role, Fantin et al. (2014) published
findings suggesting that the VEGF-binding domain of NRP1 is
important for pathological neovascularisation of the retina and
angiogenesis-dependent tumour growth. Here, we conclusively
show, however, that disrupting NRP1 function by deleting its
cytoplasmic tail or by depleting its expression in wild-type mice has
no effect on tumour growth or angiogenesis. However, we can
sensitise angiogenic responses to NRP1 perturbations by reducing
β3-integrin expression in heterozygous β3-integrin-deficient mice.
We show that β3-integrin expression is essential for the efficient
retention of NRP1 at FAs after VEGF-stimulation. NRP1 can
influence paxillin-1 (PXN) activity and FA remodelling, but only if
it is relieved from its retention within mature FAs by reducing β3-
integrin expression. This sensitisation to NRP1 perturbations that
occurs upon suppressing β3-integrin means that we can target both
molecules simultaneously to significantly improve inhibition of
growth and angiogenesis in both new and established tumours. This
finding offers a potential solution to improve anti-angiogenic
strategies.
RESULTS
Pathological angiogenesis is sensitive to NRP1 disruption in
heterozygous β3-integrin-deficient mice
We previously showed that VEGF-mediated angiogenic responses
become dependent on NRP1 in β3-integrin-knockout (β3-KO) mice
(Robinson et al., 2009). In this model, angiogenesis was
significantly blocked only by simultaneously inhibiting both β3-
integrin and NRP1, a finding that we would like to translate to the
clinic. In the β3-KO model, however, pathological angiogenesis is
elevated over the wild type (Reynolds et al., 2002). It has been
postulated that this phenotypic response occurs, in part, through the
developmental upregulation of VEGFR2 (Reynolds et al., 2004),
making it potentially difficult to interpret experimental outcomes
that depend on molecular interactions with this growth-factor
receptor. We therefore moved our analyses to β3-integrin-
heterozygous (β3-HET) mice, hypothesising that this would
circumvent developmental changes arising from the complete loss
of the protein, whilst at the same time maintaining, at least to a
degree, critical interactions between β3-integrin and VEGFR2
(Mahabeleshwar et al., 2007) and/or NRP1 (Robinson et al., 2009).
We crossed β3-integrin-wild-type (β3-WT) and β3-HET mice to
tamoxifen (OHT)-inducible Pdgfb-iCreERT2/NRP1-floxed mice
(Claxton et al., 2008; Gu et al., 2003) and examined the effect of
an acute EC-specific depletion of NRP1 (EC-NRP1-KO) on
subcutaneous allograft tumour growth with both CMT19T cells
(Fig. 1A) and B16F0 cells (supplementary material Fig. S1), as well
as on aortic ring sprouting (Fig. 1B). Depleting EC-NRP1 expression
in this way had no effect on β3-WT responses, but significantly
inhibited tumour growth and VEGF-induced microvessel sprouting
in β3-HETmice. Tumour angiogenesis was significantly inhibited in
β3-HET mice by depleting EC-NRP1, although vessel morphology
and pericyte coverage were normal (Fig. 1C). These studies are
reminiscent of the changes observed in β3-KO mice, but,
importantly, suggest that NRP1 function is already perturbed by
subtle changes in β3-integrin expression levels.
To narrow our mechanistic focus further, we crossed β3-WT and
β3-HET animals with mice carrying a global deletion of NRP1’s
cytoplasmic tail (NRP1Δcyto), which is essential for many of its
functions (Fantin et al., 2011; Lanahan et al., 2013). CMT19T
tumour growth (Fig. 1D) and microvessel sprouting (Fig. 1E)
patterns were unaltered in β3-WT mice by the introduction of the
NRP1Δcyto mutation, whereas both parameters were inhibited in
β3-HET mice. Although the loss of NRP1’s cytoplasmic tail had a
small effect on tumour angiogenesis in β3-WT mice (Fig. 1F), this
did not translate to an overall difference in tumour growth (Fig. 1D).
As in EC-NRP1-KO tumours, pericyte coverage of tumour
vasculature was not affected by an NRP1 cytoplasmic deletion
(Fig. 1F). We conclude from these studies that NRP1’s cytoplasmic
tail is normally dispensable for pathological angiogenesis, but plays
a significant role when insufficient β3-integrin is expressed.
TRANSLATIONAL IMPACT
Clinical issue
αvβ3-integrin has emerged as a key anti-angiogenic target in cancer
therapy because it plays a pivotal role in endothelial cell migration and
vascular endothelial growth factor (VEGF)-mediated signalling.
However, innate and acquired treatment resistance occurs with its
blockade, so treatment fails to block tumour growth in the long term.
Understanding the molecular mechanisms that contribute to this
resistance is necessary for developing new strategies that target αvβ3-
integrin to inhibit tumour growth and progression. It is clear that
alternative pro-angiogenic pathways become active in the absence of
αvβ3-integrin expression, which suggests that these pathways offer
routes to resistance to αvβ3-integrin blockade. This study seeks to
understand the molecular basis behind how αvβ3-integrin-regulated
pathways contribute to anti-angiogenic resistance and to test the
hypothesis that blocking αvβ3-integrin in combination with these
pathways will block tumour progression.
Results
Using heterozygous β3-integrin-deficient mice as amodel of αvβ3-integrin
blockade, the authors uncovered a neuropilin-1 (NRP1)-regulated
endothelial-cell-migration pathway that only becomes active when αvβ3-
integrin expression is suppressed. In β3-integrin heterozygous endothelial
cells, but not in wild type, NRP1 regulated paxillin-1 phosphorylation, focal
adhesion remodelling and cell migration. This newly found role for NRP1
correlates with its mobilisation away from mature focal adhesions in
VEGF-induced β3-integrin-depleted cells; this shift in cellular localisation
does not occur in wild-type cells. Finally, the authors show that
suppressing the endothelial expression of both αvβ3-integrin and NRP1
blocks the progression of already-established tumours.
Implications and future directions
This study uncovered an NRP1-dependent migration pathway that only
becomes active upon αvβ3-integrin depletion and it showed that this
pathway can be targeted to block tumour progression. These results
implicate endothelial NRP1 as a potential co-target during αvβ3-integrin-
directed therapies to prevent anti-angiogenic treatment resistance.
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NRP1-dependent functions of VEGFR2 are normal in
β3-integrin-heterozygous endothelial cells
Given that NRP1’s cytoplasmic tail is important for the regulation of
VEGFR2 signalling and trafficking (Ballmer-Hofer et al., 2011;
Herzog et al., 2011), we wanted to investigate whether the
NRP1Δcyto mutation differentially affects VEGFR2 function in
β3-WT versus β3-HET lung microvascular ECs. We employed
polyoma-middle-T-antigen immortalised ECs, isolated from the
mutant mice described above, because we and others have shown
that they present good models to study angiogenesis (Ni et al., 2014;
Robinson et al., 2009; Steri et al., 2014; Tavora et al., 2014). We first
compared total VEGFR2 levels in the four genotypes (β3-WT,
β3-HET, β3-WT;NRP1Δcyto and β3-HET;NRP1Δcyto). Unlike
β3-KO ECs, we noted only a small trend of increased VEGFR2
levels in β3-HET and β3-HET;NRP1Δcyto ECs (Fig. 2A).
To explore potential changes in VEGFR2-dependent signalling,
we seeded ECs on a complex matrix containing gelatin, collagen I
(COLI), FN and vitronectin (VN) to preserve the known
VN-dependent β3-VEGFR2 interaction (Soldi et al., 1999),
stimulated with VEGF, and immunoblotted for changes in total
Fig. 1. Tumour growth, tumour angiogenesis and microvessel sprouting in β3-integrin-deficient heterozygous mice are sensitive to NRP1
perturbations. (A) Tumour growth was measured in animals of the indicated genotypes. Mice were given subcutaneous injections of CMT19T tumour cells. To
generate NRP1-EC-KO (EC-null), 21-day slow-release OHT pellets were administered 3 days prior to tumour-cell injection. OHT-treated Cre-negative (NRP-EC-
WT) littermates served as controls. Tumour volumes were measured after 12 days of growth (mean+s.e.m. of three independent experiments; n≥10 animals per
genotype). Representative pictures of tumour macroscopic appearances are shown. Scale bar: 10 mm. (B) Microvessel sprouting of aortic ring explants of the
indicated genotypes. NRP1-EC-KO was induced in culture with 1 μM OHT. OHT-treated Cre-negative (EC-NRP-WT) rings served as controls. The bar chart
shows the total number of microvessel sprouts per aortic ring after 6 days of VEGF-stimulation (mean+s.e.m. from three independent experiments; n≥40 rings per
genotype). (C) Blood-vessel density was assessed in tumours of the indicated genotypes by counting the total number of endomucin-positive vessels across
tumour sections (mean+s.e.m.; n≥10 sections per genotype over three independent experiments). Representative micrographs of immunofluorescence staining
for endomucin, an endothelial cell marker (Endo; red) and CD146, a pericyte marker (green) in tumour sections from each genotype are shown. DAPI (blue) was
used as a nuclear counterstain. Scale bar: 100 μm. (D) CMT19T tumour growth and angiogenesis were measured in animals of the indicated genotypes. In
addition to their β3-integrin genetic status, mice were negative (NRP1 WT) or positive (NRP1 Δcyto) for the loss of NRP1’s cytoplasmic tail. Mice were given
subcutaneous injections of CMT19T cells and tumour volumes were measured 12 days later. The bar chart shows tumour volumes (mean+s.e.m. of three
independent experiments; n≥10 animals per genotype). (E) Microvessel sprouting of aortic ring explants of the indicated genotypes. The bar chart shows the total
number of microvessel sprouts per aortic ring after 6 days of VEGF-stimulation (mean+s.e.m. from three independent experiments; n≥40 rings per genotype).
(F) Blood-vessel density was assessed by endomucin (red) and CD146 (green) staining (mean+s.e.m.; n≥10 sections per genotype). DAPI was used as a
nuclear counterstain (blue). Scale bar: 100 μm. Asterisks indicate statistical significance: *P<0.05; **P<0.01; ***P<0.001; nsd, not significantly different. Unpaired
two-tailed t-test.
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Fig. 2. NRP1-dependent functions of VEGFR-2 are normal in β3-integrin-heterozygous endothelial cells. (A) Lung microvascular endothelial cells (ECs)
were isolated and immortalised (polyoma-middle-T-antigen) from β3-WT and β3-HET mice that were expressing either normal (WT NRP1) or cytoplasmic-tail-
deleted (NRP1 Δcyto) NRP1. Multiple EC lysates of each genotype were western blotted (WB) to examine total cellular levels of VEGFR2 and β3-integrin. Bar
charts of densitometric analysis of mean (+s.e.m.) changes between the four genotypes are shown to the right. Asterisks indicate statistical significance: *P<0.05.
(B-E) Representative of ≥three independent experiments per blotted protein. ECs were seeded overnight on a complex matrix containing gelatin, collagen,
fibronectin and vitronectin, and were then stimulated with VEGF over the indicated time courses. (B) ECs were lysed and blotted for levels of phosphorylated
(phospho) and total VEGFR2, NRP1, and phospho (pERK) and total (tERK) ERK1/2. (C) To examine protein degradation, the VEGF time course was extended
and EC lysates were blotted for levels of total VEGFR2, NRP1 and β3-integrin. (D) Following a VEGF time course, ECs were trypsinised and analysed by flow
cytometry for surface levels of VEGFR2. Median fluorescence intensity was measured after forward versus side scatter data were tightly gated around, and
normalised to, an isotype control. The graph shows the relative surface level of VEGFR2 (means±s.e.m.) relative to the 0 (non-stimulated) time point. (E) ECswere
stimulated with VEGF for the indicated amounts of time and then lysed and immunoprecipitated for VEGFR2 (VEGFR2 IP), before being blotted for NRP1
association. A total cell lysate (TCL) is shown for comparison. (A-E) HSC-70 served as a loading control. Data are representative of three independent
experiments.
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and phosphorylated levels of VEGFR2 and its downstream targets
ERK1/2 (Koch et al., 2011) (Fig. 2B). Although VEGF-induced
VEGFR2 phosphorylation was slightly elevated in β3-HET ECs,
VEGFR2 phosphorylation was not significantly changed by the
introduction of the NRP1Δcyto mutation in either β3-WT or
β3-HET ECs, suggesting that VEGFR2 signalling is NRP1-
independent in these microvascular ECs despite differences in
β3-integrin expression. In contrast, VEGF-induced ERK1/2
phosphorylation was sensitive to an NRP1 cytoplasmic deletion
in β3-HET ECs but not β3-WT ECs (Fig. 2B).
We observed no overt changes in the pattern of total cellular
VEGFR2 expression over time after VEGF stimulation when
comparing the four genotypes to one another (Fig. 2C). In each
case, VEGFR2 expression levels dropped over the time course of
stimulation. This is suggestive of the protein being degraded over time
in all four genotypes and is congruent with prior reports (Ewan et al.,
2006; Reynolds et al., 2009; Reynolds and Hodivala-Dilke, 2006).
Taken together, these signalling studies pointed to a VEGFR2-
independent role for NRP1 in mediating VEGF-induced responses
in β3-HET ECs. However, as previously mentioned, when
compared to their β3-WT counterparts, total VEGFR2 levels were
slightly elevated in both β3-HET and β3-HET;NRP1Δcyto ECs.
Moreover, NRP1 expression was substantially increased in both
β3-WT;NRP1Δcyto and β3-HET;NRP1Δcyto ECs (Fig. 2A,B). We
therefore decided to examine VEGFR2 behaviour in greater detail,
including its direct interactions with NRP1.
We measured VEGFR2 surface levels via flow-cytometry over a
VEGF-stimulated time course (Fig. 2D). However, surface levels
were similar between the four genotypes, and were as predicted
from previously published studies (Lampugnani et al., 2006;
Reynolds et al., 2009). Because VEGF-induced interactions
between VEGFR2 and NRP1 are elevated in β3-KO ECs
(Robinson et al., 2009), we next examined this interaction in
β3-HET ECs by co-immunoprecipitation, but observed no
alterations compared to β3-WT ECs (Fig. 2E). In contrast to
previously published studies (Prahst et al., 2008), we saw that the
VEGF-induced association between the two molecules was
preserved in both β3-WT;NRP1Δcyto and β3-HET;NRP1Δcyto
ECs (Fig. 2E). We also examined by immunoblotting other known
NRP1-dependent signalling pathways, including the activation of
focal adhesion kinase (FAK) (Herzog et al., 2011) and p130Cas
(Evans et al., 2011), but saw no changes that might explain why
β3-HET mice are sensitive to NRP1 perturbation, whereas β3-WT
mice are not (supplementary material Fig. S2); both pathways were
inhibited in both genotypes by the introduction of the NRP1Δcyto
mutation.
Although these analyses did not rule out subtle differences
between the four genotypes in VEGFR2 trafficking, they did allow
us to draw an important conclusion: the differential sensitivity of
β3-WT and β3-HET animals to NRP1 disruption does not seem to
arise from overt changes in VEGFR2 function.
The VEGF-induced migration in β3-integrin-heterozygous
microvascular endothelial cells depends on the cytoplasmic
tail of NRP1
Prior to its description as a VEGF co-receptor, NRP1 was identified
as a surface protein mediating cell adhesion (Takagi et al., 1995).
Moreover, evidence has mounted to support a VEGFR2-
independent role for NRP1 in regulating EC functions through an
FA-dependent mechanism (Fantin et al., 2014; Raimondi et al.,
2014; Seerapu et al., 2013). Because NRP1 is known to interact with
a number of integrins (Fukasawa et al., 2007; Robinson et al., 2009;
Valdembri et al., 2009), we first compared static cell adhesion
between β3-WT, β3-HET, β3-WT;NRP1Δcyto and β3-HET;
NRP1Δcyto ECs on saturating concentrations of various matrices.
The only clear difference noted on saturating matrix concentrations
in these assays was an expected reduced adhesion of β3-HET and
β3-HET.NRP1Δcyto ECs to matrices containing VN, β3-integrin’s
canonical ligand (Fig. 3A). A more vigorous examination of
adhesions (see Materials and Methods) over a range of matrix
concentrations, however, uncovered subtle changes between the
genotypes (Fig. 3B). Not surprisingly, compared to β3-WT and
β3-WT;NRP1Δcyto ECs, β3-HET and β3-HET;NRP1Δcyto ECs
showed reduced adhesion to VN over a range of concentrations
tested. β3-WT;NRP1Δcyto EC adhesion to FN was, as expected
(Valdembri et al., 2009), somewhat reduced compared to β3-WT
ECs. Compared to their WT counterparts, β3-HET and β3-HET;
NRP1Δcyto ECs exhibited reduced strength of adhesion to FN over
the gradient of concentrations tested.
We therefore used flow-cytometry to examine the surface
expression of various EC integrin subunits (Fig. 3C). Consistent
with the adhesion data, αv- and β3-integrin levels were significantly
higher in β3-WT and β3-WT;NRP1Δcyto ECs compared to their
β3-HET counterparts. Whereas α1, β1 and β5 surface levels were
unchanged, we noted a small increase in α2 surface expression in
β3-HET ECs. Most notably, however, α5-integrin surface levels
were lower in ECs expressing reduced levels of β3-integrin (Fig. 3C),
which might partially account for their reduced adhesion to FN.
Our observations of VEGFR2-independent changes in ERK1/2
phosphorylation (a known regulator of integrin-mediated migration)
that were nonetheless sensitive to alterations in NRP1 function in
β3-HET but not β3-WT ECs prompted us to examine whether cell
migration was differentially dependent on NRP1 upon reduced
levels of β3-integrin expression. Because NRP1, α5β1-integrin and
αvβ3-integrin all promote adhesion to FN (Hynes, 2002; Valdembri
et al., 2009), we next set out to measure migration on this matrix
component. In light of noted subtle differences in short-term
adhesion to FN (and in surface expression of α5-integrin), we first
tested long-term cell spreading of our four cell lines to 10 µg/ml FN,
a saturating concentration which effectively promotes cell adhesion
and migration (Clark et al., 1986; Sottile et al., 1998; Tvorogov
et al., 2005). Cell spreading after 6 h was similar in all four
genotypes (Fig. 3D). This, along with our static adhesion assays,
which showed no differences between the genotypes on this
concentration of the matrix, provided justification for examining
random (Fig. 3E) and directed (Fig. 3F) migration in cells plated
long-term (overnight) on this concentration of FN. Both types of
migration assays revealed enhanced baseline and VEGF-induced
migration in β3-HET ECs, compared to β3-WT ECs; unlike β3-WT
ECs, β3-HET ECs were sensitive to NRP1 disruption.
NRP1’s localisation to focal adhesions is altered in
β3-integrin-heterozygous endothelial cells
The findings described above suggested that aberrant integrin-
directed migration, essential for pathological angiogenesis,
correlates with the phenotypic difference in sensitivity to NRP1
perturbations that we observed in β3-HET mice. NRP1 is known to
colocalise with a number of FA-associated proteins (Seerapu et al.,
2013) and is involved in FA turnover. We therefore took a closer
look at the structural and functional characteristics of mature
endothelial FAs, focal points of cellular migration. We first
examined NRP1’s distribution in subcellular compartments after
cell fractionation and immunoblotting. Other than the previously
noted trend toward overexpression of the protein in β3-HET ECs, we
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Fig. 3. VEGF-induced migration in β3-integrin-heterozygous endothelial cells is dependent on NRP1. (A) ECs isolated from animals of the four
indicated genotypes were seeded on collagen type I (COLI), fibronectin (FN), laminin (LN), vitronectin (VN), or a complex mixture of COLI, FN, VN and
gelatin (MIX) for 90 min. Unattached cells were gently washed off, and the remaining cells were fixed and stained. Dye was extracted and measured
spectophotometrically. The bar chart shows the percentage of cell adhesion to each component relative to FN (means+s.e.m. from three independent
experiments). (B) ECs of the indicated genotypes were plated on increasing concentrations of FN or VN. After 90 min, plates were vigorously washed and
remaining cells were fixed and stained. Dye was extracted and measured spectophotometrically. The graph shows the mean (±s.e.m. from ≥two independent
experiments) number of cells that remained attached to the plate after the procedure. (C) ECs of the indicated genotypes were measured for their surface
expression of endothelial integrin subunits by flow cytometry. Median fluorescence intensity (MFI) was measured after forward versus side scatter data were
tightly gated around, and normalised to, an isotype control. The bar chart shows the relative change in MFI of β3-HET compared to β3-WT ECs, or of β3-HET.
NRP1Δcyto ECs compared to β3-WT.NRP1Δcyto ECs (means+s.e.m. from three independent experiments). Relative changes were deemed significant with a
twofold change. Representative flow-cytometric histogram profiles are shown below for significantly changed integrins. (D) 70×105 cells of the indicated
genotypes were plated for 6 h on 10 μg/ml FN in six-well plates. Phase-contrast photographs were taken and cell surface areas were measured using ImageJ™
software. The bar chart represents mean (+s.e.m.) surface area quantified from multiple images (n≥50 cells per genotype). (E) ECs were firmly attached to
FN-coated dishes and then imaged live for 15 h in low-serummedium ±VEGF. Individual cells were tracked every 10 min over this period using ImageJ™. The bar
chart shows the EC migration speed of each of the indicated genotypes (mean+s.e.m. from three independent experiments; n=50 cells per condition). (F) ECs
were plated onto FN-coated dishes overnight. After 3 h of starvation, a scratch woundwas created and cells were incubated in low-serummedium±VEGF for 24 h.
The bar chart shows the percentage closure of the scratch ‘wound’ as a result of directed cell migration (means+s.e.m. from three independent experiments; n=27
for each condition). Representative images of scratch-wound closure at 24 h are shown below. Scale bar: 200 μm. Asterisks indicate statistical significance:
*P<0.05; **P<0.01; ***P<0.001; nsd, not significantly different. Unpaired two-tailed t-test.
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Fig. 4. NRP1’s localisation in focal adhesions is altered in β3-integrin-heterozygous endothelial cells. (A) β3-WT and β3-HET ECs were subjected to a
cell-fractionation experiment following ±VEGF treatment for 10 min. Fractionated samples were then analysed by western blot for the indicated proteins.
1=cytoplasmic extract; 2=membrane extract; 3=soluble nuclear extract; 4=chromatin-bound nuclear extract; 5=cytoskeletal extract. Protein markers for each
subcellular compartment were included as controls. Data are representative of two independent experiments. The bar charts represent the relative proportion (%)
of VEGFR2 or NRP1 present in each fraction determined by ImageJ™ densitometry. (B) Left and right panels: β3-WT and β3-HET ECs were seeded overnight
onto FN-coated glass coverslips and then stimulated with VEGF for 10 min. Cells were fixed and stained with phalloidin for filamentous actin (F-actin; green), and
immunostained for neuropilin-1 (NRP1; red). Arrows point to the ends of actin filaments. Middle panel: β3-WT ECs were transfected with a β3-integrin-GFP
construct (green) and seeded on FN-coated coverslips. 48 h later, cells were fixed and immunostained for NRP1 (red). Split-channel close-ups are shown to
depict β3-integrin/NRP1 colocalisation. Scale bars: 10 μm (middle), or 20 μm. (C) ECs were allowed to adhere to FN-coated dishes for 90 min to establish ‘mature’
integrin-dependent focal adhesions (FAs). FAs were chemically cross-linked to the plates and cells were lysed with RIPA buffer. Non-cross-linked proteins and
other cellular components were rinsed away under high-sheer flow. FA-enriched complexes were eluted, subjected to SDS-PAGE and then analysed by label-
free, quantitative mass spectometry. The graphs represent log ratio plots of the proteomic data comparing unstimulated β3-WT ECs (y-axis) and β3-HET ECs
(x-axis). Proteins above the diagonal line are higher in β3-WT ECs, whereas those below the line are higher in β3-HET ECs (n=3 samples per genotype). NRP1 is
present in both adhesomes (red circle). (D) FA-enriched EC samples were processed as in C and then analysed by western blot for the indicated proteins. A total
cell lysate (TCL) is shown for comparison. Data are representative of three independent experiments.
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found no obvious differences (Fig. 4A). We next immunolocalised
NRP1 in cells plated on FN overnight. Because of the VEGF-
dependence of our phenotypic angiogenic responses, we initially
concentrated on VEGF-stimulated cells. In β3-WT ECs, NRP1
localised to mature FAs, which were found at the ends of
filamentous actin (F-actin) fibres (Fig. 4B, left); as expected from
previous studies (Robinson et al., 2009), NRP1 also colocalised
with GFP-tagged β3-integrin in cDNA-expression-construct-
transfected β3-WT ECs (Fig. 4B, middle). However, in VEGF-
stimulated β3-HET ECs, NRP1 no longer localised to these sites
(Fig. 4B, right).
To explore more precisely whether β3-integrin was required for
the initial recruitment of NRP1 to FAs, we plated cells on FN for
90 min, which allows mature, β3-integrin-rich, adhesions to form
(Schiller et al., 2011, 2013), and performed quantitative mass
spectrometry of the FA-enriched endothelial adhesome from β3-WT
and β3-HET ECs (Schiller et al., 2011) (Fig. 4C). For the present
study, we focused our attention on known adhesome proteins. β3-
and αv-integrins were, as expected, enriched in β3-WT adhesomes.
Although many differences were noted between the two genotypes,
the stoichiometry of many classical adhesome-related proteins (such
as β1-integrin, vinculin, talin and integrin-linked kinase) was
unchanged in β3-HET ECs. Most importantly, NRP1, as previously
reported by others (Kuo et al., 2011; Schiller et al., 2011), was
present within the adhesome of both genotypes. Immunoblotting of
FA-enriched cellular lysates confirmed this finding (Fig. 4D);
although the western blot (WB) signal for NRP1 was relatively
weak, it was present in both β3-WT and β3-HET ECs. Together,
these results suggest that β3-integrin is not essential for the initial
localisation of NRP1 to mature FAs, but, rather, regulates its
retention within FAs upon VEGF-stimulation.
β3-integrin directs NRP1’s control over FA remodelling
Given the noted changes inNRP1-dependentmigration and retention
within FAs following an angiogenic stimulus, we next investigated
whether NRP1’s association with FA proteins in general was altered
in β3-HET ECs. We performed NRP1 immunoprecipitations on
lysates from β3-WT and β3-HET ECs followed by label-free
quantitative mass spectrometry, which highlighted a number of
previously demonstrated NRP1 co-associations such as myosin-9,
myosin-10 and filamin-A (Seerapu et al., 2013). Many VEGF-
induced associations between NRP1 and FA-associated proteins
were similar between the two genotypes, but β3-HET cells showed a
number of significant changes in VEGF-induced interactions
between NRP1 and cytoskeletal proteins involved with cell
migration (Table 1), such as decreased interactions with filamin-A.
These observations, coupled with changes in NRP1’s mobilisation
away from mature FAs upon VEGF-stimulation, suggested that
NRP1-dependent changes in FA remodelling might be at the heart of
phenotypic differences between β3-WT and β3-HET cells.
Therefore, as a marker of FAs, we turned our attention to
examining interactions between NRP1 and PXN. As well as
demarcating FAs, PXN plays an important role in EC motility
and can be regulated by NRP1 (Raimondi et al., 2014).
Immunocytochemistry of cells plated overnight on FN showed a
predicted colocalisation of total PXN and NRP1 in non-VEGF-
stimulated β3-WT ECs. This colocalisation was maintained after
10 min of VEGF-stimulation (Fig. 5A). NRP1/PXN colocalisation
was also apparent in non-VEGF-stimulated β3-HET ECs, but it was
lost upon VEGF-stimulation. A similar pattern was observed in
β3-HET;NRP1Δcyto ECs, with β3-WT;NRP1Δcyto ECs showing
only a small loss of NRP1/PXN colocalisation after VEGF-
stimulation.
Table 1. Label-free quantitative mass-spectrometry analysis of NRP1-associated cytoskeletal-classed proteins
LFQ values normalised to
immunoprecipitated NRP1
UNIPROT ID Gene WT −V WT +V HET −V HET +V Ratio WT+V/WT−V Ratio HET+V/HET−V Fold change HET/WT
Q6IRU2 Tpm4 0.54 0.21 0.11 0.13 0.38 1.12 2.94
P21107 Tpm3 1.82 1.33 0.34 0.58 0.73 1.73 2.37
P63260 Actg1 9.99 9.22 4.73 7.06 0.92 1.49 1.62
P58771 Tpm1 0.39 0.36 0.09 0.13 0.93 1.43 1.55
Q6URW6 Myh14 5.54 3.86 4.62 4.78 0.70 1.04 1.49
Q9QXS1 Plec 3.64 2.26 1.86 1.39 0.62 0.75 1.20
P47754 Capza2 0.64 0.56 0.38 0.37 0.88 0.97 1.10
Q9WTI7 Myo1c 0.78 0.71 0.38 0.37 0.90 0.99 1.09
Q61879 Myh10 3.97 3.97 6.32 6.52 1.00 1.03 1.03
E9QA15 Cald1 1.48 1.19 0.57 0.46 0.80 0.82 1.02
Q9JHJ0 Tmod3 0.29 0.31 0.18 0.19 1.07 1.08 1.01
P63260 Actg1 166.25 172.15 109.54 110.31 1.04 1.01 −1.03
Q5RKN9 Capza1 0.25 0.26 0.21 0.21 1.05 1.01 −1.04
Q9JJ28 Flii 0.22 0.18 0.15 0.12 0.81 0.77 −1.05
P68033 Actc1 2.37 3.72 0.65 0.96 1.57 1.47 −1.07
Q8BFZ3 Actbl2 38.52 41.16 21.77 20.61 1.07 0.95 −1.13
P47757 Capzb 0.30 0.33 0.22 0.21 1.10 0.94 −1.18
Q8VDD5 Myh9 226.75 246.90 159.30 146.76 1.09 0.92 −1.18
P46735 Myo1b 0.11 0.12 0.08 0.07 1.12 0.89 −1.26
E9Q634 LOC100504972 0.10 0.11 0.08 0.07 1.13 0.88 −1.28
Q8BTM8 Flna 0.12 0.11 0.11 0.07 0.93 0.58 −1.59
P16546 Spna2 0.22 0.23 0.21 0.14 1.07 0.64 −1.67
Q9JMH9 Myo18a 0.48 0.47 0.54 0.28 0.97 0.52 −1.88
P05213 Tuba1b 0.15 0.68 0.16 0.17 4.46 1.02 −4.36
The table shows a pared-down list of cytoskeletal-classed proteins that co-immunoprecipitated with NRP1 in β3-integrin wild-type (WT) and heterozygous
β3-integrin-deficient (HET) ECs in the presence (+V) or absence (–V) of VEGF-stimulation. Although they might be biologically relevant, for the sake of
confidence we have removed from the full list proteins that were only identified in one of the four samples or whose NRP1-normalised label-free quantification
(LFQ) values fell below 0.1. Highlighted in bold are previously reported interactions (Seerapu et al., 2013).
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To pursue a potential β3-integrin-regulated NRP1 link with
PXN activation, we also analysed the phosphorylation of PXN
through tyrosine 118 by immunoblotting (Fig. 5B) and
immunocytochemistry (Fig. 5C), and found a substantial
reduction in PXN phosphorylation in β3-HET;NRP1Δcyto ECs,
but not β3-WT;NRP1Δcyto ECs, suggesting that PXN activation is
only NRP1-dependent when β3-integrin levels are suppressed.
Moreover, it seems that FA disassembly only becomes substantially
NRP1-dependent with reduced levels of β3-integrin: through the
live tracking of GFP-PXN in transfected cells (Fig. 5D), we
discovered that FA-assembly was faster in β3-HET, β3-WT;
NRP1Δcyto and β3-HET;NRP1Δcyto ECs compared to β3-WT
cells. Additionally, there was a trend toward increased FA-
disassembly rates in β3-HET ECs. However, although FA-
disassembly rates in β3-WT;NRP1Δcyto ECs were slightly
reduced compared to their β3-WT counterparts, FA-disassembly
rates were markedly retarded in β3-HET;NRP1Δcyto ECs,
illustrating the increased role for NRP1 in these cells.
Overall, our data suggest that, in the presence of β3-integrin, EC
migration is NRP1-independent; β3-integrin maintains NRP1 in
Fig. 5. Paxillin activation and focal adhesion disassembly are sensitive to NRP1 disruption in β3-integrin-heterozygous endothelial cells. (A) ECs of the
indicated genotypes were seeded overnight on FN-coated glass coverslips. After 3 h of starvation, cells were treated ±VEGF for 10 min in serum-free medium,
then fixed and immunostained for total paxillin (PXN; green) and neuropilin-1 (NRP1; red). Split-channel close-ups are shown to depict PXN/NRP1 colocalisation.
Scale bar: 20 μm. The box and whisker plot shows Pearson’s correlation coefficient of PXN/NRP1 colocalisation in each of the indicated genotypes in the
indicated regions as determined using the ImageJ™ coloc2 plugin (means±interquartile ranges and extreme values; n≥5 cells per genotype, over ≥three
independent experiments). (B) Left panel: ECs of the indicated genotype were seeded overnight on FN. They were then starved for 3 h and treated ±VEGF for
10 min in serum-free medium. Cells were lysed and western blotted (WB) for levels of phosphorylated (p) and total (t) PXN. GAPDH served as a loading control.
Data are representative of three independent experiments. Right panel: the graph shows densitometry of pPXN relative to tPXN, as determined by WB, over an
extended VEGF time course (means±s.e.m. from≥three independent experiments). (C) ECswere seeded overnight onto FN-coated glass coverslips and stained
for pPXN. ECswere starved for 3 h and treated ±VEGF for 10 min in serum-freemedium. Cells were fixed and immunostained for pPXN (green). Scale bar: 10 μm.
(D) ECs were transfected with a PXN-GFP construct and seeded at a low density on FN-coated coverslips. 72 h later, cells were starved and then treated with
VEGF in reduced-serum medium. Representative cells were then imaged live (every 2 min) on an inverted fluorescence microscope for 1 h to monitor focal
adhesion (FA) remodelling. The front and back ends of individual FAs were tracked over this period to measure FA assembly and disassembly, using the
ImageJ™ MTrack2 plugin. The box and whisker plot shows the rate of FA assembly or disassembly for each of the indicated genotypes (means±interquartile
ranges and extreme values; n≥20 FAs per genotype, from ≥two independent experiments). Asterisks indicate statistical significance: *P<0.05; **P<0.01; nsd, not
significantly different. Unpaired two-tailed t-test.
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FAs, thus ensuring a controlled migratory response to VEGF-
stimulation. Reduced levels of β3-integrin lead to changes in FA
remodelling and cell migration that are NRP1-dependent.
Simultaneous depletion of both endothelial β3-integrin and
NRP1 effectively inhibits already-established tumour growth
and angiogenesis
The identification of the mechanisms underlying increased
sensitivity to NRP1 disruption in ECs with reduced β3-integrin
expression should enable the rational design of intervention
strategies to improve anti-angiogenic outcomes in patients with
advanced cancers. To provide evidence in support of this idea, we
performed proof-of-concept studies in β3-integrin/NRP1-double-
floxed mice crossed to OHT-inducible-Pdgfb-iCreERT2 transgenics.
First, though, we confirmed the same mechanistic principle
described above in primary lung ECs acutely depleted of
β3-integrin (Fig. 6A). We observed NRP1 expression at the ends
of F-actin in OHT-treated β3-WT cells with and without VEGF-
stimulation, but not in the majority of OHT-treated β3-KO ECs after
VEGF treatment. We then initiated VEGF-induced microvessel
sprouting in aortic rings isolated from: (1) β3-floxed mice with and
without Pdgfb-iCreERT2; (2) NRP1-floxed mice with and without
Pdgfb-iCreERT2; or (3) double-floxed mice with and without Pdgfb-
iCreERT2. OHT was administered to all rings after 4 days of
sprouting, and microvessels were enumerated 4 days later. Only in
rings from double-floxed Pdgfb-iCreERT2-positive animals was
further sprouting significantly inhibited (Fig. 6B). Finally, we
performed intervention CMT19T allograft studies by establishing
vascularised tumours in these same animals. After 10 days of growth,
all animals were administered OHT and tumours were allowed to
grow for another 10 days. In concordancewith the intervention aortic
ring studies, further tumour growth and angiogenesis were
significantly inhibited in double-floxed Pdgfb-iCreERT2-positive
animals, but not in any of the other genotypes (Fig. 6C).
DISCUSSION
We previously showed that the total loss of β3-integrin expression
sensitises angiogenesis to NRP1 inhibition by siRNA or small
peptides (Robinson et al., 2009). This finding suggested to us, even
at the time, that an anti-angiogenic approach that simultaneously
targeted both molecules might offer therapeutic benefit to patients
with advanced cancers where traditional mono-target strategies
were largely failing; a concept strengthened further by our recent
findings demonstrating only transient inhibition of tumour growth
and angiogenesis after long-term depletion of endothelial β3-
integrin expression (Steri et al., 2014). Testing this notion, however,
requires that we have a deeper mechanistic understanding of, at the
very least, how the dual targeting affects its outcome. Achieving this
understanding necessitated moving away from β3-KO animals,
which are often criticised for sustaining angiogenesis through
developmental upregulation of VEGFR2, to a more subtle, albeit
global, alteration in β3-integrin expression – β3 heterozygosity.
Like their knockout counterparts (Robinson et al., 2009), β3-HET
mice display increased sensitivity to perturbations in NRP1
expression and we extend this finding to include NRP1 function,
as assayed through the deletion of its cytoplasmic tail. In marked
contrast to β3-KO animals, however, this phenomenon does not
occur through increased interactions in ECs between VEGFR2 and
NRP1 (Fig. 2). Rather, the work we present here guides us toward a
newly identified mechanism for β3-integrin function whereby it
regulates the retention of NRP1 within mature FAs upon VEGF-
stimulation (Fig. 5).
AVEGFR2-independent role for NRP1 in regulating ECmigration
is gaining ground. NRP1’s cytoplasmic domain is known to promote
FN fibrillogenesis in arterial ECs by regulating the trafficking of
activated α5β1-integrin (Valdembri et al., 2009), and NRP1 is
involved in ABL1-mediated PXN activity in human dermal ECs
(Raimondi et al., 2014) on FN. Crucially, however, herewe report that
NRP1’s involvement in EC migration, at least in microvascular ECs,
is regulated by β3-integrin. Endothelial NRP1 seems to play no role in
pathological angiogenesis in β3-WT mice (Figs 1 and 6). Although
this idea has been alluded to in a number of studies (Fantin et al.,
2011, 2013; Lanahan et al., 2013; Robinson et al., 2009), we fully
extend this conclusion to primary tumour growth and angiogenesis. In
themodels that we have employed, we demonstrate, categorically, that
NRP1 perturbations alone do not disrupt pathological angiogenesis.
When coupled to reductions in β3-integrin levels, however, NRP1’s
participation in angiogenesis becomes essential. Equally, reductions
in β3-integrin expression without concomitant changes in NRP1 do
not drastically alter tumour angiogenesis (particularly in already-
established tumours). This suggests that there is redundancy built into
the system such that the presence of either molecule in mature FAs is
sufficient to mediate adequate PXN activity.
We hypothesise a default system in wild-type microvascular ECs
in which αvβ3-integrin’s molecular associations at mature FAs
predominate and prevent NRP1 from fully participating in FA
dynamics. αvβ3-integrins are known to immobilise in static FAs
(Zamir et al., 2000) and it seems that they help to sequester NRP1 at
these sites, even after VEGF-stimulation, which prevents it from
activating PXN. In contrast, the long-term suppression of β3-
integrin triggers an escape pathway whereby PXN activation and
ECmigration become dependent on NRP1 function; mobilisation of
NRP1 away from mature/static FAs allows it to direct PXN activity
(Fig. 6D). The idea of differential FA dynamics dependent on which
integrin subclasses are engaged with an FN-rich ECM is not a new
concept (see Truong and Danen, 2009, for example). However, this
is the first time that differential NRP1 localisation and function have
been linked to these changes.
The role that NRP1 plays in mediating VEGF-induced ERK
phosphorylation seems to be controversial and dependent on the EC
source andmethod employed to elicit NRP1 inhibition. Although Pan
et al. (2007) found that anti-NRP1 monoclonal antibodies (mAbs)
had no effect on VEGF-dependent ERK phosphorylation in human
umbilical vein endothelial cells (HUVECs), Murga et al. (2005)
demonstrated reduced VEGF-induced ERK phosphorylation in these
cells afterNRP1 siRNA knockdown. Lanahan et al. (2013) found that
the loss of NRP1’s cytoplasmic tail reduced VEGF-dependent ERK
phosphorylation in both heart and arterial ECs. Raimondi et al.
(2014) report that NRP1 siRNA knockdown impairs ERK
phosphorylation in human dermal microvascular endothelial cells
(HDMECs). We report here that the deletion of NRP1’s cytoplasmic
tail does not affect VEGF-induced ERK phosphorylation in WT
microvascular ECs (Fig. 2). These apparent discrepancies need
addressing and are the focus of ongoing research in our laboratory.
It is particularly important to address these discrepancies given
our finding that β3-integrin’s regulation of NRP1 function is
dependent on the presence of VEGF, even when NRP1’s regulation
of VEGFR2 is unchanged. This is important clinically because it
provides a therapeutic opportunity to enhance the efficacy of current
strategies that largely focus on manipulating the VEGF-VEGFR2
pathway, which is linked with significant side-effects and prone to
treatment resistance (Ebos and Kerbel, 2011). We now have the
chance to affect VEGF-dependent angiogenesis in an apparently
VEGFR2-independent manner.
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Fig. 6. Simultaneously depleting both β3-integrin and
NRP1 blocks growth and angiogenesis in already-
established tumours. (A) Primary lung microvascular ECs
were isolated from β3-floxed-Pdgfb-iCreERT2-negative and
-positive animals. Tamoxifen (OHT) was administered after
pure EC populations were achieved. Cells were then plated
overnight on FN-coated glass coverslips. Cells were starved
for 3 h and then treated ±VEGF for 10 min in serum-free
medium. Cells were fixed and stained with phalloidin for
F-actin (green), and immunostained for NRP1 (red). White
arrows point to the ends of actin filaments. Scale bar: 20 μm.
The bar chart shows the percentage of cells within the
population showing NRP1 staining at the end of actin
filaments (mean+s.e.m.; n≥50 cells per condition).
(B) Microvessel sprouting of aortic ring explants of the
indicated genotypes. Protein knockout in ECs was induced in
culture with 1 μM OHT 4 days after VEGF-induced sprouting
had been established. The bar chart shows the total number
of microvessel sprouts per aortic ring after an additional
4 days of VEGF-stimulation (mean+s.e.m. from three
independent experiments; n≥40 rings per genotype). (C)
Tumour growth and angiogenesis were measured in animals
of the indicated genotypes. Mice were injected
subcutaneously with CMT19T cells and 10 days later OHT
was administered. After an additional 10 days (20 days in
total) tumours were harvested. Upper panel: the bar chart
shows mean tumour volumes measured at days 10 and 20
(+s.e.m. of two or more independent experiments; n≥10
animals per genotype). The western blot to the right shows
representative depletion of β3-integrin and NRP1 in tumour
endothelial cells (TECs) isolated from Cre-positive animals,
compared to Cre-negative littermate controls. Bottom panel:
blood-vessel density in 20-day tumours was assessed by
counting the total number of endomucin-positive vessels
around the periphery (within 150 μm of the edge of the
tumour) of midline bisected tumour sections. The bar chart
shows mean vessel number per mm2 (+s.e.m.).
Representative micrographs of endomucin staining (red) are
shown below. Scale bar: 50 μm. Asterisks indicate statistical
significance: *P<0.05; ***P<0.001; nsd, not significantly
different. Unpaired two-tailed t-test. (D) Schematic
representation of the hypothesised participation of NRP1 in
focal adhesion (FA) remodelling and migration in β3-WT (left)
and β3-suppressed (right) ECs. ITGN, integrin.
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This study provides proof-of-concept that a dual-combative
αvβ3-integrin/NRP1 targeting approach offers a clinically
beneficial way of treating advanced solid cancers. Small-molecule
inhibitors directed against NRP1 are currently under development
and we hope that these can soon be tested alongside existing or new
αvβ3-integrin antagonists, with the caveat that both molecules are
expressed by multiple cell types that contribute to tumour growth
and angiogenesis, including platelets, and off-target (i.e. non-EC)
effects will have to be examined carefully; although we can rule out
their contribution to the EC-double-KO intervention studies
(Fig. 6), these other cells types might be contributing to β3-HET
angiogenic responses. Nonetheless, we provide a strong
mechanistic foundation for understanding the molecular basis of
how a dual-targeted approach against these two endothelial
molecules might meet with success. This will allow us, in the
meantime, to more fully explore the long-term durability of such an
approach when applied to additional clinically relevant scenarios.
Moreover, detailed further analysis and extension of our mass
spectrometric studies in ECs will allow us to fully explore how
differential adhesion dynamics, mediated by distinct integrin-ECM
interactions, result in the formation of unique signalling platforms
that can be exploited to manipulate angiogenic responses.
MATERIALS AND METHODS
Reagents
VEGF-A164 was made in-house according to the method published by
Krilleke et al. (2007). All chemicals were from Sigma-Aldrich (Poole, UK)
unless otherwise indicated.
Animals
All animals were on a mixed C57BL6/129 background. Littermate controls
were used for all in vivo experiments. All animal experiments were
performed in accordance with UK Home Office regulations and the
European Legal Framework for the Protection of Animals used for
Scientific Purposes (European Directive 86/609/EEC).
In vivo tumour growth assays
Mouse melanoma (B16F0, ATCC; mycoplasma free) or mouse lung
carcinoma (CMT19T, CR-UK Cell Production; mycoplasma free) cells
(1×106) were injected subcutaneously in the flank of experimental and
littermate-control mice. 12-20 days after injection, mice were killed, tumour
sizes measured and tumour samples were fixed in 4% paraformaldehyde for
histological analysis. For prevention studies in Pdgfb-iCreERT2 mice
(Fig. 1, supplementary material Fig. S1), slow release (5 mg, 21-day release)
tamoxifen pellets (Innovative Research of America, Sarasota, FL) were
implanted subcutaneously into the scruff of the neck 3 days prior to tumour
cell injection. For intervention studies (Fig. 6), pellets were implanted after
10 days of initial tumour growth. Tumour volumes were calculated
according to the formula: length×width2×0.52.
Immunohistochemical analysis of tumour sections
At 24-h post-fixation, tumours were bisected at the midline and embedded in
paraffin (cut face toward blade) and 5-μm sections were prepared.
Immunostaining was then performed with sodium-citrate antigen retrieval
as described previously (Reynolds et al., 2002). Images were acquired on an
Axioplan (Zeiss, Cambridge, UK) epifluorescent microscope and tissue area
was quantified using ImageJ™ software available at the National Institutes
of Health website. Primary antibodies were: rat anti-endomucin (clone
V.7C7, used at 1:500, Santa Cruz Biotechnology, Santa Cruz, CA); rabbit
anti-CD146 (clone EPR3208, used at 1:500, Abcam, Cambridge, UK).
Secondary antibodies were: donkey anti-rat Alexa-Fluor®-594 and donkey
anti-rabbit Alexa-Fluor®-488 conjugates (Invitrogen, Paisley, UK), both
used at 1:500.
Blood-vessel density was assessed by counting the total number of
endomucin-positive vessels per mm2 across entire midline tumour sections
from age-matched, size-matched tumours. For tumour sections from the
intervention studies (Fig. 6), vessels around the perimeter of the sections
were counted in order to avoid the necrotic centres of tumours.
Mouse tumour endothelial cell isolation
Tumour ECs were isolated and analysed by western blot as previously
described by Steri et al. (2014).
Ex vivo aortic ring assay
Thoracic aortae were isolated from 6- to 9-week-old adult mice and prepared
for culture as described extensively by Baker et al. (2012). Protein knockout
in ECs was induced in culture with 1 μM 4-hydroxytamoxifen (OHT).
Where indicated, VEGF was added at 30 ng/ml. Microvessel growth
of aortic rings was quantified after 6-10 days. For the intervention study,
protein knockout in ECs was induced in culture with 1 μMOHT 4 days after
VEGF-induced sprouting had been established, and the microvessel sprouts
were quantified after an additional 4 days of VEGF-stimulation.
Mouse lung microvascular endothelial cell isolation and culture
Primary mouse lung ECs were isolated from adult mice as described
previously by Reynolds and Hodivala-Dilke (2006). To induce target gene
deletion in Pdgfb-iCreERT2-floxed cell lines, cells were grown for 48 h in
medium supplemented with 500 nM OHT.
For immortalisation, cells were treated with polyoma-middle-T-antigen
(PyMT) retroviral transfection as described previously by Robinson et al.
(2009). Briefly, PyMT conditioned medium was collected, filter sterilised
using a 0.45 μm filter, and stored at −80°C until use. Following two rounds
of CD102-positive selection, primary ECs in six-well plates were treated
with the preserved PyMT conditioned medium supplemented with 8 μg/ml
polybrene for 6 h at 37°C. PyMT conditioned medium was removed and
replaced with complete growth medium. This same procedure was repeated
the following day. Cells were observed and passaged for 4 weeks to ensure
their immortalisation. Subsequently, they were maintained in a 1:1 mixture
of DMEM low glucose:Ham’s F12 nutrient mixture (Invitrogen)
supplemented with 0.1 mg/ml heparin and 10% FBS, and used between
passages 5-20. Cells were routinely checked by flow cytometry for surface
expression of ICAM2, CD31 and VECAD (see supplementary material
Fig. S3) to ensure that they retained their normal EC characteristics. Cells
were also routinely checked for their ability to survive extended periods of
confluency, which indicates absence of transformation (May et al., 2005).
For experimental analyses, tissue culture plates and flasks were coated
overnight at 4°Cwith one or more of the following, as specified below: 0.1%
gelatin (type A from porcine skin,∼300 g bloom), Purecol (COLI) (Nutacon
B.V., The Netherlands), human plasma fibronectin (FN) (Millipore,
Watford, UK) and mouse multimeric vitronectin (VN) (Patriecell Ltd,
Nottingham, UK).
Western blot analysis
For the analysis of VEGFR2, NRP1, β3-integrin, ERK1/2, p130cas and
FAK, ECs were seeded at 2×105 cells per well in six-well plates coated with
0.1% gelatin, 10 μg/ml FN, 10 μg/ml COLI and 2 μg/ml VN. For paxillin
analysis, ECs were seeded at the same density, but on plates coated with only
10 μg/ml FN in PBS. 24 h later, cells were starved for 3 h in serum-free
medium (OptiMEM®; Invitrogen). VEGF was then added to a final
concentration of 30 ng/ml and cells were lysed at the indicated times (see
main text) in EB (3% SDS, 60 mM sucrose, 65 mM Tris-HCl pH 6.8).
15-30 μg of protein from each sample was loaded onto 8-10%
polyacrylamide gels. For paxillin analysis, samples were loaded onto a
4-12% gradient gel for better resolution. The protein was transferred to a
nitrocellulose membrane and incubated for 1 h in 5% milk powder/PBS
plus 0.1% Tween-20 (PBSTw), followed by an overnight incubation in
primary antibody diluted 1:1000 in 5% bovine serum albumin (BSA)/
PBSTw at 4°C. The blots were then washed 3× with PBSTw and incubated
with the relevant horseradish peroxidase (HRP)-conjugated secondary
antibody (Dako) diluted 1:2000 in 5% milk/PBSTw, for 1 h at room
temperature. Chemiluminescence was detected on a Fujifilm LAS-3000
darkroom (Fujifilm UK Ltd, Bedford, UK). Antibodies (all used at 1:1000
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and purchased from Cell Signaling Technology, unless noted otherwise)
were: anti-phospho (Y1175) VEGFR2 (clone 19A10); anti-VEGFR-2
(clone 55B11); anti-Neuropilin-1 (cat. no. 3725); anti-β3-integrin (cat. no.
4702); anti-phospho (Thr202/Tyr204) p44/42 MAPK Erk1/2 (clone
D13.14.4E); anti-total p44/42 MAPK Erk1/2 (clone 137F5); anti-phospho
(Y410) p130cas (cat. no. 4011); anti-p130cas (cat. no. 610271, BD
Biosciences, Oxford); anti-phospho (Y407) FAK (#OPA1-03887,
ThermoScientific); anti-FAK (cat. no. 3285); anti-HSC70 (clone B-6,
Santa Cruz Biotechnology); anti-phospho (Y118) paxillin (cat. no. 2541);
anti-paxillin (ab32084; Abcam); anti-GAPDH (14C10, cat. no. 2118); anti-
SP1 (cat. no. 5931); anti-histone H3 (D1H2, cat. no. 4499); anti-vimentin
(D21H3, cat. no. 5741).
Flow cytometry
For flow-cytometric analysis, cells were trypsinised, resuspended in FACS
buffer (1% FBS in PBS+1 mM CaCl2+1 mMMgCl2) and labelled with one
of the following antibodies (all used at 1:200 and, unless stated otherwise,
purchased from eBioscience, Hatfield, UK): PE-anti-mouse Flk1, PE-anti-
mouse CD49a (Cambridge Bioscience, Cambridge, UK); PE-anti-mouse
CD49b; PE-anti-mouse CD49e; PE-anti-mouse CD51; PE-anti-mouse
CD29; PE-anti-mouse CD61; PE-anti-mouse integrin beta 5; PE-anti-
mouse CD31; FITC-anti-mouse ICAM2; PE-anti-mouse VECAD;
appropriate PE/FITC-labelled isotype-matched controls were from
eBioscience. In the case of Flk1 analysis, cells were stimulated with
30 ng/ml VEGF at 37°C over a 60-min time course before trypsinisation.
Immunoprecipitation assay
Cells were grown to 80-90% confluency in 15-cm dishes coated with
10 μg/ml FN in PBS. After starvation in OptiMEM® for 3 h, cells were
stimulated with 30 ng/ml VEGF for 10 min (+VEGF), or for the indicated
times, at 37°C. Cells were then placed on ice, washed two times with PBS,
and lysed in 0.5 ml/plate of RIPA buffer (20 mMTris pH 7.4, 50 mMNaCl,
0.1% SDS, 1% Triton, 1% Deoxycholate, 1% NP40) containing PMSF
(∼1 mM) and Halt® Protease and Phosphatase inhibitor (1:100). Lysates
were centrifuged at 12,000 g for 10 min at 4°C. 400 μg of total protein from
each sample was immunoprecipitated by incubating them with protein-G
Dynabeads® (Invitrogen) coupled to a rabbit-anti-mouse-VEGFR2
antibody (clone 55B11, Cell Signaling Technology) for the VEGFR2
immunoprecipitation (IP), or a goat anti-mouse Neuropilin-1 antibody
(AF566, R&D Systems) for the NRP1 IP, on a rotator overnight at 4°C.
Immunoprecipitated complexes were washed three times with 0.2 ml
of RIPA buffer, and once in PBS, before being added to, and boiled in,
1× NuPAGE® sample reducing agent (Life Technologies), ready for
western blotting or mass spectrometry analysis.
Adhesion assays
Static adhesion
96-well plates were coated overnight at 4°C with 10 μg/ml COLI, 10 μg/ml
FN, 10 μg/ml laminin-I (LN) or 2 μg/ml VN in PBS, or a mixture (MIX)
containing 10 μg/ml COLI, 10 μg/ml FN and 2 μg/ml VN in 0.1% gelatin
was also used. The wells were then washed with PBS, and blocked for 1 h at
room temperature (RT) with 1% BSA in PBS, before a final wash in PBS.
Prior to seeding, cells were starved for 3 h in Opti-MEM®, trypsinised and
resuspended in serum-free OptiMEM®. They were then seeded in serum-
free OptiMEM® at a concentration of 1×104 cells/well for 90 min at 37°C.
Plates were washed three times gently by immersion in a bucket of PBS, and
any excess volume was removed. Wells were stained with methylene blue
for 30 min, washed for 15 min under running water and air-dried. Dye was
extracted with 50% ethanol:50% 0.1 N HCl and the absorbance of each well
was measured at 610 nm.
Adhesion on various matrix concentrations
96-well plates were coated overnight at 4°C with serial dilutions of VN or
FN. The wells were then washed with PBS, and blocked for 1 h at RT with
1% BSA in PBS. Prior to seeding, cells were starved for 3 h in Opti-MEM®,
trypsinised and resuspended in serum-free OptiMEM®. They were then
seeded in serum-free Opti-MEM® at a concentration of 3×104 cells/well for
90 min at 37°C. Plates were tapped vigorously on the bench top and wells
were washed thoroughly using a multi-channel pipette. Wells were stained
with methylene blue for 30 min, washed for 15 min under running water and
air-dried. Dye was extracted with 50% ethanol:50% 0.1 N HCl and the
absorbance of each well was measured at 610 nm.
Random-migration assay
ECs were starved in OptiMEM® for 3 h, trypsinised and seeded at 1.5×104
cells/well in 24-well plates coated with 10 μg/ml FN in PBS, and allowed to
adhere for 3 h. The media was then replaced with OptiMEM®+2% FBS, and
half of the wells were supplemented with 30 ng/ml VEGF. One phase-
contrast image/well was taken live every 10 min in a fixed field of view
using an inverted Axiovert (Zeiss) microscope for 15 h at 37°C and 4%
CO2. Individual cells were then manually tracked using the ImageJ™ cell
tracking plugin, and the speed of random migration was calculated in μm
moved/hour.
Wound-closure assay
ECs were seeded at 4×105 cells/well in six-well plates coated with 10 μg/ml
FN in PBS, and cultured until the next day, by which time they had reached
confluency. Cells were serum starved for 3 h in OptiMEM® before
scratching the confluent monolayer with a P200 pipette tip. Phase-contrast
images of scratches were then captured and the media was changed to
OptiMEM® containing 30 ng/ml VEGF. After 24 h, cells were fixed for
10 min with 4% formaldehyde and scratches were imaged again. The degree
of scratch-wound closurewas quantified bymeasuring the gap between cells
in three areas per field using Axiovision (Zeiss) software, taking an average,
and calculating the length of change between time points.
Immunocytochemistry
Either primary or immortalised ECswere seeded at 1.5×105 cells/well in six-
well plates on acid-washed and oven-sterilised glass coverslips, coated with
10 μg/ml FN in PBS and cultured until the next day. Cells were starved for
3 h in serum-free OptiMEM®, and either stimulated with 30 ng/ml VEGF at
37°C for 10 min (+VEGF), or not at all (−VEGF). Cells were then fixed in
4% formaldehyde for 10 min, washed in PBS, permeabilised with 0.5%
NP40 in PBS, blocked in 0.1% BSA+0.2% Triton in PBS, and incubated
with primary antibody diluted 1:100 in PBS for 1 h at RT. After further PBS
washes, cells were incubated with the relevant Alexa-Fluor®-conjugated
secondary antibody (Invitrogen) diluted 1:500 in PBS for 45 min at RT.
Coverslips were washed in PBS again before they were mounted on slides
with Prolong®Gold containing DAPI (Invitrogen). To stain for filamentous-
(F) actin, Alexa-Fluor®-568–phalloidin (Invitrogen) was used 1:300 in PBS
at the secondary-antibody incubation stage. To look at β3-integrin
fluorescently, 1×106 ECs were transfected with a GFP-tagged β3-integrin
cDNA expression construct (provided by Dr Maddy Parsons, King’s
College London, London, UK) by nucleofection prior to seeding on
coverslips at 1.5×105 cells/well. Antibodies (all used at 1:100) were: anti-
phospho (Y118) paxillin (Cell Signaling Technology, cat. no. 2541); anti-
paxillin (ab32084, Abcam); anti-neuropilin-1 (AF566, R&D Systems).
NRP1-PXN colocalisation was quantified using the Coloc2 ImageJ™
plugin to determine the Pearson’s correlation coefficient.
Cell fractionation assay
ECs were seeded in plates coated with 0.1% gelatin, 10 μg/ml FN, 10 μg/ml
COLI and 2 μg/ml VN. 24 h later, cells were starved for 3 h in serum-free
OptiMEM®, and either stimulated with 30 ng/ml VEGF or not. Cells were
then trypsinised and centrifuged at 500 g. Cell fractionation was carried out
following the ‘Subcellular protein fractionation kit for cultured cells’
(ThermoScientific) protocol exactly, and samples were prepared for western
blotting.
Focal-adhesion enrichment
ECs were starved in serum-free OptiMEM® for 3 h and seeded at 6×106
cells/plate in 10-cm plates that were previously coated with 10 μg/ml FN in
PBS overnight at 4°C and blocked in 1% BSA in PBS for 1 h at RT. Cells
were allowed to adhere for 90 min to allow for mature FAs to form and either
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stimulated with 30 ng/ml VEGF at 37°C for 10 min (+VEGF) or not at all
(−VEGF). Cells were washed in PBS+1 mM CaCl2+1 mMMgCl2 (PBS++)
and incubated with 0.5 mM Dithiobis(succinimidyl propionate) (DSP) and
0.05 mM 1,4-di-[30-(20-pyridyldithio)-propionamido] butane (DPP)
diluted in PBS++ for 5 min to cross-link FAs to the plate. This reaction
was quenched with 1 M Tris-HCl pH 7.5 before cells were lysed in RIPA for
30 min on ice with occasional agitation. RIPA was collected without
scraping, and the plates were blasted with a high-sheer flow jet of distilled
water to remove cell debris. Cross-linked proteins were eluted with 2 ml
dithiothereitol (DTT) buffer (25 mM Tris-HCl pH 7.5, 10 mM NaCl,
0.1% SDS, 100 mM DTT) for 1 h at 60°C in a sealed and humidified
chamber. 8 ml of acetone was added to this solution and left overnight at
−20°C to allow the proteins to precipitate. Samples were then centrifuged at
13,000 g for 40 min, and the acetone layer removed. The pellet was
resuspended in EB (see above) ready for western-blot or mass-spectrometry
analysis.
Focal-adhesion tracking
1×106 ECs were transfected with a GFP-tagged paxillin cDNA expression
construct (kindly provided by Dr Maddy Parsons, King’s College London,
London, UK) and a fraction of these were seeded on acid-washed and oven-
sterilised glass coverslips, coated with 10 μg/ml FN in PBS, in wells of a
six-well plate. Cells were cultured for ∼48 h before they were starved in
serum-free OptiMEM® for 3 h. In turn, individual coverslips were
separately transferred to OptiMEM®+2% FBS and 30 ng/ml VEGF was
added. An Axiovert (Zeiss) inverted microscope was then used to take live
images of the GFP-paxillin-positive focal adhesions in a selected field of
view every 2 min for 1 h at 37°C+4% CO2. Assembly and disassembly was
quantified by manually tracking leading and trailing edges of FAs using the
MTrackJ plugin for ImageJ™.
Mass-spectrometry analysis
Mass spectrometry was carried out by the Fingerprints Proteomics Facility,
Dundee University, Dundee, UK as per Schiller et al. (2011). Peptides were
identified and quantified using MaxQuant software using the Andromeda
peptide database. To achieve label-free quantitative results, three biological
repeats were pooled and each of these pooled samples was analysed via three
technical repeats through the spectrometer.
Statistical analysis
Significant differences between means were evaluated by Student’s t-test.
P<0.05 was considered statistically significant. For flow cytometric analysis
of integrins, relative differences were deemed significant if they were greater
than twofold.
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Supplementary Figures 
 
 
 
Supplementary Figure 1:  B16F0 tumour growth and angiogenesis  in β3-
integrin-heterozygous mice are sensitive to NRP1 perturbations. Tumour growth 
and angiogenesis were measured in animals of the indicated genotypes.   Left panels. 
Mice were given subcutaneous injections of B16F0 tumour cell lines. To generate 
NRP1-EC-KO (EC-Null), 21-day slow-release OHT pellets were administered 3-days 
prior to tumour cell injection.  OHT-treated Cre-negative (EC-NRP-WT) littermates 
served as controls.  Tumour volumes were measured after 12 days of growth (mean 
+SEM of 3 independent experiments; n≥10 animals per genotype).  Representative 
pictures of tumour macroscopic appearances are shown.  Scale bar = 10mm.    Right 
panels.  Blood vessel density was assessed by counting the total number of 
endomucin-positive vessels across tumour sections (mean +SEM; n≥10 sections per 
genotype).  
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Supplementary Figure 2: No changes in the expression/activity of proteins 
involved in NRP1-regulated VEGF signalling. ECs were seeded on a complex 
matrix containing gelatin, collagen, fibronectin and vitronectin to preserve β3-
VEGFR2 interactions, and were stimulated with 30 ng/ml VEGF at 37°C over a time 
course. ECs were lysed and analysed by Western blot (WB) for protein levels of 
phosphorylated (phospho) and total p130cas and FAK. HSC-70 served as a loading 
control. Data are representative of 3 independent experiments. 
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Supplementary Figure 3: Polyoma-middle-T-antigen immortialised endothelial 
cells maintain the endothelial identity. ECs were trypsinised and analysed by flow 
cytometry for surface levels of the EC markers VE-Cadherin, CD31, and ICAM-2.  
Median fluorescence intensity was measured after forward versus side scatter data 
were tightly gated around, and normalised to, an isotype control. Representative flow-
cytometric histogram profiles of β3-WT and β3-HET ECs are shown.  
 
 
 
Disease Models & Mechanisms | Supplementary Material
1590 Biochemical Society Transactions (2014) Volume 42, part 6
Redeﬁning the role(s) of endothelial
αvβ3-integrin in angiogenesis
Samuel J. Atkinson*1, Tim S. Ellison*1, Veronica Steri*1, Emma Gould† and Stephen D. Robinson*2
*School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, U.K.
†School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, U.K.
Abstract
For nearly two decades now, the RGD (Arg-Gly-Asp)-binding αvβ3-integrin has been a focus of anti-
angiogenic drug design. These inhibitors are well-tolerated, but have shown only limited success in patients.
Over the years, studies in β3-integrin-knockout mice have shed some light on possible explanations for
disappointing clinical outcomes. However, studying angiogenesis in β3-integrin-knockout mice is a blunt
tool to investigate β3-integrin’s role in pathological angiogenesis. Since establishing our laboratory at
University of East Anglia (UEA), we have adopted more reﬁned models of genetically manipulating the
expression of the β3-integrin subunit. The present review will highlight some of our ﬁndings from these
models and describe how data from them have forced us to rethink how targeting αvβ3-integrin expression
affects tumour angiogenesis and cancer progression. Revisiting the fundamental biology behind how this
integrin regulates tumour growth and angiogenesis, we believe, is the key not only to understanding how
angiogenesis is normally co-ordinated, but also in success with drugs directed against it.
Introduction
In 1994, Brooks et al. [1,2] published two studies which
reported αvβ3-integrin as a marker of angiogenic vasculature
and, importantly, that it could be targeted to induce
apoptosis of proliferative angiogenic vascular cells while
leavingquiescent vasculature untouched.Here, it seemed,was
an ideal therapeutic target to treat diseases characterized by
too much neovascularization (such as cancer). These seminal
findings sparked the development of inhibitors directed
against αvβ3-integrin which, in a number of in vivo studies,
demonstrated effective inhibition of tumour growth and
angiogenesis [3]
However, with the generation of β3-integrin knockout
mice [4], which display enhanced tumour growth [5], the
angiogenesis field was seemingly divided into two camps,
split across a dividing line defined by whether the molecule
was viewed as pro- or anti-angiogenic. Those in the ‘pro’
camp dismissed the knockout findings as simply reflecting a
developmental up-regulation of vascular endothelial growth
factor receptor type 2 (VEGFR2) that occurs in this model
[6]. Those in the ‘anti’ camp argued the lack of significant
results in humans [3,7] could be interpreted through the
knockout studies. The campswere further dividedby findings
indicating that the pharmacological agents being developed
could stimulate tumour growth and angiogenesis, if not used
optimally [8,9].
On the surface, the two approaches are quite different.
Certainly a systemically-administered drug directed against
Key words: angiogenesis, antagonist, cancer, endothelial cell, β3-integrin, tumour.
Abbreviations: EC, endothelial cell; ECM, extracellular matrix; FA, focal adhesion; FN, ﬁbronectin;
NRP1, neuropilin-1; TNFα, tumour necrosis factor α; VEGFR2, vascular endothelial growth factor
receptor type 2.
1These authors contributed equally to this article.
2To whom correspondence should be addressed (email stephen.robinson@uea.ac.uk).
αvβ3-integrin is going to operate differently from a genetic
alteration that removes the expression of the β3-integrin
subunit. In practice, though, both are blunt tools to dissect
the innumerable cellular and molecular pathways regulated
by the molecule; pathways that must be tightly-controlled
to maintain vascular homoeostasis, but are skewed toward
chaotic growth during cancer and other diseases. Since
establishing ourselves at theUniversity of EastAnglia (UEA),
my group has been fine-tuning our models for exploring
the fundamental biology behind the roles played by αvβ3-
integrin during tumour growth and angiogenesis. We are
trying to bring together the two camps. We believe there
remains great promise in targeting αvβ3-integrin to limit
tumour growth and progression; by returning to basic
biology we should be able to translate encouraging pre-
clinical findings with αvβ3-integrin antagonists into real
treatments in patients.
In the present mini-review, each of the current members
of my group has contributed their opinion on an area of
αvβ3-integrin biology that, they feel, holds promise and/or
needs further exploration in order to understand why, for
example, cilengitide, the furthest progressed RGD (Arg-Gly-
Asp)-mimetic, has recently failed its first Phase III clinical
trial [10] (Figure 1). Although the reasons for its failure are as
yet unknown, some of our current studies, as outlined below,
are aimed at finding out how, when and where it might be
best to employ inhibitors directed against αvβ3-integrin to
achieve maximum benefit.
Understanding the in vivo role of
endothelial β3-integrin
Ten years after the Food and Drug Administration’s (FDA’s)
approval of the first anti-angiogenic therapy (Bevacizumab),
C©The Authors Journal compilation C©2014 Biochemical Society Biochem. Soc. Trans. (2014) 42, 1590–1595; doi:10.1042/BST20140206B
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Figure 1 An artistic representation of tumour vasculature which highlights the three main themes relating to β3-integrin biology
discussed
our strategies need to be rethought. Endothelial cell
(EC) heterogeneity along with the complexity of tumour
vasculature represents a gap in our fundamental knowledge
of tumour biology that needs to be re-evaluated in order to
effectively translate theories into clinical therapies. Integrins
may hold the key to this unmet challenge. They are a
large and diverse family of cell adhesion receptors which
transduce signals bidirectionally across the plasmamembrane
[11]. Nine vertebrate integrin heterodimers are implicated
in angiogenesis, with the RGD tripeptide-binding integrins
α5β1, αvβ3, αvβ5, and αvβ8 playing major roles [12,13]. As
mentioned above, αvβ3-integrin, in particular, has garnered
therapeutic attention because its expression is up-regulated
in vasculature associated with solid tumours [14] but is
contrastingly low in quiescent vasculature [2,15], thereby
reducing the potential for side effects from its blockade.
Although this suggests that the EC expression of β3-
integrin is an ideal anti-cancer target, it is easy to forget that
themolecule is expressed by amyriad of cells, each contribut-
ing in their own way to angiogenesis. Moreover, β3-integrin
expression on tumour cells has been shown to contribute
towards tumour progression and metastasis, as well as cor-
relating with poor patient survival. However, in some human
tumours (e.g. angiosarcomas), vascular αvβ3-integrin levels
are found to diminish in the course of malignant transform-
ation and to be lower in lung metastases in comparison with
its levels in the originating primary colorectal carcinomas
[13]. These observations additionally substantiate the idea
thatαvβ3-integrin can play either a pro- or anti-tumourigenic
role in a way which is not quite fully understood.
Global genetic studies have given us many clues into
αvβ3-integrin biology, but still have not answered the
C©The Authors Journal compilation C©2014 Biochemical Society
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question. Knockin mice that express a mutant αvβ3-
integrin, which is unable to undergo cytoplasmic tyrosine
phosphorylation, show reduced tumour vascularization [16],
suggesting downstream signalling through the molecule
promotes angiogenesis. β3-integrin knockout mice exibit
enhanced tumour growth and vascularization [5] indicating
expression of the molecule negatively regulates angiogenesis.
What then is going on? It is clear in both studies that more
than one cell-type contributes to the ultimate phenotype. In
both cases, the mutant phenotype can be partially abrogated
by restoring wild-type expression of β3-integrin in bone
marrow derived cells (BMDCs) through adoptive transfer
[17,18].
Thanks to the Weilbaecher laboratory in St. Louis, we are
now finally beginning to dissect the role of β3-integrins, as
expressed by individual cell-types, in pathological conditions.
Although platelet β3-knockout has no effect on tumour
growth or angiogenesis, the myeloid β3-knockout displays
enhanced tumour burden [19] (although tumour angiogenesis
appears unaffected), a finding consistent with the bone
marrow transplant studies described above.
Although these two cell types are certainly important,
the original intended target of αvβ3-integrin antagonists
are ECs; elucidating the role of αvβ3-integrin expression
here is probably the key to developing more effective anti-
angiogenic therapies directed against it. We have recently
described the role played by EC β3-integrin in mice [20].
We show that αvβ3-integrin plays a crucial role in the very
early steps of tumour angiogenesis, whereas its EC expression
is dispensable once tumour vasculature has been established
and prolonged EC-depletion of the molecule is eventually
overcome (escape occurs). It appears that over the long term,
the plasticity of ECs leads to their cellular rewiring such
that alternative means of executing/maintaining angiogenesis
are utilized. Furthermore, our findings, in combination with
the other genetic studies described in the present paper,
reinforce the concept that there are multiple levels of cellular
complexity to angiogenic regulation, all of which will matter
when it comes to pharmacological inhibition of αvβ3-
integrin.We are just at the beginning of understanding its EC-
role, let alone its role when expressed by pericytes, stromal
fibroablasts and macrophages.
Deﬁning β3-integrin-directed escape
mechanisms
The discrepant angiogenic results garnered from targeting
αvβ3-integrin in different ways have highlighted the sheer
complexity of this molecule’s role in angiogenesis. Our
discovery that the acute depletion of endothelial αvβ3-
integin can reduce tumour angiogenesis, albeit transiently
and in a preventive manner, has suggested that we can still
think of using it as a target, but only if we discover the
right conditions that render it therapeutically useful. It is
our hope that we can use the models we have generated
(the EC-specific knockouts described above, as well as β3-
integrin-heterozygous animals) to understand EC plasticity
and determine whether there are escape pathways common
to pharmacological and genetic inhibition of αvβ3-integrin;
pathways that might be targeted alongside the molecule to
sustain, or at least extend, inhibition.
It is therefore extremely important to carefully consider
the ways in which targeting αvβ3-integrin can effectuate
resistance mechanisms in ECs. First and foremost, we need
to study the interactions that αvβ3makes in ECs, as targeting
αvβ3-integrin genetically or with inhibitors could affect
interacting molecules and potentially enhance or change their
roles.
One αvβ3-integrin interaction that has not been lacking in
attention in the field has beenwith themain receptormediator
of angiogenesis, VEGFR2. This interaction, dependent on
the presence of αvβ3-integrin’s natural extracellular matrix
(ECM) ligand vitronectin, and VEGF, has now been shown
to be a direct one between the two cytoplasmic tails and
enhanced through Tyr747 phosphorylation of the β3-integrin
subunit. The cross-talk between αvβ3-integrin and VEGFR2
enhances the activity of each and has been found to increase
VEGF-induced signalling and angiogenesis [16,21].However,
the enhanced tumour growth and angiogenesis observed
in β3-knockout mice clearly shows that this interaction is
non-essential to angiogenesis [5]. Indeed, the global loss of
β3-integrin in this model is actually associated with a vast
up-regulation of VEGFR2 expression and treatment with a
VEGFR2 inhibitor reverses the phenotype [6].
αvβ3-Integrin has also been found to associate with the
VEGF co-receptor neuropilin-1 (NRP1), which is known to
form a complex with VEGFR2 and regulate its trafficking
and signalling [22–25]. Interestingly, αvβ3-integrin can limit
this VEGF-induced association as the interaction is enhanced
in β3-knockout ECs [26], suggesting that αvβ3-integrin can
regulate NRP1’s role in angiogenesis. It may be important
to note that NRP1’s role in angiogenesis is not limited
to the confines of VEGFR2 [27]; recent evidence has
highlighted a role forNRP1 in regulating focal adhesion (FA)
turnover [28] and in promoting fibronectin (FN)-dependent
paxillin activation and actin remodelling [29]. We also know
that NRP1 can bind and regulate α5β1-integrin and, thus,
promote EC spreading on FN [30]. This duplicity in NRP1
binding two subclasses of FN-binding RGD-integrins, αvβ3
and α5β1, in ECs has led us to the present work exploring
the role of ECs for the latter in tumour growth and
angiogenesis.
The dynamic adhesion properties of ECs are crucial
for their motility and migration and therefore crucial for
angiogenesis. Integrins, as bidirectional signalling interme-
diaries between the ECM and the cell-interior and key
regulators of EC migration, are key components of FAs, the
cluster of scaffolding and enzymatic proteins that mediate
cell movement through linking the force-generating actin
machinery with the outside environment. Integrins therefore
interact with many of these so-called adhesome components
and so it would be interesting to see how targeting αvβ3-
integrin might affect FA composition and stoichiometry.
C©The Authors Journal compilation C©2014 Biochemical Society
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Indeed, with NRP1′s prominence in EC adhesion function,
the interplay between αvβ3-integrin and NRP1 may have
an added dimension. Of note, Schiller et al. [31,32] recently
profiled the integrin adhesome in fibroblasts and found
that αv-integrins are more associated with mature FAs,
whereas β1-integrins play a more prominent role in nascent
adhesions. The present work has recently led us to profile the
endothelial adhesome, the results of which we are preparing
for publication and further analysis.
EC β3-integrin: beyond an anti-angiogenic
target
αvβ3-Integrin’s up-regulation in angiogenic vasculature
[1,2] in multiple cancers (breast, renal, ovarian, glioma,
myeloma, melanoma and more) [33] and in osteoclasts [34]
provides a useful marker of particular interest to cancer
therapy/diagnostics. This expression may potentially allow
the selective delivery of compounds to these sites to impede
tumour vasculature formation, inhibit tumour cell-growth or
halt the expansion of osteolytic lesions that are common place
in bone metastases, thus overcoming dose limiting toxicity
from systemic effects.
Integrin targeting strategies have been revolutionized by
the development of selective cyclic peptides – most notably
RGD-mimetics such as cilgengitide. Several simple strategies,
such as conjugating RGD-targeting peptides to traditional
chemotherapeutics (e.g. paclitaxel and doxorubicin), have
proved successful in vivo. These approaches provide
increased chemotherapeutic dose at the tumour as well
as increased duration of effect compared with non-RGD
targeted controls [35,36]. For a comprehensive review on
integrin-targeted chemotherapeutics, see Chen and Chen
[37]. More recent strategies have included using silica
nanoparticles as platforms for assembly of a targeted therapy.
Their inherent low toxicity, innate fluorescence and high
loading ability make them ideal carriers for compounds such
as doxorubicin, camptothecin, etc. and they can be surface-
coated in integrin targeting molecules, antibodies or RGD
peptides [38]. The next generation of RGD-mimetics that
induce internalization of the ‘payload’ are also under intense
study [39].
Radiotherapy can also be focused like chemotherapy.
Radioisotopes have been conjugated to RGD-targeting
peptides such as 111In, 99mTc and 90Y [40], where all three
radio-conjugates showed selective tumour uptake and a
significant decrease in tumour growth was exhibited by 90Y.
It has been suggested that, with radiotherapy, RGD peptides
do not persist long enough before excretion to allow for a
sustained dose in most cases [41]. Hence, antibody directed
radiotherapiesmaybe abetter alternative.Veeravagu et al. [42]
have shown that a novel 90Y-labelled Abegrin (a humanized
anti-αvβ3-integrin antibody) radioimmunotherapeutic agent
is effective against glioblastoma in mouse xenograft models
and can also be used to image the tumour.
Biologics, such as tumour necrosis factor α (TNFα),
are currently being used/evaluated for several cancers as
monotherapies or in combination with chemo/radiotherapy
[43]. Several have also been conjugated to RGD peptides.
Wang et al. [44] showed that an RGD-TNFα fusion protein
was effective at reducing tumour volume by 72% compared
with TNFα at doses low enough to have no toxicity effects.
Another promising example is the chemical synthesis of a pro-
apoptotic SMAC mimetic conjugated to an RGD-mimetic
[45]. Integrin αvβ3 is also being used to direct nucleic acid
delivery, most notably siRNAs. A sophisticated liposomal
delivery system for siRNA targeting VEGFR2 (present on
more than just tumour vasculature), targeted using RGD-
peptides, produced a sustained reduction in tumour growth
with no systemic toxicity [46]. It is easy to imagine that an
extension of this strategy might be used to overcome anti-
angiogenic escape mechanisms by incorporating multiple
siRNAs into the system once appropriate targets are
identified.
The majority of data clearly indicate that even in the
unlikely event that we eventually abandon αvβ3-integrin as
a direct anti-angiogenic target, its up-regulated expression
in angiogenic vasculature will certainly prove useful. Aside
from the aforementioned therapeutic uses, the molecule has
great potential for imaging, by using the selectivity of its
targeting motifs. For example, when 64Cu is added to the
RGD–TNFα conjugate by Wang et al. [44], it allows specific
imaging of tumours by micro positron emission tomography
(μPET). Other RGD targets can be modified similarly by the
incorporation of radioactive markers such as 18F [47,48]. A
more detailed review of αvβ3-integrin-based diagnostics has
been produced by Danhier et al. [49].
Concluding remarks
We hope we have convinced the reader of the present review
that, in spite of, to date, lacklustre results in the clinic,
it would be premature to give up on αvβ3-integrin as a
cancer target. Aside from its unique angiogenic expression
profile, which reduces the likely side effects from its
blockade, inhibiting the molecule has potential benefits we
have not had space to comment on in depth: (i) inhibiting
its function simultaneously hampers and normalizes the
formation of tumour blood vessels [50], thereby possibly
increasing effective delivery of chemotherapeutic agents; and
(ii) αvβ3-integrin augments signalling through multiple pro-
angiogenic-growth-factor pathways [51], therefore inhibiting
its function may block multiple pro-angiogenic pathways at
the same time.
So, how do we move forward? Our published findings
[20,26] suggest that disappointing clinical outcomes achieved
with the existing pharmaceutical agents directed against
αvβ3-integrin (http://www.pharmatimes.com/article/13-
02-26/Merck_KGaA_s_cilengitide_fails_in_Phase_III.aspx)
[52] arise, at least in part, from treatment escape associated
with long-term αvβ3-integrin targeting. However, until we
fully understand how these antagonists function, we cannot
rule out the possibility that poor outcomes are the result
of reported mechanistic [8,53] and dosing [9] problems
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associated with these antagonists. If we wish to mirror
the successes that have been achieved with other targeted
therapies, we too must return to fundamental biology in
order to move forward with this promising target. The
models we have generated have already gone some way
towards a deeper mechanistic understanding of how EC
αvβ3-integrin regulates the initial stages of tumour growth
and angiogenesis. By extending these models into more
clinically relevant scenarios, where there is frequently a gap
between pre-clinical and clinical studies that may contribute
to eventual strategy failure, we may be able to re-direct
the use of current drugs in combination and/or spur the
development of new inhibitors, building towards directed
therapies that integrate multiple angiogenic pathways.
Acknowledgements
We thank Professor Dylan Edwards and Professor Ulrike Mayer for
their wonderful mentoring of S.D.R. during the early stages of his
independent career. We also thank Dr Sophia Akbareian for her
unquenchable spirit and her day-to-day intellectual input into all
goings-on in the laboratory.
Funding
This work was supported by the Norwich Research Park Biotech-
nology and Biological Sciences Research Council Doctoral Training
Partnership (DTP) studentship (to S.A.); BigC Ph.D. studentship (to
T.S.E.); the University of East Anglia Dean’s Ph.D. studentship; and
the John and Pamela Salter Charitable Trust.
References
1 Brooks, P.C., Clark, R.A. and Cheresh, D.A. (1994) Requirement of vascular
integrin αvβ3 for angiogenesis. Science 264, 569–571 CrossRef PubMed
2 Brooks, P.C., Montgomery, A.M., Rosenfeld, M., Reisfeld, R.A., Hu, T.,
Klier, G. and Cheresh, D.A. (1994) Integrin αvβ3 antagonists promote
tumor regression by inducing apoptosis of angiogenic blood vessels. Cell
79, 1157–1164 CrossRef PubMed
3 Tucker, G.C. (2006) Integrins: molecular targets in cancer therapy. Curr.
Oncol. Rep. 8, 96–103 CrossRef PubMed
4 Hodivala-Dilke, K.M., McHugh, K.P., Tsakiris, D.A., Rayburn, H., Crowley,
D., Ullman-Cullere´, M., Ross, F.P., Coller, B.S., Teitelbaum, S. and Hynes,
R.O. (1999) β3-integrin-deﬁcient mice are a model for Glanzmann
thrombasthenia showing placental defects and reduced survival. J. Clin.
Invest. 103, 229–238 CrossRef PubMed
5 Reynolds, L.E., Wyder, L., Lively, J.C., Taverna, D., Robinson, S.D., Huang,
X., Sheppard, D., Hynes, R.O. and Hodivala-Dilke, K.M. (2002) Enhanced
pathological angiogenesis in mice lacking β3 integrin or β3 and β5
integrins. Nat. Med. 8, 27–34 CrossRef PubMed
6 Reynolds, A.R., Reynolds, L.E., Nagel, T.E., Lively, J.C., Robinson, S.D.,
Hicklin, D.J., Bodary, S.C. and Hodivala-Dilke, K.M. (2004) Elevated Flk1
(vascular endothelial growth factor receptor 2) signaling mediates
enhanced angiogenesis in β3-integrin-deﬁcient mice. Cancer Res. 64,
8643–8650 CrossRef PubMed
7 Stupp, R. and Ruegg, C. (2007) Integrin inhibitors reaching the clinic. J.
Clin. Oncol. 25, 1637–1638 CrossRef PubMed
8 Alghisi, G.C., Ponsonnet, L. and Ruegg, C. (2009) The integrin antagonist
cilengitide activates αVβ3, disrupts VE-cadherin localization at cell
junctions and enhances permeability in endothelial cells. PLoS ONE 4,
e4449 CrossRef PubMed
9 Reynolds, A.R., Hart, I.R., Watson, A.R., Welti, J.C., Silva, R.G., Robinson,
S.D., Da Violante, G., Gourlaouen, M., Salih, M., Jones, M.C. et al. (2009)
Stimulation of tumor growth and angiogenesis by low concentrations of
RGD-mimetic integrin inhibitors. Nat. Med. 15, 392–400
CrossRef PubMed
10 Grogan, K. (2013), Merck KGaA’s cilengitide fails in Phase III.
PharmaTimes online (http://www.pharmatimes.com/article/13-02-26/
Merck_KGaA_s_cilengitide_fails_in_Phase_III.aspx)
11 Hynes, R.O. (2002) Integrins: bidirectional, allosteric signaling machines.
Cell 110, 673–687 CrossRef PubMed
12 van der Flier, A., Badu-Nkansah, K., Whittaker, C.A., Crowley, D., Bronson,
R.T., Lacy-Hulbert, A. and Hynes, R.O. (2010) Endothelial α5 and αv
integrins cooperate in remodeling of the vasculature during
development. Development 137, 2439–2449 CrossRef PubMed
13 Robinson, S.D. and Hodivala-Dilke, K.M. (2011) The role of β3-integrins
in tumor angiogenesis: context is everything. Curr. Opin. Cell Biol. 23,
630–637 CrossRef PubMed
14 Brooks, P.C., Stro¨mblad, S., Klemke, R., Visscher, D., Sarkar, F.H. and
Cheresh, D.A. (1995) Antiintegrin αvβ3 blocks human breast cancer
growth and angiogenesis in human skin. J. Clin. Invest. 96, 1815–1822
CrossRef PubMed
15 Cai, W. and Chen, X. (2006) Anti-angiogenic cancer therapy based on
integrin αvβ3 antagonism. Anticancer Agents Med. Chem. 6, 407–428
CrossRef PubMed
16 Mahabeleshwar, G.H., Feng, W., Phillips, D.R. and Byzova, T.V. (2006)
Integrin signaling is critical for pathological angiogenesis. J. Exp. Med.
203, 2495–2507 CrossRef PubMed
17 Feng, W., McCabe, N.P., Mahabeleshwar, G.H., Somanath, P.R., Phillips,
D.R. and Byzova, T.V. (2008) The angiogenic response is dictated by β3
integrin on bone marrow-derived cells. J. Cell Biol. 183, 1145–1157
CrossRef PubMed
18 Watson, A.R., Pitchford, S.C., Reynolds, L.E., Direkze, N., Brittan, M.,
Alison, M.R., Rankin, S., Wright, N.A. and Hodivala-Dilke, K.M. (2010)
Deﬁciency of bone marrow β3-integrin enhances non-functional
neovascularization. J. Pathol. 220, 435–445 PubMed
19 Morgan, E.A., Schneider, J.G., Baroni, T.E., Uluc¸kan, O., Heller, E., Hurchla,
M.A., Deng, H., Floyd, D., Berdy, A., Prior, J.L. et al. (2010) Dissection of
platelet and myeloid cell defects by conditional targeting of the
β3-integrin subunit. FASEB J. 24, 1117–1127 CrossRef PubMed
20 Steri, V., Ellison, T.S., Gontarczyk, A.M., Weilbaecher, K., Schneider, J.G.,
Edwards, D., Fruttiger, M., Hodivala-Dilke, K.M. and Robinson, S.D. (2014)
Acute depletion of endothelial β3-integrin transiently inhibits tumor
growth and angiogenesis in mice. Circ. Res. 114, 79–91
CrossRef PubMed
21 West, X.Z., Meller, N., Malinin, N.L., Deshmukh, L., Meller, J.,
Mahabeleshwar, G.H., Weber, M.E., Kerr, B.A., Vinogradova, O. and
Byzova, T.V. (2012) Integrin β3 crosstalk with VEGFR accommodating
tyrosine phosphorylation as a regulatory switch. PLoS ONE 7, e31071
CrossRef PubMed
22 Whitaker, G.B., Limberg, B.J. and Rosenbaum, J.S. (2001) Vascular
endothelial growth factor receptor-2 and neuropilin-1 form a receptor
complex that is responsible for the differential signaling potency of
VEGF165 and VEGF121. J. Biol. Chem. 276, 25520–25531
CrossRef PubMed
23 Soker, S., Miao, H.Q., Nomi, M., Takashima, S. and Klagsbrun, M. (2002)
VEGF165 mediates formation of complexes containing VEGFR-2 and
neuropilin-1 that enhance VEGF165-receptor binding. J. Cell. Biochem. 85,
357–368 CrossRef PubMed
24 Herzog, B., Pellet-Many, C., Britton, G., Hartzoulakis, B. and Zachary, I.C.
(2011) VEGF binding to NRP1 is essential for VEGF stimulation of
endothelial cell migration, complex formation between NRP1 and
VEGFR2, and signalling via FAK Tyr407 phosphorylation. Mol. Biol. Cell 22,
2766–2776 CrossRef PubMed
25 Ballmer-Hofer, K., Andersson, A.E., Ratcliffe, L.E. and Berger, P. (2011)
Neuropilin-1 promotes VEGFR-2 trafﬁcking through Rab11 vesicles
thereby specifying signal output. Blood 118, 816–826
CrossRef PubMed
26 Robinson, S.D., Reynolds, L.E., Kostourou, V., Reynolds, A.R., da Silva,
R.G., Tavora, B., Baker, M., Marshall, J.F. and Hodivala-Dilke, K.M. (2009)
αvβ3 integrin limits the contribution of neuropilin-1 to vascular
endothelial growth factor-induced angiogenesis. J. Biol. Chem. 284,
33966–33981 CrossRef PubMed
27 Fantin, A., Herzog, B., Mahmoud, M., Yamaji, M., Plein, A., Denti, L.,
Ruhrberg, C. and Zachary, I. (2014) Neuropilin 1 (NRP1) hypomorphism
combined with defective VEGF-A binding reveals novel roles for NRP1 in
developmental and pathological angiogenesis. Development 141,
556–562 CrossRef PubMed
C©The Authors Journal compilation C©2014 Biochemical Society
Angiogenesis and Vascular Remodelling: New Perspectives 1595
28 Seerapu, H.R., Borthakur, S., Kong, N., Agrawal, S., Drazba, J., Vasanji, A.,
Fantin, A., Ruhrberg, C., Buck, M. and Horowitz, A. (2013) The
cytoplasmic domain of neuropilin-1 regulates focal adhesion turnover.
FEBS Lett. 587, 3392–3399 CrossRef PubMed
29 Raimondi, C., Fantin, A., Lampropoulou, A., Denti, L., Chikh, A. and
Ruhrberg, C. (2014) Imatinib inhibits VEGF-independent angiogenesis by
targeting neuropilin 1-dependent ABL1 activation in endothelial cells. J.
Exp. Med. 211, 1167–1183 CrossRef PubMed
30 Valdembri, D., Caswell, P.T., Anderson, K.I., Schwarz, J.P., Ko¨nig, I.,
Astanina, E., Caccavari, F., Norman, J.C., Humphries, M.J., Bussolino, F.
and Serini, G. (2009) Neuropilin-1/GIPC1 signaling regulates α5β1
integrin trafﬁc and function in endothelial cells. PLoS Biol. 7, e25
CrossRef PubMed
31 Schiller, H.B., Friedel, C.C., Boulegue, C. and Fassler, R. (2011)
Quantitative proteomics of the integrin adhesome show a myosin
II-dependent recruitment of LIM domain proteins. EMBO Rep. 12,
259–266 CrossRef PubMed
32 Schiller, H.B., Hermann, M.R., Polleux, J., Vignaud, T., Zanivan, S., Friedel,
C.C., Sun, Z., Raducanu, A., Gottschalk, K.E., The´ry, M. et al. (2013) β1-
and αv-class integrins cooperate to regulate myosin II during rigidity
sensing of ﬁbronectin-based microenvironments. Nat. Cell Biol. 15,
625–636 CrossRef PubMed
33 Mulgrew, K., Kinneer, K., Yao, X.T., Ward, B.K., Damschroder, M.M.,
Walsh, B., Mao, S.Y., Gao, C., Kiener, P.A., Coats, S. et al. (2006) Direct
targeting of αvβ3 integrin on tumor cells with a monoclonal antibody,
abegrin. Mol. Cancer Ther. 5, 3122–3129 CrossRef PubMed
34 Teti, A., Migliaccio, S. and Baron, R. (2002) The role of the αVβ3 integrin
in the development of osteolytic bone metastases: a pharmacological
target for alternative therapy? Calcif. Tissue Int. 71, 293–299 CrossRef
35 Burkhart, D.J., Kalet, B.T., Coleman, M.P., Post, G.C. and Koch, T.H. (2004)
Doxorubicin-formaldehyde conjugates targeting αvβ3 integrin. Mol.
Cancer Ther. 3, 1593–1604 PubMed
36 Cao, Q., Li, Z.B., Chen, K., Wu, Z., He, L., Neamati, N. and Chen, X. (2008)
Evaluation of biodistribution and anti-tumor effect of a dimeric RGD
peptide–paclitaxel conjugate in mice with breast cancer. Eur. J. Nucl.
Med. Mol. Imaging 35, 1489–1498 CrossRef PubMed
37 Chen, K. and Chen, X. (2011) Integrin targeted delivery of
chemotherapeutics. Theranostics 1, 189–200 CrossRef PubMed
38 Chen, H., Zhen, Z., Tang, W., Todd, T., Chuang, Y.J., Wang, L., Pan, Z. and
Xie, J. (2013) Label-free luminescent mesoporous silica nanoparticles for
imaging and drug delivery. Theranostics 3, 650–657 CrossRef PubMed
39 Wang, K., Zhang, X., Liu, Y., Liu, C., Jiang, B. and Jiang, Y. (2014) Tumor
penetrability and anti-angiogenesis using iRGD-mediated delivery of
doxorubicin–polymer conjugates. Biomaterials 35, 8735–8747
CrossRef PubMed
40 Janssen, M.L., Oyen, W.J., Dijkgraaf, I., Massuger, L.F., Frielink, C.,
Edwards, D.S., Rajopadhye, M., Boonstra, H., Corstens, F.H. and Boerman,
O.C. (2002) Tumor targeting with radiolabeled αvβ3 integrin binding
peptides in a nude mouse model. Cancer Res. 62, 6146–6151 PubMed
41 Liu, Z., Wang, F. and Chen, X. (2008) Integrin αvβ3-targeted cancer
therapy. Drug Dev. Res. 69, 329–339 CrossRef PubMed
42 Veeravagu, A., Liu, Z., Niu, G., Chen, K., Jia, B., Cai, W., Jin, C., Hsu, A.R.,
Connolly, A.J., Tse, V. et al. (2008) Integrin αvβ3-targeted
radioimmunotherapy of glioblastoma multiforme. Clin. Cancer Res. 14,
7330–7339 CrossRef PubMed
43 van Horssen, R., Ten Hagen, T.L. and Eggermont, A.M. (2006) TNF-α in
cancer treatment: molecular insights, antitumor effects, and clinical
utility. Oncologist 11, 397–408 CrossRef PubMed
44 Wang, H., Chen, K., Cai, W., Li, Z., He, L., Kasheﬁ, A. and Chen, X. (2008)
Integrin-targeted imaging and therapy with RGD4C–TNF fusion protein.
Mol. Cancer Ther. 7, 1044–1053 CrossRef PubMed
45 Mingozzi, M., Manzoni, L., Arosio, D., Dal Corso, A., Manzotti, M.,
Innamorati, F., Pignataro, L., Lecis, D., Delia, D., Seneci, P. and Gennari, C.
(2014) Synthesis and biological evaluation of dual action
cyclo-RGD/SMAC mimetic conjugates targeting αvβ3/αvβ5 integrins
and IAP proteins. Org. Biomol. Chem. 12, 3288–3302 CrossRef PubMed
46 Sakurai, Y., Hatakeyama, H., Sato, Y., Hyodo, M., Akita, H., Ohga, N., Hida,
K. and Harashima, H. (2014) RNAi-mediated gene knockdown and
anti-angiogenic therapy of RCCs using a cyclic RGD-modiﬁed
liposomal–siRNA system. J. Control. Release 173, 110–118
CrossRef PubMed
47 Morrison, M.S., Ricketts, S.A., Barnett, J., Cuthbertson, A., Tessier, J. and
Wedge, S.R. (2009) Use of a novel Arg-Gly-Asp radioligand,
18F-AH111585, to determine changes in tumor vascularity after
antitumor therapy. J Nucl. Med. 50, 116–122 CrossRef PubMed
48 Durkan, K., Jiang, Z., Rold, T.L., Sieckman, G.L., Hoffman, T.J., Bandari, R.P.,
Szczodroski, A.F., Liu, L., Miao, Y., Reynolds, T.S. and Smith, C.J. (2014) A
heterodimeric [RGD-Glu-[64Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting
antagonist radiotracer for PET imaging of prostate tumors. Nucl. Med.
Biol. 41, 133–139 CrossRef PubMed
49 Danhier, F., Le Breton, A. and Pre´at, V. (2012) RGD-based strategies to
target αvβ3 integrin in cancer therapy and diagnosis. Mol. Pharm. 9,
2961–2973 CrossRef PubMed
50 Bouzin, C. and Feron, O. (2007) Targeting tumor stroma and exploiting
mature tumor vasculature to improve anti-cancer drug delivery. Drug
Resist. Updat. 10, 109–120 CrossRef PubMed
51 Switala-Jelen, K., Dabrowska, K., Opolski, A., Lipinska, L., Nowaczyk, M.
and Gorski, A. (2004) The biological functions of β3 integrins. Folia Biol.
50, 143–152 PubMed
52 Smith, J.W. (2003) Cilengitide Merck. Curr. Opin. Invest. Drugs 4,
741–745 PubMed
53 Ghitti, M., Spitaleri, A., Valentinis, B., Mari, S., Asperti, C., Traversari, C.,
Rizzardi, G.P. and Musco, G. (2012) Molecular dynamics reveal that
isoDGR-containing cyclopeptides are true αvβ3 antagonists unable to
promote integrin allostery and activation. Angew. Chem. Int. Ed. Engl.
51, 7702–7705 CrossRef PubMed
Received 30 July 2014
doi:10.1042/BST20140206
C©The Authors Journal compilation C©2014 Biochemical Society
228 
Abbreviations 
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ECM – Extracellular matrix 
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IMD – Integrin-mediated death 
IP – Immunoprecipitation 
KDR – Kinase domain receptor (VEGFR2) 
LFQ – Label-free quantification 
LIM – LIN-11, Isl1, and MEC- 3 
LLC – Lewis lung carcinoma 
LN – Laminin 
MACS – Magnetic activated cell sorting 
MAPK – Mitogen activated protein kinase 
MMP – Matrix metalloproteinase 
mTOR – Mammalian target of rapamycin 
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TE – Tris-EDTA 
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TGFβ – Transforming growth factor-beta 
TIMP – Tissue inhibitor of metalloproteinases 
TM – Transmembrane 
VCAM – Vascular cell adhesion molecule 
VEGF – Vascular endothelial growth factor (-A unless otherwise stated) 
VEGFs – vascular endothelial growth factors 
VEGFR1/2/3 – Vascular Endothelial Growth Factor Receptor 1/2/3 
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